pdb_id,protein_name,num_residues,volume_A3,hydrophobic_sasa_nm2,hbond_donors,hbond_acceptors,net_charge,polarity_score
1li6,t4 lysozyme mutant l99a/m102q bound by 5-methylpyrrole,12,1869.4,13.22,3,3,0.0,0.17
1lgw,t4 lysozyme mutant l99a/m102q bound by 2-fluoroaniline,12,1869.4,13.39,3,3,0.0,0.17
187l,specificity of ligand binding in a buried non-polar cavity of t4 lysozyme: linkage of dynamics and structural plasticity,9,1347.5,10.44,6,1,1.0,0.22
184l,specificity of ligand binding in a buried non-polar cavity of t4 lysozyme: linkage of dynamics and structural plasticity,15,2334.1,16.67,2,2,0.0,0.13
1li2,t4 lysozyme mutant l99a/m102q bound by phenol,12,1869.4,13.22,3,3,0.0,0.17
1li3,t4 lysozyme mutant l99a/m102q bound by 3-chlorophenol,12,1869.4,13.64,3,3,0.0,0.17
185l,specificity of ligand binding in a buried non-polar cavity of t4 lysozyme: linkage of dynamics and structural plasticity,12,1888.5,15.13,1,1,0.0,0.08
1l83,a cavity-containing mutant of t4 lysozyme is stabilized by buried benzene,12,1888.5,14.72,1,1,0.0,0.08
186l,specificity of ligand binding in a buried non-polar cavity of t4 lysozyme: linkage of dynamics and structural plasticity,15,2334.1,16.38,2,2,0.0,0.13
188l,specificity of ligand binding in a buried non-polar cavity of t4 lysozyme: linkage of dynamics and structural plasticity,9,1347.5,10.39,6,1,1.0,0.22
2vzr,c-terminal cbm35 from amycolatopsis orientalis exo-chitosanase csxa in complex with glucuronic acid,13,1823.0,3.42,20,16,0.5,0.77
1n4k,"crystal structure of the inositol 1,4,5-trisphosphate receptor binding core in complex with ip3",13,1917.1,1.24,34,5,6.0,0.85
1uho,crystal structure of human phosphodiesterase 5 complexed with vardenafil(levitra),21,3039.9,16.79,11,11,0.5,0.33
5wuk,crystal structure of eed [g255d] in complex with ezh2 peptide and eed226 compound,13,2009.5,5.18,17,10,0.0,0.69
1yqy,structure of b. anthrax lethal factor in complex with a hydroxamate inhibitor,20,2772.9,7.23,15,17,-2.0,0.60
3p8z,dengue methyltransferase bound to a sam-based inhibitor,27,3495.3,9.11,28,12,2.5,0.52
4dv8,anthrax lethal factor metalloproteinase in complex with the hydroxamic acid based small molecule pt8421,24,3261.7,6.82,19,23,-3.0,0.62
4r0a,crystal structure of human tlr8 in complex with uridine mononucleoside,10,1564.8,6.74,11,3,2.0,0.50
5ost,beta-glucosidase from thermoanaerobacterium xylolyticum gh116 in complex with gluco-1h-imidazole,18,2938.6,4.50,23,19,-1.5,0.83
5tef,crystal structure of gemin5 wd40 repeats in complex with m7gpppg,16,2289.3,3.77,18,12,1.0,0.75
5gsa,eed in complex with an allosteric prc2 inhibitor,14,2187.9,7.32,19,9,1.0,0.64
1kc7,pyruvate phosphate dikinase with bound mg-phosphonopyruvate,14,1879.8,5.95,13,9,-1.0,0.57
1jzs,isoleucyl-trna synthetase complexed with mupirocin,25,3238.4,16.43,13,17,-1.5,0.36
3ebp,glycogen phosphorylase b/flavopiridol complex,14,2025.1,5.70,13,14,-1.5,0.64
5jhb,structure of phosphoinositide 3-kinase gamma (pi3k) bound to the potent inhibitor pikin3,26,3744.2,14.61,13,13,-2.0,0.42
3ebo,glycogen phosphorylase b/chrysin complex,14,2025.1,5.73,13,14,-1.5,0.64
3hu3,structure of p97 n-d1 r155h mutant in complex with atpgs,23,2759.3,9.66,14,10,0.5,0.39
3l4w,crystal complex of n-terminal human maltase-glucoamylase with miglitol,4,429.5,3.08,4,4,0.0,0.50
4b9z,"crystal structure of agd31b, alpha-transglucosylase, complexed with acarbose",20,3164.3,9.78,13,18,-4.5,0.55
3ctt,crystal complex of n-terminal human maltase-glucoamylase with casuarine,6,690.8,1.42,9,9,0.0,0.83
6phx,spaga d472n structure in complex with raffinose,7,1161.5,2.16,7,10,-1.5,0.86
3l4v,crystal complex of n-terminal human maltase-glucoamylase with kotalanol,23,3523.6,10.40,24,20,-2.5,0.65
3l4x,crystal complex of n-terminal human maltase-glucoamylase with nr4-8,19,3013.7,11.63,18,15,-2.5,0.58
3l4u,crystal complex of n-terminal human maltase-glucoamylase with de-o- sulfonated kotalanol,22,3409.5,10.75,22,18,-2.5,0.64
2vc9,"family 89 glycoside hydrolase from clostridium perfringens in complex with 2-acetamido-1,2-dideoxynojirmycin",18,3061.8,13.65,14,14,-1.5,0.50
4ko8,structure of p97 n-d1 r155h mutant in complex with atpgs,25,3101.3,9.44,22,10,2.5,0.44
3l4z,crystal complex of n-terminal human maltase-glucoamylase with salacinol,18,2897.6,11.63,17,14,-2.5,0.56
3l4y,crystal complex of n-terminal human maltase-glucoamylase with nr4-8ii,21,3240.9,10.98,19,18,-3.5,0.62
1ez9,structure of maltotetraitol bound to open-form maltodextrin binding protein in p1 crystal form,5,785.0,2.71,4,7,-2.0,0.80
5m7u,structure of human o-glcnac hydrolase with new iminocyclitol type inhibitor,20,3006.1,9.95,17,14,-1.0,0.60
4oc0,"x-ray structure of of human glutamate carboxypeptidase ii (gcpii) in a complex with ccibzl, a urea-based inhibitor n~2~-[(1- carboxycyclopropyl)carbamoyl]-n~6~-(4-iodobenzoyl)-l-lysine",27,3572.8,5.92,33,22,-0.5,0.67
4cu8,"unravelling the multiple functions of the architecturally intricate streptococcus pneumoniae beta-galactosidase, bgaa",15,2384.9,6.00,18,17,-1.0,0.73
2ya6,crystal structure of streptococcus pneumoniae nana (tigr4) in complex with dana,21,3353.6,9.50,26,16,-1.0,0.67
4cu7,"unravelling the multiple functions of the architecturally intricate streptococcus pneumoniae beta-galactosidase, bgaa",15,2384.9,5.98,18,17,-1.0,0.73
5dxt,p110alpha with gdc-0326,22,3290.3,11.64,17,14,-0.5,0.50
5m7s,structure of human o-glcnac hydrolase with bound transition state analog thiametg,17,2381.9,6.14,12,14,-2.0,0.65
3w37,sugar beet alpha-glucosidase with acarbose,19,2991.9,13.80,17,13,-2.5,0.47
4kxb,crystal structure of human aminopeptidase a complexed with bestatin,19,2641.3,4.69,18,18,-2.0,0.68
2zxg,"aminopeptidase n complexed with the aminophosphinic inhibitor of pl250, a transition state analogue",20,2934.3,3.01,22,21,-2.0,0.75
6gvf,"crystal structure of pi3k alpha in complex with 3-(2-amino- benzooxazol-5-yl)-1-isopropyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine",19,2880.6,13.03,13,10,-1.0,0.47
4r5t,structure of the m1 alanylaminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor,21,2987.2,9.83,13,20,-4.0,0.57
2ya8,crystal structure of streptococcus pneumoniae nana (tigr4) in complex with oseltamivir carboxylate,19,3126.4,10.03,25,13,0.0,0.63
4kx8,crystal structure of human aminopeptidase a complexed with amastatin,5,629.4,2.97,4,5,-1.0,0.60
3q44,x-ray crystal structure of pfa-m1 bound to bestatin derivative 16,24,3336.6,10.25,20,22,-2.0,0.62
3ebh,structure of the m1 alanylaminopeptidase from malaria complexed with bestatin,20,2832.2,8.94,17,17,-1.0,0.60
4zw7,x-ray crystal structure of pfa-m1 in complex with hydroxamic acid- based inhibitor 9m,23,3245.7,10.96,16,21,-3.0,0.57
4k5p,phosphonic arginine mimetics as inhibitors of the m1 aminopeptidases from plasmodium falciparum,17,2455.1,6.14,13,20,-3.0,0.71
4zx4,x-ray crystal structure of pfa-m1 in complex with hydroxamic acid- based inhibitor 10o,22,3105.7,9.39,16,21,-3.0,0.59
3ebi,structure of the m1 alanylaminopeptidase from malaria complexed with the phosphinate dipeptide analog,21,2944.7,5.90,19,21,-2.0,0.67
4zw6,x-ray crystal structure of pfa-m1 in complex with hydroxamic acid- based inhibitor 9q,22,3032.2,7.54,17,22,-3.0,0.64
3ddg,"golgi mannosidase ii complex with (3r,4r,5r)-3,4-dihydroxy-5-({[(1r)- 2-hydroxy-1 phenylethyl]amino}methyl) methylpyrrolidin-2-one",19,2770.9,4.70,22,22,-2.5,0.79
4zw5,x-ray crystal structure of pfa-m1 in complex with hydroxamic acid- based inhibitor 9f,22,3079.0,9.29,16,21,-3.0,0.59
4oc5,"x-ray structure of of human glutamate carboxypeptidase ii (gcpii) in a complex with chibzl, a urea-based inhibitor n~2~-{[(s)-carboxy(4- hydroxyphenyl)methyl]carbamoyl}-n~6~-(4-iodobenzoyl)-l-lysine",31,4187.0,9.59,37,23,0.5,0.65
4zw8,x-ray crystal structure of pfa-m1 in complex with hydroxamic acid- based inhibitor 9r,24,3334.3,11.82,16,21,-3.0,0.54
3t8v,a bestatin-based chemical biology strategy reveals distinct roles for malaria m1- and m17-family aminopeptidases,25,3462.5,7.25,25,25,-1.0,0.68
3d52,golgi mannosidase ii complex with an n-aryl carbamate derivative of gluco-hydroxyiminolactam,17,2626.4,5.69,21,17,-0.5,0.71
3w5n,crystal structure of streptomyces avermitilis alpha-l-rhamnosidase complexed with l-rhamnose,13,2171.5,9.16,12,12,-2.5,0.62
4oc1,"x-ray structure of of human glutamate carboxypeptidase ii (gcpii) in a complex with coibzl, a urea-based inhibitor (2s)-2-[({(1s)-1-carboxy- 2-[(2s)-oxiran-2-yl]ethyl}carbamoyl)amino]-6-[(4-iodobenzoyl) amino]hexanoic acid",29,3931.3,7.38,36,22,0.5,0.66
4zx3,x-ray crystal structure of pfa-m1 in complex with hydroxamic acid- based inhibitor 10b,16,2267.5,6.97,13,16,-2.0,0.62
4ou3,crystal structure of porcine aminopeptidase n complexed with cngrcg tumor-homing peptide,6,845.1,1.63,9,8,-1.0,0.83
4ngn,crystal structure of glutamate carboxypeptidase ii in a complex with urea-based inhibitor,23,3233.5,5.71,33,17,1.5,0.65
1ps3,golgi alpha-mannosidase ii in complex with kifunensine,16,2459.7,4.75,21,17,-0.5,0.75
6eed,x-ray crystal structure of pf-m1 in complex with inhibitor (6p) and catalytic zinc ion,22,3024.5,8.73,13,23,-4.0,0.64
2f7p,golgi alpha-mannosidase ii complex with benzyl-mannostatin a,19,2770.9,4.77,22,22,-2.5,0.79
3d50,golgi mannosidase ii complex with n-octyl-6-epi-valienamine,18,2791.7,4.71,22,20,-1.5,0.78
3d51,golgi mannosidase ii complex with gluco-hydroxyiminolactam,16,2459.7,4.66,21,17,-0.5,0.75
3ejq,golgi alpha-mannosidase ii in complex with 5-substitued swainsonine analog: (5r)-5-[2'-oxo-2'-(4-methylphenyl)ethyl]-swainsonine,18,2791.7,4.80,22,20,-1.5,0.78
3dx2,golgi mannosidase ii complex with mannostatin b,15,2399.6,4.97,21,17,-0.5,0.80
3ejp,golgi alpha-mannosidase ii in complex with 5-substituted swainsonine analog: (5r)-5-[2'-oxo-2'-(phenyl)ethyl]-swainsonine,18,2791.7,4.80,22,20,-1.5,0.78
3d4z,golgi mannosidase ii complex with gluco-imidazole,16,2459.7,4.64,21,17,-0.5,0.75
3ejr,golgi alpha-mannosidase ii in complex with 5-substitued swainsonine analog: (5r)-5-[2'-oxo-2'-(4-tert-butylphenyl)ethyl]-swainsonine,18,2791.7,4.77,22,20,-1.5,0.78
3sjf,x-ray structure of human glutamate carboxypeptidase ii in complex with a urea-based inhibitor (a25),29,3830.4,5.37,37,23,0.5,0.69
1i1e,crystal structure of clostridium botulinum neurotoxin b complexed with doxorubicin,16,2422.5,7.26,14,11,-0.5,0.62
3ddf,"golgi mannosidase ii complex with (3r,4r,5r)-3,4-dihydroxy-5-({[(1r)- 2-hydroxy-1 phenylethyl]amino}methyl) pyrrolidin-2-one",18,2543.1,3.27,21,22,-2.5,0.83
5uk8,the co-structure of (r)-4-(6-(1-(cyclopropylsulfonyl)cyclopropyl)-2- (1h-indol-4-yl)pyrimidin-4-yl)-3-methylmorpholine and a rationally designed pi3k-alpha mutant that mimics atr,22,3215.6,14.42,11,13,-2.0,0.45
4ngp,crystal structure of glutamate carboxypeptidase ii in a complex with urea-based inhibitor,31,4252.3,8.68,42,25,1.5,0.68
3iww,"crystal structure of human glutamate carboxypeptidase ii (gcpii) in a complex with dbibzl, a urea-based inhibitor",28,3739.5,7.36,33,22,-0.5,0.64
3o56,catalytic domain of human phosphodiesterase 4b2b in complex with a 5- heterocycle pyrazolopyridine inhibitor,17,2610.1,13.75,12,13,-0.5,0.53
2w4x,btgh84 in complex with stz,18,2751.2,10.42,12,14,-1.5,0.56
4lko,crystal structure of human dpp-iv in complex with bms-744891,14,2199.8,4.24,15,15,-1.5,0.79
4oc2,"x-ray structure of of human glutamate carboxypeptidase ii (gcpii) in a complex with ceibzl, a urea-based inhibitor n~2~-{[(1s)-1-carboxybut- 3-yn-1-yl]carbamoyl}-n~6~-(4-iodobenzoyl)-l-lysine",28,3739.5,7.32,33,22,-0.5,0.64
2ole,crystal structure of human dipeptidyl peptidase iv (dppiv) complex with cyclic hydrazine derivatives,16,2478.7,7.18,16,16,-1.5,0.75
2wca,btgh84 in complex with n-butyl pugnac,18,2729.9,8.34,15,14,-0.5,0.61
2j47,bacteroides thetaiotaomicron gh84 o-glcnacase in complex with a imidazole-pugnac hybrid inhibitor,19,2841.0,8.47,15,16,-1.5,0.63
2vvs,btgh84 structure in complex with pugnac,19,2841.0,7.94,15,16,-1.5,0.63
3sww,"crystal structure of human dpp-iv in complex with sa-(+)-3- (aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyphenyl)- 2-methyl- 5h-pyrrolo[3,4-b]pyridin-7(6h)-one",16,2487.7,6.40,16,15,-1.5,0.69
5wyz,crystal structure of human tlr8 in complex with cu-cpt9b,19,2763.4,12.91,11,8,1.0,0.37
5wyx,crystal structure of human tlr8 in complex with cu-cpt8m,18,2674.4,13.03,10,7,1.0,0.33
2qta,e. coli pyruvate dehydrogenase e1 component e401k mutant with thiamin diphosphate,28,3813.6,6.60,31,30,-1.5,0.71
4fl1,structural and biophysical characterization of the syk activation switch,19,2447.9,12.72,13,9,0.0,0.37
3fqe,crystal structure of spleen tyrosine kinase complexed with ym193306,22,2788.0,13.16,12,10,-1.0,0.36
2xej,"human glutamate carboxypeptidase ii in complex with arm-m4, urea- based inhibitor",29,3889.1,7.14,37,20,2.5,0.62
4oc3,"x-ray structure of of human glutamate carboxypeptidase ii (gcpii) in a complex with cfibzl, a urea-based inhibitor n~2~-{[(1s)-1-carboxy-2- (furan-2-yl)ethyl]carbamoyl}-n~6~-(4-iodobenzoyl)-l-lysine",29,3830.4,5.31,37,23,0.5,0.69
5gmh,crystal structure of monkey tlr7 in complex with r848,20,2881.5,9.45,12,13,-1.0,0.50
4ngm,crystal structure of glutamate carboxypeptidase ii in a complex with urea-based inhibitor,31,4247.8,9.29,37,23,1.5,0.61
1n1m,human dipeptidyl peptidase iv/cd26 in complex with an inhibitor,8,1068.1,2.41,7,9,-1.0,0.75
3lpl,e. coli pyruvate dehydrogenase complex e1 component e571a mutant,12,1685.1,3.90,9,14,-3.0,0.75
4jh0,"crystal structure of dipeptidyl-peptidase 4 (cd26, adenosine deaminase complexing protein 2) (dpp-iv-wt) complex with bms-767778 aka 2-(3- (aminomethyl)-4-(2,4- dichlorophenyl)-2-methyl-5-oxo-5,7-dihydro-6h- pyrrolo[3,4- b]pyridin-6-yl)-n,n-dimethylacetamide",15,2368.4,4.27,18,15,-0.5,0.80
3lq2,e. coli pyruvate dehydrogenase complex e1 e235a mutant with low tdp concentration,26,3470.6,5.92,29,26,-1.0,0.69
1rp7,e. coli pyruvate dehydrogenase inhibitor complex,29,4007.2,5.76,32,31,-1.5,0.72
3nox,"crystal structure of human dpp-iv in complex with sa-(+)-(6- (aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidin- 2-yl)(morpholino)methanone",15,2427.6,6.66,16,15,-1.5,0.73
2xei,human glutamate carboxypeptidase ii in complex with antibody- recruiting molecule arm-p2,38,5363.6,8.60,56,29,3.5,0.74
2xef,human glutamate carboxypeptidase ii in complex with antibody- recruiting molecule arm-p8,43,5711.4,9.68,55,29,3.5,0.65
1dar,elongation factor g in complex with gdp,19,2320.6,4.64,20,12,2.5,0.63
2xeg,human glutamate carboxypeptidase ii in complex with antibody- recruiting molecule arm-p4,40,5483.7,10.40,53,29,2.5,0.68
3qfz,crystal structure of cellvibrio gilvus cellobiose phosphorylase complexed with sulfate and 1-deoxynojirimycin,6,627.7,3.23,2,4,-1.0,0.50
6d50,"bacteroides uniforms beta-glucuronidase 2 bound to d-glucaro-1,5- lactone",15,2356.9,2.69,26,18,1.0,0.87
2vw1,crystal structure of the nanb sialidase from streptococcus pneumoniae,20,2989.5,5.53,29,18,-1.0,0.80
3qfy,crystal structure of cellvibrio gilvus cellobiose phosphorylase complexed with sulfate and isofagomine,6,627.7,3.23,2,4,-1.0,0.50
5e3a,structure of human dpp3 in complex with opioid peptide leu-enkephalin,9,1194.0,1.00,8,10,0.5,0.67
2vw2,crystal structure of the nanb sialidase from streptococcus pneumoniae,16,2449.3,5.30,23,15,-1.0,0.81
6ma3,crystal structure of human o-glcnac transferase bound to a peptide from hcf-1 pro-repeat 2 (11-26) and inhibitor 2a,21,3034.4,8.93,28,17,5.0,0.62
2x09,inhibition of the exo-beta-d-glucosaminidase csxa by a glucosamine- configured castanospermine and an amino-australine analogue,16,2602.7,12.66,11,10,-3.0,0.56
6ma5,crystal structure of human o-glcnac transferase bound to a peptide from hcf-1 pro-repeat 2 (11-26) and inhibitor 1a,18,2521.0,9.00,21,13,3.5,0.56
6ma4,crystal structure of human o-glcnac transferase bound to a peptide from hcf-1 pro-repeat 2 (11-26) and inhibitor 3a,24,3400.5,11.49,29,18,5.0,0.58
1r1j,structural analysis of neprilysin with various specific and potent inhibitors,22,3422.2,12.47,25,17,0.5,0.55
4iid,crystal structure of beta-glucosidase 1 from aspergillus aculeatus in complex with 1-deoxynojirimycin,15,1997.8,8.88,6,11,-3.0,0.47
3lvw,glutathione-inhibited scgcl,20,3129.5,11.18,22,10,1.0,0.60
2vo5,structural and biochemical evidence for a boat-like transition state in beta-mannosidases,15,2666.0,12.52,14,13,-2.5,0.53
6ma2,crystal structure of human o-glcnac transferase bound to a peptide from hcf-1 pro-repeat 2 (11-26) and inhibitor ent-1a,19,2632.1,8.65,21,15,2.5,0.58
4iif,crystal structure of beta-glucosidase 1 from aspergillus aculeatus in complex with castanospermine,15,1997.8,8.97,6,11,-3.0,0.47
3fee,the high resolution structure of human glutamate carboxypeptidase iii (gcpiii/naaladase ii) in complex with quisqualic acid,6,613.1,1.76,6,6,0.0,0.67
2vmf,structural and biochemical evidence for a boat-like transition state in beta-mannosidases,13,2324.1,10.17,11,11,-2.5,0.54
6faa,crystal structure of the deah-box helicase prp2 in complex with adp,21,2621.4,7.08,21,16,-1.0,0.67
2vjx,structural and biochemical evidence for a boat-like transition state in beta-mannosidases,14,2438.2,9.67,13,13,-2.5,0.57
1r1h,structural analysis of neprilysin with various specific and potent inhibitors,24,3592.3,11.85,25,17,0.5,0.50
4fl2,structural and biophysical characterization of the syk activation switch,26,3390.5,10.61,22,14,1.5,0.46
4ufl,mouse galactocerebrosidase complexed with deoxy-galacto-noeurostegine dgn,5,736.9,2.05,12,4,2.0,0.80
2vqt,structural and biochemical evidence for a boat-like transition state in beta-mannosidases,14,2551.9,12.95,12,11,-2.5,0.50
1ro6,crystal structure of pde4b2b complexed with rolipram (r & s),21,3177.3,14.18,14,17,-1.0,0.52
3ff3,the high resolution structure of human glutamate carboxypeptidase iii (gcpiii/naaladase ii) in complex with l-glutamate,6,613.1,1.77,6,6,0.0,0.67
4ufk,mouse galactocerebrosidase complexed with dideoxy-imino-lyxitol dil,7,990.6,1.57,13,5,2.0,0.71
3fed,the high resolution structure of human glutamate carboxypeptidase iii (gcpiii/naaladase ii) in complex with a transition state analog of glu-glu,24,3355.5,5.73,30,21,0.0,0.71
4ufm,mouse galactocerebrosidase complexed with 1-deoxy-galacto-nojirimycin dgj,6,930.5,1.58,13,5,2.0,0.83
4ufi,mouse galactocerebrosidase complexed with aza-galacto-fagomine agf,5,736.9,2.08,12,4,2.0,0.80
2vot,structural and biochemical evidence for a boat-like transition state in beta-mannosidases,17,2868.3,12.27,14,15,-3.5,0.59
1h2t,structure of the human nuclear cap-binding-complex (cbc) in complex with a cap analogue m7gpppg,5,874.0,1.30,12,2,2.0,0.80
2vl4,structural and biochemical evidence for a boat-like transition state in beta-mannosidases,13,2324.1,10.13,11,11,-2.5,0.54
4ufh,mouse galactocerebrosidase complexed with iso-galacto-fagomine igf,6,930.5,1.56,13,5,2.0,0.83
4iie,crystal structure of beta-glucosidase 1 from aspergillus aculeatus in complex with calystegine b(2),15,1997.8,8.88,6,11,-3.0,0.47
4bb9,crystal structure of glucokinase regulatory protein complexed to fructose-1-phosphate,22,2639.1,5.80,22,15,0.5,0.59
4iic,crystal structure of beta-glucosidase 1 from aspergillus aculeatus in complex with isofagomine,15,1997.8,8.88,6,11,-3.0,0.47
4ufj,mouse galactocerebrosidase complexed with iso-galacto-fagomine lactam igl,6,797.0,2.04,12,4,2.0,0.67
6n9l,crystal structure of t. maritima uvra d117-399 with adp,17,1990.4,2.16,19,13,2.5,0.71
4l2l,human leukotriene a4 hydrolase complexed with ligand 4-(4- benzylphenyl)thiazol-2-amine,22,3231.0,14.19,11,10,-1.0,0.36
3b7u,leukotriene a4 hydrolase complexed with kelatorphan,17,2432.7,3.68,17,17,-1.0,0.71
2ya7,crystal structure of streptococcus pneumoniae nana (tigr4) in complex with zanamivir,22,3442.6,9.73,27,17,-1.0,0.68
3fh7,leukotriene a4 hydrolase complexed with inhibitor 4-[(2s)-2-{[4-(4- chlorophenoxy)phenoxy]methyl}pyrrolidin-1-yl]butanoate.,24,3496.7,14.27,13,20,-3.0,0.50
2r59,leukotriene a4 hydrolase complexed with inhibitor rb3041,25,3427.9,7.40,23,25,-2.0,0.68
3b7r,leukotriene a4 hydrolase complexed with inhibitor rb3040,21,3078.2,5.26,24,21,-1.0,0.71
4cr9,creating novel f1 inhibitors through fragment based lead generation and structure aided drug design,15,1732.6,5.06,7,7,-1.0,0.53
5exm,factor xia in complex with the inhibitor methyl ~{n}-[4-[2-[(1~{s})-1- [[4-(aminomethyl)cyclohexyl]carbonylamino]-2-phenyl-ethyl]pyridin-4- yl]phenyl]carbamate,23,2771.1,6.57,17,12,1.0,0.61
4cra,creating novel f1 inhibitors through fragment based lead generation and structure aided drug design,25,3182.8,7.58,18,13,1.0,0.60
4cr5,creating novel f1 inhibitors through fragment based lead generation and structure aided drug design,15,1787.8,4.51,8,6,0.0,0.53
4crb,creating novel f1 inhibitors through fragment based lead generation and structure aided drug design,26,3321.2,7.00,18,15,0.0,0.62
6c0s,factor xia in complex with the inhibitor methyl (4-{6-[(1s)-2-[(3r)-1- acetylpiperidin-3-yl]-1-({(2e)-3-[5-chloro-2- (1h-tetrazol-1-yl) phenyl]prop-2-enoyl}amino)ethyl]-3-chloropyridazin-4-yl}phenyl) carbamate,31,4049.8,11.24,21,18,0.0,0.58
4x6m,factor xia in complex with the inhibitor 1-{(1s)-1-[4-(3-amino-1h- indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl}-3-[2- (aminomethyl)-5-chlorobenzyl]urea,29,3635.5,7.50,21,17,0.0,0.62
4y8x,factor xia in complex with the inhibitor methyl (4-{4-chloro-2-[(1s)- 1-({(2e)-3-[5-chloro-2-(1h-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)- 2-phenylethyl]-1h-imidazol-5-yl}phenyl)carbamate,28,3522.5,9.68,18,15,0.0,0.57
4ty6,factor xia in complex with the inhibitor 4-{2-[(1s)-1-({[trans-4- (aminomethyl)cyclohexyl]carbonyl}amino)-2-phenylethyl]-1h-imidazol-4- yl}benzamide,27,3335.6,8.05,22,14,1.0,0.59
5exn,"factor xia (c500s [c122s]) in complex with the inhibitor methyl ~{n}- [4-[2-[(1~{s})-1-[[(~{e})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl) phenyl]prop-2-enoyl]amino]-2-phenyl-ethyl]pyridin-4- yl]phenyl]carbamate",34,4362.4,11.27,23,22,-1.0,0.59
5exl,factor xia in complex with the inhibitor 4-(aminomethyl)-~{n}- [(1~{s})-1-[4-(3-oxidanyl-1~{h}-indazol-5-yl)pyridin-2-yl]-2-phenyl- ethyl]cyclohexane-1-carboxamide,24,2911.1,6.96,17,12,1.0,0.58
5qqp,"factor xia in complex with the inhibitor methyl [(5e,8s)-8-[(4s)-4-(3- chlorophenyl)-2-oxopiperidin-1-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2h- 12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate",28,3600.9,9.76,19,14,1.0,0.57
5e2o,factor xia in complex with the inhibitor 4-[(n-{(2e)-3-[5-chloro-2- (1h-tetrazol-1-yl)phenyl]prop-2-enoyl}-l-phenylalanyl)amino]benzoic acid,28,3522.5,9.53,18,15,0.0,0.57
5e2p,factor xia in complex with the inhibitor n-[(1s)-1-benzyl-2-[2-[5- chloro-2-(tetrazol-1-yl)phenyl]ethylamino]-2-oxo-ethyl]-4-hydroxy-2- oxo-1h-quinoline-6-carboxamide,28,3522.5,9.54,18,15,0.0,0.57
5qtt,"factor xia in complex with the inhibitor methyl [(3r,7s)-7-{[5-amino- 1-(3-chloro-2-fluorophenyl)-1h-pyrazole-4-carbonyl]amino}-3-methyl-2- oxo-2,3,4,5,6,7-hexahydro-1h-12,8-(metheno)-1,9- benzodiazacyclotetradecin-15-yl]carbamate",28,3554.8,8.01,21,16,1.0,0.61
4crf,creating novel f1 inhibitors through fragment based lead generation and structure aided drug design,26,3321.2,6.99,18,15,0.0,0.62
4crc,creating novel f1 inhibitors through fragment based lead generation and structure aided drug design,27,3514.8,6.71,19,16,0.0,0.63
2vj8,complex of human leukotriene a4 hydrolase with a hydroxamic acid inhibitor,24,3453.2,11.46,20,19,-1.0,0.54
4x6o,factor xia in complex with the inhibitor methyl (4-{4-chloro-2-[(1s)- 1-({3-[5-chloro-2-(1h-tetrazol-1-yl)phenyl]propanoyl}amino)-2- phenylethyl]-1h-imidazol-5-yl}phenyl)carbamate,26,3321.2,7.00,18,15,0.0,0.62
4x6n,factor xia in complex with the inhibitor 1-{(1s)-1-[4-(3-amino-1h- indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro- 2-(1h-tetrazol-1-yl)benzyl]urea,29,3691.1,9.09,21,15,1.0,0.59
4ty7,factor xia in complex with the inhibitor (2s)-6-amino-n-{(1s)-1-[4-(3- amino-2h-indazol-6-yl)-5-chloro-1h-imidazol-2-yl]-2-phenylethyl}-2- ethylhexanamide,23,2771.1,6.43,17,12,1.0,0.61
2j4g,bacteroides thetaiotaomicron gh84 o-glcnacase in complex with n-butyl- thiazoline inhibitor,20,3003.9,8.40,15,16,-1.5,0.60
2jiw,bacteroides thetaiotaomicron gh84 o-glcnacase in complex with 2- acetylamino-2-deoxy-1-epivalienamine,18,2613.2,5.42,14,16,-1.5,0.67
2w67,btgh84 in complex with fma34,18,2613.2,5.41,14,16,-1.5,0.67
2w66,btgh84 in complex with hq602,18,2613.2,5.36,14,16,-1.5,0.67
5d6j,crystal structure of a mycobacterial protein,25,2942.8,8.34,19,17,-2.0,0.60
2rkd,the structure of rat cytosolic pepck in complex with 3- phosphonopropionate,12,1781.9,5.43,19,5,3.5,0.58
2rke,the structure of rat cytosolic pepck in complex with sulfoacetate.,12,1694.4,4.77,21,5,4.0,0.58
2xj7,btgh84 in complex with 6-acetamido-6-deoxy-castanospermine,18,2613.2,5.56,14,16,-1.5,0.67
6p5o,the structure of rat cytosolic pepck in complex with 3- (carboxymethylthiol)-picolinic acid,15,2098.7,5.59,23,9,3.5,0.60
4b73,discovery of an allosteric mechanism for the regulation of hcv ns3 protein function,23,3252.9,7.86,16,23,-4.5,0.65
4b76,discovery of an allosteric mechanism for the regulation of hcv ns3 protein function,15,2160.8,5.79,12,15,-2.5,0.67
2x91,crystal structure of ance-lisinopril complex,21,3163.0,5.25,25,25,0.0,0.81
2jkp,structure of a family 97 alpha-glucosidase from bacteroides thetaiotaomicron in complex with castanospermine,15,2523.3,9.98,11,16,-4.0,0.60
4b74,discovery of an allosteric mechanism for the regulation of hcv ns3 protein function,25,3425.7,8.42,16,23,-4.5,0.60
5vsj,sco glgei-v279s in complex with a pyrolidene-based ethyl-phosphonate compound,22,3240.7,3.28,32,24,0.0,0.86
2vvn,btgh84 in complex with nh-butylthiazoline,20,2888.8,7.58,14,16,-1.5,0.60
2xm1,btgh84 in complex with n-acetyl gluconolactam,18,2613.2,5.44,14,16,-1.5,0.67
2xm2,btgh84 in complex with lognac,19,2841.0,7.73,15,16,-1.5,0.63
1x38,crystal structure of barley beta-d-glucan glucohydrolase isoenzyme exo1 in complex with gluco-phenylimidazole,18,2797.8,11.20,20,10,0.5,0.50
2x8z,crystal structure of ance-captopril complex,3,394.9,2.17,4,4,0.0,0.67
2xhm,crystal structure of ance-k26 complex,23,3306.5,6.42,23,23,0.5,0.70
1x39,crystal structure of barley beta-d-glucan glucohydrolase isoenzyme exo1 in complex with gluco-phenylimidazole,19,2936.2,10.81,20,12,-0.5,0.53
2x95,"crystal structure of ance-lisinopril-tryptophan analogue, lisw-s complex",23,3414.2,8.28,25,25,0.0,0.74
2x96,crystal structure of ance-rxpa380 complex,26,3934.6,6.87,32,27,2.5,0.77
1tkb,specificity of coenzyme binding in thiamin diphosphate dependent enzymes: crystal structures of yeast transketolase in complex with analogs of thiamin diphosphate,27,3566.3,12.31,12,22,-3.5,0.48
2x97,crystal structure of ance-rxp407 complex,22,3429.2,10.36,26,21,2.5,0.68
6jtc,crystal structure of dipeptidyl peptidase 11 (dpp11) with sh-5 from porphyromonas gingivalis (space),13,1752.4,3.45,22,13,1.5,0.77
5uv2,crystal structure of (+)-limonene synthase complexed with 2- fluoroneryl diphosphate,18,2690.8,9.89,13,14,-3.0,0.61
4ca8,drosophila angiotensin converting enzyme (ance) in complex with a phosphinic tripeptide fii,28,4235.6,8.76,32,29,1.5,0.75
6md6,crystal structure analysis of plant exohydrolase in complex with methyl 2-thio-beta-sophoroside,7,907.0,2.06,9,8,0.0,0.86
3hig,crystal structure of human diamine oxidase in complex with the inhibitor berenil,15,2284.9,7.71,10,13,-2.0,0.67
4ly9,"human gkrp complexed to amg-1694 [(2r)-1,1,1-trifluoro-2-{4-[(2s)-2- {[(3s)-3-methylmorpholin-4-yl]methyl}-4-(thiophen-2-ylsulfonyl) piperazin-1-yl]phenyl}propan-2-ol] and sorbitol-6-phosphate",29,4020.6,10.47,36,18,4.0,0.59
6ouv,1-deoxy-d-xylulose 5-phosphate synthase (dxps) from deinococcus radiodurans with methylacetylphosphonate (map) bound,30,3925.4,10.52,30,25,2.5,0.57
4ca7,drosophila angiotensin converting enzyme (ance) in complex with a phosphinic tripeptide fi,29,4324.6,8.60,33,30,1.5,0.76
6eq1,structure of the periplasmic binding protein (pbp) melb (atu4661) in complex with stachyose from agrobacterium fabrum c58,10,1244.2,7.13,8,8,0.0,0.40
6eqp,human butyrylcholinesterase in complex with ethopropazine,18,2587.6,14.28,12,11,-0.5,0.44
6ep4,human butyrylcholinesterase in complex with decamethonium,17,2326.4,10.29,8,10,-1.5,0.41
2jke,structure of a family 97 alpha-glucosidase from bacteroides thetaiotaomicron in complex with deoxynojirimycin,15,2523.3,9.91,11,16,-4.0,0.60
5oht,a gh31 family sulfoquinovosidase from e. coli in complex with aza- sugar inhibitor ifgsq,16,2709.1,9.14,22,12,0.5,0.62
2zq0,crystal structure of susb complexed with acarbose,20,3299.8,12.11,15,20,-4.0,0.60
6j72,crystal structure of inia from mycobacterium smegmatis with gtp bound,27,3383.6,8.59,26,20,0.0,0.63
1k1y,crystal structure of thermococcus litoralis 4-alpha-glucanotransferase complexed with acarbose,15,2392.8,6.72,20,19,-3.0,0.80
2x6x,tailspike protein mutant d339n of e.coli bacteriophage hk620 in complex with hexasaccharide,9,1280.6,6.38,8,8,-1.0,0.56
5a6k,"gh20c, beta-hexosaminidase from streptococcus pneumoniae in complex with gal-ngt",14,2406.4,6.72,15,14,-2.5,0.71
3jrx,crystal structure of the bc domain of acc2 in complex with soraphen a,23,3345.2,15.32,21,12,0.0,0.48
3bkk,tesis ace co-crystal structure with ketone ace inhibitor kaf,23,3448.8,11.03,24,22,1.5,0.65
3l3n,testis ace co-crystal structure with novel inhibitor lisw,21,3117.1,9.14,16,23,-2.0,0.67
3drg,lactococcal oppa complexed with bradykinin in the closed conformation,6,735.5,3.18,4,3,0.0,0.50
3i73,structural characterization for the nucleotide binding ability of subunit a with adp of the a1ao atp synthase,21,2613.6,10.28,14,15,-1.0,0.48
3bkl,testis ace co-crystal structure with ketone ace inhibitor kaw,25,3757.4,11.57,27,22,2.5,0.64
2oc2,structure of testis ace with rxpa380,25,3720.1,11.84,20,25,-0.5,0.64
1o86,crystal structure of human angiotensin converting enzyme in complex with lisinopril.,21,3014.7,8.76,16,21,-1.0,0.62
5bwc,acetylcholinesterase (e.c. 3.1.1.7) from torpedo californica in complex with the bis-pyridinium oxime ortho-7,18,2542.9,11.47,9,9,-0.5,0.39
1gpn,structure of acetylcholinesterase complexed with huperzine b at 2.35a resolution,19,2597.7,9.16,10,11,-0.5,0.47
3zv7,torpedo californica acetylcholinesterase inhibition by bisnorcymserine,8,1489.4,8.68,4,5,-1.0,0.50
1h22,"structure of acetylcholinesterase (e.c. 3.1.1.7) complexed with (s,s)- (-)-bis(10)-hupyridone at 2.15a resolution",27,3971.5,13.81,18,13,0.5,0.44
1gpk,structure of acetylcholinesterase complex with (+)-huperzine a at 2.1a resolution,19,2597.7,9.28,10,11,-0.5,0.47
1h23,"structure of acetylcholinesterase (e.c. 3.1.1.7) complexed with (s,s)- (-)-bis(12)-hupyridone at 2.15a resolution",27,3971.5,13.81,18,13,0.5,0.44
1e66,structure of acetylcholinesterase complexed with (-)-huprine x at 2.1a resolution,22,3099.5,11.43,11,13,-1.5,0.45
4ca5,human angiotensin converting enzyme in complex with a phosphinic tripeptide fi,27,4083.7,9.65,26,28,0.5,0.70
1hk4,"human serum albumin complexed with thyroxine (3,3',5,5'-tetraiodo-l- thyronine) and myristic acid (tetradecanoic acid)",15,2128.1,3.88,15,13,-1.0,0.73
5nau,torpedo californica acetylcholinesterase in complex with a non-chiral donepezil-like compound 20,17,2638.4,11.80,9,11,-1.5,0.47
5nap,torpedo californica acetylcholinesterase in complex with a non-chiral donepezil-like inhibitor 17,21,3257.4,12.83,15,12,-0.5,0.48
6ezq,human serum albumin complexed with nbd-c12 fatty acid,20,3121.1,13.91,29,7,5.5,0.50
1os5,crystal structure of hcv ns5b rna polymerase complexed with a novel non-competitive inhibitor.,18,2836.9,12.94,21,6,3.5,0.44
2xyd,human angiotenisn converting enzyme n-domain in complex with phosphinic tripeptide,31,4389.5,6.59,32,33,-0.5,0.77
1oz0,crystal structure of the homodimeric bifunctional transformylase and cyclohydrolase enzyme avian atic in complex with a multisubstrate adduct inhibitor beta-dadf.,34,4449.1,13.97,35,25,1.0,0.53
2b1i,crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase,28,3486.7,9.16,22,12,2.0,0.50
1thz,crystal structure of avian aicar transformylase in complex with a novel inhibitor identified by virtual ligand screening,15,2236.5,13.88,16,7,2.0,0.47
5m77,a gh76 family enzyme structure,15,2185.5,7.28,14,17,-4.0,0.73
2epn,n-acetyl-b-d-glucosaminidase (gcna) from streptococcus gordonii,14,2401.4,6.40,14,15,-3.5,0.71
4ca6,human angiotensin converting enzyme n-domain in complex with a phosphinic tripeptide fi,28,4102.0,6.74,31,30,0.5,0.79
2rk8,the structure of rat cytosolic pepck in complex with phosphonoformate,14,2042.0,6.92,22,8,3.5,0.64
2rka,the structure of rat cytosolic pepck in complex with phosphoglycolate,11,1588.3,5.48,18,4,3.5,0.55
3arq,crystal structure analysis of chitinase a from vibrio harveyi with novel inhibitors - complex structure with idarubicin,14,2188.8,7.31,13,9,-1.0,0.57
3mof,the structure of rat cytosolic pepck mutant a467g in complex with oxalate and gtp,29,3924.4,16.14,27,14,2.5,0.48
3arw,crystal structure analysis of chitinase a from vibrio harveyi with novel inhibitors - complex structure with chelerythrine,8,1223.6,7.30,9,6,-1.0,0.62
3nxq,angiotensin converting enzyme n domain glycsoylation mutant (ndom389) in complex with rxp407,23,3578.7,8.54,32,22,3.5,0.74
3arp,crystal structure analysis of chitinase a from vibrio harveyi with novel inhibitors - complex structure with dequalinium,13,2224.0,16.57,18,6,1.5,0.46
3arx,crystal structure analysis of chitinase a from vibrio harveyi with novel inhibitors - complex structure with propentofylline,13,2047.0,10.92,12,6,0.0,0.46
1j36,crystal structure of drosophila ance,21,3170.1,6.58,28,21,2.0,0.76
1j37,crystal structure of drosophila ance,14,2146.6,4.56,16,17,1.0,0.79
5dqf,horse serum albumin (esa) in complex with cetirizine,14,1932.2,11.31,6,4,0.0,0.29
3fql,hepatitis c virus polymerase ns5b (con1 1-570) with hcv-796 inhibitor,24,3436.3,14.72,13,10,0.0,0.46
3o5x,crystal structure of the oncogenic tyrosine phosphatase shp2 complexed with a salicylic acid-based small molecule inhibitor,21,2989.6,3.34,35,15,4.5,0.81
6euc,reactivating oxime bound to tc ache's catalytic gorge.,13,1939.2,7.76,7,8,-0.5,0.46
3vtr,crystal structure of insect beta-n-acetyl-d-hexosaminidase ofhex1 e328a complexed with tmg-chitotriomycin,2,396.4,2.80,4,0,1.0,0.50
3d2e,"crystal structure of a complex of sse1p and hsp70, selenomethionine- labeled crystals",26,3147.3,3.75,33,22,1.5,0.69
4jne,allosteric opening of the polypeptide-binding site when an hsp70 binds atp,29,3372.7,7.74,18,23,-5.0,0.55
3k1j,crystal structure of lon protease from thermococcus onnurineus na1,22,3015.6,9.29,21,14,0.0,0.50
3s6t,crystal structure of insect beta-n-acetyl-d-hexosaminidase ofhex1 v327g complexed with pugnac,14,2261.1,8.14,12,15,-4.5,0.71
6f90,structure of the family gh92 alpha-mannosidase bt3130 from bacteroides thetaiotaomicron in complex with mannoimidazole (mani),16,2149.9,7.57,11,16,-4.0,0.62
3ozp,crystal structure of insect beta-n-acetyl-d-hexosaminidase ofhex1 complexed with pugnac,16,2539.5,9.31,12,17,-5.5,0.69
3wmc,crystal structure of insect beta-n-acetyl-d-hexosaminidase ofhex1 complexed with naphthalimide derivative q2,11,1979.5,10.58,8,10,-2.5,0.55
2cbj,"structure of the clostridium perfringens nagj family 84 glycoside hydrolase, a homologue of human o-glcnacase in complex with pugnac",25,3751.3,14.07,17,17,-2.0,0.52
2j62,structure of a bacterial o-glcnacase in complex with glcnacstatin,25,3751.3,14.02,17,17,-2.0,0.52
4y2q,structure of soluble epoxide hydrolase in complex with 1-[3- (trifluoromethyl)pyridin-2-yl]piperazine,13,2174.8,14.26,5,6,-0.5,0.31
2x0y,screening-based discovery of drug-like o-glcnacase inhibitor scaffolds,19,2941.8,10.65,14,13,-1.0,0.53
2wvz,structure of the family gh92 inverting mannosidase bt3990 from bacteroides thetaiotaomicron vpi-5482,15,2231.7,8.30,10,17,-4.5,0.67
2wb5,glcnacstatins are nanomolar inhibitors of human o-glcnacase inducing cellular hyper-o-glcnacylation,25,3751.3,13.79,17,17,-2.0,0.52
3k4d,crystal structure of e. coli beta-glucuronidase with the glucaro-d- lactam inhibitor bound,13,2030.3,3.35,19,16,-0.5,0.85
6f9u,crystal structure of human testis angiotensin-1 converting enzyme in complex with sampatrilat-asp.,28,4286.2,14.44,28,24,1.5,0.61
5z66,structure of periplasmic trehalase from diamondback moth gut bacteria complexed with validoxylamine,25,4009.3,11.04,30,20,-2.0,0.60
2xpk,"cell-penetrant, nanomolar o-glcnacase inhibitors selective against lysosomal hexosaminidases",27,4110.5,15.62,18,17,-2.0,0.52
5wqc,crystal structure of human orexin 2 receptor bound to the selective antagonist empa determined by the synchrotron light source at spring- 8.,23,3419.8,11.65,18,19,0.0,0.61
4ih7,hepatitis c virus polymerase ns5b (bk) with fragment-based compounds,16,2138.2,6.64,15,10,1.0,0.56
4ih6,hepatitis c virus polymerase ns5b (bk) with fragment-based compounds,16,2012.2,4.27,15,10,1.0,0.62
6i5g,x-ray structure of human soluble epoxide hydrolase c-terminal domain (hseh ctd)in complex with 15d-pgj2,19,2911.4,15.61,10,8,0.5,0.37
3ppm,crystal structure of a noncovalently bound alpha-ketoheterocycle inhibitor (phenhexyl/oxadiazole/pyridine) to a humanized variant of fatty acid amide hydrolase,26,3626.3,17.04,13,9,1.0,0.46
5o9o,crystal structure of scgas2 in complex with compound 7.,23,3226.7,5.68,19,28,-6.0,0.78
3mf5,hepatitis c virus polymerase ns5b (bk) with amide bioisostere thumb site inhibitor,14,2235.4,12.68,15,4,2.5,0.36
5o9p,crystal structure of gas2 in complex with compound 10,22,3115.6,6.05,19,26,-5.0,0.77
4dmw,crystal structure of the gt domain of clostridium difficile toxin a (tcda) in complex with udp and manganese,17,2487.8,11.77,14,13,-2.0,0.53
2oag,crystal structure of human dipeptidyl peptidase iv (dppiv) with pyrrolidine-constrained phenethylamine 29g,20,3070.6,10.00,21,16,-0.5,0.65
4ih5,hepatitis c virus polymerase ns5b (bk) with fragment-based compounds,14,1859.3,4.58,14,9,1.0,0.57
3gbe,crystal structure of the isomaltulose synthase smua from protaminobacter rubrum in complex with the inhibitor deoxynojirimycin,8,1122.2,2.60,17,4,3.5,0.62
5o9y,crystal structure of scgas2 in complex with compound 11,23,3226.7,5.70,19,28,-6.0,0.78
1atr,threonine 204 of the chaperone protein hsc70 influences the structure of the active site but is not essential for atp hydrolysis,22,2410.7,1.58,20,15,-1.0,0.64
5o9q,crystal structure of scgas2 in complex with compound 6,22,3082.9,5.70,17,26,-6.0,0.77
6f92,structure of the family gh92 alpha-mannosidase bt3965 from bacteroides thetaiotaomicron in complex with mannoimidazole (mani),15,2113.9,7.69,9,14,-4.0,0.60
4xas,mglur2 ecd ligand complex,18,2262.5,0.70,27,15,1.0,0.89
2d3u,x-ray crystal structure of hepatitis c virus rna dependent rna polymerase in complex with non-nucleoside analogue inhibitor,14,2235.4,12.80,15,4,2.5,0.36
5oa6,crystal structure of scgas2 in complex with compound 12,24,3340.8,5.62,21,30,-6.0,0.79
1a1e,c-src (sh2 domain) complexed with ace-phosphotyr-glu-(3- butylpiperidine),8,952.7,3.04,2,6,-2.0,0.62
3hky,"hcv ns5b polymerase genotype 1b in complex with 1,5 benzodiazepine 6",21,2689.7,6.80,23,15,1.0,0.67
5o9r,crystal structure of scgas2 in complex with compound 9,22,3088.3,5.70,19,26,-5.0,0.77
2d3z,x-ray crystal structure of hepatitis c virus rna-dependent rna polymerase in complex with non-nucleoside analogue inhibitor,15,2351.5,12.36,16,5,2.5,0.40
5kby,crystal structure of dipeptidyl peptidase iv in complex with syr-472,16,2566.5,9.23,16,13,-0.5,0.62
4m0f,structure of human acetylcholinesterase in complex with territrem b,23,3276.9,8.78,17,14,-0.5,0.52
4ybk,c-helix-out dasatinib analog crystallized with c-src kinase,29,3998.7,19.86,10,10,-1.0,0.31
3ies,firefly luciferase inhibitor complex,29,3551.3,11.28,26,15,1.5,0.48
4xaq,mglur2 ecd and mglur3 ecd with ligands,16,2084.7,0.69,25,13,1.0,0.88
3ldq,crystal structure of hsc70/bag1 in complex with small molecule inhibitor,14,1599.5,1.59,15,10,-1.0,0.64
3m3z,crystal structure of hsc70/bag1 in complex with small molecule inhibitor,16,1909.2,1.64,17,12,-1.0,0.69
3gnw,"hcv ns5b polymerase in complex with 1,5 benzodiazepine inhibitor 4c",22,2841.0,6.47,29,14,3.0,0.68
1q84,crystal structure of the mouse acetylcholinesterase-tz2pa6 anti complex,30,4549.8,12.84,24,22,-1.0,0.57
2ha6,crystal structure of mutant s203a of mouse acetylcholinesterase complexed with succinylcholine,15,2281.4,10.07,8,10,-1.5,0.47
1n5r,crystal structure of the mouse acetylcholinesterase-propidium complex,11,1670.9,3.35,9,12,-1.5,0.73
3d7k,crystal structure of benzaldehyde lyase in complex with the inhibitor mbp,32,3734.5,8.79,19,22,-1.0,0.47
2ha3,crystal structure of mouse acetylcholinesterase complexed with choline,16,2385.3,13.22,10,9,1.0,0.31
2ha2,crystal structure of mouse acetylcholinesterase complexed with succinylcholine,16,2475.4,8.84,10,12,-1.5,0.56
1ai4,"penicillin acylase complexed with 3,4-dihydroxyphenylacetic acid",15,2210.3,15.81,8,7,0.0,0.33
1ajn,penicillin acylase complexed with p-nitrophenylacetic acid,15,2210.3,15.81,8,7,0.0,0.33
5ehq,mache-anti tz2pa5 complex,30,4495.8,12.85,24,22,-1.0,0.57
4m0e,structure of human acetylcholinesterase in complex with dihydrotanshinone i,12,2085.4,6.82,11,7,0.0,0.58
1ajp,"penicillin acylase complexed with 2,5-dihydroxyphenylacetic acid",13,1842.5,13.62,7,7,0.0,0.38
3cj2,crystal structure of hepatitis c virus rna-dependent rna polymerase ns5b in complex with optimized small molecule fragments,12,2040.6,8.36,20,4,3.5,0.50
3cj4,crystal structure of hepatitis c virus rna-dependent rna polymerase ns5b in complex with optimized small molecule fragments,13,2129.6,8.38,21,5,3.5,0.54
1ajq,penicillin acylase complexed with thiopheneacetic acid,14,1982.5,13.21,7,7,0.0,0.36
4bqh,crystal structure of the uridine diphosphate n-acetylglucosamine pyrophosphorylase from trypanosoma brucei in complex with inhibitor,21,2449.0,10.67,8,9,-0.5,0.33
1ai5,penicillin acylase complexed with m-nitrophenylacetic acid,14,1982.5,14.10,7,7,0.0,0.36
2wly,chitinase a from serratia marcescens atcc990 in complex with chitotrio-thiazoline.,13,2066.6,13.09,14,5,0.0,0.38
2wm0,chitinase a from serratia marcescens atcc990 in complex with chitobio- thiazoline thioamide.,10,1531.0,9.93,6,6,-1.0,0.50
3t1a,crystal structure of hiv-1 reverse transcriptase (k103n mutant) in complex with inhibitor m05,20,3063.2,14.35,17,7,3.5,0.40
1pfu,methionyl-trna synthetase from escherichia coli complexed with methionine phosphinate,10,1148.9,2.16,7,1,2.0,0.70
1ai7,penicillin acylase complexed with phenol,13,1906.3,13.49,6,5,0.0,0.31
1nhu,hepatitis c virus rna polymerase in complex with non-nucleoside analogue inhibitor,12,2013.5,8.81,20,4,3.5,0.50
3cj5,crystal structure of hepatitis c virus rna-dependent rna polymerase ns5b in complex with optimized small molecule fragments,14,2298.2,8.12,24,5,4.5,0.57
4ara,mus musculus acetylcholinesterase in complex with (r)-c5685 at 2.5 a resolution.,16,2549.1,10.14,13,8,0.0,0.50
3iae,structure of benzaldehyde lyase a28s mutant with benzoylphosphonate,35,4292.3,13.64,21,23,-1.0,0.46
2whp,"crystal structure of acetylcholinesterase, phosphonylated by sarin and in complex with hi-6",13,2060.6,6.30,11,9,-1.0,0.69
5z5f,"crystal structure of a thermostable glycoside hydrolase family 43 {beta}-1,4-xylosidase from geobacillus thermoleovorans it-08 in complex with l-arabinose",16,2225.0,8.29,13,14,-0.5,0.56
2wlz,chitinase a from serratia marcescens atcc990 in complex with chitobio- thiazoline.,13,2071.9,8.98,10,9,-2.0,0.54
6nu5,pyruvate kinase m2 mutant - s437y in complex with l-cysteine,12,1578.6,3.38,10,12,-2.0,0.75
4arb,mus musculus acetylcholinesterase in complex with (s)-c5685 at 2.25 a resolution.,14,2493.1,9.84,14,9,0.5,0.57
4eo8,hcv ns5b polymerase inhibitors: tri-substituted acylhydrazines as tertiary amide bioisosteres,14,2230.6,13.51,13,4,2.5,0.36
4eo6,hcv ns5b polymerase inhibitors: tri-substituted acylhydrazines as tertiary amide bioisosteres,14,2235.4,12.86,15,4,2.5,0.36
4o2p,kinase domain of csrc in complex with a substituted pyrazolopyrimidine,22,3112.4,15.33,10,9,-1.0,0.36
2jf4,family 37 trehalase from escherichia coli in complex with validoxylamine,25,4009.3,11.08,30,20,-2.0,0.60
3lpp,crystal complex of n-terminal sucrase-isomaltase with kotalanol,21,3326.5,14.38,18,16,-2.5,0.52
2oiq,crystal structure of chicken c-src kinase domain in complex with the cancer drug imatinib.,28,4068.6,19.06,14,12,-0.5,0.36
3f6e,crystal structure of benzoylformate decarboxylase in complex with the pyridyl inhibitor 3-pkb,11,1263.7,6.03,7,9,-0.5,0.45
4l9i,bovine g protein coupled receptor kinase 1 in complex with paroxetine,20,2666.4,13.19,10,8,-1.0,0.35
1wcq,mutagenesis of the nucleophilic tyrosine in a bacterial sialidase to phenylalanine.,17,2575.9,12.27,21,9,0.0,0.53
2jg0,family 37 trehalase from escherichia coli in complex with 1- thiatrehazolin,25,4009.3,10.87,30,20,-2.0,0.60
2xg9,crystal structure of barley beta-amylase complexed with 4-o-alpha-d- glucopyranosylmoranoline,11,1522.5,6.30,11,7,0.0,0.55
4u54,importin-alpha minor nls site inhibitor,7,999.8,5.97,7,7,-1.0,0.57
4u5s,importin-alpha minor nls site inhibitor,20,2402.1,7.72,16,17,-2.0,0.60
4u5n,importin-alpha minor nls site inhibitor,19,2418.3,6.26,15,18,-3.0,0.63
4u5o,importin-alpha minor nls site inhibitor,14,1719.4,6.43,10,12,-2.0,0.57
1u0g,crystal structure of mouse phosphoglucose isomerase in complex with erythrose 4-phosphate,19,2326.4,6.04,20,11,2.5,0.58
5ehr,non-receptor protein tyrosine phosphatase shp2 in complex with allosteric inhibitor shp099,18,2664.2,4.25,20,19,-1.5,0.78
5w1e,pobr in complex with phb,17,2294.6,11.23,16,8,1.0,0.47
4b1j,structure of human parg catalytic domain in complex with adp-hpd,27,3435.6,11.71,11,16,-3.0,0.41
1g98,"crystal structure analysis of rabbit phosphoglucose isomerase complexed with 5-phosphoarabinonate, a transition state analogue",21,2608.6,5.31,22,15,1.5,0.62
3hww,crystal structure of menaquinone synthesis protein mend from e. coli in complex with oxoglutarate,12,1451.0,6.40,11,8,0.0,0.50
1koj,crystal structure of rabbit phosphoglucose isomerase complexed with 5- phospho-d-arabinonohydroxamic acid,21,2530.3,5.57,22,13,2.5,0.57
3aho,pz peptidase a with inhibitor 2,24,3731.7,7.20,25,23,0.5,0.79
2wzf,legionella pneumophila glucosyltransferase crystal structure,20,2769.2,11.42,15,14,-2.0,0.50
4qge,phosphodiesterase-9a in complex with inhibitor wyq-c36d,14,2190.9,12.85,9,11,0.0,0.43
3o84,"structure of base n-terminal domain from acinetobacter baumannii bound to 6-phenyl-1-(pyridin-4-ylmethyl)-1h-pyrazolo[3,4-b]pyridine-4- carboxylic acid.",16,1955.9,13.61,5,5,0.5,0.19
3ahn,pz peptidase a with inhibitor 1,28,4162.0,9.61,27,27,-0.5,0.75
3sur,crystal structure of beta-hexosaminidase from paenibacillus sp. ts12 in complex with nag-thiazoline.,16,2622.2,11.71,12,15,-4.5,0.56
6cfc,crystal structure of soluble lytic transglycosylase cj0843 of campylobacter jejuni in complex with bulgecin a,20,2729.5,11.75,10,14,-1.5,0.45
3f48,crystal structure of leut bound to l-alanine and sodium,7,1119.8,7.62,6,1,1.0,0.29
3f3c,crystal structure of leut bound to 4-fluoro-l-phenylalanine and sodium,7,1119.8,7.72,6,1,1.0,0.29
6eq8,structure of the periplasmic binding protein (pbp) melb (atu4661) in complex with galactinol from agrobacterium fabrum c58,17,2520.5,6.65,20,15,-2.0,0.65
3suv,crystal structure of beta-hexosaminidase from paenibacillus sp. ts12 in complex with nhac-dnj,15,2464.3,11.03,13,14,-3.5,0.60
3sut,crystal structure of beta-hexosaminidase from paenibacillus sp. ts12 in complex with pugnac,16,2622.2,11.73,12,15,-4.5,0.56
3sus,crystal structure of beta-hexosaminidase from paenibacillus sp. ts12 in complex with gal-nag-thiazoline,15,2511.1,12.03,12,13,-3.5,0.53
6epy,structure of the pbp melb (atu4661) in complex with raffinose from a.fabrum c58,10,1676.9,10.13,17,4,2.0,0.50
3f3d,crystal structure of leut bound to l-methionine and sodium,8,1259.8,8.93,6,1,1.0,0.25
2pwg,crystal structure of the trehalulose synthase mutb from pseudomonas mesoacidophila mx-45 complexed to the inhibitor castanospermine,16,2478.0,8.68,18,16,-1.0,0.69
3suw,crystal structure of beta-hexosaminidase from paenibacillus sp. ts12 in complex with nhac-cas,14,2324.3,9.59,13,14,-3.5,0.64
2b1g,crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase,23,2891.0,8.38,19,10,2.0,0.52
6epz,structure of the periplasmic binding protein melb (atu4661) in complex with melibiose from agrobacterium fabrum c58,10,1618.3,8.46,13,7,0.0,0.60
2pwd,crystal structure of the trehalulose synthase mutb from pseudomonas mesoacidophila mx-45 complexed to the inhibitor deoxynojirmycin,15,2271.6,4.79,23,16,0.0,0.80
3zq9,structure of a paenibacillus polymyxa xyloglucanase from glycoside hydrolase family 44,11,1590.9,4.19,13,13,-1.5,0.73
3suu,crystal structure of beta-hexosaminidase from paenibacillus sp. ts12 in complex with gal-pugnac,15,2511.1,12.03,12,13,-3.5,0.53
3f3e,crystal structure of leut bound to l-leucine (30 mm) and sodium,7,1119.8,7.68,6,1,1.0,0.29
5ohy,a gh31 family sulfoquinovosidase in complex with aza-sugar inhibitor ifgsq,17,2819.0,10.22,20,12,-0.5,0.59
3o9p,the structure of the escherichia coli murein tripeptide binding protein mppa,26,3687.7,13.10,26,15,1.5,0.50
1b46,oligo-peptide binding protein (oppa) complexed with kpk,5,700.1,1.81,6,5,0.0,0.80
4xar,mglur2 ecd and mglur3 ecd complex with ligands,15,1946.3,0.69,25,11,2.0,0.87
1b2h,oligo-peptide binding protein complexed with lysyl-ornithyl-lysine,9,1346.5,3.41,17,8,2.5,0.78
1b52,oligo-peptide binding protein (oppa) complexed with ktk,4,580.7,2.28,3,4,-1.0,0.75
3zj6,crystal of raucaffricine glucosidase in complex with inhibitor,19,3108.7,11.50,25,21,-1.0,0.68
2aj8,"porcine dipeptidyl peptidase iv (cd26) in complex with 7-benzyl-1,3- dimethyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione (bdpx)",16,2566.5,9.18,16,13,-0.5,0.62
2olb,oligopeptide binding protein (oppa) complexed with tri-lysine,8,1257.5,3.96,16,7,2.5,0.75
1b7h,oligo-peptide binding protein complexed with lysyl-norleucyl-lysine,4,580.7,2.23,3,4,-1.0,0.75
6f9v,crystal structure of human angiotensin-1 converting enzyme n-domain in complex with sampatrilat.,35,5075.0,9.02,41,34,1.5,0.74
4qfo,crystal structure of dipeptide binding protein from pseudoalteromonas sp. sm9913 in complex with met-leu,13,1871.1,8.56,11,8,0.5,0.46
1pkx,crystal structure of human atic in complex with xmp,27,3346.7,8.87,22,12,2.0,0.52
4qfp,crystal structure of dipeptide binding protein from pseudoalteromonas sp. sm9913 in complex with val-thr,12,1782.5,7.68,11,8,0.5,0.50
4qfl,crystal structure of dipeptide binding protein from pseudoalteromonas sp. sm9913 in complex with ala-phe,13,1649.9,6.48,9,11,-0.5,0.54
1b32,oligo-peptide binding protein (oppa) complexed with kmk,2,280.8,2.62,2,2,0.0,0.50
6h5x,crystal structure of human angiotensin-1 converting enzyme n-domain in complex with omapatrilat.,25,3602.6,7.68,31,20,2.0,0.60
5wl0,co-crystal structure of influenza a h3n2 pb2 (241-741) bound to vx-787,20,2910.6,9.16,25,16,2.0,0.60
3t2q,e. coli (lacz) beta-galactosidase (s796d) in complex with galactonolactone,15,2330.2,6.64,15,21,-2.5,0.73
1hp5,streptomyces plicatus beta-n-acetylhexosaminidase complexed with intermediate analouge nag-thiazoline,16,2622.2,11.55,12,15,-4.5,0.56
4pfu,"crystal structure of mannobiose bound oligopeptide abc transporter, periplasmic oligopeptide-binding protein (tm1226) from thermotoga maritima at 2.05 a resolution",11,1686.8,10.27,11,7,0.0,0.45
5oa2,crystal structure of scgas2 in complex with compound 8,21,2947.5,6.01,19,24,-4.0,0.76
1jak,"streptomyces plicatus beta-n-acetylhexosaminidase in complex with (2r, 3r,4s,5r)-2-acetamido-3,4-dihydroxy-5-hydroxymethyl-piperidinium chloride (ifg)",16,2664.3,11.56,14,15,-3.0,0.56
3hkw,"hcv ns5b genotype 1a in complex with 1,5 benzodiazepine inhibitor 6",21,2737.3,8.00,23,10,2.0,0.62
3buf,bace-1 complexed with compound 2,11,1730.1,8.75,6,4,0.0,0.36
5yh8,the crystal structure of staphylococcus aureus cnta in complex with staphylopine and nickel,16,2516.4,4.77,27,12,2.0,0.69
3bug,bace-1 complexed with compound 3,13,1804.2,7.12,8,6,0.0,0.38
5yhg,the crystal structure of staphylococcus aureus cnta in complex with staphylopine and zinc,15,2456.3,4.72,27,12,2.0,0.73
3bra,bace-1 complexed with compound 1,12,1790.2,8.80,6,4,0.0,0.33
3t08,e. coli (lacz) beta-galactosidase (s796a) iptg complex,15,2318.6,9.81,13,17,-2.0,0.60
4pft,"crystal structure of mannobiose bound oligopeptide abc transporter, periplasmic oligopeptide-binding protein (tm1223) from thermotoga maritima at 1.75 a resolution",15,2442.6,16.47,16,10,0.0,0.33
4re2,different transition state conformations for the hydrolysis of beta- mannosides and beta-glucosides in the rice os7bglu26 family gh1 beta- mannosidase/beta-glucosidase,12,2084.7,6.59,16,8,0.5,0.67
3buh,bace-1 complexed with compound 4,16,2170.3,7.78,9,7,0.0,0.38
3udh,crystal structure of bace with compound 1,14,1864.7,6.05,9,9,-1.0,0.50
4re4,different transition state conformations for the hydrolysis of beta- mannosides and beta-glucosides in the rice os7bglu26 family gh1 beta- mannosidase/beta-glucosidase,12,2022.4,7.55,11,10,-1.5,0.67
3rsx,structure of bace-1 (beta-secretase) in complex with 6-(thiophen-3- yl)quinolin-2-amine,16,2086.6,7.20,10,9,-1.0,0.50
6nu1,crystal structure of human pkm2 in complex with l-cysteine,20,2558.0,7.58,26,6,4.0,0.50
3ru1,structure of bace-1 (beta-secretase) in complex with 3-(2- aminoquinolin-3-yl)-n-(cyclohexylmethyl)propanamide,17,2367.6,10.64,11,9,-1.0,0.47
3ckb,b. thetaiotaomicron susd with maltotriose,10,1413.7,4.80,11,10,-2.0,0.70
6gg4,crystal structure of m2 pyk in complex with phenyalanine.,10,1127.7,3.22,12,4,2.0,0.60
6ej3,bace1 compound 23,21,2783.3,9.83,16,13,-1.0,0.48
5ie1,"crystal structure of bace1 in complex with 3-(2-amino-6-(o-tolyl) quinolin-3-yl)-n-(3,3-dimethylbutyl)propanamide",19,2674.3,9.37,16,10,0.0,0.53
3i3b,e.coli (lacz) beta-galactosidase (m542a) in complex with d- galactopyranosyl-1-on,15,2330.2,6.62,15,21,-2.5,0.73
4fm8,crystal structure of bace with compound 12a,23,3036.7,6.75,22,16,0.0,0.61
3vd4,e. coli (lacz) beta-galactosidase (n460d) in complex with iptg,14,2204.5,9.91,11,15,-2.0,0.57
3mv0,e. coli (lacz) beta-galactosidase (r599a) in complex with d- galctopyranosyl-1-one,15,2330.2,6.56,15,21,-2.5,0.73
3t0b,e. coli (lacz) beta-galactosidase (s796t) iptg complex,14,2204.5,9.90,11,15,-2.0,0.57
4fm7,crystal structure of bace with compound 14g,23,3110.5,7.32,21,15,0.0,0.57
3dyo,e. coli (lacz) beta-galactosidase (h418n) in complex with iptg,15,2279.5,9.87,13,17,-2.5,0.60
1px4,e. coli (lacz) beta-galactosidase (g794a) with iptg bound,15,2398.1,9.55,12,16,-2.0,0.60
4mme,crystal structure of leubat (delta6 mutant) in complex with mazindol,20,2529.6,11.21,6,10,-2.0,0.40
5i3x,crystal structure of bace1 in complex with aminoquinoline inhibitor 6,29,3905.9,14.70,21,14,0.0,0.45
5i3v,crystal structure of bace1 in complex with aminoquinoline compound 1,24,3360.3,10.24,24,13,1.0,0.54
3vdb,e. coli (lacz) beta-galactosidase (n460t) in complex with galactonolactone,15,2332.2,6.75,14,20,-2.5,0.73
6ej2,bace1 compound 28,21,2807.0,10.61,15,12,-1.0,0.43
3muz,e.coli (lacz) beta-galactosidase (r599a) in complex with iptg,14,2204.5,9.94,11,15,-2.0,0.57
1e6q,myrosinase from sinapis alba with the bound transition state analogue gluco-tetrazole,7,697.1,1.75,6,6,0.0,0.71
3m8u,crystal structure of glutathione-binding protein a (gbpa) from haemophilus parasuis sh0165 in complex with glutathione disulfide (gssg),39,5361.0,18.24,34,28,-1.0,0.51
3t0d,e.coli (lacz) beta-galactosidase (s796t) in complex with galactonolactone,15,2330.2,6.61,15,21,-2.5,0.73
3vd9,e. coli (lacz) beta-galactosidase (n460s) in complex with iptg,15,2357.7,9.69,13,17,-1.5,0.60
1e6s,myrosinase from sinapis alba with bound gluco-hydroximolactam and sulfate,7,697.1,1.74,6,6,0.0,0.71
5i3y,crystal structure of bace1 in complex with aminoquinoline inhibitor 9,32,4411.3,13.83,27,17,0.0,0.50
5i3w,crystal structure of bace1 in complex with 2-aminooxazoline-3- azaxanthene inhibitor 2,25,3455.5,12.54,18,15,-1.0,0.48
1b3l,oligo-peptide binding protein (oppa) complexed with kgk,4,580.7,2.27,3,4,-1.0,0.75
3t09,e. coli (lacz) beta-galactosidase (s796a) galactonolactone complex,15,2330.2,6.55,15,21,-2.5,0.73
1w96,crystal structure of biotin carboxylase domain of acetyl-coenzyme a carboxylase from saccharomyces cerevisiae in complex with soraphen a,25,3535.7,15.84,21,13,1.0,0.44
4gqq,human pancreatic alpha-amylase with bound ethyl caffeate,12,1595.7,4.82,8,8,-1.0,0.58
1ppi,the active center of a mammalian alpha-amylase. the structure of the complex of a pancreatic alpha-amylase with a carbohydrate inhibitor refined to 2.2 angstroms resolution,18,2719.2,8.60,19,16,1.0,0.61
4zei,pbp acca from a. tumefaciens c58 in complex with l-arabinose-2- phosphate,15,2200.3,7.02,13,15,-2.0,0.67
1u33,in situ extension as an approach for identifying novel alpha-amylase inhibitors,22,3183.2,10.52,19,20,-1.0,0.55
4zek,pbp acca from a. tumefaciens c58 in complex with l-arabinose-2- isopropylphosphate,17,2479.3,9.29,14,16,-2.0,0.65
1xd0,acarbose rearrangement mechanism implied by the kinetic and structural analysis of human pancreatic alpha-amylase in complex with analogues and their elongated counterparts,28,3920.7,8.89,27,27,-1.0,0.61
4zec,pbp acca from a. tumefaciens c58 in complex with agrocin 84,25,3894.2,11.33,31,23,-1.0,0.68
4ra1,pbp acca from a. tumefaciens c58 in complex with d-glucose-2-phosphate,17,2544.2,8.64,15,16,-2.0,0.65
5fcz,streptomyces plicatus n-acetyl-beta-hexosaminidase in complex with thio-naglucal (tnx),19,3030.3,10.77,16,21,-5.0,0.63
3old,crystal structure of alpha-amylase in complex with acarviostatin i03,8,999.1,2.79,10,8,-1.0,0.62
4gqr,human pancreatic alpha-amylase in complex with myricetin,11,1646.0,7.38,7,10,-1.5,0.55
5jox,bacteroides ovatus xyloglucan pul gh43a in complex with aradnj,14,1890.1,7.63,9,10,-1.5,0.50
6i11,crystal structure of fascin in complex with compound 3,16,2578.7,17.56,13,4,1.0,0.25
6i18,crystal structure of fascin in complex with bdp-13176,18,2779.2,19.80,12,3,1.0,0.22
3l59,structure of bace bound to sch710413,13,1852.5,8.73,5,8,-2.0,0.46
4phu,crystal structure of human gpr40 bound to allosteric agonist tak-875,22,3179.6,16.27,15,6,1.0,0.27
5yhe,the crystal structure of staphylococcus aureus cnta in complex with staphylopine and cobalt,16,2541.2,4.94,28,10,3.0,0.69
6i13,crystal structure of fascin in complex with compound 7,14,2210.5,16.64,7,3,0.0,0.21
5oxk,peptst in complex with dipeptide ala-gln,9,1239.7,11.19,1,1,0.0,0.11
6ghj,peptst in complex with tripeptide phe-ala-gln,9,1239.7,11.28,1,1,0.0,0.11
6i12,crystal structure of fascin in complex with compound 5,15,2461.6,18.03,11,2,1.0,0.20
6i14,crystal structure of fascin in complex with compound 9,16,2550.6,17.37,12,3,1.0,0.25
1ogg,chitinase b from serratia marcescens mutant d142n in complex with inhibitor allosamidin,17,2631.5,9.37,14,13,-2.0,0.59
3kmy,structure of bace bound to sch12472,15,1977.7,5.48,12,11,-1.0,0.60
3kmx,structure of bace bound to sch346572,20,2500.5,6.96,13,13,-1.0,0.50
4h3j,"structure of bace bound to 2-fluoro-5-(5-(2-imino-3-methyl-4-oxo-6- phenyloctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-2-yl) benzonitrile",24,3105.3,12.63,19,16,-1.0,0.50
5upe,crystal structure of human nampt with isoindoline urea inhibitor compound 5,22,3014.8,10.36,23,12,1.5,0.50
4dju,"structure of bace bound to 2-imino-3-methyl-5,5-diphenylimidazolidin- 4-one",14,2028.6,9.29,8,7,-1.0,0.43
1y3p,"structure of algq1, alginate-binding protein, complexed with an alginate tetrasaccharide",9,1282.1,2.83,16,11,-1.0,0.89
5upf,crystal structure of human nampt with isoindoline urea inhibitor compound 53,24,3343.1,9.99,26,14,1.5,0.54
2v3d,acid-beta-glucosidase with n-butyl-deoxynojirimycin,18,2748.4,9.54,13,17,-2.5,0.67
6i17,crystal structure of fascin in complex with compound 24,19,2843.9,19.09,13,4,1.0,0.26
2gvj,crystal structure of human nmprtase in complex with fk866,24,3367.2,9.74,26,14,1.5,0.54
4djv,"structure of bace bound to 2-imino-5-(3'-methoxy-[1,1'-biphenyl]-3- yl)-3-methyl-5-phenylimidazolidin-4-one",23,3035.6,11.24,14,13,-1.0,0.48
4ha5,"structure of bace bound to (s)-3-(5-(2-imino-1,4-dimethyl-6- oxohexahydropyrimidin-4-yl)thiophen-3-yl)benzonitrile",18,2217.0,8.13,9,12,-2.0,0.50
3sfg,crystal structure of murine norovirus rna dependent rna polymerase in complex with 2thiouridine(2tu),13,1750.2,8.18,7,12,-3.0,0.62
1ur9,"interactions of a family 18 chitinase with the designed inhibitor hm508, and its degradation product, chitobiono-delta-lactone",15,2431.4,9.80,13,10,-1.0,0.53
2f2h,structure of the yici thiosugar michaelis complex,24,3754.5,12.05,30,17,-0.5,0.67
4fs4,"structure of bace bound to (s)-4-(3'-methoxy-[1,1'-biphenyl]-3-yl)-1, 4-dimethyl-6-oxotetrahydropyrimidin-2(1h)-iminium",21,2667.8,8.28,13,13,-1.0,0.52
6hlx,structure of the pbp agaa in complex with agropinic acid from a.tumefacien r10,27,3819.2,10.01,33,19,2.0,0.59
4djw,structure of bace bound to 2-imino-3-methyl-5-phenyl-5-(3-(pyridin-3- yl)phenyl)imidazolidin-4-one,20,2584.8,10.37,10,12,-2.0,0.45
1y3n,"structure of algq1, alginate-binding protein, complexed with an alginate disaccharide",11,1759.0,2.10,27,10,2.0,0.91
4djx,structure of bace bound to 5-(3-(5-chloropyridin-3-yl)phenyl)-5- cyclopropyl-2-imino-3-methylimidazolidin-4-one,20,2449.4,8.59,11,14,-2.0,0.50
1fkn,structure of beta-secretase complexed with inhibitor,20,2706.2,11.18,10,15,-3.0,0.50
4x5z,menin in complex with mi-136,20,2784.5,11.39,8,13,-2.5,0.50
4ury,the crystal structure of h-ras and sos in complex with ligands,16,2234.8,4.21,12,15,-1.5,0.69
5htz,"bace1 in complex with (s)-5-(3-chloro-5-(5-(prop-1-yn-1-yl)pyridin-3- yl)thiophen-2-yl)-2,5-dimethyl-1,2,4-thiadiazinan-3-iminium 1,1- dioxide",23,2871.7,8.54,15,15,-1.0,0.52
4og3,human menin with bound inhibitor miv-3r,20,2784.5,11.97,8,13,-2.5,0.50
2qmg,structure of bace bound to sch745966,30,4025.8,11.39,30,17,2.0,0.53
4x5y,menin in complex with mi-503,23,3174.0,12.11,8,17,-4.5,0.52
3lpk,structure of bace bound to sch747123,31,4114.8,11.52,31,18,2.0,0.55
4h3g,"structure of bace bound to 2-((7ar)-7a-(4-(3-cyanophenyl)thiophen-2- yl)-2-imino-3-methyl-4-oxohexahydro-1h-pyrrolo[3,4-d]pyrimidin-6(2h)- yl)nicotinonitrile",23,3039.0,11.54,17,14,-1.0,0.48
1m4h,crystal structure of beta-secretase complexed with inhibitor om00-3,20,2752.4,10.99,7,14,-4.0,0.45
4urz,the crystal structure of h-ras and sos in complex with ligands,15,2118.7,4.43,11,14,-1.5,0.67
3lpi,structure of bace bound to sch745132,31,4114.8,11.47,31,18,2.0,0.55
4og4,human menin with bound inhibitor miv-3s,20,2784.5,11.87,8,13,-2.5,0.50
2ewb,the crystal structure of bovine lens leucine aminopeptidase in complex with zofenoprilat,15,1973.6,4.77,15,12,-1.0,0.67
3v5t,calcium-dependent protein kinase 1 from toxoplasma gondii (tgcdpk1) in complex with inhibitor uw1299,24,3327.4,18.18,7,7,-1.0,0.25
4n9c,fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (nampt),12,1649.8,7.56,10,7,0.5,0.50
1lan,leucine aminopeptidase complex with l-leucinal,7,830.3,7.57,3,4,-1.0,0.29
3rv4,crystal structure of e.coli biotin carboxylase r16e mutant in complex with mg-adp and bicarbonate,24,3380.9,7.59,23,15,2.5,0.50
4h3f,"structure of bace bound to 3-(5-((7ar)-2-imino-6-(6-methoxypyridin-2- yl)-3-methyl-4-oxooctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl) thiophen-3-yl)benzonitrile",26,3254.6,11.56,19,16,-1.0,0.50
6exs,crystal structure of a pot family transporter in complex with thioalcohol conjugated peptide.,17,2733.6,19.61,6,5,0.0,0.24
4djy,structure of bace bound to (r)-5-cyclopropyl-2-imino-3-methyl-5-(3-(5- (prop-1-yn-1-yl)pyridin-3-yl)phenyl)imidazolidin-4-one,21,2667.8,8.42,13,13,-1.0,0.52
3v51,calcium-dependent protein kinase 1 from toxoplasma gondii (tgcdpk1) in complex with inhibitor rm-1-176,29,4115.6,19.87,9,11,-1.5,0.28
3sxf,"calcium-dependent protein kinase 1 from toxoplasma gondii (tgcdpk1) in complex with bumped kinase inhibitor, rm-1-89",23,3267.3,18.04,7,7,-1.0,0.26
4gq4,human menin with bound inhibitor mi-2-2,18,2493.2,6.77,9,17,-3.5,0.67
3t3u,"calcium-dependent protein kinase 1 from toxoplasma gondii (tgcdpk1) in complex with bumped kinase inhibitor, rm-1-130",21,3010.3,16.45,4,9,-3.0,0.29
3v5p,calcium-dependent protein kinase 1 from toxoplasma gondii (tgcdpk1) in complex with inhibitor uw1288,21,2989.0,14.26,7,9,-2.0,0.33
3ckp,crystal structure of bace-1 in complex with inhibitor,28,3788.7,13.70,20,18,-1.0,0.50
1uou,crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor,19,2459.6,6.44,20,7,3.5,0.47
6ftw,crystal structure of human phosphodiesterase 4d2 catalytic domain with inhibitor npd-048,20,3079.7,15.28,12,13,-0.5,0.45
2fdp,crystal structure of beta-secretase complexed with an amino-ethylene inhibitor,27,3628.5,12.41,24,17,0.0,0.52
5dqc,co-crystal of bace1 with compound 0211,34,4508.6,13.99,29,21,1.0,0.56
6iiu,crystal structure of the human thromboxane a2 receptor bound to ramatroban,27,3829.5,21.51,14,9,0.5,0.30
3lmk,ligand binding domain of metabotropoc glutamate receptor mglur5 complexed with glutamate,2,280.8,2.40,2,2,0.0,0.50
5v0n,bace1 in complex with inhibitor 5g,28,3741.2,15.23,24,17,0.0,0.50
4zeb,pbp acca from a. tumefaciens c58 in complex with agrocinopine a,11,1734.3,8.76,10,9,0.0,0.64
1pgp,"crystallographic study of coenzyme, coenzyme analogue and substrate binding in 6-phosphogluconate dehydrogenase: implications for nadp specificity and the enzyme mechanism",18,2180.1,3.37,22,13,2.5,0.61
5z99,crystal structure of sialic acid binding protein from haemophilus ducreyi with neu5ac,24,3407.2,13.54,18,12,0.5,0.46
6hza,x-ray structure of furin in complex with the cyclic peptide c[glutaryl-arg-arg-lys]-arg-4-amba,17,2107.8,4.74,19,13,0.5,0.65
6hzb,x-ray structure of furin in complex with the cyclic inhibitor c[glutaryl-arg-arg-lys]-lys-4-amba,17,2103.0,4.73,17,13,0.5,0.65
6eqv,x-ray structure of the proprotein convertase furin bound with the competitive inhibitor phac-cit-val-arg-amba,17,2079.2,5.91,16,13,-0.5,0.59
3i25,potent beta-secretase 1 hydroxyethylene inhibitor,39,5252.7,11.62,45,21,5.0,0.59
3hp9,crystal structure of ssb/exonuclease i in complex with inhibitor cfam,11,1667.2,7.08,16,2,3.0,0.45
6nv7,bace1 in complex with a macrocyclic inhibitor,28,3768.5,12.91,24,17,0.0,0.50
6nw3,bace1 in complex with a macrocyclic inhibitor,32,4335.9,11.97,33,20,2.0,0.56
6eqx,x-ray structure of the proprotein convertase furin bound with the competitive inhibitor arg-arg-arg-val-arg-amba,17,2079.2,5.88,16,13,-0.5,0.59
6eqw,x-ray structure of the proprotein convertase furin bound with the competitive inhibitor 4-aminomethyl-phenylacetyl-arg-val-arg-amba,7,735.7,2.71,5,4,-1.0,0.57
6i0z,crystal structure of fascin in complex with compound 1,15,2580.8,19.79,3,2,0.0,0.13
4oeu,crystal structure of nikz from campylobacter jejuni in complex with ni(l-his),6,862.5,4.16,3,5,-1.0,0.67
4hw3,discovery of potent mcl-1 inhibitors using fragment-based methods and structure-based design,17,2587.2,17.62,6,1,1.0,0.12
2uz9,human guanine deaminase (guad) in complex with zinc and its product xanthine.,16,2347.7,6.47,16,16,-0.5,0.62
6nv9,bace1 in complex with a macrocyclic inhibitor,36,4792.5,12.77,34,23,1.0,0.56
2jjb,family 37 trehalase from escherichia coli in complex with casuarine-6- o-alpha-glucopyranose,17,2841.1,11.14,13,14,-3.0,0.47
6d5e,ras:sos:ras in complex with a small molecule activator,17,2573.1,10.90,9,12,-1.5,0.47
6d5g,ras:sos:ras in complex with a small molecule activator,31,3579.1,7.51,19,20,-2.0,0.55
6d5j,ras:sos:ras in complex with a small molecule activator,31,3579.1,7.42,19,20,-2.0,0.55
4b7j,h1n1 2009 pandemic influenza virus: resistance of the i223r neuraminidase mutant explained by kinetic and structural analysis,18,2652.1,1.48,41,15,2.0,0.89
3fzn,intermediate analogue in benzoylformate decarboxylase,34,3993.8,10.10,19,25,-2.0,0.53
6d55,ras:sos:ras in complex with a small molecule activator,18,2716.9,10.78,11,14,-1.5,0.50
2v59,crystal structure of biotin carboxylase from e.coli in complex with potent inhibitor 2,18,2720.2,8.92,15,13,1.5,0.50
6d5h,ras:sos:ras in complex with a small molecule activator,17,2608.1,10.46,14,10,0.5,0.47
5dit,"the fk1 domain of fkbp51 in complex with the new synthetic ligand (1r)-3-(3,4-dimethoxyphenyl)-1-f3-[2-(morpholin-4-yl) ethoxy]phenylgpropyl(2s)-1-[(2s,3r)-2-cyclohexyl-3- hydroxybutanoyl]piperidine-2-carboxylate",21,3269.6,12.31,17,6,3.0,0.38
4jfm,"increasing the efficiency efficiency of ligands for the fk506-binding protein 51 by conformational control: complex of fkbp51 with 2-(3,4- dimethoxyphenoxy)ethyl (2s)-1-[(2-oxo-2,3-dihydro-1,3-benzothiazol-6- yl)sulfonyl]piperidine-2-carboxylate",15,2510.7,10.90,14,7,1.0,0.47
5b2d,crystal structure of mumps virus hemagglutinin-neuraminidase bound to 3-sialyllactose,17,2641.8,5.51,24,10,2.0,0.71
5d0r,crystal structure of human soluble adenylyl cyclase with the inhibitor bithionol,17,2612.9,16.65,8,2,1.0,0.18
6d56,ras:sos:ras in complex with a small molecule activator,18,2716.9,10.70,11,14,-1.5,0.50
4jfk,"increasing the efficiency efficiency of ligands for the fk506-binding protein 51 by conformational control: complex of fkbp51 with (1s,6r)- 3-[2-(3,4-dimethoxyphenoxy)ethyl]-10-[(2-oxo-2,3-dihydro-1,3- benzothiazol-6-yl)sulfonyl]-3,10-diazabicyclo[4.3.1]decan-2-one",18,2765.4,14.23,9,7,0.0,0.33
2v58,crystal structure of biotin carboxylase from e.coli in complex with potent inhibitor 1,18,2720.2,8.60,15,13,1.5,0.50
2ceq,beta-glycosidase from sulfolobus solfataricus in complex with glucoimidazole,16,2627.7,11.33,15,17,-2.5,0.56
4ipn,the complex structure of 6-phospho-beta-glucosidase bgla-2 with thiocellobiose-6p from streptococcus pneumoniae,15,2257.5,5.48,15,15,-0.5,0.73
1uwu,"structure of beta-glycosidase from sulfolobus solfataricus in complex with d-glucohydroximo-1,5-lactam",16,2627.7,11.39,15,17,-2.5,0.56
1uwt,"structure of beta-glycosidase from sulfolobus solfataricus in complex with d-galactohydroximo-1,5-lactam",15,2513.6,11.57,13,15,-2.5,0.53
5ndf,small-molecule inhibition of ppgalnac-ts selectively reduces mucin- type o-glycosylation,21,3072.5,8.31,28,18,2.0,0.67
2wk6,structural features of native human thymidine phosphorylase and in complex with 5-iodouracil,14,1989.8,7.27,14,6,2.5,0.50
2cer,beta-glycosidase from sulfolobus solfataricus in complex with phenethyl-substituted glucoimidazole,21,3212.6,13.07,20,22,-2.0,0.57
1lcp,bovine lens leucine aminopeptidase complexed with l-leucine phosphonic acid,14,1668.1,5.46,8,10,-2.0,0.57
4w9o,"the fk1 domain of fkbp51 in complex with (1s,5s,6r)-10-[(3,5- dichlorophenyl)sulfonyl]-5-[(1r)-1,2-dihydroxyethyl]-3-[2-(3,4- dimethoxyphenoxy)ethyl]-3,10-diazabicyclo[4.3.1]decan-2-one",19,2828.7,11.38,11,9,0.0,0.42
3c2u,"structure of the two subsite d-xylosidase from selenomonas ruminantium in complex with 1,3-bis[tris(hydroxymethyl)methylamino]propane",19,2809.3,10.00,15,12,-0.5,0.53
4w9p,"the fk1 domain of fkbp51 in complex with (1s,5s,6r)-10-[(3,5- dichlorophenyl)sulfonyl]-5-[(1s)-1,2-dihydroxyethyl]-3-[2-(3,4- dimethoxyphenoxy)ethyl]-3,10-diazabicyclo[4.3.1]decan-2-one",20,3002.1,11.39,16,9,1.0,0.45
2o0u,"crystal structure of human jnk3 complexed with n-{3-cyano-6-[3-(1- piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}- 1-naphthalenecarboxamide",21,2988.9,16.63,7,8,-1.0,0.24
4fsl,crystal structure of beta-site app-cleaving enzyme 1 (bace-db-mut) complex with n-(n-(4- acetamido-3-chloro-5-methylbenzyl) carbamimidoyl)-3-(4- methoxyphenyl)-5-methyl-4-isothiazolecarboxamide,24,3464.4,9.96,23,12,2.0,0.54
5mz8,crystal structure of aldehyde dehydrogenase 21 (aldh21) from physcomitrella patens in complex with the reaction product succinate,13,1915.4,4.27,19,9,2.0,0.69
2oym,endo-glycoceramidase ii from rhodococcus sp.: five-membered iminocyclitol complex,20,3173.6,11.24,23,22,-2.0,0.70
2p4j,crystal structure of beta-secretase bond to an inhibitor with isophthalamide derivatives at p2-p3,32,4311.5,12.76,31,21,0.0,0.56
4cg9,human choline kinase a1 in complex with compound 12,13,2267.4,7.61,15,12,-1.0,0.69
2g94,crystal structure of beta-secretase bound to a potent and highly selective inhibitor.,31,4143.2,13.23,28,18,1.0,0.55
2vkm,crystal structure of grl-8234 bound to bace (beta-secretase),33,4317.4,13.22,30,20,1.0,0.55
4cga,human choline kinase a1 in complex with compound 5,15,2599.4,6.72,16,15,-2.0,0.73
5ftg,"human choline kinase a1 in complex with compound 1-[[4-[2-[4-[[4- (dimethylamino)pyridin-1- yl]methyl]phenoxy]ethoxy]phenyl]methyl]-n, n- dimethyl-pyridin-4-amine (compound 10a)",17,2823.2,9.01,19,17,-2.0,0.71
1gai,glucoamylase-471 complexed with d-gluco-dihydroacarbose,19,3243.6,11.37,21,11,-1.0,0.53
5mby,crystal structure of arg184gln mutant of human prolidase with mn ions and glypro ligand,6,912.4,4.33,1,5,-2.0,0.50
4cg8,human choline kinase a1 in complex with compound 14,17,2936.6,9.60,13,16,-3.0,0.65
5fut,human choline kinase a1 in complex with compound 4-(dimethylamino)-1- {4-[4-(4-{[4-(pyrrolidin- 1-yl)pyridinium-1-yl]methyl}phenyl) butyl]benzyl}pyridinium (compound br25),17,3010.4,11.57,12,15,-3.0,0.59
6m8q,cleavage and polyadenylation specificity factor subunit 3 (cpsf3) in complex with nvp-ltm531,30,4009.4,17.41,14,13,0.0,0.33
3b2q,intermediate position of atp on its trail to the binding pocket inside the subunit b mutant r416w of the energy converter a1ao atp synthase,25,3428.4,20.02,12,11,-1.0,0.32
5nze,complex of s247n mutant variant of neuraminidase from h1n1 influenza virus with oseltamivir,18,2670.5,2.91,37,16,1.0,0.83
2wvt,crystal structure of an alpha-l-fucosidase gh29 from bacteroides thetaiotaomicron in complex with a novel iminosugar fucosidase inhibitor,14,2424.1,10.18,16,13,-0.5,0.64
6hk3,crystal structure of gsk-3b in complex with pyrazine inhibitor c44,20,2744.7,10.74,12,12,-2.0,0.50
4gid,structure of beta-secretase complexed with inhibitor,36,4715.0,13.30,34,21,2.0,0.56
1q5k,crystal structure of glycogen synthase kinase 3 in complexed with inhibitor,16,2271.1,10.38,10,6,0.0,0.44
3hl8,crystal structure of exonuclease i in complex with inhibitor bcbp,12,1778.0,10.70,13,2,2.0,0.33
4j28,crystal structure of a gh29 alpha-l-fucosidase gh29 from bacteroides thetaiotaomicron in complex with a 5-membered iminocyclitol inhibitor,11,1952.3,9.49,11,13,-1.5,0.64
4dcs,crystal structure of b. subtilis enga in complex with sulfate ion and gdp,23,3174.6,10.43,33,12,4.0,0.61
1bxr,structure of carbamoyl phosphate synthetase complexed with the atp analog amppnp,29,3734.2,9.09,31,19,0.5,0.55
3f5k,"semi-active e176q mutant of rice bglu1, a plant exoglucanase/beta- glucosidase",3,523.5,4.76,1,1,0.0,0.33
2xii,crystal structure of an alpha-l-fucosidase gh29 from bacteroides thetaiotaomicron in complex with an extended 9-fluorenone iminosugar inhibitor,17,2810.8,10.16,23,15,1.0,0.65
4jfs,crystal structure of a bacterial fucosidase with iminosugar inhibitor 4-epi-(+)-codonopsinine,13,2234.2,8.63,16,13,-0.5,0.69
5nz4,complex of i223v mutant variant of neuraminidase from h1n1 influenza virus with oseltamivir,18,2618.7,2.73,36,15,1.0,0.83
5oss,beta-glucosidase from thermotoga maritima in complex with gluco-1h- imidazole,16,2600.7,11.12,15,17,-2.5,0.56
4axd,"inositol 1,3,4,5,6-pentakisphosphate 2-kinase in complex with amppnp",23,3004.4,8.62,25,17,-0.5,0.57
4qll,crystal structure of rice bglu1 e176q/y341a/q187a mutant complexed with cellotetraose,11,1674.1,9.92,11,5,1.5,0.45
4qlk,crystal structure of rice bglu1 e176q/y341a mutant complexed with cellotetraose,11,1674.1,9.88,11,5,1.5,0.45
6hzy,crystal structure of a bacterial fucosidase with inhibitor fucpug,15,2484.2,10.18,16,13,-0.5,0.60
2j77,beta-glucosidase from thermotoga maritima in complex with deoxynojirimycin,16,2600.7,10.97,15,17,-2.5,0.56
3f5j,"semi-active e176q mutant of rice bglu1, a plant exoglucanase/beta- glucosidase",8,1377.8,6.46,11,5,1.0,0.62
4e1k,glmu in complex with a quinazoline compound,23,2918.7,10.04,13,14,-1.0,0.43
2pqc,cp4 epsps liganded with (r)-phosphonate tetrahedral reaction intermediate analog,25,3469.3,5.88,49,16,5.5,0.76
2pqb,cp4 epsps liganded with (r)-difluoromethyl tetrahedral intermediate analog,29,3885.3,5.74,53,20,6.0,0.72
4acc,gsk3b in complex with inhibitor,19,2684.6,11.14,12,12,-2.0,0.53
1oif,family 1 b-glucosidase from thermotoga maritima,16,2600.7,11.04,15,17,-2.5,0.56
2j7f,beta-glucosidase from thermotoga maritima in complex with carboxylate- substituted glucoimidazole,18,2828.9,10.99,19,21,-2.5,0.61
3k37,crystal structure of b/perth neuraminidase in complex with peramivir,20,3039.5,7.07,36,14,1.0,0.70
2vrj,beta-glucosidase from thermotoga maritima in complex with n-octyl-5- deoxy-6-oxa-n-(thio)carbamoylcalystegine,21,3260.9,13.67,17,21,-3.0,0.52
2j79,beta-glucosidase from thermotoga maritima in complex with galacto- hydroximolactam,15,2437.8,10.42,15,17,-2.5,0.60
4us3,crystal structure of the bacterial nss member mhst in an occluded inward-facing state,13,2132.4,13.24,5,4,0.0,0.15
3i4b,crystal structure of gsk3b in complex with a pyrimidylpyrrole inhibitor,27,3600.3,12.12,20,17,-1.0,0.52
2cbu,beta-glucosidase from thermotoga maritima in complex with castanospermine,15,2437.8,10.24,15,17,-2.5,0.60
3f5l,"semi-active e176q mutant of rice bglu1, a plant exoglucanase/beta- glucosidase",12,1936.1,8.68,10,14,-3.0,0.67
2j7h,beta-glucosidase from thermotoga maritima in complex with azafagomine,15,2437.8,10.09,15,17,-2.5,0.60
6hk4,crystal structure of gsk-3b in complex with pyrazine inhibitor c22,20,2853.2,10.15,15,12,-1.0,0.55
2ces,beta-glucosidase from thermotoga maritima in complex with glucoimidazole,15,2437.8,10.21,15,17,-2.5,0.60
2j7e,beta-glucosidase from thermotoga maritima in complex with methyl acetate-substituted glucoimidazole,19,3082.6,14.17,18,19,-2.5,0.53
2cbv,beta-glucosidase from thermotoga maritima in complex with calystegine b2,15,2437.8,10.11,15,17,-2.5,0.60
2cet,beta-glucosidase from thermotoga maritima in complex with phenethyl- substituted glucoimidazole,19,3008.0,11.70,19,21,-2.0,0.58
2j7b,beta-glucosidase from thermotoga maritima in complex with gluco- tetrazole,16,2600.7,11.07,15,17,-2.5,0.56
2j7d,beta-glucosidase from thermotoga maritima in complex with methoxycarbonyl-substituted glucoimidazole,18,2854.8,12.41,17,19,-2.5,0.56
4cpy,structure of the neuraminidase from the b/lyon/chu/15.216/2011 virus in complex with oseltamivir,19,2872.8,6.30,36,14,1.0,0.74
1uz1,family 1 b-glucosidase from thermotoga maritima in complex with isofagomine lactam,16,2600.7,11.07,15,17,-2.5,0.56
1ua4,crystal structure of an adp-dependent glucokinase from pyrococcus furiosus,24,3209.8,8.49,23,18,-0.5,0.58
2j7g,beta-glucosidase from thermotoga maritima in complex with methyl acetic acid-substituted glucoimidazole,19,2968.9,12.42,19,21,-2.5,0.58
5nw7,crystal structure of candida albicans phosphomannose isomerase in complex with inhibitor,20,3112.1,5.69,25,18,1.0,0.75
5eqe,"crystal structure of choline kinase alpha-1 bound by [4-[(4-methyl-1, 4-diazepan-1-yl)methyl]phenyl]methanamine (compound 11)",13,2291.7,6.50,13,12,-2.0,0.69
2j75,beta-glucosidase from thermotoga maritima in complex with noeuromycin,16,2600.7,11.02,15,17,-2.5,0.56
5eqp,"crystal structure of choline kinase alpha-1 bound by 6-[(4-methyl-1,4- diazepan-1-yl)methyl]quinoline (compound 37)",12,2153.3,7.23,13,10,-1.0,0.67
1w3j,family 1 b-glucosidase from thermotoga maritima in complex with tetrahydrooxazine,15,2437.8,10.11,15,17,-2.5,0.60
4z2b,the structure of human pde12 residues 161-609 in complex with gsk3036342a,21,3038.8,10.18,23,21,0.0,0.71
2j78,beta-glucosidase from thermotoga maritima in complex with gluco- hydroximolactam,17,2714.8,11.02,17,19,-2.5,0.59
4br3,determination of potential scaffolds for human choline kinase alpha 1 by chemical deconvolution studies,16,2559.8,8.09,21,15,-1.0,0.69
4oks,"crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with compound 19 [[6-(3,5-diaminophenyl)-1-(2-methoxy-5- nitrobenzyl)-1h-indol-3-yl]acetic acid]",15,1881.1,9.13,8,8,-1.0,0.47
5e2l,3-deoxy-d-arabino-heptulosonate 7-phosphate synthase from mycobacterium tuberculosis in complex with d-phenylalanine,6,843.5,4.01,5,4,0.0,0.50
5afv,pharmacophore-based virtual screening to discover new active compounds for human choline kinase alpha1.,10,1793.0,6.71,12,9,-1.0,0.70
4da5,"choline kinase alpha acts through a double-displacement kinetic mechanism involving enzyme isomerisation, as determined through enzyme and inhibitor kinetics and structural biology",13,2213.4,7.30,13,10,-1.0,0.62
2vk6,the structure of clostridium perfringens nani sialidase and its catalytic intermediates,20,3225.5,10.08,27,14,0.0,0.65
5eqy,"crystal structure of choline kinase alpha-1 bound by 5-[(4-methyl-1,4- diazepan-1-yl)methyl]-2-[4-[(4-methyl-1,4-diazepan-1-yl) methyl]phenyl]benzenecarbonitrile (compound 65)",16,2813.6,7.41,14,15,-3.0,0.69
4gbd,crystal structure of adenosine deaminase from pseudomonas aeruginosa pao1 with bound zn and methylthio-coformycin,27,4009.5,14.81,16,20,-0.5,0.44
4bc5,crystal structure of human d-xylulokinase in complex with inhibitor 5- deoxy-5-fluoro-d-xylulose,14,2080.5,6.98,18,14,1.0,0.71
3tfu,"crystal structure of 7,8-diaminopelargonic acid synthase (bioa) from mycobacterium tuberculosis, post-reaction complex with a 3,6- dihydropyrid-2-one heterocycle inhibitor",26,3369.2,16.98,11,14,-2.5,0.38
3zm9,the mechanism of allosteric coupling in choline kinase a1 revealed by a rationally designed inhibitor,27,4272.5,15.35,32,18,0.0,0.56
4ncn,crystal structure of eukaryotic translation initiation factor eif5b (517-858) from chaetomium thermophilum in complex with gtp,27,3341.9,3.90,30,22,2.5,0.67
2wzs,structure of the family gh92 inverting mannosidase bt3990 from bacteroides thetaiotaomicron vpi-5482 in complex with mannoimidazole,15,2231.7,8.45,10,17,-4.5,0.67
3hfb,crystal structure of human tryoptophan hydroxylase type 1 with lp- 534193,22,3043.0,13.65,15,14,-0.5,0.55
3hf8,crystal structure of human tryoptophan hydroxylase type 1 with bound lp-533401 and fe,23,3282.2,13.22,14,15,-1.5,0.57
5ne5,"crystal structure of family 47 alpha-1,2-mannosidase from caulobacter k31 strain in complex with kifunensine",14,2046.2,4.93,13,13,-3.0,0.71
3pfp,structure of 3-deoxy-d-arabino-heptulosonate 7-phosphate synthase from mycobacterium tuberculosis in complex with an active site inhibitor,20,2785.2,3.46,33,13,2.5,0.80
4ayp,"structure of the gh47 processing alpha-1,2-mannosidase from caulobacter strain k31 in complex with thiomannobioside",15,2053.4,6.67,11,14,-3.0,0.60
5meh,"crystal structure of alpha-1,2-mannosidase from caulobacter k31 strain in complex with 1-deoxymannojirimycin",13,1935.1,5.08,13,11,-2.0,0.69
6pga,wdr5delta32 bound to methyl (4-(4-(hydroxymethyl)-1h-imidazol-2-yl) butyl)carbamate,17,2398.3,8.99,9,8,0.0,0.59
6d9x,"discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design",15,2036.1,9.00,5,7,-1.0,0.53
4ayq,"structure of the gh47 processing alpha-1,2-mannosidase from caulobacter strain k31 in complex with mannoimidazole",15,2184.6,4.82,13,15,-4.0,0.73
5k0m,targeting the prc2 complex through a novel protein-protein interaction inhibitor of eed,13,2003.8,6.62,14,10,-1.0,0.62
4idn,"human atlastin-1 1-446, c-his6, gppnhp",32,4424.5,13.83,37,18,2.5,0.53
4ido,"human atlastin-1 1-446, c-his6, gdpalf4-",25,3566.4,15.43,29,9,4.5,0.44
6pg7,wdr5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1h-imidazol-4-yl) methanol,20,2609.0,13.04,6,8,-1.0,0.45
6pge,wdr5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1h-imidazol-2-yl) propanoate,19,2493.3,13.29,5,7,-1.0,0.42
6pgb,wdr5delta32 bound to n-(4-(5-(hydroxymethyl)-1h-imidazol-2-yl)butyl)- 2-phenylacetamide,17,2398.3,9.01,9,8,0.0,0.59
6dai,"discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design",18,2380.0,12.58,5,7,-1.0,0.44
6pg4,wdr5delta32 bound to (2-methyl-1h-imidazol-4-yl)methanol,13,1675.8,7.81,4,6,-1.0,0.54
6dy7,wdr5 in complex with a win site inhibitor,18,2353.3,12.00,5,7,-1.0,0.44
5uf0,brd4_bd2-a-35165,13,1939.8,9.72,7,8,-0.5,0.46
5g5z,s.pneumoniae abc-transporter substrate binding protein fusa in complex with kestose,8,1080.2,4.60,10,8,-1.0,0.62
4c6u,crystal structure of m. tuberculosis kasa in complex with tlm5,19,2265.5,8.93,10,12,0.5,0.42
4lzs,crystal structure of brd4(1) bound to inhibitor xd46,12,1924.1,10.91,7,6,0.0,0.42
5w2s,crystal structure of mycobacterium tuberculosis kasa in complex with kmg,18,2310.0,12.20,3,11,-3.5,0.33
4lzr,crystal structure of brd4(1) bound to colchicine,12,1891.4,11.51,5,6,-1.0,0.42
5g60,s.pneumoniae abc-transporter substrate binding protein fusa in complex with nystose,4,544.2,1.34,7,4,0.0,0.75
2zwz,"alpha-l-fucosidase complexed with inhibitor, core1",15,2522.5,8.23,16,15,-0.5,0.67
2zxd,"alpha-l-fucosidase complexed with inhibitor, iso-6fnj",15,2522.5,8.58,16,15,-0.5,0.67
1ew8,alkaline phosphatase (e.c. 3.1.3.1) complex with phosphonoacetic acid,11,1366.1,0.97,12,17,-2.5,0.91
4azb,"differential inhibition of the tandem gh20 catalytic modules in the pneumococcal exo-beta-d-n-acetylglucosaminidase, strh",18,2667.8,8.55,20,17,-2.5,0.61
1pdz,x-ray structure and catalytic mechanism of lobster enolase,14,1758.8,1.37,18,13,1.0,0.79
1uz4,common inhibition of beta-glucosidase and beta-mannosidase by isofagomine lactam reflects different conformational intineraries for glucoside and mannoside hydrolysis,13,2157.9,8.13,13,15,-2.5,0.62
1zhy,structure of yeast oxysterol binding protein osh4 in complex with cholesterol,24,3918.7,23.83,20,9,2.0,0.33
1n51,aminopeptidase p in complex with the inhibitor apstatin,15,2087.9,4.24,15,18,-1.5,0.73
2zx7,"alpha-l-fucosidase complexed with inhibitor, f10-2c",17,2776.6,9.72,18,17,-0.5,0.65
5d3n,first bromodomain of brd4 bound to inhibitor xd40,14,2203.8,9.78,10,8,0.0,0.50
6pg5,wdr5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1h-imidazol-2-yl) butyl)carbamate,19,2728.2,12.60,9,8,0.0,0.53
5d3t,first bromodomain of brd4 bound to inhibitor xd47,15,2316.5,10.73,10,8,0.0,0.47
1m7y,crystal structure of apple acc synthase in complex with l- aminoethoxyvinylglycine,25,3322.9,8.52,26,16,1.0,0.60
6pgc,wdr5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1h-imidazol-2- yl)butyl)carbamate,20,2713.9,10.42,9,10,-1.0,0.55
1dy4,cbh1 in complex with s-propranolol,21,3005.6,5.93,18,23,-4.5,0.76
5d3h,first bromodomain of brd4 bound to inhibitor xd29,14,2206.8,10.16,12,8,1.0,0.50
5d3p,first bromodomain of brd4 bound to inhibitor xd41,14,2203.8,9.70,10,8,0.0,0.50
2zx6,"alpha-l-fucosidase complexed with inhibitor, f10-1c",20,3119.5,10.70,19,18,-0.5,0.60
6jfk,gdp bound mitofusin2 (mfn2),24,3001.4,10.61,28,15,2.0,0.62
2zx8,"alpha-l-fucosidase complexed with inhibitor, f10-2c-o",21,3259.1,11.30,19,20,-1.5,0.62
5dlx,"first domain of human bromodomain brd4 in complex with inhibitor n-{3- [4-(3-chlorophenyl)piperazin-1-yl]propyl}-1-{3-methyl-[1,2, 4]triazolo[4,3-b]pyridazin-6-yl}piperidine-4-carboxamide",15,2410.9,14.42,5,6,-1.0,0.33
6dak,"discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design",19,2754.9,13.18,9,8,0.0,0.53
4lhm,thymidine phosphorylase from e.coli with 3'-azido-3'-deoxythymidine,14,2122.5,11.24,11,7,0.0,0.50
5d3j,first bromodomain of brd4 bound to inhibitor xd33,14,2203.8,9.78,10,8,0.0,0.50
5m25,modulation of mll1 methyltransferase activity,23,3075.9,13.75,9,12,-2.0,0.52
5eis,"first domain of human bromodomain brd4 in complex with inhibitor 3-(4- chlorobenzyl)-7-ethyl-3,7-dihydropurine-2,6-dione",13,2054.3,12.00,5,6,-1.0,0.38
3u5j,crystal structure of the first bromodomain of human brd4 in complex with alprazolam,14,2198.1,11.20,7,8,-1.0,0.43
5d24,first bromodomain of brd4 bound to inhibitor xd26,14,2236.5,9.81,12,8,1.0,0.50
6u8o,discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction,16,2364.0,10.47,14,7,2.0,0.44
6dar,"discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design",22,3147.6,15.52,9,8,0.0,0.45
5uez,brd4_bd2_a-1342843,14,2130.0,10.92,7,8,-0.5,0.43
4qb3,crystal structure of the first bromodomain of human brd4 in complex with olinone,14,2165.4,11.83,5,8,-2.0,0.43
4az6,"differential inhibition of the tandem gh20 catalytic modules in the pneumococcal exo-beta-d-n-acetylglucosaminidase, strh",16,2651.8,11.49,15,16,-3.5,0.62
4az5,"differential inhibition of the tandem gh20 catalytic modules in the pneumococcal exo-beta-d-n-acetylglucosaminidase, strh",10,1511.4,3.38,8,7,0.0,0.70
4cfl,n-terminal bromodomain of human brd4 with ly303511,12,1894.4,11.86,7,6,0.0,0.42
4nuc,crystal structure of the first bromodomain of human brd4 in complex with ms435 inhibitor,13,2092.7,10.19,10,6,1.0,0.46
4xya,crystal structure of the first bromodomain of human brd4 in complex with a 2-amine-9h-purine ligand,14,2147.9,11.05,7,8,-1.0,0.43
5dw2,x-ray crystal structure of human brd4(bd1) in complex with rvx297 to 1.12 a resolution,12,1891.4,11.33,5,6,-1.0,0.42
4mr3,crystal structure of the first bromodomain of human brd4 in complex with a quinazolinone ligand (rvx-oh),12,1924.1,10.95,7,6,0.0,0.42
5d25,first bromodomain of brd4 bound to inhibitor xd27,13,2092.7,10.12,10,6,1.0,0.46
6fsy,"crystal structure of the first bromodomain of human brd4 in complex with a 3,5-dimethylisoxazol ligand",14,2198.1,11.35,7,8,-1.0,0.43
5m23,modulation of mll1 methyltransferase activity,26,3505.0,14.85,15,13,-1.0,0.54
5d3l,first bromodomain of brd4 bound to inhibitor xd35,14,2203.8,9.83,10,8,0.0,0.50
5d26,first bromodomain of brd4 bound to inhibitor xd28,13,2092.7,10.23,10,6,1.0,0.46
4lyw,crystal structure of brd4(1) bound to inhibitor xd14,14,2203.8,9.79,10,8,0.0,0.50
5i88,"brd4 in complex with cpd4 ((e)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro- 1h-pyrrolo[2,3-c]pyridin-4-yl)-n,n-dimethylbenzamide)",17,2636.6,15.58,7,8,-1.0,0.35
5dx4,crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand,13,2054.3,12.16,5,6,-1.0,0.38
3u5l,crystal structure of the first bromodomain of human brd4 in complex with a benzo-triazepine ligand (bzt-7),14,2198.1,11.16,7,8,-1.0,0.43
4wiv,"crystal structure of the first bromodomain of human brd4 in complex with a novel inhibitor umb32 (n-tert-butyl-2-[4-(3,5-dimethyl-1,2- oxazol-4-yl) phenyl]imidazo[1,2-a]pyrazin-3-amine)",13,2054.3,12.26,5,6,-1.0,0.38
5nzf,complex of h275y/i223v mutant variant of neuraminidase from h1n1 influenza virus with oseltamivir,19,2812.3,2.71,37,16,1.0,0.84
5nzn,complex of h275y/s247n mutant variant of neuraminidase from h1n1 influenza virus with oseltamivir,18,2670.5,2.76,37,16,1.0,0.83
6fo5,first domain of human bromodomain brd4 in complex with inhibitor #17,15,2410.9,14.26,5,6,-1.0,0.33
5u28,brd4 first bromodomain (bd1) in complex with dual pi3 kinase inhibitor sf2523,13,2038.2,10.91,9,8,0.0,0.46
4nue,crystal structure of the first bromodomain of human brd4 in complex with ms267 inhibitor,13,2092.7,10.12,10,6,1.0,0.46
5i80,"brd4 in complex with cpd2 (n,n-dimethyl-3-(6-methyl-7-oxo-6,7-dihydro- 1h-pyrrolo[2,3-c]pyridin-4-yl)benzamide)",13,2087.0,11.92,7,6,0.0,0.38
2yel,crystal structure of the first bromodomain of human brd4 with the inhibitor gw841819x,13,2054.3,12.00,5,6,-1.0,0.38
5nwe,complex of h275y mutant variant of neuraminidase from h1n1 influenza virus with oseltamivir,19,2759.5,2.94,38,17,1.0,0.84
6cks,crystal structure of brd4 with qc4956,15,2316.5,10.63,10,8,0.0,0.47
3p5o,crystal structure of the first bromodomain of human brd4 in complex with ibet inhibitor,14,2198.1,11.20,7,8,-1.0,0.43
6pg3,wdr5delta23 bound to (2-butyl-1h-imidazol-4-yl)methanol,13,1675.8,7.77,4,6,-1.0,0.54
6c7q,brd4 bd2 in complex with compound ce277,15,2322.2,11.57,9,10,-0.5,0.47
5uoo,brd4 bromodomain 2 in complex with cd161,17,2603.5,11.87,12,10,0.5,0.47
5ttw,crystal structure of eed in complex with unc4859,6,678.0,4.87,3,3,0.0,0.50
6pg6,wdr5delta23 bound to n-(4-(5-(hydroxymethyl)-1h-imidazol-2-yl)butyl) acetamide,16,2229.7,8.93,6,8,-1.0,0.56
5wa5,crystal structure of the first bromodomain of human brd4 in complex with the inhibitor xmd11-50,15,2291.7,10.85,9,10,-1.0,0.47
6r4k,structure of beta-glucosidase a from paenibacillus polymyxa complexed with a monovalent inhibitor,21,3324.9,14.11,20,21,-2.0,0.57
1qbq,structure of rat farnesyl protein transferase complexed with a cvim peptide and alpha-hydroxyfarnesylphosphonic acid.,22,3582.1,6.82,29,11,5.0,0.73
4ogj,crystal structure of the first bromodomain of human brd4 in complex with the inhibitor tg-101348,16,2554.7,16.07,7,8,-1.0,0.38
5ueu,brd4_bd2_a-1107604,15,2386.4,12.91,8,6,0.0,0.40
5f5z,crystal structure of the first bromodomain of human brd4 in complex with ma2-014,19,2851.4,11.27,16,14,0.0,0.53
4b7r,h1n1 2009 pandemic influenza virus: resistance of the i223r neuraminidase mutant explained by kinetic and structural analysis,18,2645.4,2.90,36,15,1.0,0.83
6pg9,wdr5delta23 bound to n-(4-(5-(hydroxymethyl)-1h-imidazol-2-yl)butyl) benzamide,19,2728.2,12.66,9,8,0.0,0.53
4pcs,"crystal structure of a bacterial fucosidase with iminosugar (2s,3s,4r, 5s)-3,4-dihydroxy-2-[2'-phenyl]ethynyl-5-methylpyrrolidine",14,2424.1,10.10,16,13,-0.5,0.64
4pee,"crystal structure of a bacterial fucosidase with inhibitor 1-phenyl-4- [(2s,3s,4r,5s)-3,4-dihydroxy-5-methylpyrrolidin-2-yl]triazole",14,2424.1,10.08,16,13,-0.5,0.64
4z93,"brd4 bromodomain 2 in complex with gamma-carboline-containing compound, number 18.",20,2966.1,13.40,12,12,-0.5,0.45
5ula,crystal structure of the first bromodomain of human brd4 in complex with cyclic vinylogous amide inhibitor ms402,20,2990.8,15.87,12,12,-1.0,0.45
1o1s,structure of fpt bound to isoprenoid analog 3b,25,3989.5,8.40,34,15,5.5,0.72
3zyu,crystal structure of the first bromodomain of human brd4 in complex with i-bet151(gsk1210151a),14,2198.1,11.40,7,8,-1.0,0.43
4azg,"differential inhibition of the tandem gh20 catalytic modules in the pneumococcal exo-beta-d-n-acetylglucosaminidase, strh",17,2627.9,11.51,14,16,-3.5,0.59
4zl4,plasmepsin v from plasmodium vivax bound to a transition state mimetic (wehi-842),30,4136.6,10.10,18,25,-3.5,0.63
5f62,crystal structure of the first bromodomain of human brd4 in complex with ma4-022-2,17,2537.4,9.99,11,14,-2.0,0.53
6q3z,crystal structure of the first bromodomain of human brd4 in complex with the inhibitor 16k,22,3382.9,16.68,14,14,-0.5,0.45
6ckr,crystal structure of brd4 with qc4956,19,2989.1,16.06,13,12,-1.0,0.47
6e4a,crystal structure of human brd4(1) in complex with cn750,16,2477.8,10.82,10,10,-1.0,0.50
2rio,structure of the dual enzyme ire1 reveals the basis for catalysis and regulation of non-conventional splicing,21,2704.8,8.72,14,17,-2.0,0.57
6q3y,crystal structure of the first bromodomain of human brd4 in complex with the inhibitor 16i,13,2067.9,10.51,9,8,0.0,0.46
5f60,crystal structure of the first bromodomain of human brd4 in complex with sg3-014,17,2586.2,11.79,9,12,-2.0,0.47
5ld8,gsk3011724a cocrystallised with mycobacterium tuberculosis h37rv kasa,19,2503.6,11.30,4,12,-3.5,0.37
5acy,"n-terminal bromodomain of human brd4 with 1-(2r,4s)-2-methyl-4- (phenylamino)-6-4-(piperidin-1-ylmethyl)phenyl-1,2,3,4- tetrahydroquinolin-1-yl-ethan-1-one",14,2255.6,11.31,10,6,1.0,0.43
4ql1,crystal structure of human wdr5 in complex with compound oicr-9429,24,3083.9,16.30,7,11,-2.0,0.46
2xib,crystal structure of an alpha-l-fucosidase gh29 from bacteroides thetaiotaomicron in complex with deoxyfuconojirimycin,14,2424.1,10.16,16,13,-0.5,0.64
5f63,crystal structure of the first bromodomain of human brd4 in complex with sg3-179,18,2700.3,11.44,11,14,-2.0,0.50
5wmg,n-terminal bromodomain of brd4 in complex with otx-015,15,2366.7,10.63,10,8,0.0,0.47
5khm,the first bet bromodomain of brd4 bound to compound 13 in a bivalent manner,24,3714.1,20.61,9,12,-2.0,0.42
5n6s,thermotoga maritima family 1 glycoside hydrolase complexed with carba- cyclophellitol transition state mimic,22,3530.3,14.00,21,22,-2.5,0.55
6u6w,discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction,19,2834.0,8.14,16,13,0.0,0.58
4azi,"differential inhibition of the tandem gh20 catalytic modules in the pneumococcal exo-beta-d-n-acetylglucosaminidase, strh",18,2821.5,11.45,15,17,-3.5,0.61
5sxm,wdr5 in complex with mll win motif peptidomimetic,2,333.6,1.95,1,1,0.0,0.50
6en5,crystal structure a of the angiotensin-1 converting enzyme n-domain in complex with a diprolyl inhibitor.,29,4339.1,11.21,40,20,4.0,0.59
5d2r,inhibitor bound cell shape determinant protein csd4 from helicobacter pylori,28,3890.6,10.24,30,23,-1.0,0.61
5egu,"first domain of human bromodomain brd4 in complex with inhibitor 3- butyl-8-(6-butyl-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylsulfanylmethyl)-7-ethyl-3,7-dihydropurine-2,6-dione",15,2316.5,10.32,10,8,0.0,0.47
6u5y,discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction,16,2364.0,10.54,14,7,2.0,0.44
4ek9,crystal structure of dot1l in complex with epz000004,20,2500.8,11.55,7,10,-2.0,0.35
6u8b,discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction,18,2667.3,8.02,16,13,0.0,0.61
6mh7,"crystal structure of the first bromodomain of human brd4 in complex with skt-68, a 1,4,5-trisubstituted imidazole analogue",21,3139.6,15.15,9,14,-3.0,0.43
3sr4,crystal structure of human dot1l in complex with a selective inhibitor,27,3480.1,13.75,10,17,-4.0,0.41
6e23,displacement of wdr5 from chromatin by a pharmacological win site inhibitor with picomolar affinity,31,4069.7,17.98,12,13,-1.0,0.45
1m0o,structure of dialkylglycine decarboxylase complexed with 1-amino-1- methylpropanephosphonate,18,2267.0,4.31,20,17,-0.5,0.67
2wc3,structure of family 1 beta-glucosidase from thermotoga maritima in complex with 3-imino-2-oxa-(+)-8-epi-castanospermine,17,2806.8,14.61,15,17,-2.0,0.53
1m0q,structure of dialkylglycine decarboxylase complexed with s-1- aminoethanephosphonate,19,2429.9,5.83,20,17,-0.5,0.63
1m0n,structure of dialkylglycine decarboxylase complexed with 1- aminocyclopentanephosphonate,19,2356.0,4.03,21,18,-0.5,0.68
1zc9,the crystal structure of dialkylglycine decarboxylase complex with pyridoxamine 5-phosphate,16,1875.9,3.07,14,16,-1.5,0.69
6exi,nad-free crystal structure of s-adenosyl-l-homocysteine hydrolase from bradyrhizobium elkanii complexed with adenosine,21,2951.5,9.21,18,19,0.5,0.62
4pb2,structure of vccnt-7c8c bound to 5-fluorouridine,13,1857.6,18.07,5,0,1.0,0.08
2wc4,structure of family 1 beta-glucosidase from thermotoga maritima in complex with 3-imino-2-thia-(+)-castanospermine,18,2920.9,14.37,17,19,-2.0,0.56
6mh1,"crystal structure of the first bromodomain of human brd4 in complex with hu-10, a 1,4,5-trisubstituted imidazole analogue",21,3139.6,15.10,9,14,-3.0,0.43
6e22,displacement of wdr5 from chromatin by a pharmacological win site inhibitor with picomolar affinity,19,2752.3,12.08,9,8,0.0,0.53
2wbg,structure of family 1 beta-glucosidase from thermotoga maritima in complex with 3-imino-2-oxa-(+)-castanospermine,19,3009.9,14.22,18,20,-2.0,0.58
2w8w,n100y spt with plp-ser,17,2123.7,2.33,16,17,0.0,0.76
4ual,mrck beta in complex with bdp00005290,20,2614.8,8.19,13,13,-2.0,0.50
2ptz,"crystal structure of the t. brucei enolase complexed with phosphonoacetohydroxamate (pah), his156-out conformation",22,2693.0,3.07,25,21,-1.5,0.77
5laq,crystal structure of human phosphodiesterase 4b catalytic domain with inhibitor npd-001,20,3080.7,12.83,13,14,-0.5,0.50
2pu1,crystal structure of the t. brucei enolase complexed with fluoro- phosphonoacetohydroxamate (fpah),20,2494.5,3.09,25,19,-0.5,0.80
2w8j,spt with plp-ser,17,2103.5,2.36,20,16,1.0,0.76
2pq9,e. coli epsps liganded with (r)-difluoromethyl tetrahedral reaction intermediate analog,28,3697.9,4.42,50,22,5.5,0.82
1h46,the catalytic module of cel7d from phanerochaete chrysosporium as a chiral selector: structural studies of its complex with the b-blocker (r)-propranolol,19,2642.9,7.45,15,20,-4.5,0.68
3o7u,crystal structure of cytosine deaminase from escherichia coli complexed with zinc and phosphono-cytosine,8,1329.9,4.49,12,8,0.0,0.75
1x8t,epsps liganded with the (r)-phosphonate analog of the tetrahedral reaction intermediate,25,3321.8,3.90,43,20,4.5,0.84
6p3v,crystal structure of eis from mycobacterium tuberculosis in complex with inhibitor sgt416,16,2489.5,14.98,9,8,-2.0,0.38
3t01,crystal structure of phosphonoacetate hydrolase from sinorhizobium meliloti 1021 in complex with phosphonoformate,11,1498.8,2.58,12,16,-0.5,0.82
1x8r,epsps liganded with the (s)-phosphonate analog of the tetrahedral reaction intermediate,28,3697.9,4.41,50,22,5.5,0.82
6p3t,crystal structure of eis from mycobacterium tuberculosis in complex with inhibitor sgt449,16,2542.6,18.24,9,4,0.0,0.25
5f61,crystal structure of the first bromodomain of human brd4 in complex with ma4-022-1,23,3466.4,12.94,22,16,1.0,0.57
5o2d,parp14 macrodomain 2 with inhibitor,22,3232.7,18.41,9,6,1.0,0.23
5zkc,crystal structure of rationally thermostabilized m2 muscarinic acetylcholine receptor bound with nms,16,2390.0,8.36,12,12,-1.0,0.62
3pgu,phe3glu mutant of ecfadl,4,781.7,4.97,3,2,0.0,0.50
1tq4,crystal structure of iigp1: a paradigm for interferon inducible p47 resistance gtpases,23,2683.5,4.03,24,18,1.0,0.74
5gof,"truncated mitofusin-1, gtp-bound",22,2586.5,7.09,26,13,2.0,0.64
3wz7,endothiapepsin in complex with gewald reaction-derived inhibitor (6),23,2974.7,13.08,6,16,-5.0,0.48
5er2,high-resolution x-ray diffraction study of the complex between endothiapepsin and an oligopeptide inhibitor. the analysis of the inhibitor binding and description of the rigid body shift in the enzyme,33,4477.3,24.25,8,20,-6.0,0.42
4er1,the active site of aspartic proteinases,33,4453.6,21.33,9,21,-6.0,0.45
4pzv,crystal structure of francisella tularensis hppk-dhps in complex with bisubstrate analog hppk inhibitor j1d,24,3539.4,13.27,32,11,4.5,0.54
3tz0,crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/s-alpha-chloroisocaproate complex,12,1844.3,10.95,13,3,2.5,0.33
5er1,a rational approach to the design of antihypertensives. x-ray studies of complexes between aspartic proteinases and aminoalcohol renin inhibitors,22,2864.2,14.68,6,14,-4.0,0.45
5vr8,human udp-glucose dehydrogenase with udp-xylose bound to the co-enzyme site,28,3493.5,9.57,27,15,2.0,0.57
2v00,x-ray crystal structure of endothiapepsin complexed with compound 1,15,1724.3,7.16,4,12,-4.0,0.53
3wz6,endothiapepsin in complex with gewald reaction-derived inhibitor (5),20,2579.4,10.24,5,13,-4.0,0.45
3pww,endothiapepsin in complex with saquinavir,30,3979.8,18.11,7,21,-7.0,0.47
4er2,the active site of aspartic proteinases,10,1428.0,11.12,2,2,0.0,0.20
4o3f,crystal structure of mouse pgk1 3pg and terazosin(tzn) ternary complex,20,2311.3,11.28,5,4,0.0,0.25
2h21,structure of rubisco lsmt bound to adomet,20,2576.7,7.07,14,17,-2.5,0.60
4h7q,crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase in complex with alpha-ketoisocaproic acid and adp,22,2609.0,14.73,10,7,0.0,0.27
4h81,crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/(r)-2-chloro-3-phenylpropanoic acid complex with adp,22,2609.0,14.38,10,7,0.0,0.27
3uri,endothiapepsin-db5 complex.,23,2912.2,13.52,8,16,-3.5,0.48
1epo,"endothia aspartic proteinase (endothiapepsin) complexed with cp-81,282 (mor phe nle chf nme)",28,3748.4,18.84,7,19,-6.0,0.46
3wz8,endothiapepsin in complex with gewald reaction-derived inhibitor (8),23,3107.3,13.24,5,17,-6.0,0.48
4h85,crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/(r)-alpha-chloroisocaproate complex with adp,22,2609.0,14.35,10,7,0.0,0.27
1gvw,"endothiapepsin complex with pd-130,328",30,4031.2,21.09,8,20,-6.0,0.47
3prs,endothiapepsin in complex with ritonavir,32,4184.9,16.94,9,23,-7.0,0.50
1gvx,endothiapepsin complexed with h256,23,2981.0,12.80,11,18,-5.0,0.57
3upk,e. cloacae mura in complex with unag,24,3293.4,15.21,23,12,1.5,0.46
4dzy,crystal structure of branched-chain alpha-ketoacid dehydrogenase kinase/(s)-2-chloro-3-phenylpropanoic acid complex with adp,22,2609.0,14.33,10,7,0.0,0.27
4xmb,"crystal structure of 2,2'-(naphthalene-1,4-diylbis(((4-methoxyphenyl) sulfonyl)azanediyl))diacetamide bound to human keap1 kelch domain",26,3161.2,8.72,26,13,2.0,0.50
4cd5,the structure of gh26 beta-mannanase cjman26c from cellvibrio japonicus in complex with manmim,12,1978.2,8.38,9,15,-3.0,0.67
3jya,"discovery of 3h-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective and orally bioavailable pim kinases inhibitors",15,2156.3,13.28,8,4,0.0,0.27
3rv8,"structure of a m. tuberculosis salicylate synthase, mbti, in complex with an inhibitor with cyclopropyl r-group",19,2458.6,8.06,18,9,1.5,0.47
4aq4,substrate bound sn-glycerol-3-phosphate binding periplasmic protein ugpb from escherichia coli,17,2323.2,7.22,14,11,-1.0,0.53
3bgz,human pim-1 kinase in complex with diphenyl indole inhibitor vx3,17,2460.9,14.46,9,7,-1.0,0.35
1grp,regulatory and catalytic mechanisms in escherichia coli isocitrate dehydrogenase: multiple roles for n115,9,1359.0,1.88,17,6,1.0,0.78
2c3i,crystal structure of human pim1 in complex with imidazopyridazin i,19,2636.2,12.53,11,11,-2.0,0.42
4cd4,the structure of gh26 beta-mannanase cjman26c from cellvibrio japonicus in complex with manifg,9,1480.6,6.71,11,10,-1.5,0.67
3bgq,human pim-1 kinase in complex with an triazolo pyridazine inhibitor vx2,20,2769.4,12.40,10,14,-4.0,0.45
2xj2,protein kinase pim-1 in complex with small molecule inhibitor,20,2848.2,13.66,10,12,-3.0,0.40
6pg8,wdr5delta23 bound to (2-(3-phenylpropyl)-1h-imidazol-4-yl)methanol,19,2415.4,13.40,5,7,-1.0,0.42
3jy0,"discovery of 3h-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective and orally bioavailable pim kinases inhibitors",18,2655.7,13.15,13,10,-1.0,0.44
1xws,crystal structure of the human pim1 kinase domain,19,2658.3,12.08,10,12,-3.0,0.42
2xj1,protein kinase pim-1 in complex with small molecule inibitor,21,2937.2,13.33,11,13,-3.0,0.43
4k0y,"structure of pim-1 kinase bound to n-(4-fluorophenyl)-7-hydroxy-5- (piperidin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide",20,2879.3,13.03,12,14,-3.0,0.45
4k18,"structure of pim-1 kinase bound to 5-(4-cyanobenzyl)-n-(4- fluorophenyl)-7-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxamide",21,2837.1,12.04,11,13,-3.0,0.43
4rd6,structure of aif2-gamma from sulfolobus solfataricus bound to gdp,20,2695.3,9.69,18,17,0.5,0.60
5ipj,crystal structure of human pim-1 kinase in complex with a quinazolinone-pyrrolopyrrolone inhibitor.,20,2848.2,13.87,10,12,-3.0,0.40
4n6z,pim1 complexed with a pyridylcarboxamide,21,2858.4,11.86,11,15,-4.0,0.48
6e1z,displacement of wdr5 from chromatin by a pharmacological win site inhibitor with picomolar affinity,20,2736.2,8.91,11,10,0.0,0.65
5v82,"pim1 kinase in complex with cpd17 (1-(6-(4,4-difluoropiperidin-3-yl) pyridin-2-yl)-6-(6-methylpyrazin-2-yl)-1h-pyrazolo[4,3-c]pyridine)",19,2658.3,12.21,10,12,-3.0,0.42
3mi3,homocitrate synthase lys4 bound to lysine,6,923.9,1.69,9,8,1.0,0.83
4rd3,structure of aif2-gamma h97a variant from sulfolobus solfataricus bound to gdp and pi,21,2760.4,9.58,19,16,1.5,0.57
5dwr,"identification of n-(4-((1r,3s,5s)-3-amino-5-methylcyclohexyl)pyridin- 3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (pim447), a potent and selective proviral insertion site of moloney murine leukemia (pim) 1,2 and 3 kinase inhibitor in clinical trials for hematological malignancies",21,2891.1,11.93,13,15,-3.0,0.48
6no9,"pim1 in complex with cpd16 (5-amino-n-(5-((4r,5r)-4-amino-5- fluoroazepan-1-yl)-1-methyl-1h-pyrazol-4-yl)-2-(2,6-difluorophenyl) thiazole-4-carboxamide)",20,2802.1,12.16,12,14,-3.0,0.45
4kwf,crystal structure analysis of aldh2+aldib33,18,2678.8,14.16,4,9,-3.0,0.44
4y4j,endothiapepsin in complex with fragment b97,14,1664.6,4.17,5,13,-4.0,0.64
1w9v,specificity and affinity of natural product cyclopentapeptide argifin against aspergillus fumigatus,17,2201.7,10.26,10,9,-2.0,0.65
4rd0,structure of aif2-gamma d19a variant from sulfolobus solfataricus bound to gdp,23,3011.9,11.59,19,16,1.5,0.52
4y3j,endothiapepsin in complex with fragment b30,9,1189.3,4.68,7,4,1.0,0.44
5hi7,co-crystal structure of human smyd3 with an aza-sah compound,28,3790.7,6.82,24,24,-1.5,0.71
2iuz,crystal structure of aspergillus fumigatus chitinase b1 in complex with c2-dicaffeine,16,2588.0,9.82,17,10,-1.0,0.56
6e1y,"discovery of potent 2-aryl-6,7-dihydro-5hpyrrolo[ 1,2-a]imidazoles as wdr5 win-site inhibitors using fragment-based methods and structure- based design",28,3802.1,18.63,11,10,0.0,0.46
4y3y,endothiapepsin in complex with fragment b42,8,1045.5,5.22,5,2,1.0,0.38
4kwg,crystal structure analysis of aldh2+aldib13,15,2235.3,14.05,4,5,-1.0,0.40
3cct,thermodynamic and structure guided design of statin hmg-coa reductase inhibitors,26,3361.1,7.30,31,18,3.0,0.69
5hct,endothiapepsin in complex with biacylhydrazone,20,2451.4,9.22,6,16,-5.0,0.55
3cd7,thermodynamic and structure guided design of statin hmg-coa reductase inhibitors,28,3509.8,8.23,31,18,3.0,0.64
1w9u,specificity and affnity of natural product cyclopentapeptide inhibitor argadin against aspergillus fumigatus chitinase,7,897.5,5.26,10,4,2.0,0.71
6hqy,crystal structure of schistosoma mansoni hdac8 complexed with pci- 34051,16,2159.4,3.59,19,19,0.0,0.75
3jzj,crystal structures of the gach receptor of streptomyces glaucescens gla.o in the unliganded form and in complex with acarbose and an acarbose homolog. comparison with acarbose-loaded maltose binding protein of salmonella typhimurium.,16,2225.6,6.50,16,11,-1.0,0.50
3veh,"structure of a m. tuberculosis salicylate synthase, mbti, in complex with an inhibitor methylamt",19,2458.6,7.90,18,9,1.5,0.47
3cd0,thermodynamic and structure guided design of statin hmg-coa reductase inhibitors,27,3452.7,7.55,33,18,4.0,0.67
3ccw,thermodynamic and structure guided design of statin hmg-coa reductase inhibitors,26,3299.5,8.26,31,16,3.5,0.65
5j6a,crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor ps46,18,2162.3,10.64,10,11,-2.0,0.44
3k02,crystal structures of the gach receptor of streptomyces glaucescens gla.o in the unliganded form and in complex with acarbose and an acarbose homolog. comparison with acarbose-loaded maltose binding protein of salmonella typhimurium.,28,4082.8,12.93,31,21,-2.0,0.54
3c39,crystal structure of human phosphoglycerate kinase bound to 3- phosphoglycerate,15,1823.5,0.86,29,11,4.5,0.67
3cda,thermodynamic and structure guided design of statin hmg-coa reductase inhibitors,28,3509.8,8.17,31,18,3.0,0.64
3k00,crystal structures of the gach receptor of streptomyces glaucescens gla.o in the unliganded form and in complex with acarbose and an acarbose homolog. comparison with acarbose-loaded maltose binding protein of salmonella typhimurium.,10,1615.4,9.55,12,8,-1.0,0.60
3cdb,thermodynamic and structure guided design of statin hmg-coa reductase inhibitors,27,3361.9,6.83,28,20,2.0,0.67
4mpn,crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor ps10,17,2023.9,10.63,10,9,-1.0,0.41
4omc,x-ray structure of human furin in complex with the competitive inhibitor meta-guanidinomethyl-phac-rvr-amba,13,1583.6,4.43,7,10,-3.0,0.54
5x54,crystal structure of the keap1 kelch domain in complex with a tetrapeptide,6,958.2,2.68,11,3,1.0,0.67
2v77,crystal structure of human carboxypeptidase a1,20,2974.6,8.39,26,17,1.0,0.70
6g9x,crystal structure of a mfs transporter at 2.54 angstroem resolution,10,1649.8,9.42,7,3,1.0,0.40
1hyo,crystal structure of fumarylacetoacetate hydrolase complexed with 4- (hydroxymethylphosphinoyl)-3-oxo-butanoic acid,17,2399.7,5.95,16,16,-1.5,0.71
3ccz,thermodynamic and structure guided design of statin hmg-coa reductase inhibitors,26,3299.5,8.21,31,16,3.5,0.65
6htg,crystal structure of schistosoma mansoni hdac8 complexed with a benzohydroxamate inhibitor 4,16,2046.1,3.53,14,19,-1.0,0.69
2q8h,structure of pyruvate dehydrogenase kinase isoform 1 in complex with dichloroacetate (dca),11,1678.4,7.47,15,5,2.5,0.55
2hzy,mouse fumarylacetoacetate hydrolase complexes with a transition-state mimic of the complete substrate,20,2980.3,7.21,21,16,-0.5,0.65
3cd5,thermodynamic and structure guided design of statin hmg-coa reductase inhibitors,28,3724.9,10.37,33,15,5.0,0.61
1ecq,e. coli glucarate dehydratase bound to 4-deoxyglucarate,20,2790.9,3.04,30,27,0.5,0.90
6j9w,crystal structure of abc transporter alpha-glycoside-binding protein in complex with trehalose,9,1103.8,1.89,16,6,3.5,0.56
6jap,crystal structure of abc transporter alpha-glycoside-binding mutant protein r356a in complex with sucrose,9,1103.8,1.87,16,6,3.5,0.56
3zns,hdac7 bound with tfmo inhibitor tmp942,21,2743.1,7.91,18,18,-1.0,0.57
6jaq,crystal structure of abc transporter alpha-glycoside-binding mutant protein r356a in complex with glucose,9,1103.8,1.86,16,6,3.5,0.56
6j9y,crystal structure of abc transporter alpha-glycoside-binding protein in complex with maltose,9,1103.8,1.89,16,6,3.5,0.56
6czf,the structure of e. coli purf in complex with ppgpp-mg,23,3293.3,5.60,57,13,10.0,0.78
6jao,crystal structure of abc transporter alpha-glycoside-binding mutant protein r356a in complex with palatinose,9,1103.8,1.88,16,6,3.5,0.56
1ec9,e. coli glucarate dehydratase bound to xylarohydroxamate,22,3064.9,4.47,30,29,-0.5,0.86
6jag,crystal structure of abc transporter alpha-glycoside-binding protein in complex with sucrose,9,1103.8,1.87,16,6,3.5,0.56
6jad,crystal structure of abc transporter alpha-glycoside-binding protein in complex with palatinose,9,1103.8,1.85,16,6,3.5,0.56
6hsh,crystal structure of schistosoma mansoni hdac8 complexed with quisinostat,17,2482.7,7.79,13,20,-2.0,0.65
4d1j,the structure of the gh35 beta-galactosidase bgl35a from cellvibrio japonicas in complex with 1-deoxygalactonojirimycin,16,2311.9,6.76,16,21,-3.0,0.75
6jbb,crystal structure of abc transporter alpha-glycoside-binding mutant protein w287a in complex with sucrose,9,1103.8,1.86,16,6,3.5,0.56
3znr,hdac7 bound with inhibitor tmp269,20,2569.7,8.17,13,18,-2.0,0.55
6jbe,crystal structure of abc transporter alpha-glycoside-binding mutant protein w287a in complex with glucose,9,1103.8,1.89,16,6,3.5,0.56
6jan,crystal structure of abc transporter alpha-glycoside-binding mutant protein r356a in complex with maltose,9,1103.8,1.86,16,6,3.5,0.56
3k5x,crystal structure of dipeptidase from streptomics coelicolor complexed with phosphinate pseudodipeptide l-ala-d-asp at 1.4a resolution.,16,2241.9,4.13,20,18,1.0,0.75
6jam,crystal structure of abc transporter alpha-glycoside-binding mutant protein r356a in complex with trehalose,9,1103.8,1.86,16,6,3.5,0.56
6jb4,crystal structure of abc transporter alpha-glycoside-binding mutant protein w287a in complex with maltose,9,1103.8,1.89,16,6,3.5,0.56
6jb0,crystal structure of abc transporter alpha-glycoside-binding mutant protein w287a in complex with trehalose,9,1103.8,1.86,16,6,3.5,0.56
6hrq,crystal structure of schistosoma mansoni hdac8 complexed with ncc-149,16,2205.5,4.92,17,17,0.0,0.69
2i19,t. brucei farnesyl diphosphate synthase complexed with bisphosphonate,18,2451.0,1.15,20,23,-4.0,0.94
3egt,t. brucei farnesyl diphosphate synthase complexed with bisphosphonate bph-722,26,3552.7,6.12,24,31,-5.5,0.81
4ryd,x-ray structure of human furin in complex with the competitive inhibitor para-guanidinomethyl-phac-r-tle-r-amba,14,1556.3,3.68,7,10,-3.0,0.57
6hm1,structural and thermodynamic signatures of ligand binding to an enigmatic chitinase-d from serratia proteamaculans,20,2859.8,9.94,12,15,-4.0,0.55
4azc,"differential inhibition of the tandem gh20 catalytic modules in the pneumococcal exo-beta-d-n-acetylglucosaminidase, strh",13,2029.3,7.12,12,15,-3.5,0.69
2ihj,crystal structure of multifunctional sialyltransferase from pasteurella multocida with cmp-3f-neu5ac bound,30,3816.2,16.08,20,17,-0.5,0.50
4oma,the crystal structure of methionine gamma-lyase from citrobacter freundii in complex with l-cycloserine pyridoxal-5'-phosphate,19,2517.3,9.16,15,11,0.0,0.58
5my8,crystal structure of srpk1 in complex with sphinx31,25,3430.3,15.17,11,13,-1.0,0.36
3jyr,crystal structures of the gach receptor of streptomyces glaucescens gla.o in the unliganded form and in complex with acarbose and an acarbose homolog. comparison with acarbose-loaded maltose binding protein of salmonella typhimurium.,11,1803.6,5.55,16,9,-1.0,0.73
2zym,crystal structure of cyclo/maltodextrin-binding protein complexed with alpha-cyclodextrin,10,1467.2,8.70,9,7,0.0,0.50
3hmp,crystal structure of human mps1 catalytic domain in complex with a quinazolin ligand compound 4,15,2069.6,10.81,7,8,-1.0,0.40
5yl2,crystal structure of t2r-ttl-y28 complex,32,3729.8,10.05,20,25,-3.0,0.50
3ldp,crystal structure of human grp78 (70kda heat shock protein 5 / bip) atpase domain in complex with small molecule inhibitor,18,2244.5,3.31,20,12,0.0,0.67
4f6w,crystal structure of human cdk8/cycc in complex with compound 1 (n-[3- tert-butyl-1-(4-methylphenyl)-1h-pyrazol-5-yl]-4-[2-({[3-tert-butyl- 1-(4-methylphenyl)-1h-pyrazol-5-yl]carbamoyl}amino)ethyl]piperazine- 1-carboxamide),33,4721.5,19.93,23,15,1.0,0.36
5f2r,crystal structure of human grp78 (70kda heat shock protein 5 / bip) atpase domain in complex with amp-pcp,28,3402.0,5.66,22,22,-4.0,0.64
3hmo,crystal structure of human mps1 catalytic domain in complex with the inhibitor staurosporine,18,2307.3,11.16,8,9,-1.0,0.39
2qrk,crystal structure of amp-bound saccharopine dehydrogenase (l-lys forming) from saccharomyces cerevisiae,15,2049.1,12.23,7,3,0.0,0.33
4crl,crystal structure of human cdk8-cyclin c in complex with cortistatin a,18,2575.7,11.74,15,10,0.5,0.44
4hwp,crystal structure of e. coli threonyl-trna synthetase bound to a novel inhibitor,27,3891.9,7.18,42,18,5.0,0.70
4hws,crystal structure of e. coli threonyl-trna synthetase bound to a novel inhibitor,28,4030.3,6.51,42,20,4.0,0.71
4hwo,crystal structure of e. coli threonyl-trna synthetase bound to a novel inhibitor,28,4030.3,6.48,42,20,4.0,0.71
2qrl,crystal structure of oxalylglycine-bound saccharopine dehydrogenase (l-lys forming) from saccharomyces cerevisiae,9,1413.8,4.32,15,6,1.5,0.67
5ey4,crystal structure of human grp78 (70kda heat shock protein 5 / bip) atpase domain in complex with 2'-deoxy-atp,11,1407.8,1.50,23,7,3.0,0.82
6fv4,the structure of n-acetyl-d-glucosamine-6-phosphate deacetylase d267a mutant from mycobacterium smegmatis in complex with n-acetyl-d- glucosamine-6-phosphate,22,2968.8,10.13,23,15,3.5,0.50
1xr9,crystal structures of hla-b*1501 in complex with peptides from human ubch6 and epstein-barr virus ebna-3,10,1406.4,4.02,9,8,-1.0,0.70
4f6u,crystal structure of human cdk8/cycc in complex with compound 5 (1-[3- tert-butyl-1-(4-methylphenyl)-1h-pyrazol-5-yl]-3-[3-(morpholin-4-yl) propyl]urea),24,3544.2,15.84,18,11,0.5,0.42
5mks,hsp72-nbd bound to compound tci 8 - tyr15 in down-conformation,19,2306.6,2.97,21,13,0.0,0.68
4zow,crystal structure of e. coli multidrug transporter mdfa in complex with chloramphenicol,19,2791.9,17.65,7,9,-1.0,0.32
5x62,crystal structure of a carnosine n-methyltransferase bound by adohcy,7,941.1,2.32,7,6,0.5,0.57
5f1x,crystal structure of human grp78 (70kda heat shock protein 5 / bip) atpase domain in complex with atp,27,3235.8,6.14,22,18,-2.0,0.59
6fyz,development and characterization of a cns-penetrant benzhydryl hydroxamic acid class iia histone deacetylase inhibitor,18,2350.1,8.28,13,16,-1.0,0.50
4gzp,n2 neuraminidase of a/tanzania/205/2010 h3n2 in complex with oseltamivir carboxylate,19,2798.2,4.24,37,16,1.5,0.79
5aqz,hsp72 with adenosine-derived inhibitor,15,1793.1,1.59,16,11,-1.0,0.67
4ks4,"influenza neuraminidase in complex with antiviral compound (3s,4r,5r)- 4-(acetylamino)-3-{4-[(1r)-1-hydroxypropyl]-1h-1,2,3-triazol-1-yl}-5- (pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid",20,3005.3,5.14,36,15,1.0,0.75
1v1m,crosstalk between cofactor binding and the phosphorylation loop conformation in the bckd machine,18,2437.5,7.68,22,11,1.0,0.56
5evz,crystal structure of human grp78 (70kda heat shock protein 5 / bip) atpase domain in complex with adp and inorganic phosphate,25,2877.3,4.44,19,18,-3.0,0.60
1v16,crosstalk between cofactor binding and the phosphorylation loop conformation in the bckd machine,17,2264.1,7.79,17,11,0.0,0.53
5exw,crystal structure of human grp78 (70kda heat shock protein 5 / bip) atpase domain in complex with 7-deaza-atp,26,3124.7,6.58,22,16,-1.0,0.58
4ks1,"influenza neuraminidase in complex with antiviral compound (3s,4r,5r)- 4-(acetylamino)-3-amino-5-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid",19,2838.6,4.12,36,15,1.0,0.79
3mz6,crystal structure of d101l fe2+ hdac8 complexed with m344,13,1898.6,6.75,8,12,-0.5,0.54
4o2b,tubulin-colchicine complex,31,3591.4,9.58,20,23,-2.0,0.48
1v11,crosstalk between cofactor binding and the phosphorylation loop conformation in the bckd machine,17,2264.1,7.73,17,11,0.0,0.53
3zi0,structure of mycobacterium tuberculosis dxr in complex with a fosmidomycin analogue,18,2010.5,4.64,15,18,-1.5,0.72
5mkr,hsp72-nbd bound to compound tci 8 - tyr15 in up-conformation,16,1909.2,1.56,17,12,-1.0,0.69
2clh,tryptophan synthase in complex with (naphthalene-2'-sulfonyl)-2-amino- 1-ethylphosphate (f19),24,3209.7,15.42,10,9,-1.0,0.33
2cle,tryptophan synthase in complex with n-(4'-trifluoromethoxybenzoyl)-2- amino-1-ethylphosphate (f6) - lowf6 complex,21,2753.5,15.51,4,8,-2.0,0.29
1olx,roles of his291-alpha and his146-beta' in the reductive acylation reaction catalyzed by human branched-chain alpha-ketoacid dehydrogenase,20,2729.1,6.68,24,15,0.5,0.60
2cli,tryptophan synthase in complex with n-(4'- trifluoromethoxybenzenesulfonyl)-2-amino-1-ethylphosphate (f9),26,3360.0,15.57,11,10,-1.0,0.31
1olu,roles of his291-alpha and his146-beta' in the reductive acylation reaction catalyzed by human branched-chain alpha-ketoacid dehydrogenase,16,2095.8,6.07,15,11,-1.0,0.56
3zhx,structure of mycobacterium tuberculosis dxr in complex with a fosmidomycin analogue,18,2020.9,3.93,15,17,-2.0,0.72
6ibk,crystal structure of human alpha-galactosidase a in complex with alpha-galactose configured cyclosulfamidate me763,16,2286.1,6.22,11,14,-4.0,0.75
4uac,eur_01830 with acarbose,17,2111.6,3.99,18,21,-3.0,0.76
2clk,tryptophan synthase in complex with d-glyceraldehyde 3-phosphate (g3p),22,2231.4,6.05,13,12,0.5,0.45
3rr4,trna-guanine transglycosylase in complex with n-methyl-lin- benzoguanine inhibitor,16,1782.5,6.43,4,8,-2.0,0.38
4ua8,eur_01830 (maltotriose-binding protein) complexed with maltotriose,15,1988.8,4.75,18,15,-1.0,0.73
6jay,crystal structure of ostrinia furnacalis group ii chitinase catalytic domain 1 in complex with a dipyrido-pyrimidine derivative,11,1837.2,13.62,13,6,0.0,0.45
1ols,roles of his291-alpha and his146-beta' in the reductive acylation reaction catalyzed by human branched-chain alpha-ketoacid dehydrogenase,20,2729.1,6.74,24,15,0.5,0.60
6jaw,crystal structure of ostrinia furnacalis group ii chitinase catalytic domain 1 in complex with a napthalimide derivative,11,1937.6,11.54,9,10,-2.0,0.55
6jav,crystal structure of ostrinia furnacalis group ii chitinase catalytic domain 1 in complex with a piperidine-thienopyridine derivative,10,1730.3,17.62,10,3,0.0,0.30
2qwb,the x-ray structure of a complex of sialic acid and a drug resistant variant r292k of tern n9 influenza virus neuraminidase,18,2640.2,4.27,33,14,1.0,0.78
2qwf,"the x-ray structure of a complex of n-acetyl-4-guanidino-6- methyl(propyl)carboxamide-4,5-dihydro-2h-pyran-2-carboxylic acid and a drug resistant variant r292k of tern n9 influenza virus neuraminidase",19,2752.9,5.37,31,12,1.0,0.68
2z1w,"trna guanine transglycosylase tgt e235q mutant in complex with bdi (2- butyl-5,6-dihydro-1h-imidazo[4,5-d]pyridazine-4,7-dione)",17,1898.0,5.15,6,12,-3.0,0.47
1f8b,native influenza virus neuraminidase in complex with neu5ac2en,19,2811.7,5.53,35,14,1.0,0.74
1q65,"crystal structure of tgt in complex with 2,6-diamino-8-(2- dimethylaminoethylsulfanylmethyl)-3h-quinazolin-4-one crystallized at ph 5.5",15,1837.6,8.95,6,10,-2.0,0.40
2qwc,the x-ray structure of a complex of neu5ac2en and a drug resistant variant r292k of tern n9 influenza virus neuraminidase,19,2806.9,5.55,33,14,1.0,0.74
1f8c,"native influenza neuraminidase in complex with 4-amino-2-deoxy-2,3- dehydro-n-neuraminic acid",18,2645.0,4.22,35,14,1.0,0.78
2qwd,the x-ray structure of a complex of 4-amino-neu5ac2en and a drug resistant variant r292k of tern n9 influenza virus neuraminidase,18,2640.2,4.24,33,14,1.0,0.78
1f8d,"native influenza neuraminidase in complex with 9-amino-2-deoxy-2,3- dehydro-n-neuraminic acid",19,2811.7,5.55,35,14,1.0,0.74
2qwe,the x-ray structure of a complex of 4-guanidino-neu5ac2en and a drug resistant variant r292k of tern n9 influenza virus neuraminidase,19,2806.9,5.28,33,14,1.0,0.74
1f8e,"native influenza neuraminidase in complex with 4,9-diamino-2-deoxy-2, 3-dehydro-n-acetyl-neuraminic acid",18,2645.0,4.23,35,14,1.0,0.78
1s38,crystal structure of tgt in complex with 2-amino-8-methylquinazolin- 4(3h)-one,16,1917.2,5.99,6,12,-3.0,0.50
1enu,a new target for shigellosis: rational design and crystallographic studies of inhibitors of trna-guanine transglycosylase,13,1573.3,6.45,3,7,-2.0,0.38
1tjp,crystal structure of wild-type tryptophan synthase complexed with 1- [(2-hydroxylphenyl)amino]3-glycerolphosphate,24,3079.0,13.42,10,9,-1.0,0.33
3s5y,pharmacological chaperoning in human alpha-galactosidase,12,1597.0,3.35,13,9,0.5,0.67
6d3q,crystal structure of escherichia coli enolase complexed with a natural inhibitor sf2312.,18,2232.5,2.04,20,19,-1.5,0.83
1k4h,"crystal structure of trna-guanine transglycosylase (tgt) complexed with 2,6-diamino-8-propylsulfanylmethyl-3h-quinazoline-4-one",21,2671.6,10.42,9,15,-3.0,0.48
6hq7,structure of eal enzyme bd1971 - cgmp bound form,20,2904.7,12.51,24,6,3.0,0.40
4q4q,"trna-guanine transglycosylase (tgt) in complex with 2-[(thiophen-2- ylmethyl)amino]-1h,7h,8h-imidazo[4,5-g]quinazolin-8-one",12,1462.2,6.61,3,5,-1.0,0.33
6kjd,lovastatin esterase pcest inactive mutant s57a in complex with lovastatin,22,2985.7,15.14,8,6,0.5,0.23
1k4g,"crystal structure of trna-guanine transglycosylase (tgt) complexed with 2,6-diamino-8-(1h-imidazol-2-ylsulfanylmethyl)-3h-quinazoline-4- one",20,2522.2,10.32,5,11,-3.0,0.45
4q4r,"trna-guanine transglycosylase (tgt) in complex with 2-{[2-(morpholin- 4-yl)ethyl]amino}-1h,7h,8h-imidazo[4,5-g]quinazolin-8-one",16,2050.8,9.21,8,5,0.0,0.38
4kwo,trna guanine transglycosylase (tgt) in complex with furanoside-based lin-benzoguanine 3,23,2823.1,9.07,10,16,-3.0,0.48
4q4p,"trna-guanine transglycosylase (tgt) in complex with 2-{[2-(piperidin- 1-yl)ethyl]amino}-3,5-dihydro-8h-imidazo[4,5-g]quinazolin-8-one",16,2050.8,9.15,8,5,0.0,0.38
1r5y,"crystal structure of tgt in complex with 2,6-diamino-3h-quinazolin-4- one crystallized at ph 5.5",15,1750.9,7.16,4,8,-2.0,0.40
3rm9,amcase in complex with compound 3,14,2293.7,11.22,10,11,-3.0,0.57
6bs3,crystal structure of adp-bound bacterial get3-like a and b in mycobacterium tuberculosis,19,2308.4,5.72,22,12,1.0,0.63
6bs4,crystal structure of atpgammas-bound bacterial get3-like a and b in mycobacterium tuberculosis,19,2370.7,6.31,27,10,3.0,0.63
2qzr,"trna-guanine transglycosylase(tgt) in complex with 6-amino-2-[(1- naphthylmethyl)amino]-3,7-dihydro-8h-imidazo[4,5-g]quinazolin-8-one",20,2349.0,8.37,10,9,-1.0,0.45
2zkj,crystal structure of human pdk4-adp complex,24,2871.3,13.21,12,9,0.0,0.33
3gc5,"trna-guanine transglycosylase in complex with 6-amino-4-(2- aminoethyl)-2-(methylamino)-1,7-dihydro-8h-imidazo[4,5-g]quinazolin- 8-one",20,2451.7,7.12,9,15,-3.0,0.50
4leq,trna guanine transglycosylase (tgt) in complex with furanoside-based lin-benzoguanine 1,27,3289.7,11.52,12,18,-2.5,0.44
1f3e,a new target for shigellosis: rational design and crystallographic studies of inhibitors of trna-guanine transglycosylase,14,1662.3,6.43,4,8,-2.0,0.43
4pum,"trna-guanine transglycosylase (tgt) mutant d156n in complex with 6- amino-2-(methylamino)-1h,7h,8h-imidazo[4,5-g]quinazolin-8-one",15,1725.4,6.13,6,8,-1.0,0.40
4lbu,trna guanine transglycosylase (tgt) in complex with furanoside-based lin-benzoguanine 2,26,3199.5,9.63,12,20,-3.5,0.50
3rm4,amcase in complex with compound 1,19,3051.5,17.24,11,11,-3.0,0.42
1s39,crystal structure of tgt in complex with 2-aminoquinazolin-4(3h)-one,14,1610.9,6.32,4,8,-2.0,0.43
4hym,"pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.",18,2473.9,9.46,17,10,0.0,0.50
4q4s,"trna-guanine transglycosylase (tgt) in complex with 6-amino-2- [(thiophen-2-ylmethyl)amino]-1h,7h,8h-imidazo[4,5-g]quinazolin-8-one",16,1811.0,7.00,4,8,-2.0,0.38
3gc4,trna-guanine transglycosylase in complex with inhibitor,23,2857.2,9.71,10,16,-2.5,0.48
3ge7,"trna-guanine transglycosylase in complex with 6-amino-4-{2- [(cyclopentylmethyl)amino]ethyl}-2-(methylamino)-1,7-dihydro-8h- imidazo[4,5-g]quinazolin-8-one",25,3047.9,10.73,10,16,-3.0,0.44
4hy1,"pyrrolopyrimidine inhibitors of dna gyrase b and topoisomerase iv, part i: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.",17,2362.8,9.55,17,8,1.0,0.47
1kv1,p38 map kinase in complex with inhibitor 1,18,2742.4,16.55,6,7,-0.5,0.28
3iw6,human p38 map kinase in complex with a benzylpiperazin-pyrrol,24,3188.4,16.33,8,11,-1.5,0.29
5jxq,"trna-guanine transglycosylase (tgt) in complex with 6-amino-2-{[4-(2- hydroxyethyl)phenethyl]amino}-1,7-dihydro-8h-imidazo[4,5- g]quinazolin-8-one",21,2488.6,9.39,10,9,-1.0,0.43
4do4,pharmacological chaperones for human alpha-n-acetylgalactosaminidase,5,647.5,2.19,4,6,-1.0,0.80
4q4o,"trna-guanine transglycosylase (tgt) in complex with 6-amino-2-{[2- (piperidin-1-yl)ethyl]amino}-1h,7h,8h-imidazo[4,5-g]quinazolin-8-one",20,2399.6,9.75,9,8,-1.0,0.40
3iw5,human p38 map kinase in complex with an indole derivative,25,3324.3,18.08,6,9,-1.5,0.24
4do5,pharmacological chaperones for human alpha-n-acetylgalactosaminidase,5,647.5,2.18,4,6,-1.0,0.80
2zb1,crystal structure of p38 in complex with biphenyl amide inhibitor,22,3117.7,16.44,7,10,-1.5,0.32
3huc,human p38 map kinase in complex with rl40,17,2511.7,15.33,5,4,0.0,0.24
2bal,p38alpha map kinase bound to pyrazoloamine,21,2794.9,14.79,8,11,-1.5,0.33
3g0i,complex of aspergillus niger epoxide hydrolase with valpromide (2- propylpentanamide),16,2527.4,11.75,8,10,-1.5,0.50
3gcs,human p38 map kinase in complex with sorafenib,25,3765.4,19.71,13,9,1.0,0.28
5lz7,fragment-based inhibitors of lipoprotein associated phospholipase a2,20,2891.2,13.67,15,11,1.0,0.40
2bak,p38alpha map kinase bound to mpaq,25,3625.4,20.14,8,9,0.0,0.24
2gsu,structure of xac nucleotide pyrophosphatase/phosphodiesterase in complex with amp,19,2835.8,7.60,16,22,-2.5,0.74
3o8p,conformational plasticity of p38 map kinase dfg motif mutants in response to inhibitor binding,19,2751.5,15.75,6,5,0.5,0.21
3qfd,human class i mhc hla-a2 in complex with mart-1(27-35) nonameric peptide,8,1147.8,4.53,8,8,1.0,0.62
5lz4,fragment-based inhibitors of lipoprotein associated phospholipase a2,20,2777.9,14.35,10,11,0.0,0.35
5lz5,fragment-based inhibitors of lipoprotein associated phospholipase a2,20,2911.4,13.89,11,12,0.0,0.40
3gcp,human p38 map kinase in complex with sb203580,19,2831.6,16.17,7,6,0.5,0.26
4f9y,human p38 alpha mapk in complex with a novel and selective small molecule inhibitor,19,2622.3,13.07,9,10,-0.5,0.37
3hub,human p38 map kinase in complex with scios-469,25,3203.5,15.48,10,9,0.5,0.28
3hl7,crystal structure of human p38alpha complexed with sd-0006,24,3057.1,14.58,8,11,-1.5,0.33
2ewa,dual binding mode of pyridinylimidazole to map kinase p38,18,2586.6,16.25,7,4,1.5,0.22
6fhk,structure of a modified protein containing a genetically encoded phosphoserine,23,2545.5,2.82,19,16,-2.0,0.61
3roc,crystal structure of human p38 alpha complexed with a pyrimidinone compound,23,2949.8,16.68,9,8,0.5,0.26
5tbe,human p38alpha map kinase in complex with dibenzosuberone compound 2,28,3801.9,20.53,9,12,-1.5,0.29
5vi6,crystal structure of histone deacetylase 8 in complex with trapoxin a,22,2749.7,9.50,10,15,-1.5,0.45
4f9w,human p38alpha mapk in complex with a novel and selective small molecule inhibitor,20,2735.0,14.49,9,10,-0.5,0.35
3iph,crystal structure of p38 in complex with a biphenylamide inhibitor,22,3038.2,15.82,8,11,-1.5,0.32
2baj,p38alpha bound to pyrazolourea,24,3596.0,16.89,16,7,1.5,0.29
1yqj,crystal structure of p38 alpha in complex with a selective pyridazine inhibitor,25,3228.6,14.99,12,13,-0.5,0.36
3d7z,crystal structure of p38 kinase in complex with a biphenyl amide inhibitor,22,3117.7,15.49,7,10,-1.5,0.32
3hll,crystal structure of human p38alpha complexed with ph-797804,22,2861.2,16.13,9,8,0.5,0.27
3e92,crystal structure of p38 kinase in complex with a biaryl amide inhibitor,23,3257.7,16.75,7,10,-1.5,0.30
4loo,structural basis of autoactivation of p38 alpha induced by tab1 (monoclinic crystal form),21,2798.5,16.14,8,9,-0.5,0.33
2yix,triazolopyridine inhibitors of p38,27,3797.9,17.43,12,10,-0.5,0.30
4cpz,structure of the neuraminidase from the b/lyon/chu/15.216/2011 virus in complex with zanamivir,20,3039.5,7.28,36,14,1.0,0.70
3d83,crystal structure of p38 kinase in complex with a biphenyl amide inhibitor,26,3872.0,21.93,8,9,0.0,0.23
2gh9,thermus thermophilus maltotriose binding protein bound with maltotriose,9,1548.4,6.21,11,9,-0.5,0.67
3cl0,n1 neuraminidase h274y + oseltamivir,19,2839.0,2.96,37,16,1.0,0.84
3e93,crystal structure of p38 kinase in complex with a biaryl amide inhibitor,23,3505.2,20.04,8,9,0.0,0.26
4e70,crystal structure analysis of coniferyl alcohol 9-o-methyltransferase from linum nodiflorum in complex with coniferyl alcohol,16,2567.6,16.77,2,3,-1.0,0.25
3ckz,n1 neuraminidase h274y + zanamivir,21,3199.3,3.91,38,17,1.0,0.81
4v27,"structure of the gh99 endo-alpha-mannanase from bacteroides xylanisolvens in complex with mannose-alpha-1,3-isofagomine",9,1532.1,6.42,13,10,0.5,0.67
6of5,the crystal structure of dodecyloxy(naphthalen-1-yl)methylphosphonic acid in complex with red kidney bean purple acid phosphatase,15,2267.9,1.09,26,22,2.0,0.93
6hmg,"structure of the gh99 endo-alpha-mannanase from bacteroides xylanisolvens in complex with alpha-glc-1,3-(1,2-anhydro-carba- glucosamine)",12,2007.0,5.44,13,12,-1.5,0.75
5lyr,"structure of the gh99 endo-alpha-mannanase from bacteroides xylanisolvens in complex with mannose-alpha-1,3-noeuromycin",9,1532.1,6.46,13,10,0.5,0.67
5m5d,"structure of the gh99 endo-alpha-mannanase from bacteroides xylanisolvens in complex with mannose-alpha-1,3-d-glucal",9,1532.1,6.41,13,10,0.5,0.67
5m17,"structure of the gh99 endo-alpha-mannanase from bacteroides xylanisolvens in complex with mannose-alpha-1,3-1,2-dideoxymannose",9,1532.1,6.43,13,10,0.5,0.67
2qpu,sugar tongs mutant s378p in complex with acarbose,12,1569.4,4.15,8,11,-1.5,0.58
1kzn,crystal structure of e. coli 24kda domain in complex with clorobiocin,20,2650.6,12.08,15,11,-1.0,0.40
2ovv,crystal structure of the catalytic domain of rat phosphodiesterase 10a,17,2535.1,13.78,6,6,0.0,0.29
2ojg,"crystal structure of erk2 in complex with n,n-dimethyl-4-(4-phenyl-1h- pyrazol-3-yl)-1h-pyrrole-2-carboxamide",21,2830.8,7.71,13,17,-3.0,0.62
4pqa,crystal structure of succinyl-diaminopimelate desuccinylase from neisseria meningitidis mc58 in complex with the inhibitor captopril,16,1979.4,1.85,14,19,-3.0,0.75
1pme,structure of penta mutant human erk2 map kinase complexed with a specific inhibitor of human p38 map kinase,19,2727.6,14.05,12,8,1.5,0.42
2sim,the structures of salmonella typhimurium lt2 neuraminidase and its complex with a transition state analogue at 1.6 angstroms resolution,20,3056.8,8.20,29,15,0.0,0.65
2ojj,crystal structure of erk2 in complex with (s)-n-(1-(3-chloro-4- fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1h-pyrazol-3-yl)- 1h-pyrrole-2-carboxamide,26,3369.2,11.55,13,17,-3.0,0.50
2ovy,crystal structure of the catalytic domain of rat phosphodiesterase 10a,17,2535.1,13.81,6,6,0.0,0.29
3i60,crystal structure of erk2 bound to (s)-4-(2-(2-chlorophenylamino)-5- methylpyrimidin-4-yl)-n-(2-hydroxy-1-phenylethyl)-1h-pyrrole-2- carboxamide,27,3616.1,11.50,16,19,-3.0,0.56
3i5z,crystal structure of erk2 bound to (s)-n-(2-hydroxy-1-phenylethyl)-4- (5-methyl-2-(phenylamino)pyrimidin-4-yl)-1h-pyrrole-2-carboxamide,26,3447.5,11.50,13,19,-4.0,0.54
2o8h,crystal structure of the catalytic domain of rat phosphodiesterase 10a,16,2314.6,16.65,4,4,0.0,0.19
4rwj,"crystal structure of fgfr1 (c488a, c584s) in complex with azd4547 (n- {3-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-5-yl}-4-[(3r,5s)-3,5- dimethylpiperazin-1-yl]benzamide)",26,3502.5,14.74,10,12,-2.0,0.35
5k1d,crystal structure of a class c beta lactamase/compound1 complex,15,2043.2,5.88,19,8,3.0,0.60
4v01,fgfr1 in complex with ponatinib (co-crystallisation).,27,3920.4,20.03,11,9,-0.5,0.30
5am6,native fgfr1 with an inhibitor,16,2143.9,8.73,11,6,1.0,0.44
5k1f,crystal structure of a class c beta lactamase/compound2 complex,14,1874.6,5.91,16,8,2.0,0.57
4ocq,n-acetylhexosamine 1-phosphate kinase in complex with galnac,20,3164.3,10.51,21,14,1.0,0.60
5hjq,"crystal structure of the tbc domain of skywalker/tbc1d24 from drosophila melanogaster in complex with inositol(1,4,5)triphosphate",12,1738.2,2.03,25,6,4.0,0.75
1yq7,human farnesyl diphosphate synthase complexed with risedronate,18,2447.3,2.71,19,22,-4.0,0.89
5ja0,crystal structure of human fpps with allosterically bound fpp,20,2869.5,11.69,18,9,2.0,0.45
3gcu,human p38 map kinase in complex with rl48,26,3938.8,19.98,18,9,2.0,0.31
3q6w,structure of dually-phosphorylated met receptor kinase in complex with an mk-2461 analog with specificity for the activated receptor,22,2917.3,9.05,23,11,2.5,0.45
5am7,fgfr1 mutant with an inhibitor,13,1741.0,9.71,5,6,-1.0,0.38
2f94,crystal structure of human fpps in complex with ibandronate,21,2809.9,4.89,19,24,-5.0,0.81
2f9k,crystal structure of human fpps in complex with zoledronate and zn2+,17,2279.5,1.52,18,23,-5.0,0.94
1r0p,crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with the microbial alkaloid k-252a,21,3022.2,12.05,18,6,2.0,0.38
3zbx,"x-ray structure of c-met kinase in complex with inhibitor 6-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl) quinoline.",19,2475.6,10.96,11,10,-1.0,0.37
4ap7,"crystal structure of c-met kinase domain in complex with 4-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl)phenol",19,2524.0,10.72,11,10,-1.0,0.42
2xn3,crystal structure of thyroxine-binding globulin complexed with mefenamic acid,17,2445.9,10.35,22,8,3.0,0.53
3r7o,structure of dually phosphorylated c-met receptor kinase in complex with an mk-2461 analog,22,2917.3,9.24,23,11,2.5,0.45
3zc5,"x-ray structure of c-met kinase in complex with inhibitor (s)-6-(1-(6- (1-methyl-1h-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl) ethyl) quinoline.",22,2977.1,10.23,19,12,0.0,0.50
3a9i,crystal structure of homocitrate synthase from thermus thermophilus complexed with lys,5,780.1,1.69,7,6,1.0,0.80
3zcl,"x-ray structure of c-met kinase in complex with inhibitor (s)-3-(1- (1h-pyrrolo(2,3-b)pyridin-3-yl)ethyl)-n-isopropyl-(1,2,4)triazolo(4, 3- b)pyridazin-6-amine",19,2643.4,10.60,17,8,1.0,0.42
2xn5,crystal structure of thyroxine-binding globulin complexed with furosemide,17,2445.9,10.38,22,8,3.0,0.53
4zvi,"gyrase b in complex with 4,5-dibromopyrrolamide-based inhibitor",14,1804.1,10.60,8,7,-1.0,0.36
4pvy,crystal structure of human fpps in complex with [({5-[4-(propan-2- yloxy)phenyl]pyridin-3-yl}amino)methanediyl]bis(phosphonic acid),23,3217.8,6.00,21,25,-5.0,0.78
6gzd,crystal structure of human csnk1a1 with a86,19,2338.7,10.54,7,10,-2.0,0.37
3zxz,x-ray structure of pf-04217903 bound to the kinase domain of c-met,21,2695.2,10.58,11,12,-2.0,0.43
4pvx,crystal structure of human fpps in complex with [({4-[4- (cyclopropyloxy)phenyl]pyridin-2-yl}amino)methanediyl]bis(phosphonic acid),21,2882.5,5.29,18,25,-6.0,0.81
2fxu,x-ray structure of bistramide a- actin complex at 1.35 a resolution.,22,3174.6,13.92,15,7,1.0,0.36
3u6h,crystal structure of c-met in complex with pyrazolone inhibitor 26,27,3809.1,17.36,14,7,1.5,0.26
4aoi,"crystal structure of c-met kinase domain in complex with 4-(3-((1h- pyrrolo(2,3-b)pyridin-3-yl)methyl)-(1,2,4)triazolo(4,3-b)(1,2,4) triazin-6-yl)benzonitrile",18,2415.5,11.12,11,10,-1.0,0.39
3zze,"crystal structure of c-met kinase domain in complex with n'-((3z)-4- chloro-7-methyl-2-oxo-1,2-dihydro-3h-indol-3-ylidene)-2-(4- hydroxyphenyl)propanohydrazide",22,2977.1,10.24,19,12,0.0,0.50
2wgj,x-ray structure of pf-02341066 bound to the kinase domain of c-met,21,2849.3,9.64,17,8,2.5,0.43
3u6i,crystal structure of c-met in complex with pyrazolone inhibitor 58a,28,4005.8,21.82,7,5,0.0,0.18
5zo8,eg5 motor domain in complex with stlc-type inhibitor pvei0021 (p21 type),17,2450.6,10.48,13,10,-2.0,0.47
4m6u,p. putida mandelate racemase co-crystallized with tartronic acid,16,2433.2,7.74,13,15,-1.5,0.69
4fp1,"p. putida mandelate racemase co-crystallized with 3,3,3-trifluoro-2- hydroxy-2-(trifluoromethyl) propionic acid",15,2270.2,9.05,9,12,-1.5,0.53
3l3m,parp complexed with a927929,18,2517.4,7.18,13,15,-1.5,0.61
5xsr,novel orally efficacious inhibitors complexed with parp1,17,2380.0,4.15,15,17,-1.5,0.71
4v24,sphingosine kinase 1 in complex with pf-543,29,4138.5,24.61,4,10,-2.5,0.21
3l3l,parp complexed with a906894,13,1894.9,4.21,10,10,-0.5,0.62
2p53,crystal structure of n-acetyl-d-glucosamine-6-phosphate deacetylase d273n mutant complexed with n-acetyl phosphonamidate-d-glucosamine-6- phosphate,24,3244.8,7.95,29,23,3.0,0.67
2gyi,"design, synthesis, and characterization of a potent xylose isomerase inhibitor, d-threonohydroxamic acid, and high-resolution x-ray crystallographic structure of the enzyme-inhibitor complex",16,2406.8,8.61,13,18,-3.0,0.69
2rd6,parp complexed with a861695,12,1756.5,4.29,10,8,0.5,0.58
3gjw,parp complexed with a968427,16,2215.6,4.21,19,16,-0.5,0.75
4zo5,"pde10 complexed with 4-isopropoxy-2-(2-(3-(4-methoxyphenyl)-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)isoindoline-1,3-dione",23,3217.0,16.26,9,10,-1.0,0.35
4m0r,trianthranilate-like analogue bound to anthranilate phosphoribosyltransferase (anprt; trpd).,17,2236.7,8.82,24,9,4.0,0.47
2vb8,beta-ketoacyl-acp synthase i (kas) from e. coli with bound inhibitor thiolactomycin,18,2183.6,9.55,6,10,-1.0,0.39
4n8q,alternative substrates of mycobacterium tuberculosis anthranilate phosphoribosyl transferase,10,1373.2,5.89,15,5,2.5,0.50
1d2e,crystal structure of mitochondrial ef-tu in complex with gdp,23,2797.5,7.69,16,18,-1.0,0.61
4ij1,bianthranilate-like analogue bound to anthranilate phosphoribosyltransferase (anprt; trpd) in absence of substrates.,16,2232.6,8.00,23,8,4.0,0.50
3ewc,crystal structure of adenosine deaminase from plasmodial vivax in complex with mt-coformycin,26,3418.3,9.86,15,25,-2.0,0.54
4q93,crystal structure of resveratrol bound human tyrosyl trna synthetase,16,2189.1,8.88,11,13,-0.5,0.50
4qp2,crystal structure of erks in complex with 5-chlorobenzo[d]oxazol-2- amine,11,1620.2,10.52,5,6,-1.0,0.36
2v95,structure of corticosteroid-binding globulin in complex with cortisol,14,1999.8,9.33,12,7,0.0,0.43
4owv,anthranilate phosphoribosyl transferase from mycobacterium tuberculosis in complex with anthranilate,9,1341.0,9.80,2,3,-1.0,0.22
1ydr,"structure of camp-dependent protein kinase, alpha-catalytic subunit in complex with h7 protein kinase inhibitor 1-(5-isoquinolinesulfonyl)- 2-methylpiperazine",17,2403.6,9.61,6,12,-3.0,0.47
3r88,anthranilate phosphoribosyltransferase (trpd) from mycobacterium tuberculosis (complex with inhibitor acs145),29,3221.6,8.51,25,18,0.5,0.52
6cpw,discovery of 3(s)-thiomethyl pyrrolidine erk inhibitors for oncology,32,4467.6,15.51,26,20,-1.0,0.56
4owm,"anthranilate phosphoribosyl transferase from mycobacterium tuberculosis in complex with 3-fluoroanthranilate, prpp and magnesium",28,3048.2,8.76,20,18,-0.5,0.50
4gkm,bianthranilate-like analogue bound in the outer site of anthranilate phosphoribosyltransferase (anprt; trpd),29,3108.3,8.80,20,18,-0.5,0.48
1q8w,the catalytic subunit of camp-dependent protein kinase in complex with rho-kinase inhibitor fasudil (ha-1077),17,2321.1,10.12,5,13,-4.0,0.47
4qyy,"discovery of novel, dual mechanism erk inhibitors by affinity selection screening of an inactive kinase state",24,3390.2,15.61,14,12,-1.0,0.46
2erz,crystal structure of c-amp dependent kinase (pka) bound to hydroxyfasudil,21,2811.8,9.61,13,13,-2.0,0.48
6r1b,crystal structure of ugpb from mycobacterium tuberculosis in complex with glycerophosphocholine,19,2319.3,5.45,19,12,0.0,0.58
3dnd,camp-dependent protein kinase pka catalytic subunit with pki-5-24,15,2093.9,9.74,4,10,-3.0,0.40
1q8t,the catalytic subunit of camp-dependent protein kinase (pka) in complex with rho-kinase inhibitor y-27632,20,2660.9,9.67,8,15,-4.0,0.50
1yds,"structure of camp-dependent protein kinase, alpha-catalytic subunit in complex with h8 protein kinase inhibitor [n-(2-methylamino)ethyl]-5- isoquinolinesulfonamide",16,2205.0,9.78,4,12,-4.0,0.44
2vba,beta-ketoacyl-acp synthase i (kas) from e. coli with bound amino- thiazole inhibitor,17,2192.0,11.00,4,6,-0.5,0.29
1xh5,crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants,34,4623.8,16.91,25,22,-1.5,0.47
3dne,camp-dependent protein kinase pka catalytic subunit with pki-5-24,15,2121.1,9.02,5,8,-2.0,0.40
4hf4,crystal structure of pde10a with a biaryl ether inhibitor (1-(1-(3-(4- (benzo[d]thiazol-2-ylamino)phenoxy)pyrazin-2-yl)piperidin-4-yl) ethanol),19,2803.0,13.00,11,12,-0.5,0.47
6e7t,heterodimer of the glun1b-glun2b nmda receptor amino-terminal domains bound to allosteric inhibitor 93-6,26,3775.4,18.43,16,14,-1.0,0.46
1ydt,"structure of camp-dependent protein kinase, alpha-catalytic subunit in complex with h89 protein kinase inhibitor n-[2-(4- bromocinnamylamino)ethyl]-5-isoquinoline",25,3395.6,12.74,14,14,-2.0,0.44
6c85,crystal structure of aspartate semialdehyde dehydrogenase from blastomyces dermatitidis with p-benzoquinone,9,1109.3,1.52,14,5,2.0,0.78
3bwj,complex of pka with the bisubstrate protein kinase inhibitor lead compound arc-1034,29,3874.7,14.04,18,17,-2.0,0.48
1q8u,the catalytic subunit of camp-dependent protein kinase in complex with rho-kinase inhibitor h-1152p,16,2210.0,10.23,5,11,-3.0,0.44
6e7r,heterodimer of the glun1b-glun2b nmda receptor amino-terminal domains bound to allosteric inhibitor 93-4,24,3528.9,16.68,17,13,0.0,0.50
5isz,crystal structure of ls01-tcr/m1-hla-a*02 complex,5,769.8,2.19,9,5,0.0,0.80
1xh4,crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants,34,4690.4,15.18,26,23,-1.0,0.50
4uj2,protein kinase a in complex with an inhibitor,22,2950.0,10.21,13,13,-2.0,0.45
5m28,maltodextrin binding protein male1 from l. casei bl23 bound to maltotriose,12,1515.0,4.23,11,16,-3.0,0.75
6e7u,heterodimer of the glun1b-glun2b nmda receptor amino-terminal domains bound to allosteric inhibitor 93-31,27,3891.5,18.09,17,15,-1.0,0.48
1xh9,crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants,34,4524.7,14.56,24,23,-2.0,0.50
1stc,"camp-dependent protein kinase, alpha-catalytic subunit in complex with staurosporine",22,2990.8,12.35,8,15,-4.0,0.45
4gzx,n2 neuraminidase d151g mutant of a/tanzania/205/2010 h3n2 in complex with human sialic acid receptor,19,2747.2,4.24,37,14,2.5,0.74
4gzw,n2 neuraminidase d151g mutant of a/tanzania/205/2010 h3n2 in complex with avian sialic acid receptor,19,2747.2,4.25,37,14,2.5,0.74
4l4v,structure of human mait tcr in complex with human mr1-rl-6-me-7-oh,18,3058.7,10.04,26,10,3.5,0.61
5izf,complex of pka with the bisubstrate protein kinase inhibitor arc-1408,13,1841.4,10.30,2,6,-2.0,0.31
5mxf,photorhabdus asymbiotica lectin (phl) in complex with alpha-methyl fucoside,9,1283.1,7.13,8,3,0.0,0.33
4uj1,protein kinase a in complex with an inhibitor,25,3395.6,12.59,14,14,-2.0,0.44
6hgj,crystal structure of alpha1-antichymotrypsin variant newbg-iii: a new binding globulin in complex with aldosterone,14,1883.3,9.81,11,9,-0.5,0.43
2jds,structure of camp-dependent protein kinase complexed with a-443654,26,3508.6,12.65,17,16,-2.0,0.50
5om3,crystal structure of alpha1-antichymotrypsin variant dbs-i5: a mmp14- cleavable drug-binding serpin for doxycycline,13,1872.1,9.07,9,12,-1.5,0.54
4gzt,n2 neuraminidase d151g mutant of a/tanzania/205/2010 h3n2 in complex with oseltamivir carboxylate,17,2435.4,4.53,32,12,2.5,0.71
6abx,crystal structure of citrate synthase (msed_1522) from metallosphaera sedula in complex with citrate,14,1935.9,4.36,25,12,3.5,0.64
4ujb,protein kinase a in complex with an inhibitor,24,3306.6,12.85,13,13,-2.0,0.42
4zzy,structure of human parp2 catalytic domain bound to an isoindolinone inhibitor,17,2382.8,6.96,15,13,0.5,0.59
6ftp,crystal form 1 of alpha1-antichymotrypsin variant dbs-ii-allo: an allosterically modulated drug-binding serpin for doxorubicin,15,2192.3,8.69,10,15,-3.0,0.60
4uja,protein kinase a in complex with an inhibitor,25,3395.6,12.45,14,14,-2.0,0.44
6hgg,crystal structure of alpha1-antichymotrypsin variant newbg-iii: a new binding globulin in complex with cortisol,15,2034.6,9.16,17,8,1.5,0.47
6hgf,crystal structure of alpha1-antichymotrypsin variant newbg-ii: a new binding globulin in complex with cortisol,13,1804.6,12.67,11,5,1.5,0.31
3vhk,crystal structure of the vegfr2 kinase domain in complex with a back pocket binder,19,2825.2,19.85,5,6,-0.5,0.26
5g17,"bordetella alcaligenes hdah (t101a) bound to 9,9,9-trifluoro-8,8- dihydroxy-n-phenylnonanamide.",19,2468.0,11.83,7,13,-1.5,0.42
5om7,crystal structure of alpha1-antichymotrypsin variant dbs-ii: a drug- binding serpin for doxorubicin,17,2319.1,9.51,13,16,-2.0,0.59
4zzz,structure of human parp1 catalytic domain bound to an isoindolinone inhibitor,13,1945.9,4.20,10,12,-1.5,0.69
2x2r,crystal structure of human kinesin eg5 in complex with (r)-2-amino-3- ((4-chlorophenyl)diphenylmethylthio)propanoic acid,16,2020.5,2.91,20,11,1.0,0.75
6hgi,crystal structure of alpha1-antichymotrypsin variant newbg-iii: a new binding globulin in complex with corticosterone,13,1772.2,10.09,11,7,0.5,0.38
1moq,isomerase domain of glucosamine 6-phosphate synthase complexed with glucosamine 6-phosphate,20,2240.5,5.66,15,14,0.0,0.65
5g1a,bordetella alcaligenes hdah bound to pfsaha,16,2209.6,10.07,7,13,-1.5,0.44
2p4s,structure of purine nucleoside phosphorylase from anopheles gambiae in complex with dadme-immh,19,2532.8,9.08,11,13,0.5,0.47
4aqh,plasminogen activator inhibitor type-1 in complex with the inhibitor az3976,19,2707.7,11.59,16,8,1.0,0.47
6b98,pde2 in complex with compound 1,13,2126.1,12.82,8,8,0.5,0.38
4und,human artd1 (parp1) - catalytic domain in complex with inhibitor talazoparib,21,2869.2,4.90,21,18,-0.5,0.67
2ydt,structure of the alpha-l-arabinofuranosidase arb93a from fusarium graminearum in complexe with an iminosugar inhibitor,13,1840.4,4.99,14,12,-1.0,0.62
6b97,crystal structure of pde2 in complex with complex 9,21,3233.8,14.82,12,16,-1.0,0.48
1dgm,crystal structure of adenosine kinase from toxoplasma gondii,14,1638.0,5.21,7,11,-2.0,0.57
6b96,crystal structure of pde2 in complex with compound 16,21,3233.8,14.86,12,16,-1.0,0.48
5efj,crystal structure of danio rerio histone deacetylase 6 catalytic domain 2 in complex with hc toxin,21,2313.6,6.10,10,16,-1.5,0.57
4q3u,crystal structure of schistosoma mansoni arginase in complex with inhibitor nor-noha,8,1154.3,4.26,7,7,-1.0,0.62
4z84,pkab3 in complex with pyrrolidine inhibitor 34a,28,3742.5,12.07,22,14,0.0,0.46
1uml,crystal structure of adenosine deaminase complexed with a potent inhibitor fr233624,25,3434.1,14.51,13,18,-3.0,0.52
2e1w,crystal structure of adenosine deaminase complexed with potent inhibitors,22,3216.1,13.24,14,18,-2.5,0.55
6i8t,the catalytic fragment of poly(adp-ribose) polymerase complexed with an isoindolinone inhibitor,16,2295.2,5.44,14,14,-0.5,0.62
1efy,crystal structure of the catalytic fragment of poly (adp-ribose) polymerase complexed with a benzimidazole inhibitor,15,2174.3,6.25,12,12,-0.5,0.60
1v7a,crystal structures of adenosine deaminase complexed with potent inhibitors,21,2947.9,11.47,14,16,-1.5,0.52
1ndw,crystal structure of adenosine deaminase complexed with fr221647,18,2610.0,11.14,14,14,-0.5,0.56
6i8m,the catalytic fragment of poly(adp-ribose) polymerase complexed with isoindolinone inhibitor,16,2295.2,5.39,14,14,-0.5,0.62
4q3t,crystal structure of schistosoma mansoni arginase in complex with inhibitor noha,8,1154.3,4.24,7,7,-1.0,0.62
1qxl,crystal structure of adenosine deaminase complexed with fr235380,26,3740.2,16.08,14,20,-4.0,0.54
1o5r,crystal structure of adenosine deaminase complexed with a potent inhibitor,26,3804.8,15.41,16,22,-3.5,0.58
4a95,plasmodium vivax n-myristoyltransferase with quinoline inhibitor,40,5990.7,21.30,34,16,4.0,0.42
5eek,crystal structure of danio rerio histone deacetylase 6 catalytic domain 2 in complex with trichostatin a,16,2068.2,5.97,10,16,-1.0,0.56
1ndy,crystal structure of adenosine deaminase complexed with fr230513,21,2947.9,11.36,14,16,-1.5,0.52
1ndv,crystal structure of adenosine deaminase complexed with fr117016,20,2846.3,17.05,4,12,-3.5,0.35
3ag9,complex of pka with the bisubstrate protein kinase inhibitor arc-1012,33,4509.0,18.31,17,20,-4.0,0.48
3agl,complex of pka with the bisubstrate protein kinase inhibitor arc-1039,36,5067.3,16.84,25,23,-3.0,0.53
1ndz,crystal structure of adenosine deaminase complexed with fr235999,29,4194.5,16.52,16,22,-3.5,0.52
5g1z,plasmodium vivax n-myristoyltransferase in complex with a quinoline inhibitor (compound 1),40,5990.7,21.25,34,16,4.0,0.42
4z83,pkab3 in complex with pyrrolidine inhibitor 47a,24,3173.7,11.26,14,14,-2.0,0.46
3uxk,p. putida mandelate racemase co-crystallized with the intermediate analogue benzohydroxamate,19,2800.8,9.53,13,17,-2.5,0.63
3uxl,p. putida mandelate racemase co-crystallized with the intermediate analogue cupferron,18,2711.8,9.83,12,16,-2.5,0.61
5cbm,crystal structure of pfa-m17 with virtual ligand inhibitor,22,2741.7,9.01,17,14,-1.0,0.55
5izj,complex of pka with the bisubstrate protein kinase inhibitor arc-1411,13,1841.4,10.26,2,6,-2.0,0.31
5om2,crystal structure of alpha1-antichymotrypsin variant dbs-i1: a drug- binding serpin for doxycycline,18,2604.8,11.22,16,14,-0.5,0.50
4ad2,"structure of the gh99 endo-alpha-mannosidase from bacteroides xylanisolvens in complex with glucose-1,3-isofagomine",9,1532.1,6.41,13,10,0.5,0.67
6eif,dyrk1a in complex with xmd7-117,18,2537.4,13.04,7,10,-2.0,0.39
4zzx,structure of parp2 catalytic domain bound to an isoindolinone inhibitor,16,2294.4,5.15,13,13,-0.5,0.62
4r76,structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor,24,3069.8,10.11,17,14,-1.0,0.50
4r3w,"crystal structure analysis of the 1,2,3-tricarboxylate benzoic acid bound to sp-asadh-2'5'-adp complex",22,2337.3,8.20,15,7,2.0,0.41
4n9a,"e. coli sliding clamp in complex with (r)-6-chloro-2,3,4,9-tetrahydro- 1h-carbazole-1-carboxylic acid",11,1565.2,9.44,13,3,2.5,0.36
4ovh,"e. coli sliding clamp in complex with (r)-6-bromo-9-(2- (carboxymethylamino)-2-oxoethyl)-2,3,4,9-tetrahydro-1h-carbazole-2- carboxylic acid",16,2292.6,9.22,19,8,2.5,0.50
3kjd,"human poly(adp-ribose) polymerase 2, catalytic fragment in complex with an inhibitor abt-888",14,2067.6,4.23,13,13,-0.5,0.71
4mjp,e. coli sliding clamp in complex with (r)-vedaprofen,16,2460.2,7.19,25,7,3.5,0.56
3qqs,anthranilate phosphoribosyltransferase (trpd) from mycobacterium tuberculosis (complex with inhibitor acs172),28,2968.3,7.47,20,18,-0.5,0.50
3uu1,anthranilate phosphoribosyltransferase (trpd) from mycobacterium tuberculosis (complex with inhibitor acs142),23,2604.0,7.56,17,15,-0.5,0.48
4ovg,"e. coli sliding clamp in complex with (r)-9-(2-amino-2-oxoethyl)-6- chloro-2,3,4,9-tetrahydro-1h-carbazole-2-carboxylic acid",15,2181.5,9.30,19,6,3.5,0.47
5n9r,"crystal structure of usp7 in complex with a potent, selective and reversible small-molecule inhibitor",19,2927.8,6.27,23,19,1.0,0.74
4ovf,"e. coli sliding clamp in complex with (r)-6-chloro-2,3,4,9-tetrahydro- 1h-carbazole-2-carboxylic acid",15,2130.5,8.26,20,7,3.5,0.53
4ad3,"structure of the gh99 endo-alpha-mannosidase from bacteroides xylanisolvens in complex with glucose-1,3-deoxymannojirimycin",9,1532.1,6.49,13,10,0.5,0.67
6eir,dyrk1a in complex with xmd15-27-2,21,2885.0,13.13,14,12,-1.0,0.43
5tcj,crystal structure of tryptophan synthase from m. tuberculosis - aminoacrylate and brd4592-bound form,32,3332.3,8.09,20,18,1.0,0.47
6eiq,dyrk1a in complex with xmd14-124,18,2591.4,12.71,9,12,-2.0,0.44
5m04,structure of obge from escherichia coli,18,2184.4,9.38,14,10,1.0,0.50
4pnu,"e. coli sliding clamp in complex with (r)-6-bromo-9-(2-((r)-1-carboxy- 2-phenylethylamino)-2-oxoethyl)-2,3,4,9-tetrahydro-1h-carbazole-2- carboxylic acid",16,2292.6,9.30,19,8,2.5,0.50
6fh3,protein arginine kinase mcsb in the parg-bound state,11,1474.2,4.06,16,9,0.0,0.73
3twp,crystal structure of m. tuberculosis trpd in complex with an inhibitor,29,3221.6,8.45,25,18,0.5,0.52
6eij,dyrk1a in complex with hg-8-60-1,21,2933.4,12.72,11,13,-2.0,0.48
2hzl,crystal structures of a sodium-alpha-keto acid binding subunit from a trap transporter in its closed forms,12,1905.7,6.96,10,8,-1.0,0.50
4k3n,phosphonic arginine mimetics as inhibitors of the m17 aminopeptidases from plasmodium falciparum,7,1179.7,3.49,9,6,1.5,0.71
6eis,dyrk1a in complex with jwc-055,21,2956.9,11.12,12,16,-3.0,0.52
5efh,crystal structure of danio rerio histone deacetylase 6 catalytic domain 2 in complex with trifluoroketone transition state analogue,17,2110.9,6.05,8,14,-1.5,0.53
3npc,crystal structure of jnk2 complexed with birb796,31,4681.2,22.03,18,11,0.5,0.29
2gz2,"structure of aspartate semialdehyde dehydrogenase (asadh) from streptococcus pneumoniae complexed with 2',5'-adp",21,2248.7,6.63,15,7,2.0,0.43
3pwk,"crystal structure of aspartate beta-semialdehide dehydrogenase from streptococcus pneumoniae with 2',5'-adenosine diphosphate and d-2- aminoadipate",22,2337.3,8.18,15,7,2.0,0.41
5een,crystal structure of danio rerio histone deacetylase 6 catalytic domain 2 in complex with belinostat,16,2095.5,6.20,10,16,-1.0,0.56
6csq,crystal structure of danio rerio histone deacetylase 6 catalytic domain 2 in complex with cyclohexylhydroxamate,13,1691.2,5.91,8,12,-0.5,0.54
4p5z,human epha3 kinase domain in complex with quinoxaline derivatives,28,3923.7,16.69,9,14,-2.5,0.36
4llp,crystal structure of pde10a2 with fragment zt401,8,1380.2,12.23,3,3,0.0,0.25
4lm2,crystal structure of pde10a2 with fragment zt462,12,1855.7,9.22,5,7,-1.0,0.50
2rcn,crystal structure of the ribosomal interacting gtpase yjeq from the enterobacterial species salmonella typhimurium.,16,1904.7,2.32,22,13,2.5,0.75
4mrw,crystal structure of pde10a2 with fragment zt0120 (7-chloroquinolin-4- ol),13,1974.0,11.13,5,7,-1.0,0.38
4llx,crystal structure of pde10a2 with fragment zt434,11,1829.7,9.11,6,6,0.0,0.45
4lm3,crystal structure of pde10a2 with fragment zt464,13,2007.5,12.36,6,6,0.0,0.38
6css,crystal structure of danio rerio histone deacetylase 6 catalytic domain 2 in complex with cyclopentenylhydroxamate,13,1691.2,5.87,8,12,-0.5,0.54
6csr,crystal structure of danio rerio histone deacetylase 6 catalytic domain 2 in complex with phenylhydroxamate,13,1691.2,5.89,8,12,-0.5,0.54
4llj,crystal structure of pde10a2 with fragment zt214,11,1802.8,11.98,5,5,0.0,0.36
4msa,crystal structure of pde10a2 with fragment zt0449 (5-nitro-1h- benzimidazole),11,1747.2,9.43,5,7,-1.0,0.45
4msn,crystal structure of pde10a2 with fragment zt0451 (8-nitroquinoline),11,1669.3,12.40,4,4,0.0,0.27
5dh4,"pde10 complexed with 5-chloro-n-[(2,4-dimethylthiazol-5-yl) methyl]pyrazolo[1,5-a]pyrimidin-7-amine",19,2730.8,12.07,10,12,-0.5,0.47
4llk,crystal structure of pde10a2 with fragment zt217,11,1802.8,12.03,5,5,0.0,0.36
4lkq,crystal structure of pde10a2 with fragment zt017,12,1862.9,11.86,5,5,0.0,0.33
4lm1,crystal structure of pde10a2 with fragment zt450,12,1862.9,11.88,5,5,0.0,0.33
4mrz,crystal structure of pde10a2 with fragment zt0429 (4-methyl-3- nitropyridin-2-amine),12,1996.4,11.07,6,6,0.0,0.42
3c4h,"human poly(adp-ribose) polymerase 3, catalytic fragment in complex with an inhibitor dr2313",12,1707.9,4.22,11,9,0.5,0.67
4msc,crystal structure of pde10a2 with fragment zt1595 (2-[(quinolin-7- yloxy)methyl]quinoline),16,2422.6,13.55,8,7,0.0,0.38
5ef7,crystal structure of danio rerio histone deacetylase 6 catalytic domain 2 in complex with hpob,19,2463.6,7.24,17,16,0.5,0.58
4lm0,crystal structure of pde10a2 with fragment zt448,8,1380.2,12.07,3,3,0.0,0.25
5c2a,"pde10 complexed with 6-chloro-2-cyclopropyl-n-[(2,4-dimethylthiazol-5- yl)methyl]-5-methyl-pyrimidin-4-amine",16,2459.2,10.01,8,12,-1.5,0.50
4lm4,crystal structure of pde10a2 with fragment zt902,11,1720.3,12.30,4,6,-1.0,0.36
3fhb,"human poly(adp-ribose) polymerase 3, catalytic fragment in complex with an inhibitor 3-aminobenzoic acid",11,1591.8,4.26,10,8,0.5,0.64
3ui7,discovery of orally active pyrazoloquinoline as a potent pde10 inhibitor for the management of schizophrenia,15,2320.8,10.72,8,10,-0.5,0.47
2bo4,dissection of mannosylglycerate synthase: an archetypal mannosyltransferase,11,1657.1,8.37,14,3,2.0,0.45
5dh5,"pde10 complexed with n-[(1-methylpyrazol-4-yl)methyl]-5-[[(1s,2s)-2- (2-pyridyl)cyclopropyl]methoxy]pyrazolo[1,5-a]pyrimidin-7-amine",20,2941.0,13.61,10,11,-0.5,0.40
5n0f,"the catalytic domain, bcgh76, of bacillus circulans aman6 in complex with 1,6-mansifg",14,2074.4,7.85,14,15,-3.0,0.71
6g38,crystal structure of haspin in complex with tubercidin,19,2462.4,12.49,4,12,-4.0,0.32
5c1w,"pde10 complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidine",14,2167.6,10.63,6,8,-1.0,0.43
5c2h,"pde10 complexed with 6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5- methyl-2-[3-(2-quinolyl)propoxy]pyrimidin-4-amine",20,3018.9,11.76,11,14,-1.5,0.50
5c28,pde10 complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-amine,15,2334.3,11.51,6,8,-1.0,0.40
1pvn,the crystal structure of the complex between imp dehydrogenase catalytic domain and a transition state analogue mzp,32,4022.7,8.46,23,16,0.5,0.47
2i80,allosteric inhibition of staphylococcus aureus d-alanine:d-alanine ligase revealed by crystallographic studies,19,2534.5,12.97,6,8,-0.5,0.26
6g37,crystal structure of haspin in complex with 5-fluorotubercidin,19,2462.4,12.42,4,12,-4.0,0.32
4d4d,"the catalytic domain, bcgh76, of bacillus circulans aman6 in complex with 1,6-manifg",11,1550.6,4.18,14,12,-1.0,0.82
6rfn,crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-1018,21,2982.5,16.48,11,12,-0.5,0.38
6rfw,crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-1039,21,3033.5,17.53,10,11,-0.5,0.33
6g35,crystal structure of haspin in complex with 5-bromotubercidin,19,2519.9,11.88,7,10,-2.0,0.32
3v4t,e. cloacae c115d mura liganded with unag,24,3378.2,13.19,28,12,2.5,0.50
5l8y,crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-937,23,3392.5,16.93,13,16,-1.5,0.43
6g34,crystal structure of haspin in complex with 5-iodotubercidin,19,2519.9,11.96,7,10,-2.0,0.32
1nwl,"crystal structure of the ptp1b complexed with sp7343-sp7964, a ptyr mimetic",18,2458.8,2.44,27,12,3.0,0.78
5ka7,"protein tyrosine phosphatase 1b t178a mutant in complex with tcs401, closed state",16,2037.3,3.82,15,11,0.0,0.62
6g3a,crystal structure of haspin f605t mutant in complex with 5- iodotubercidin,20,2557.2,9.92,8,13,-3.0,0.40
6g36,crystal structure of haspin in complex with 5-chlorotubercidin,20,2631.0,11.31,7,12,-3.0,0.35
2azr,crystal structure of ptp1b with bicyclic thiophene inhibitor,16,2088.3,5.93,14,10,0.0,0.56
4lxz,structure of human hdac2 in complex with saha (vorinostat),17,2261.4,5.74,11,19,-2.0,0.59
2hb1,crystal structure of ptp1b with monocyclic thiophene inhibitor,16,2088.3,5.96,14,10,0.0,0.56
3ip5,structure of atu2422-gaba receptor in complex with alanine,8,1070.0,1.43,12,5,2.0,0.75
3ip9,structure of atu2422-gaba receptor in complex with gaba,14,1696.7,4.41,8,12,-2.0,0.57
1no6,"potent, selective protein tyrosine phosphatase 1b inhibitor compound 5 using a linked-fragment strategy",18,2275.1,4.81,16,11,0.0,0.56
5iwg,hdac2 with ligand brd4884,24,3149.9,10.04,16,17,-0.5,0.50
1c87,"crystal structure of protein tyrosine phosphatase 1b complexed with 2- (oxalyl-amino-4,7-dihydro-5h-thieno[2,3-c]pyran-3-carboxylic acid",14,1782.4,4.50,13,7,1.0,0.57
4ly1,structure of human hdac2 in complex with inhibitor 4-(acetylamino)-n- [2-amino-5-(thiophen-2-yl)phenyl]benzamide,23,3060.9,10.55,15,16,-0.5,0.48
5ka1,"protein tyrosine phosphatase 1b delta helix 7 mutant in complex with tcs401, closed state",16,2037.3,3.77,15,11,0.0,0.62
5g5v,crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-038,22,3170.4,13.50,15,16,-0.5,0.50
6g39,crystal structure of haspin f605y mutant in complex with 5- iodotubercidin,19,2523.6,10.48,8,11,-2.0,0.37
5ka9,"protein tyrosine phosphatase 1b l192a mutant in complex with tcs401, open state",14,1736.3,2.08,15,9,1.0,0.64
4i8n,"crystal structure of protein tyrosine phosphatase 1b in complex with an inhibitor [(4-{(2s)-2-(1,3-benzoxazol-2-yl)-2-[(4-fluorophenyl) sulfamoyl]ethyl}phenyl)amino](oxo)acetic acid",16,2032.3,5.30,14,8,0.0,0.50
5k9w,"protein tyrosine phosphatase 1b (1-301) in complex with tcs401, closed state",16,2037.3,3.99,15,11,0.0,0.62
5g2b,crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-008,22,3229.6,15.40,13,16,-1.5,0.45
5kab,"protein tyrosine phosphatase 1b delta helix 7, p185g mutant in complex with tcs401, open state",14,1736.3,2.07,15,9,1.0,0.64
3ip6,structure of atu2422-gaba receptor in complex with proline,5,522.2,0.87,6,3,0.0,0.60
5l8c,crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-039,21,3089.6,14.82,13,16,-1.5,0.48
1c86,"crystal structure of protein tyrosine phosphatase 1b (r47v,d48n) complexed with 2-(oxalyl-amino-4,7-dihydro-5h-thieno[2,3-c]pyran-3- carboxylic acid",17,2149.0,4.05,17,13,0.0,0.65
6gxq,crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-1335,20,2792.6,14.60,11,12,-0.5,0.40
5ih9,melk in complex with nvs-melk8a,17,2345.4,9.78,5,8,-2.0,0.47
3eb1,crystal structure ptp1b complex with small molecule inhibitor lzp-25,11,1418.6,2.52,11,8,0.0,0.64
5t19,"structure of ptp1b complexed with n-(3'-(1,1-dioxido-4-oxo-1,2,5- thiadiazolidin-2-yl)-4'-methyl-[1,1'-biphenyl]-4-yl)acetamide",18,2259.5,5.09,14,12,-1.0,0.56
5ix0,hdac2 with ligand brd7232,24,3149.9,10.19,16,17,-0.5,0.50
5g57,crystal structure of t. brucei pde-b1 catalytic domain with inhibitor npd-001,19,2699.7,15.71,10,11,-0.5,0.37
2f6t,protein tyrosine phosphatase 1b with sulfamic acid inhibitors,18,2289.9,5.21,18,9,1.0,0.56
2nta,crystal structure of ptp1b-inhibitor complex,16,1952.5,5.06,11,10,-1.0,0.50
1b57,"class ii fructose-1,6-bisphosphate aldolase in complex with phosphoglycolohydroxamate",17,2025.6,2.65,17,20,-0.5,0.71
1c83,crystal structure of protein tyrosine phosphatase 1b complexed with 6- (oxalyl-amino)-1h-indole-5-carboxylic acid,15,1893.5,3.97,13,9,0.0,0.60
1qxk,"monoacid-based, cell permeable, selective inhibitors of protein tyrosine phosphatase 1b",20,2738.7,5.99,23,12,1.0,0.60
3eax,crystal structure ptp1b complex with small molecule compound lzp-6,18,2465.0,6.65,19,11,1.0,0.56
1pyn,"dual-site potent, selective protein tyrosine phosphatase 1b inhibitor using a linked fragment strategy and a malonate head on the first site",22,3117.0,6.54,31,11,3.0,0.59
1gfy,residue 259 is a key determinant of substrate specificity of protein- tyrosine phosphatase 1b and alpha,16,2040.3,3.78,17,11,1.0,0.62
1bzc,human ptp1b catalytic domain complexed with tpi,17,2240.3,4.01,23,9,2.0,0.65
1c84,crystal structure of protein tyrosine phosphatase 1b complexed with 3- (oxalyl-amino)-naphthalene-2-carboxlic acid,15,1948.3,3.89,14,10,0.0,0.60
4yrd,crystal structure of capf with inhibitor 3-isopropenyl-tropolone,11,1650.2,7.16,11,10,1.5,0.55
2h4k,crystal structure of ptp1b with a monocyclic thiophene inhibitor,17,2199.4,5.58,14,12,-1.0,0.59
1ecv,crystal structure of protein tyrosine phosphatase 1b complexed with 5- iodo-2-(oxalyl-amino)-benzoic acid,15,1948.3,3.83,14,10,0.0,0.60
1onz,"oxalyl-aryl-amino benzoic acid inhibitors of ptp1b, compound 8b",18,2358.3,4.47,19,11,1.0,0.61
1kav,human tyrosine phosphatase 1b complexed with an inhibitor,17,2210.7,3.97,20,11,1.0,0.65
1c88,"crystal structure of protein tyrosine phosphatase 1b complexed with 2- (oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid",15,1893.5,4.02,13,9,0.0,0.60
2h4g,crystal structure of ptp1b with monocyclic thiophene inhibitor,16,2086.7,4.31,14,12,-1.0,0.62
1nl9,"potent, selective protein tyrosine phosphatase 1b inhibitor compound 12 using a linked-fragment strategy",19,2447.7,5.89,21,9,2.0,0.53
1l8g,"crystal structure of ptp1b complexed with 7-(1,1-dioxo-1h- benzo[d]isothiazol-3-yloxymethyl)-2-(oxalyl-amino)-4,7-dihydro-5h- thieno[2,3-c]pyran-3-carboxylic acid",16,2027.5,5.29,12,8,0.0,0.50
1bzj,human ptp1b complexed with tpicooh,17,2210.7,3.79,20,11,1.0,0.65
1xbo,ptp1b complexed with isoxazole carboxylic acid,21,2823.2,7.64,23,9,2.0,0.52
2b07,crystal structure of ptp1b with tricyclic thiophene inhibitor.,20,2595.8,6.53,19,12,0.0,0.55
2nt7,crystal structure of ptp1b-inhibitor complex,25,3247.8,9.07,25,15,0.0,0.56
1nz7,"potent, selective inhibitors of protein tyrosine phosphatase 1b using a second phosphotyrosine binding site, complexed with compound 19.",24,3099.7,8.60,27,12,2.0,0.54
1g7g,human ptp1b catalytic domain complexes with pnu179326,20,2709.1,7.06,24,12,1.0,0.60
6dpz,x-ray crystal structure of ampc beta-lactamase with inhibitor,19,2362.6,5.83,19,13,2.0,0.58
6dpy,x-ray crystal structure of ampc beta-lactamase with inhibitor,18,2194.0,5.61,16,13,1.0,0.56
2qbs,crystal structure of ptp1b-inhibitor complex,20,2595.8,6.69,19,12,0.0,0.55
2qbr,crystal structure of ptp1b-inhibitor complex,20,2595.8,6.70,19,12,0.0,0.55
2qbp,crystal structure of ptp1b-inhibitor complex,25,3247.8,9.07,25,15,0.0,0.56
1g7f,human ptp1b catalytic domain complexed with pnu177496,18,2366.0,1.92,29,10,3.0,0.67
6dpt,x-ray crystal structure of ampc beta-lactamase with nanomolar inhibitor,21,2565.7,5.20,22,16,2.0,0.62
1xgi,ampc beta-lactamase in complex with 3-(3-nitro-phenylsulfamoyl)- thiophene-2-carboxylic acid,17,2079.9,6.25,14,11,1.0,0.53
1ony,"oxalyl-aryl-amino benzoic acid inhibitors of ptp1b, compound 17",21,2754.7,5.75,24,11,2.0,0.57
3gqz,ampc beta-lactamase in complex with fragment-based inhibitor,9,1351.3,6.84,9,3,1.0,0.44
2zmm,crystal structure of ptp1b-inhibitor complex,20,2595.8,6.71,19,12,0.0,0.55
2qbq,crystal structure of ptp1b-inhibitor complex,20,2595.8,6.71,19,12,0.0,0.55
3gv9,ampc beta-lactamase in complex with fragment-based inhibitor,14,1736.7,3.23,13,13,0.0,0.64
4agc,crystal structure of vegfr2 (juxtamembrane and kinase domains) in complex with axitinib (ag-013736) (n-methyl-2-(3-((e)-2-pyridin-2-yl- vinyl)-1h-indazol-6-ylsulfanyl)-benzamide),22,3194.0,17.76,6,6,-1.0,0.32
2zn7,crystal structures of ptp1b-inhibitor complexes,20,2595.8,6.67,19,12,0.0,0.55
3gr2,ampc beta-lactamase in complex with fragment-based inhibitor,10,1187.5,2.09,10,10,0.5,0.70
3gtc,ampc beta-lactamase in complex with fragment-based inhibitor,12,1466.6,3.42,12,9,0.5,0.58
2pu2,ampc beta-lactamase with bound phthalamide inhibitor,19,2363.0,4.50,20,14,2.0,0.63
1nny,"potent, selective protein tyrosine phosphatase 1b inhibitor compound 23 using a linked-fragment strategy",27,3581.9,7.22,33,15,2.0,0.59
4asd,crystal structure of vegfr2 (juxtamembrane and kinase domains) in complex with sorafenib (bay 43-9006),25,3707.3,21.24,8,8,-0.5,0.32
4ag8,crystal structure of the vegfr2 kinase domain in complex with axitinib (ag-013736) (n-methyl-2-(3-((e)-2-pyridin-2-yl-vinyl)-1h- indazol-6- ylsulfanyl)-benzamide),21,3027.3,15.75,6,6,-1.0,0.33
4kif,crystal structure of methyltransferase from streptomyces hygroscopicus complexed with phenylpyruvic acid,16,2522.5,14.61,10,8,0.0,0.38
6dpx,x-ray crystal structure of ampc beta-lactamase with inhibitor,20,2352.5,5.38,17,14,1.5,0.55
4jxs,x-ray crystal structure of ampc beta-lactamase from e. coli in complex with a non-covalent inhibitor 3-[(4-carboxybenzyl) sulfamoyl]thiophene-2-carboxylic acid (compound 4),19,2322.1,4.88,17,14,1.5,0.58
4ase,crystal structure of vegfr2 (juxtamembrane and kinase domains) in complex with tivozanib (av-951),26,3740.7,19.76,8,8,-0.5,0.31
3gvb,ampc beta-lactamase in complex with fragment-based inhibitor,17,2269.1,4.36,23,11,3.0,0.71
2r9x,ampc beta-lactamase with bound phthalamide inhibitor,19,2254.5,4.34,17,14,1.0,0.58
3aaq,crystal structure of lp1ntpdase from legionella pneumophila in complex with the inhibitor arl 67156,23,2623.6,5.32,16,17,-2.0,0.57
5aa9,"structure of l1198f mutant human anaplastic lymphoma kinase in complex with pf-06463922 ((10r)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo- 10,15,16,17-tetrahydro-2h-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).",18,2275.6,9.08,10,8,-1.0,0.39
4mo4,crystal structure of anmk bound to amppcp,20,2289.5,6.76,13,16,-3.0,0.50
2q7q,crystal structure of alcaligenes faecalis aadh in complex with p- chlorobenzylamine.,17,2210.5,9.88,9,14,-3.0,0.47
2xb7,structure of human anaplastic lymphoma kinase in complex with nvp- tae684,24,2951.6,10.70,13,15,-2.5,0.42
4kz6,"crystal structure of ampc beta-lactamase in complex with fragment 13 ((2r,6r)-6-methyl-1-(3-sulfanylpropanoyl)piperidine-2-carboxylic acid)",15,1820.7,4.89,12,12,0.0,0.53
4kz3,crystal structure of ampc beta-lactamase in complex with fragment 44 (5-chloro-3-sulfamoylthiophene-2-carboxylic acid),10,1063.3,3.89,6,6,0.0,0.50
5kz0,"structure of human anaplastic lymphoma kinase in complex with 2-[(1r)- 1-{[2-amino-5-(1,3-dimethyl-1h-pyrazol-4-yl)pyridin-3-yl]oxy}ethyl]- 4-fluoro-n,n-dimethylbenzamide",21,2605.7,10.05,12,10,-0.5,0.38
2hjb,crystal structure of alcaligenes faecalis aadh in complex with p- methoxybenzylamine,17,2210.5,9.89,9,14,-3.0,0.47
5fto,crystal structure of the alk kinase domain in complex with entrectinib,23,2934.0,11.41,12,12,-1.5,0.39
2r9w,ampc beta-lactamase with bound phthalamide inhibitor,18,2194.4,4.44,17,14,1.0,0.61
1xkk,egfr kinase domain complexed with a quinazoline inhibitor- gw572016,28,4031.7,17.09,22,8,2.0,0.39
2yfx,structure of l1196m mutant anaplastic lymphoma kinase in complex with crizotinib,19,2388.6,10.23,10,8,-1.0,0.37
4kz7,"crystal structure of ampc beta-lactamase in complex with fragment 16 ((1r,4s)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1- carboxylic acid)",14,1791.2,3.31,14,11,1.0,0.64
5cap,"egfr kinase domain mutant ""tmlr"" with compound 30",20,2649.3,12.31,8,9,-1.0,0.40
4kz4,crystal structure of ampc beta-lactamase in complex with fragment 60 (2-[(propylsulfonyl)amino]benzoic acid),17,2133.9,5.94,16,13,1.0,0.59
3kr4,structure of a protease 3,24,3075.1,11.28,17,14,-1.0,0.50
5kad,"protein tyrosine phosphatase 1b n193a mutant in complex with tcs401, closed state",16,2037.3,3.77,15,11,0.0,0.62
1xjd,crystal structure of pkc-theta complexed with staurosporine at 2a resolution,23,2897.6,8.99,13,17,-3.0,0.52
4cmo,structure of the human anaplastic lymphoma kinase in complex with the inhibitor 2-((1r)-1-((3-amino-6-(2-methoxypyridin-3-yl)pyrazin-2-yl) oxy)ethyl)-4-fluoro-n-methylbenzamide,19,2392.4,10.06,10,8,-1.0,0.37
3ug2,crystal structure of the mutated egfr kinase domain (g719s/t790m) in complex with gefitinib,17,2429.8,14.97,6,5,0.0,0.24
5c8n,"egfr kinase domain mutant ""tmlr"" with compound 23",20,2649.3,12.44,8,9,-1.0,0.40
4clj,"structure of l1196m mutant human anaplastic lymphoma kinase in complex with pf-06463922 ((10r)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo- 10,15,16,17-tetrahydro-2h-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).",19,2388.6,9.94,10,8,-1.0,0.37
4dkq,crystal structure of clade a/e 93th057 hiv-1 gp120 core in complex with dmj-i-228,22,3042.0,11.61,14,16,-2.0,0.45
5caq,"egfr kinase domain mutant ""tmlr"" with compound 33",19,2535.2,12.67,6,7,-1.0,0.37
5hcy,"egfr kinase domain mutant ""tmlr"" with 3-carboxamide azaindole compound 13",22,3012.6,13.88,13,9,0.0,0.41
4rj8,egfr kinase (t790m/l858r) with inhibitor compound 8,19,2535.2,12.65,6,7,-1.0,0.37
1m2p,"crystal structure of 1,8-di-hydroxy-4-nitro-anthraquinone/ck2 kinase complex",17,2402.0,12.01,14,9,0.5,0.41
5cas,"egfr kinase domain mutant ""tmlr"" with compound 41a",20,2646.3,12.60,6,9,-2.0,0.40
5cau,"egfr kinase domain mutant ""tmlr"" with compound 41b",20,2646.3,12.63,6,9,-2.0,0.40
1m2q,"crystal structure of 1,8-di-hydroxy-4-nitro-xanten-9-one/ck2 kinase complex",17,2466.7,10.61,11,8,-1.0,0.41
1fkw,murine adenosine deaminase (d295e),20,2881.3,11.29,13,16,-1.5,0.55
1add,a pre-transition state mimic of an enzyme: x-ray structure of adenosine deaminase with bound 1-deaza-adenosine and zinc-activated water,23,3249.0,12.21,15,18,-1.5,0.57
2pvm,"structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2",18,2572.6,9.04,14,9,0.0,0.44
2oxx,"protein kinase ck2 in complex with tetrabromobenzoimidazole derivatives k17, k22 and k32",14,2039.9,11.14,10,7,0.0,0.36
1m2r,"crystal structure of 5,8-di-amino-1,4-di-hydroxy-anthraquinone/ck2 kinase complex",16,2319.6,9.41,13,9,0.0,0.44
2pvh,"structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2",16,2366.5,10.47,17,9,1.5,0.44
2oxd,"protein kinase ck2 in complex with tetrabromobenzoimidazole k17, k22 and k32 inhibitors",14,2039.9,11.05,10,7,0.0,0.36
1zog,crystal structure of protein kinase ck2 in complex with tbb- derivatives,16,2358.7,9.31,13,9,0.5,0.44
3fl5,protein kinase ck2 in complex with the inhibitor quinalizarin,19,2656.1,11.81,16,11,0.5,0.42
1om1,crystal structure of maize ck2 alpha in complex with iqa,18,2581.2,11.86,14,11,-1.0,0.44
4dff,the sar development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10a inhibitors for the treatment of schizophrenia,21,3222.9,15.67,10,11,-0.5,0.38
1zoh,crystal structure of protein kinase ck2 in complex with tbb- derivatives inhibitors,14,2032.1,10.14,6,7,-1.0,0.36
3pwd,crystal structure of maize ck2 in complex with nbc (z1),15,2155.3,13.12,7,7,-1.0,0.33
2pvl,"structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2",16,2304.2,9.67,12,11,-0.5,0.44
1zoe,crystal structure of protein kinase ck2 in complex with tbb- derivatives inhibitors,17,2354.6,9.84,12,8,0.0,0.41
3be9,"structure-based design and synthesis of novel macrocyclic pyrazolo[1, 5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase ck2 and their anticancer activities",19,2745.9,11.46,14,11,-1.0,0.42
2pvk,"structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2",19,2773.8,10.22,15,13,-0.5,0.47
1h2k,factor inhibiting hif-1 alpha in complex with hif-1 alpha fragment peptide,15,2272.0,7.21,17,15,1.0,0.67
2pvj,"structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2",17,2472.8,8.29,15,11,0.5,0.47
2qu6,crystal structure of the vegfr2 kinase domain in complex with a benzoxazole inhibitor,29,4245.3,20.94,14,9,0.5,0.38
3uuo,"the discovery of potent, selectivity, and orally bioavailable pyrozoloquinolines as pde10 inhibitors for the treatment of schizophrenia",19,2828.4,12.99,9,11,-0.5,0.42
5eei,crystal structure of danio rerio histone deacetylase 6 catalytic domain 2 in complex with saha,22,2807.8,7.08,14,22,-1.5,0.59
3owj,human ck2 catalytic domain in complex with a pyridocarbazole derivative inhibitor,16,2319.9,10.30,13,9,1.0,0.44
5osl,the crystal structure of ck2alpha in complex with compound 7,17,2508.2,9.61,13,14,0.0,0.53
6csp,crystal structure of danio rerio histone deacetylase 6 catalytic domain 2 in complex with cyclohexenylhydroxamate,18,2359.4,8.03,11,14,-0.5,0.56
5otr,the crystal structure of ck2alpha in complex with compound 14,13,1942.9,11.65,6,10,-1.0,0.38
5os8,the crystal structure of ck2alpha in complex with compound 11,13,1912.1,11.65,9,6,0.5,0.31
5csp,crystal structure of ck2alpha with compound 5 bound,12,1890.5,12.15,4,6,-2.0,0.33
5otz,the crystal structure of ck2alpha in complex with compound 1,17,2750.9,15.18,5,5,0.5,0.24
5cqu,monoclinic complex structure of protein kinase ck2 catalytic subunit with a benzotriazole-based inhibitor generated by click-chemistry,19,2703.1,9.91,17,10,1.5,0.47
6j7e,crystal structure of central domain of fleq in complex with atpgs and mg,20,2722.9,7.40,26,11,1.0,0.60
4ipj,crystal structure of r314k n-acetyl neuraminic acid synthase from neiserria meningitidis with malate bound,16,2235.9,3.57,20,18,1.5,0.81
2zjw,crystal structure of human ck2 alpha complexed with ellagic acid,13,2032.9,13.87,6,6,-1.0,0.31
3bqc,high ph-value crystal structure of emodin in complex with the catalytic subunit of protein kinase ck2,15,2207.1,12.80,8,8,-1.0,0.33
6jdl,central domain of fleq h287a mutant in complex with atpgs and mg,20,2722.9,7.47,26,11,1.0,0.60
5cu4,crystal structure of ck2alpha bound to cam4066,28,4452.2,26.30,12,12,-0.5,0.29
6hoq,human protein kinase ck2 alpha in complex with ferulic acid,14,2210.4,12.92,6,8,-1.5,0.36
6jdi,central domain of fleq h287n mutant in complex with atpgs and mg,20,2722.9,7.37,26,11,1.0,0.60
5h8g,crystal structure of ck2 with compound 7b,23,3215.0,10.53,21,17,-0.5,0.52
4del,"active site loop dynamics of a class iia fructose 1,6-bisphosphate aldolase from m. tuberculosis",13,1538.1,4.10,11,9,0.0,0.54
6ppy,"crystal structure of neunac oxime complexed with neub, an n- acetylneuraminate synthase from neisseria meningitidis",30,3997.0,12.67,23,25,-0.5,0.60
2ot1,"fructose-1,6-bisphosphate aldolase from rabbit muscle in complex with naphthol as-e phosphate, a competitive inhibitor",10,1287.1,2.48,14,6,1.0,0.60
3pe2,crystal structure of human protein kinase ck2 in complex with the inhibitor cx-5011,20,2860.3,11.13,16,13,0.0,0.45
3pe1,crystal structure of human protein kinase ck2 alpha subunit in complex with the inhibitor cx-4945,18,2711.2,11.19,15,12,0.0,0.44
4ipi,crystal structure of r314a n-acetyl neuraminic acid synthase from neiserria meningitidis with malate bound,18,2340.3,3.56,19,17,1.0,0.78
2yhw,"high-resolution crystal structures of n-acetylmannosamine kinase: insights about substrate specificity, activity and inhibitor modelling.",7,1142.6,5.04,7,3,1.0,0.57
4cd0,"structure of l1196m mutant human anaplastic lymphoma kinase in complex with 2-(5-(6-amino-5-((r)-1-(5-fluoro-2-(2h-1,2,3-triazol-2- yl) phenyl)ethoxy)pyridin-3-yl)-4-methylthiazol-2-yl)propane-1,2-diol",23,2751.0,9.28,13,11,-0.5,0.39
4dko,crystal structure of clade a/e 93th057 hiv-1 gp120 core in complex with ts-ii-224,21,2981.9,11.96,14,16,-2.0,0.48
6om8,caenorhabditis elegans udp-glucose dehydrogenase in complex with udp- xylose,28,3516.8,9.68,26,16,2.0,0.57
4i54,crystal structure of clade a/e 93th057 hiv-1 gp120 h375s core in complex with dmj-ii-121,23,3107.1,11.43,15,15,-1.0,0.43
3tzm,tgf-beta receptor type 1 in complex with sb431542,26,3585.6,9.60,24,17,0.5,0.58
4dkr,crystal structure of clade a/e 93th057 hiv-1 gp120 core in complex with aws-i-169,21,2814.2,10.02,13,16,-2.0,0.48
4dkp,crystal structure of clade a/e 93th057 hiv-1 gp120 core in complex with aws-i-50,20,2787.1,12.74,12,12,-1.0,0.40
2am4,crystal structure of n-acetylglucosaminyltransferase i in complex with udp-2-deoxy-2-fluoro-glucose,24,3379.8,9.06,22,15,-0.5,0.62
5uxf,crystal structure of mouse recon (akr1c13) in complex with cyclic di- amp,21,2845.0,11.78,13,14,-1.0,0.52
3gsm,vibrio cholerae family 3 glycoside hydrolase (nagz) bound to n- valeryl-pugnac,15,2313.8,10.49,17,10,1.0,0.53
2oxy,"protein kinase ck2 in complex with tetrabromobenzoimidazole derivatives k17, k22 and k32",11,1692.3,12.09,3,5,-1.0,0.27
3r24,crystal structure of nsp10/nsp16 complex of sars coronavirus,23,2745.0,5.61,13,18,-2.5,0.57
5t8p,crystal structure of murine nf-kappab inducing kinase (nik) bound to benzoxepin compound 2,18,2388.1,7.53,13,13,-2.0,0.56
6hly,structure in p212121 form of the pbp agtb in complex with agropinic acid from a.tumefacien r10,18,2496.1,6.12,14,12,-1.0,0.61
5t8o,crystal structure of murine nf-kappab inducing kinase (nik) bound to imidazobenzoxepin compound 3,21,2793.8,10.09,9,11,-3.0,0.48
3gs6,vibrio cholerea family 3 glycoside hydrolase (nagz)in complex with n- butyryl-pugnac,16,2476.7,13.10,17,10,1.0,0.50
2h6t,secreted aspartic proteinase (sap) 3 from candida albicans complexed with pepstatin a,7,1007.7,5.26,2,4,-1.0,0.43
2oxn,vibrio cholerae family 3 glycoside hydrolase (nagz) in complex with pugnac,17,2585.6,11.19,18,11,1.0,0.59
4lj8,clpb nbd2 r621q from t. thermophilus in complex with adp,18,2415.2,8.64,19,8,2.0,0.44
1oba,multimodular pneumococcal cell wall endolysin from phage cp-1 complexed with choline,6,1012.2,6.12,4,4,-1.0,0.50
4lj5,clpb nbd2 from t. thermophilus in complex with adp,18,2415.2,8.82,19,8,2.0,0.44
3exh,crystal structure of the pyruvate dehydrogenase (e1p) component of human pyruvate dehydrogenase complex,22,2994.9,7.98,20,16,-0.5,0.50
5cs6,crystal structure of ck2alpha with compound 3 bound,7,1108.8,6.74,3,5,-1.0,0.43
2r75,aquifex aeolicus ftsz with 8-morpholino-gtp,33,3592.9,11.74,16,14,0.0,0.33
5mod,"crystal structure of ck2alpha with n-(3-(((2-chloro-[1,1'-biphenyl]-4- yl)methyl)amino)propyl)methanesulfonamide bound",13,2008.4,13.90,6,6,0.5,0.31
5ork,the crystal structure of ck2alpha in complex with compound 6,20,2797.0,8.95,16,14,1.0,0.50
5orh,the crystal structure of ck2alpha in complex with compound 2,14,1915.5,8.66,9,10,-1.0,0.50
4btk,ttbk1 in complex with inhibitor,17,2265.6,10.36,7,8,-1.0,0.35
5mo8,"crystal structure of ck2alpha with n-(3-(((2-chloro-[1,1'-biphenyl]-4- yl)methyl)amino)propyl)methanesulfonamide bound",24,3782.2,24.99,9,11,-1.5,0.29
6k3l,crystal structure of cx-4945 bound cka1 from c. neoformans,18,2532.9,10.85,12,9,-1.0,0.44
5fns,structure of the keap1 kelch domain in complex with a small molecule inhibitor.,20,2531.1,5.24,23,13,2.0,0.60
5l9i,crystal structure of the periplasmic binding protein mota in complex with dfg from a. tumefaciens b6,22,3124.6,10.32,25,21,-1.0,0.64
5os7,the crystal structure of ck2alpha in complex with compound 4,17,2374.7,9.00,12,13,0.0,0.47
2i6b,human adenosine kinase in complex with an acetylinic inhibitor,15,2208.5,16.37,7,7,0.0,0.33
5fnr,structure of the keap1 kelch domain in complex with a small molecule inhibitor.,14,1741.4,3.59,16,6,2.0,0.50
5owl,"low salt structure of human protein kinase ck2alpha in complex with 3- aminopropyl-4,5,6,7-tetrabromobenzimidazol",15,2324.5,12.22,8,10,-1.5,0.40
6pi6,"the evolving story of atzt, a periplasmic binding protein",19,2464.0,4.91,14,19,-3.0,0.74
5oei,r. palustris rpa4515 with oxoadipate,23,2357.1,5.78,13,17,-2.0,0.57
5l9g,crystal structure of the pbp mota in complex with mannopine from a. tumefaciens b6,22,3263.4,12.24,25,20,-1.0,0.59
6pid,crystal structure of marinobacter subterrani acetylpolyamine amidohydrolase (msapah) complexed with 8-amino-n-hydroxyoctanamide,17,2379.1,6.39,9,19,-3.5,0.65
6hh3,adp-ribosylserine hydrolase arh3 of latimeria chalumnae in complex with adp-hpd,29,3379.0,7.87,14,25,-5.5,0.59
5oku,r. palustris rpa4515 with adipate,22,2268.5,5.12,13,17,-2.0,0.59
3ttm,crystal structure of spud in complex with putrescine,11,1649.9,5.22,7,12,-3.0,0.73
1x8j,crystal structure of retinol dehydratase in complex with androsterone and inactive cofactor pap,23,3314.2,10.08,33,12,5.5,0.61
5fnt,structure of the keap1 kelch domain in complex with a small molecule inhibitor.,19,2417.0,5.32,21,11,2.0,0.58
6qmk,small molecule inhibitor of the keap1-nrf2 protein-protein interaction,20,2506.0,5.28,22,12,2.0,0.60
3g0e,kit kinase domain in complex with sunitinib,20,2627.3,7.09,9,9,-1.0,0.55
6hh5,adp-ribosylserine hydrolase arh3 of latimeria chalumnae in complex with adp-hpm,26,3118.0,6.02,14,23,-4.5,0.58
4hzm,"crystal structure of salmonella typhimurium family 3 glycoside hydrolase (nagz) bound to n-[(3s,4r,5r,6r)-4,5-dihydroxy-6- (hydroxymethyl)piperidin-3-yl]butanamide",15,2313.8,10.57,17,10,1.0,0.53
5o58,structure of the inactive t.maritima pde (tm1595) d80n d154n mutant with substrate 5'-papg,18,2028.0,3.07,16,11,3.0,0.44
5l9l,crystal structure of the pbp mota from a. tumefaciens b6 in complex with glucopine,24,3412.5,11.73,26,21,-1.0,0.58
5fnu,structure of the keap1 kelch domain in complex with a small molecule inhibitor.,20,2531.1,5.22,23,13,2.0,0.60
4bps,crystal structure of chorismatase at 1.08 angstrom resolution.,24,3276.7,10.82,22,9,2.0,0.46
3ebl,crystal structure of rice gid1 complexed with ga4,23,3272.4,8.21,22,13,1.5,0.57
4oag,crystal structure of the cytosolic domain of mouse mid51 bound to adp,20,2762.8,10.94,23,12,2.5,0.55
6qmj,small molecule inhibitor of the keap1-nrf2 protein-protein interaction,19,2417.0,5.31,21,11,2.0,0.58
3kv2,high resolution structure of human arginase i in complex with the strong inhibitor n(omega)-hydroxy-nor-l-arginine (nor-noha),8,802.3,0.73,3,11,-3.5,0.88
6dsp,lsrb from clostridium saccharobutylicum in complex with ai-2,17,2506.4,8.46,16,17,-2.0,0.65
3lp4,"crystal structure of human arginase i in complex with l-lysine, 1.90a resolution.",8,970.9,0.70,6,11,-2.5,0.88
3f80,(s)-2-amino-6-nitrohexanoic acid binds to human arginase i through multiple nitro-metal coordination interactions in the binuclear manganese cluster. resolution 1.60 a.,8,802.3,0.71,3,11,-3.5,0.88
3h30,"crystal structure of the catalytic subunit of human protein kinase ck2 with 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole",14,1961.8,12.04,10,7,0.0,0.36
6pi5,"the evolving story of atzt, a periplasmic binding protein",12,1587.4,6.32,9,12,-2.0,0.67
3lp7,"crystal structure of human arginase i in complex with inhibitor n(omega)-hydroxy-l-arginine (noha), 2.04a resolution",8,802.3,0.70,3,11,-3.5,0.88
5h8e,crystal structure of ck2 with compound 7h,23,3140.4,8.84,22,19,0.0,0.57
2e92,s. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and bph-261,18,2446.4,2.91,18,23,-5.0,0.89
3d0e,crystal structure of human akt2 in complex with gsk690693,25,3640.5,16.74,9,13,-3.0,0.40
6bdy,crystal structure of the meth reactivation domain bound to sinefungin,18,2526.6,7.38,14,12,-2.0,0.61
2q8z,crystal structure of plasmodium falciparum orotidine 5'-phosphate decarboxylase complexed with 6-amino-ump,25,3328.0,11.26,25,17,1.0,0.56
2iko,crystal structure of human renin complexed with inhibitor,18,2150.4,9.61,6,10,-2.0,0.39
6bm5,crystal structure of the meth reactivation domain bound to adomet,18,2526.6,7.43,14,12,-2.0,0.61
2e91,s. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and bph-91,17,2357.4,3.68,17,22,-5.0,0.88
3d91,human renin in complex with remikiren,26,3316.1,14.49,12,16,-1.5,0.46
4s1g,renin in complex with (s)-1-(3-fluoro-5-(((s)-1-phenylethyl) carbamoyl)benzyl)-4-isopropyl-4-methyl-6-oxotetrahydropyrimidin- 2(1h)-iminium,22,2839.3,12.23,11,14,-1.5,0.45
4nkt,structure of cid1 in complex with the utp analog umpnpp,17,2162.8,5.63,17,15,0.5,0.71
4nku,structure of cid1 in complex with its short product apu,14,1711.5,5.61,9,13,-1.5,0.64
3own,potent macrocyclic renin inhibitors,32,4171.4,18.65,20,19,-0.5,0.47
1ado,"fructose 1,6-bisphosphate aldolase from rabbit muscle",14,1739.5,4.66,16,5,2.0,0.50
1lee,crystal structure of plasmepsin from p. falciparum in complex with inhibitor rs367,27,3726.3,22.47,9,13,-2.0,0.37
6ets,crystal structure of kdm4d with tetrazolhydrazide compound 1,14,2028.8,5.91,16,14,1.0,0.71
2e94,s. cerevisiae geranylgeranyl pyrophosphate synthase in complex with magnesium and bph-364,20,2959.0,9.44,23,17,-0.5,0.70
3exe,crystal structure of the pyruvate dehydrogenase (e1p) component of human pyruvate dehydrogenase complex,25,3480.1,7.26,23,21,-1.0,0.56
1lf2,crystal structure of plasmepsin ii from p falciparum in complex with inhibitor rs370,28,3840.8,20.46,12,16,-2.0,0.43
3pb8,crystal structure of the catalytic domain of human golgi-resident glutaminyl cyclase in complex with n-acetylhistamine,13,1946.0,7.41,5,16,-5.0,0.62
3pb9,crystal structure of the catalytic domain of human golgi-resident glutaminyl cyclase in complex with 1-benzylimidazole,14,2173.8,9.64,6,16,-5.0,0.57
3pb7,crystal structure of the catalytic domain of human golgi-resident glutaminyl cyclase in complex with pbd150,16,2378.9,8.40,8,18,-5.0,0.62
6g9i,crystal structure of ebolavirus glycoprotein in complex with clomipramine,14,2177.9,18.31,5,0,1.0,0.07
4i74,crystal structure of the trypanosoma brucei inosine-adenosine- guanosine nucleoside hydrolase in complex with compound uamc-00312 and allosterically inhibited by a ni2+ ion,20,2901.3,8.81,13,26,-7.5,0.70
3ubd,structure of n-terminal domain of rsk2 kinase in complex with flavonoid glycoside sl0101,26,3829.7,19.18,15,10,1.0,0.35
3hb4,17beta-hydroxysteroid dehydrogenase type1 complexed with e2b,26,3661.4,20.52,8,10,-0.5,0.31
4gue,structure of n-terminal kinase domain of rsk2 with flavonoid glycoside quercitrin,24,3517.3,20.47,10,8,0.0,0.29
1i5r,type 1 17-beta hydroxysteroid dehydrogenase em1745 complex,39,5172.0,21.25,21,17,-0.5,0.41
5ive,"linked kdm5a jmj domain bound to the inhibitor n8 ( 5-methyl-7-oxo-6- (propan-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile)",16,2173.3,5.63,16,14,1.0,0.62
4i71,crystal structure of the trypanosoma brucei inosine-adenosine- guanosine nucleoside hydrolase in complex with a trypanocidal compound,20,2842.6,8.61,16,22,-6.0,0.65
5ivv,"linked kdm5a jmj domain bound to the inhibitor n12 [3-((1-methyl-1h- pyrrolo[2,3-b]pyridin-3-yl)amino)isonicotinic acid]",15,2226.9,4.82,20,15,1.0,0.73
6gwr,structure of the kinase domain of human ddr1 in complex with a potent and selective inhibitor of ddr1 and ddr2,27,3938.3,20.44,7,10,-1.5,0.26
3lxk,structural and thermodynamic characterization of the tyk2 and jak3 kinase domains in complex with cp-690550 and cmp-6,22,2792.6,8.80,15,8,1.0,0.41
4u6w,hsmetap (f220m) in complex with 1-amino-2-propylpentyl]phosphonic acid,17,2466.8,5.12,13,20,-2.5,0.76
4u73,hsmetap(f309m) in complex with (amino(phenyl)methyl)phosphonic acid,16,2350.9,6.89,11,18,-2.5,0.69
2jxr,structure of yeast proteinase a,27,3601.5,15.49,14,18,-2.0,0.48
4u6c,hsmetap in complex with [(1r)-1-amino-3-cyclopentylpropyl]phosphonic acid,15,2211.2,5.52,11,18,-2.5,0.73
4u1b,hsmetap in complex with (1-amino-2-propylpentyl)phosphonic acid,16,2377.9,6.87,11,18,-2.5,0.69
6fba,"crystal structure of truncated aspartate transcarbamoylase from plasmodium falciparum with bound inhibitor 2,3-naphthalenediol",14,1962.2,12.34,7,4,0.0,0.36
6dq4,linked kdm5a jmj domain bound to the inhibitor gsk-j1,20,2868.5,9.65,20,17,0.0,0.65
4u6z,hsmetap(f309m) in complex with 1-amino-2-propylpentyl)phosphonic acid,15,2184.2,5.54,11,18,-2.5,0.73
1fq5,"x-ray structure of a cyclic statine inhibitor pd-129,541 bound to yeast proteinase a",29,3931.1,20.64,12,16,-2.0,0.41
4u69,hsmetap complex with (1-amino-2-methylpentyl)phosphonic acid,15,2211.2,5.55,11,18,-2.5,0.73
4u71,hsmetap(f309m) in complex with 1- amino(cyclohexyl)methy)phosphonic acid,17,2439.9,6.46,12,19,-2.5,0.71
4dq2,structure of staphylococcus aureus biotin protein ligase in complex with biotinol-5'-amp,32,4314.3,9.59,45,19,5.5,0.56
5ivy,linked kdm5a jmj domain bound to the inhibitor n16 [3-(2-(4- chlorophenyl)acetamido)isonicotinic acid],15,2305.0,6.55,20,15,1.0,0.73
5lwm,crystal structure of jak3 in complex with compound 4 (fm381),18,2364.0,9.06,13,9,-1.0,0.44
4u70,hsmetap (f309m) in complex with (1-amino-2-cyclohexylethyl)phosphonic acid,16,2273.2,5.26,12,19,-2.5,0.75
5ivc,"linked kdm5a jmj domain bound to the inhibitor n3 (4'-[(2- phenylethyl)carbamoyl][2,2'-bipyridine]-4-carboxylic acid)",15,2305.0,6.48,20,15,1.0,0.73
4f09,discovery and optimization of c-2 methyl imidazo-pyrrolopyridines as potent and orally bioavailable jak1 inhibitors with selectivity over jak2,16,2031.5,8.21,9,8,-1.0,0.38
4u43,map4k4 in complex with inhibitor (compound 6),18,2196.0,8.50,10,11,-1.0,0.44
5l3a,fragment-based discovery of 6-arylindazole jak inhibitors,14,1914.8,9.13,10,4,1.0,0.36
1m83,"crystal structure of tryptophanyl-trna synthetase complexed with atp in a closed, pre-transition state conformation",28,3380.7,8.26,25,17,1.0,0.54
4ytc,discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune disease,18,2337.8,9.31,10,9,-1.0,0.39
3qt6,crystal structure of staphylococcus epidermidis mevalonate diphosphate decarboxylase complexed with inhibitor dpgp,19,2525.3,9.48,22,7,3.0,0.53
4iva,"jak2 kinase (jh1 domain) in complex with the inhibitor trans-4-[(8as)- 2-[(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(8ah)- yl]cyclohexanecarbonitrile",19,2371.3,8.19,12,10,-1.0,0.42
2q8m,"t-like fructose-1,6-bisphosphatase from escherichia coli with amp, glucose 6-phosphate, and fructose 1,6-bisphosphate bound",17,2466.6,7.52,19,10,2.5,0.59
4gfm,"jak2 kinase (jh1 domain) with 2,6-dichloro-n-(2-oxo-2,5- dihydropyridin-4-yl)benzamide",17,2277.8,10.16,11,7,0.0,0.35
1e2l,kinetics and crystal structure of the wild-type and the engineered y101f mutant of herpes simplex virus type 1 thymidine kinase interacting with (north)-methanocarba-thymidine,16,2572.4,7.76,22,10,1.5,0.56
4yth,discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases,19,2535.4,9.16,15,8,1.0,0.42
6ndl,crystal structure of staphylococcus aureus biotin protein ligase in complex with a sulfonamide inhibitor,32,4336.4,10.02,44,20,4.5,0.56
1a99,putrescine receptor (potf) from e. coli,11,1687.8,5.72,8,12,-3.0,0.73
2on6,crystal structure of human purine nucleoside phosphorylase mutant h257f with imm-h,22,2890.3,11.71,16,13,0.5,0.45
3bgs,structure of human purine nucleoside phosphorylase with l-dadme-immh and phosphate,18,2256.4,10.36,9,11,0.0,0.39
1rr6,structure of human purine nucleoside phosphorylase in complex with immucillin-h and phosphate,18,2256.8,9.16,10,12,0.0,0.44
4jia,jak2 kinase (jh1 domain) in complex with compound 9,17,2298.5,10.15,8,6,0.0,0.35
3k8q,crystal structure of human purine nucleoside phosphorylase in complex with serme-immucillin h,16,2027.4,9.67,8,10,0.0,0.38
6p85,e.coli lpxd in complex with compound 3,25,3140.0,15.05,8,9,-1.0,0.24
4mhz,crystal structure of apo-form glutaminyl cyclase from ixodes scapularis in complex with pbd150,16,2425.4,11.05,7,17,-5.0,0.56
1pot,spermidine/putrescine-binding protein complexed with spermidine (monomer form),16,2426.3,4.77,13,20,-5.0,0.81
1e2k,kinetics and crystal structure of the wild-type and the engineered y101f mutant of herpes simplex virus type 1 thymidine kinase interacting with (north)-methanocarba-thymidine,16,2576.1,6.23,23,11,1.5,0.62
6p84,e.coli lpxd in complex with compound 2o,25,3140.0,14.98,8,9,-1.0,0.24
6pl1,trk-a in complex with ligand 1b,26,3957.5,20.06,11,9,-0.5,0.27
6p88,e.coli lpxd in complex with compound 6,25,3140.0,15.03,8,9,-1.0,0.24
4pmm,"the structure of trka kinase bound to the inhibitor n-(3-cyclopropyl- 1-phenyl-1h-pyrazol-5-yl)-2-{4-[3-methoxy-4-(4-methyl-1h-imidazol-1- yl)phenyl]-1h-1,2,3-triazol-1-yl}acetamide",24,3621.2,19.65,6,9,-1.5,0.25
6p83,e.coli lpxd in complex with compound 1o,26,3228.6,15.87,8,9,-1.0,0.23
6p8a,e.coli lpxd in complex with compound 8.1,30,3914.4,23.64,8,6,0.0,0.20
4mhy,crystal structure of a glutaminyl cyclase from ixodes scapularis in complex with pbd150,17,2592.1,11.69,7,17,-5.0,0.53
6p87,e.coli lpxd in complex with compound 5,26,3189.6,16.61,9,10,-1.0,0.27
3pn1,novel bacterial nad+-dependent dna ligase inhibitors with broad spectrum potency and antibacterial efficacy in vivo,16,2418.6,12.26,14,6,1.0,0.44
6p86,e.coli lpxd in complex with compound 4.1,28,3336.1,16.16,7,9,-0.5,0.25
2wec,"acid proteinase (penicillopepsin) (e.c.3.4.23.20) complex with phosphonate inhibitor: methyl(2s)-[1-(((n-(1-naphthaleneacetyl))-l- valyl)aminomethyl)hydroxy phosphinyloxy]-3-phenylpropanoate, sodium salt",27,3358.7,10.71,12,22,-5.0,0.52
6p89,e.coli lpxd in complex with compound 7,25,3111.1,19.32,9,8,0.0,0.24
2web,"acid proteinase (penicillopepsin) (e.c.3.4.23.20) complex with phosphonate inhibitor: methyl(2s)-[1-(((n-formyl)-l-valyl)amino-2-(2- naphthyl)ethyl)hydroxyphosphinyloxy]-3-phenylpropanoate, sodium salt",26,3397.8,12.97,12,22,-5.0,0.54
2wed,"acid proteinase (penicillopepsin) (e.c.3.4.23.20) complex with phosphonate macrocyclic inhibitor:methyl[cyclo-7[(2r)-((n-valyl) amino)-2-(hydroxyl-(1s)-1-methyoxycarbonyl-2-phenylethoxy) phosphinyloxy-ethyl]-1-naphthaleneacetamide], sodium salt",22,2896.9,15.40,8,14,-3.0,0.45
1ppm,crystallographic analysis of transition-state mimics bound to penicillopepsin: phosphorus-containing peptide analogues,28,3681.6,16.07,11,19,-4.0,0.46
3vjc,crystal structure of the human squalene synthase in complex with zaragozic acid a,30,4375.3,20.69,28,14,2.0,0.47
6mnc,crystal structure of human 17beta-hydroxysteroid dehydrogenase type 1 complexed with estrone,18,2548.3,12.54,8,10,-0.5,0.44
6gzm,crystal structure of human ckidelta with a86,20,2509.2,10.53,9,12,-3.0,0.40
4lkk,the structure of hemagglutinin l226q mutant (h3 numbering) from a avian-origin h7n9 influenza virus (a/anhui/1/2013) in complex with human receptor analog 6'slnln,16,2010.7,7.69,10,11,-0.5,0.50
6idb,"crystal structure of h7 hemagglutinin mutant h7-svtq ( a138s, p221t, l226q) with 6'sln",16,2011.1,6.80,11,12,-0.5,0.56
1bxq,acid proteinase (penicillopepsin) complex with phosphonate inhibitor.,27,3671.3,15.10,11,21,-5.0,0.52
4fai,crystal structure of mitochondrial isoform of glutaminyl cyclase from drosophila melanogaster,16,2530.4,12.99,6,16,-5.0,0.50
2c3l,identification of a buried pocket for potent and selective inhibition of chk1: prediction and verification,13,1607.4,8.87,3,5,-1.0,0.38
2brb,structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity,17,2085.6,7.43,6,9,-2.0,0.47
1nvq,the complex structure of checkpoint kinase chk1/ucn-01,20,2659.4,6.97,8,17,-5.0,0.60
4umc,structural analysis of substrate-mimicking inhibitors in complex with neisseria meningitidis 3-deoxy-d-arabino-heptulosonate 7-phosphate synthase - the importance of accommodating the active site water,15,2073.1,1.51,24,11,1.5,0.80
1ppk,crystallographic analysis of transition state mimics bound to penicillopepsin: phosphorous-containing peptide analogues,24,3170.9,14.73,9,19,-5.0,0.54
3jvs,characterization of the chk1 allosteric inhibitor binding site,15,2067.8,6.89,9,9,-2.0,0.53
2brm,structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity,17,2055.4,8.29,3,11,-4.0,0.47
3jvr,characterization of the chk1 allosteric inhibitor binding site,13,1760.8,7.50,6,7,-2.0,0.46
3uug,crystal structure of the periplasmic sugar binding protein chve,14,2148.8,5.27,23,14,0.0,0.79
1nvs,the complex structure of checkpoint kinase chk1/sb218078,20,2659.4,6.84,8,17,-5.0,0.60
6gl9,crystal structure of jak3 in complex with compound 10 (fm475),18,2364.0,9.23,13,9,-1.0,0.44
1nvr,the complex structure of checkpoint kinase chk1/staurosporine,19,2521.0,6.97,8,15,-4.0,0.58
5cks,dahp (3-deoxy-d-arabinoheptulosonate-7-phosphate) synthase in complex with dahp oxime.,18,2632.9,3.56,31,13,2.5,0.83
6glb,crystal structure of jak3 in complex with compound 20 (fm484),19,2532.6,9.19,16,9,0.0,0.47
2e9u,structure of h-chk1 complexed with a780125,20,2501.5,7.69,6,16,-5.0,0.55
4uma,structural analysis of substrate-mimicking inhibitors in complex with neisseria meningitidis 3 deoxy d arabino heptulosonate 7 phosphate synthase the importance of accommodating the active site water,15,2073.1,1.52,24,11,1.5,0.80
4i72,crystal structure of the trypanosoma brucei inosine-adenosine- guanosine nucleoside hydrolase in complex with immucillin a,19,2860.6,9.20,16,22,-6.0,0.68
3a5y,crystal structure of genx from escherichia coli in complex with lysyladenylate analog,30,4083.6,9.03,23,24,-3.5,0.57
1ppl,crystallographic analysis of transition-state mimics bound to penicillopepsin: phosphorus-containing peptide analogues,28,3782.4,14.77,11,23,-6.0,0.54
2br1,structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity,18,2115.5,8.00,3,11,-4.0,0.44
1apv,crystallographic analysis of transition state mimics bound to penicillopepsin: difluorostatine-and difluorostatone-containing peptides,6,604.8,6.11,1,1,0.0,0.17
1nw7,structure of the beta class n6-adenine dna methyltransferase rsri bound to s-adenosyl-l-homocysteine,10,1130.6,2.44,9,8,0.5,0.60
3pbb,crystal structure of human secretory glutaminyl cyclase in complex with pbd150,18,2741.2,11.02,10,18,-4.0,0.56
5ya5,crystal structure of c-met in complex with novel inhibitor,19,2575.0,11.81,11,12,-2.0,0.47
4uc5,neisseria meningitidis dah7ps-phenylalanine regulated,9,1127.4,6.43,1,6,-3.0,0.33
4umb,structural analysis of substrate-mimicking inhibitors in complex with neisseria meningitidis 3-deoxy-d-arabino-heptulosonate 7-phosphate synthase - the importance of accommodating the active site water,16,2236.0,2.96,24,11,1.5,0.75
1nw5,structure of the beta class n6-adenine dna methyltransferase rsri bound to s-adenosylmethionine,21,2580.0,11.17,10,12,-1.5,0.48
6jon,crystal structures of phage nrs-1 n300-dntps-mg2+ complex provide molecular mechanisms for substrate specificity,19,2435.8,6.23,15,15,-1.5,0.63
4gg7,crystal structure of cmet in complex with novel inhibitor,22,2965.2,10.68,19,10,1.5,0.45
6gla,crystal structure of jak3 in complex with compound 11 (fm481),18,2364.0,9.22,13,9,-1.0,0.44
6pia,crystal structure of marinobacter subterrani acetylpolyamine amidohydrolase (msapah) complexed with 6-[(3-aminopropyl)amino]-n- hydroxyhexanamide,20,2730.8,6.07,11,23,-4.0,0.65
4mss,"crystal structure of burkholderia cenocepacia family 3 glycoside hydrolase (nagz) bound to (3s,4r,5r,6s)-3-acetamido-4,5,6- trihydroxyazepane",22,3222.3,12.19,20,15,0.5,0.55
2afw,crystal structure of human glutaminyl cyclase in complex with n- acetylhistamine,14,2118.1,8.80,7,16,-4.0,0.57
6eyt,crystal structure of the salmonella effector ssek3 in complex with udp-glcnac and manganese,21,3168.1,7.47,31,17,0.0,0.71
2afx,crystal structure of human glutaminyl cyclase in complex with 1- benzylimidazole,14,2205.9,10.57,8,16,-4.0,0.57
3p7i,crystal structure of escherichia coli phnd in complex with 2- aminoethyl phosphonate,19,2426.9,4.02,18,21,-1.5,0.74
4o0x,back pocket flexibility provides group-ii pak selectivity for type 1 kinase inhibitors,24,3179.9,14.45,4,11,-4.0,0.29
4r75,structure of the periplasmic binding protein afua from actinobacillus pleuropneumoniae (exogenous sedoheptulose-7-phosphate bound),27,2918.9,4.03,22,18,0.5,0.59
1duv,crystal structure of e. coli ornithine transcarbamoylase complexed with ndelta-l-ornithine-diaminophosphinyl-n-sulphonic acid (psorn),23,3184.0,6.11,37,18,3.5,0.74
4eu0,crystal structure of peld 158-ct from pseudomonas aeruginosa pao1,13,1633.5,2.18,20,7,2.0,0.62
4hge,jak2 kinase (jh1 domain) in complex with compound 8,22,2689.0,7.51,16,11,0.0,0.45
5bv3,yeast scavenger decapping enzyme in complex with m7gdp,22,3420.8,9.34,25,18,2.0,0.64
5xvg,crystal structure of pak4 in complex with inhibitor czh226,23,2785.6,10.28,5,14,-5.0,0.39
4app,"crystal structure of the human p21-activated kinase 4 in complex with (s)-n-(5-(3-benzyl-1-methylpiperazine-4-carbonyl)-6,6-dimethyl-1,4,5, 6-tetrahydropyrrolo(3,4-c)pyrazol-3-yl)-3-phenoxybenzamide",27,3433.3,12.34,14,15,-3.0,0.44
2x4z,crystal structure of the human p21-activated kinase 4 in complex with pf-03758309,25,3040.3,12.79,6,13,-4.0,0.36
4o0y,back pocket flexibility provides group-ii pak selectivity for type 1 kinase inhibitors,22,2827.2,13.92,4,9,-3.0,0.27
4euo,structure of atu4243-gaba sensor,10,1631.8,4.94,10,7,-1.0,0.60
4e6q,jak2 kinase (jh1 domain) triple mutant in complex with compound 12,22,2712.6,8.74,15,10,0.0,0.41
2vhj,p4 protein from bacteriophage phi12 s252a mutant in complex with adp,11,1228.5,1.02,11,10,0.0,0.73
5mek,sulphotransferase-18 from arabidopsis thaliana in complex with 3'- phosphoadenosine 5'-phosphate (pap),26,3718.2,5.79,37,14,5.5,0.73
2fqy,pnra from treponema pallidum complexed with adenosine.,24,2866.9,9.00,11,16,-3.0,0.50
2fqx,pnra from treponema pallidum complexed with guanosine,22,2717.8,10.37,10,15,-3.0,0.50
2fqw,pnra from treponema pallidum as purified from e. coli (bound to inosine),20,2494.9,8.64,10,15,-3.0,0.55
5xva,crystal structure of pak4 in complex with inhibitor czh216,22,2645.6,9.42,5,14,-5.0,0.41
4e6d,jak2 kinase (jh1 domain) triple mutant in complex with compound 7,23,2853.6,10.57,15,8,1.0,0.35
6hni,"the ligand-bound, closed structure of cd0873, a substrate binding protein with adhesive properties from clostridium difficile.",6,759.5,5.25,3,2,0.0,0.33
4gii,"tyk2 (jh1) in complex with 2,6-dichloro-4-cyano-n-{2- [(cyclopropylcarbonyl)amino]pyridin-4-yl}benzamide",21,2682.8,10.13,14,10,-1.0,0.38
6c9s,"mycobacterium tuberculosis adenosine kinase bound to (2r,3r,4s,5r)-2- (6-([1,1'-biphenyl]-4-ylethynyl)-9h-purin-9-yl)-5-(hydroxymethyl) tetrahydrofuran-3,4-diol",25,3135.3,12.56,17,18,-2.0,0.48
6f1j,structure of a talaromyces pinophilus gh62 arabinofuranosidase in complex with aradnj at 1.25a resolution,15,2093.1,5.48,12,14,-3.0,0.67
4gj2,"tyk2 (jh1) in complex with 2,6-dichloro-n-[2-({[(1r,2r)-2- fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide",21,2760.5,11.05,13,9,-1.0,0.33
4gj3,"tyk2 (jh1) in complex with 2,6-dichloro-4-cyano-n-[2-({[(1r,2r)-2- fluorocyclopropyl]carbonyl}amino)pyridin-4-yl]benzamide",21,2760.5,11.16,13,9,-1.0,0.33
4gih,"tyk2 (jh1) in complex with 2,6-dichloro-n-{2-[(cyclopropylcarbonyl) amino]pyridin-4-yl}benzamide",20,2593.8,10.37,13,9,-1.0,0.35
5c3p,crystal structure of the full-length neurospora crassa t7h in complex with alpha-kg,15,2277.9,7.70,21,10,3.0,0.60
5wal,identification of an imidazopyridine scaffold to generate potent and selective tyk2 inhibitors that demonstrate activity in an in vivo psoriasis model,20,2593.8,10.48,13,9,-1.0,0.35
4jyb,"meab, a bacterial homolog of mmaa, bound to gmppnp",22,2554.4,7.92,19,10,2.5,0.45
4cc5,fragment-based discovery of 6 azaindazoles as inhibitors of bacterial dna ligase,13,2104.6,9.49,14,6,1.0,0.54
1wm1,"crystal structure of prolyl aminopeptidase, complex with pro-tboda",20,2753.1,7.69,15,13,0.0,0.55
5e1s,the crystal structure of insr tyrosine kinase in complex with the inhibitor bi 885578,23,2835.1,10.81,15,13,-0.5,0.39
3iss,crystal structure of enolpyruvyl-udp-glcnac synthase (mura):udp-n- acetylmuramic acid:phosphite from escherichia coli,28,3884.6,17.35,28,14,1.5,0.46
1tsy,thymidylate synthase r179k mutant,15,1981.4,4.35,20,12,2.0,0.67
1jmg,contributions of orientation and hydrogen bonding to catalysis in asn- 229 mutants of thymidylate synthase,15,1927.4,4.47,18,10,2.0,0.60
1nje,thymidylate synthase with 2'-deoxycytidine 5'-monophosphate (dcmp),15,1981.4,4.47,20,12,2.0,0.67
6c9v,"mycobacterium tuberculosis adenosine kinase bound to (2r,3s,4r,5r)-2- (hydroxymethyl)-5-(6-(4-phenylpiperazin-1-yl)-9h-purin-9-yl) tetrahydrofuran-3,4-diol",24,2950.8,11.15,19,18,-1.0,0.50
1bp0,thymidylate synthase r23i mutant,15,1974.7,7.28,15,12,1.0,0.60
1jmf,contributions of orientation and hydrogen bonding to catalysis in asn- 229 mutants of thymidylate synthase,15,1955.9,5.51,18,10,2.0,0.60
1njc,"thymidylate synthase, mutation, n229d with 2'-deoxycytidine 5'- monophosphate (dcmp)",16,2168.3,6.65,18,12,1.0,0.62
1nja,"thymidylate synthase, mutation, n229c with 2'-deoxycytidine 5'- monophosphate (dcmp)",14,1867.3,4.69,18,10,2.0,0.64
1cet,chloroquine binds in the cofactor binding site of plasmodium falciparum lactate dehydrogenase.,12,1780.3,9.88,4,5,-1.0,0.33
1njd,"thymidylate synthase, mutation, n229d with 2'-deoxyuridine 5'- monophosphate (dump)",15,1978.4,4.41,18,12,1.0,0.67
2isw,"structure of giardia fructose-1,6-biphosphate aldolase in complex with phosphoglycolohydroxamate",17,1949.7,0.81,19,22,-0.5,0.82
4l4z,crystal structures of the lsrr proteins complexed with phospho-ai-2 and its two different analogs reveal distinct mechanisms for ligand recognition,17,2119.8,9.28,7,8,-1.0,0.35
4l50,crystal structures of the lsrr proteins complexed with phospho-ai-2 and its two different analogs reveal distinct mechanisms for ligand recognition,18,2340.1,9.06,8,9,-1.0,0.39
4l51,crystal structures of the lsrr proteins complexed with phospho-ai-2 and its two different analogs reveal distinct mechanisms for ligand recognition,17,2119.8,8.31,7,8,-1.0,0.35
3fcq,thermolysin inhibition,16,2440.1,9.95,16,15,0.5,0.56
4tln,binding of hydroxamic acid inhibitors to crystalline thermolysin suggests a pentacoordinate zinc intermediate in catalysis,13,1969.4,7.72,14,13,0.5,0.62
3ohi,"structure of giardia fructose-1,6-biphosphate aldolase in complex with 3-hydroxy-2-pyridone",23,2648.3,1.56,32,25,1.5,0.78
4aq6,"substrate bound homogentisate 1,2-dioxygenase",12,1696.7,5.14,17,12,-2.0,0.75
1zdp,crystal structure analysis of thermolysin complexed with the inhibitor (s)-thiorphan,18,2608.3,9.66,14,17,-1.5,0.56
1z9g,crystal structure analysis of thermolysin complexed with the inhibitor (r)-retro-thiorphan,16,2386.1,9.92,14,13,0.5,0.50
2tmn,crystallographic structural analysis of phosphoramidates as inhibitors and transition-state analogs of thermolysin,16,2553.8,12.30,15,13,0.5,0.50
1os0,thermolysin with an alpha-amino phosphinic inhibitor,23,3336.8,7.04,19,24,-2.5,0.65
4etz,crystal structure of peld 158-ct from pseudomonas aeruginosa pao1,13,1633.5,2.07,20,7,2.0,0.62
1qf0,thermolysin (e.c.3.4.24.27) complexed with (2-sulphanyl-3- phenylpropanoyl)-phe-tyr. parameters for zn-bidentation of mercaptoacyldipeptides in metalloendopeptidase,25,3704.6,9.10,20,24,-2.5,0.60
4eb8,"crystal structure of purine nucleoside phosphorylase (w16y, w94y, w178y, h257w) mutant from human complexed with dadme-immg and phosphate",19,2520.9,13.44,8,9,-0.5,0.32
1bxo,acid proteinase (penicillopepsin) (e.c.3.4.23.20) complex with phosphonate inhibitor: methyl cyclo[(2s)-2-[[(1r)-1-(n-(l-n-(3- methylbutanoyl)valyl-l-aspartyl)amino)-3-methylbut yl] hydroxyphosphinyloxy]-3-(3-aminomethyl) phenylpropanoate,30,3905.6,14.75,13,23,-5.0,0.50
1qf2,thermolysin (e.c.3.4.24.27) complexed with (2-sulphanyl-3- phenylpropanoyl)-gly-(5-phenylproline). parameters for zn- monodentation of mercaptoacyldipeptides in metalloendopeptidase,19,2731.1,6.45,18,19,-0.5,0.63
5tmn,slow-and fast-binding inhibitors of thermolysin display different modes of binding. crystallographic analysis of extended phosphonamidate transition-state analogues,19,2893.1,11.42,19,19,-0.5,0.58
1qf1,thermolysin (e.c.3.4.24.27) complexed with (2-sulphanylheptanoyl)-phe- ala. parameters for zn-bidentation of mercaptoacyldipeptides in metalloendopeptidase,22,3254.9,9.96,18,22,-2.5,0.59
6n79,structure of the human jak1 kinase domain with compound 20,23,2902.0,9.62,14,11,-1.0,0.39
1tmn,binding of n-carboxymethyl dipeptide inhibitors to thermolysin determined by x-ray crystallography. a novel class of transition- state analogues for zinc peptidases,18,2744.8,9.91,17,18,-0.5,0.61
6n7b,structure of the human jak1 kinase domain with compound 38,22,2762.0,8.86,14,11,-1.0,0.41
1tlp,crystallographic structural analysis of phosphoramidates as inhibitors and transition-state analogs of thermolysin,20,3086.7,11.57,20,20,-0.5,0.60
6n78,structure of the human jak1 kinase domain with compound 21,23,2902.0,9.84,14,11,-1.0,0.39
6n7d,structure of the human jak1 kinase domain with compound 54,23,2902.0,9.63,14,11,-1.0,0.39
4tmn,slow-and fast-binding inhibitors of thermolysin display different modes of binding. crystallographic analysis of extended phosphonamidate transition-state analogues,19,2969.6,11.66,16,18,-1.5,0.58
6nyv,structure of spastin aaa domain in complex with a quinazoline-based inhibitor,18,2061.1,7.42,13,10,0.0,0.44
4wov,"crystal structure of tyrosine kinase 2 jh2 (pseudo kinase domain) complexed with bms-066 aka 2-methoxy-n-({6-[3-methyl-7-(methylamino)- 3,5,8,10-tetraazatricyclo[7.3.0.0, 6]dodeca-1(9),2(6),4,7,11-pentaen- 11-yl]pyridin-2-yl}methy l)acetamide",23,3032.6,7.30,24,15,2.0,0.57
3rwp,"discovery of a novel, potent and selective inhibitor of 3- phosphoinositide dependent kinase (pdk1)",23,2857.4,7.10,13,17,-3.0,0.57
2gvv,structure of diisopropyl fluorophosphatase (dfpase) in complex with dicyclopentylphosphoroamidate (dcppa),17,2236.8,8.12,10,15,-2.5,0.53
4r73,structure of the periplasmic binding protein afua from actinobacillus pleuropneumoniae (endogenous glucose-6-phosphate and mannose-6- phosphate bound),25,2769.8,4.05,21,17,0.5,0.60
5n84,ttk kinase domain in complex with mps-bay2b,20,2817.3,12.11,10,12,-2.0,0.45
5b25,crystal structure of human pde1b with inhibitor 3,21,3141.1,17.64,10,12,0.0,0.38
5n93,ttk kinase domain in complex with tc-mps1-12,22,2895.3,12.12,13,11,0.0,0.41
5mrb,crystal structure of human mps1 (ttk) in complex with cpd-5,25,3168.1,8.99,18,18,-1.0,0.52
4aj4,"rat ldha in complex with 4-((2-allylsulfanyl-1,3-benzothizol-6-yl) amino)-4-oxo-butanoic acid",17,2123.6,12.45,7,4,0.0,0.24
1fh7,crystal structure of the xylanase cex with xylobiose-derived inhibitor deoxynojirimycin,7,1248.3,8.24,10,6,0.0,0.57
4aji,"rat ldha in complex with 2-((3,4-dimethoxyphenyl)methyl))propanedioic acid",18,2436.4,8.93,25,12,2.5,0.61
1fh9,crystal structure of the xylanase cex with xylobiose-derived lactam oxime inhibitor,15,2397.1,6.01,21,21,-1.0,0.80
1j01,crystal structure of the xylanase cex with xylobiose-derived inhibitor isofagomine lactam,14,2203.5,6.00,20,20,-1.0,0.79
4aje,rat ldha in complex with 2-(4-bromophenoxy)propanedioic acid,14,1954.5,6.72,24,9,3.5,0.64
5yfs,"crystal structure of ribose-1,5-bisphosphate isomerase mutant c135s from pyrococcus horikoshii ot3 in complex with ribose-1,5- bisphosphate",25,3160.6,8.23,34,14,5.0,0.56
1fhd,crystal structure of the xylanase cex with xylobiose-derived imidazole inhibitor,15,2397.1,6.12,21,21,-1.0,0.80
4qpd,crystal structure of the hydrolase domain of 10-formyltetrahydrofolate dehydrogenase (wild-type) complex with tetrahydrofolate,24,3221.4,12.41,12,15,-2.0,0.46
1fh8,crystal structure of the xylanase cex with xylobiose-derived isofagomine inhibitor,7,1248.3,8.21,10,6,0.0,0.57
4ajl,"rat ldha in complex with 3-(ethylcarbamoylamino)-n-(2-methyl-1,3- benzothiazol-6-yl)propanamide",20,2492.6,14.74,8,5,0.0,0.25
1v0l,xylanase xyn10a from streptomyces lividans in complex with xylobio- isofagomine at ph 5.8,7,1248.3,8.36,10,6,0.0,0.57
1v0k,xylanase xyn10a from streptomyces lividans in complex with xylobio- deoxynojirimycin at ph 5.8,7,1248.3,8.32,10,6,0.0,0.57
4mnp,structure of the sialic acid binding protein from fusobacterium nucleatum subsp. nucleatum atcc 25586,18,2407.0,7.10,24,17,-1.0,0.67
5lvd,thermolysin in complex with inhibitor (jc67),19,2786.5,9.51,19,19,-0.5,0.58
5m9w,experimental mad phased structure of thermolysin in complex with inhibitor jc65.,19,2786.5,9.76,19,19,-0.5,0.58
5yft,"crystal structure of ribose-1,5-bisphosphate isomerase mutant d204n from pyrococcus horikoshii ot3 in complex with ribose-1,5- bisphosphate",24,3016.4,7.03,35,13,6.0,0.58
1t5f,arginase i-aoh complex,16,1833.8,0.99,9,25,-7.0,0.88
5n34,thermolysin in complex with inhibitor jc276,20,2902.2,10.05,19,17,0.5,0.50
5n3y,thermolysin in complex with inhibitor jc267,21,3013.3,10.09,19,19,-0.5,0.52
5n31,thermolysin in complex with inhibitor jc277,23,3323.0,8.86,21,21,-0.5,0.57
5ma7,structure of thermolysin in complex with inhibitor (jc306).,20,2953.2,10.51,19,19,-0.5,0.55
5mnr,thermolysin in complex with inhibitor jc256,21,3013.3,10.13,19,19,-0.5,0.52
5n3v,thermolysin in complex with inhibitor jc292,24,3458.0,9.53,20,22,-1.5,0.54
3b50,structure of h. influenzae sialic acid binding protein bound to neu5ac.,19,2493.6,8.03,25,18,-1.0,0.63
5n2t,thermolysin in complex with inhibitor jc287,20,2902.2,10.18,19,17,0.5,0.50
5n2z,thermolysin in complex with inhibitor jc286,20,2902.2,10.20,19,17,0.5,0.50
5lif,thermolysin in complex with inhibitor,24,3434.1,8.45,21,23,-1.5,0.58
5jss,thermolysin in complex with jc149.,22,3124.4,9.79,19,21,-1.5,0.55
5lwd,thermolysin in complex with inhibitor (jc96),21,3013.3,10.15,19,19,-0.5,0.52
6hke,matc (rpa3494) from rhodopseudomonas palustris with bound malate,17,1767.5,4.30,9,11,-0.5,0.47
2uyq,crystal structure of ml2640c from mycobacterium leprae in complex with s-adenosylmethionine,16,2092.9,10.40,9,8,-1.0,0.38
5js3,thermolysin in complex with jc114.,22,3124.4,9.79,19,21,-1.5,0.55
4i5c,the jak1 kinase domain in complex with inhibitor,22,2762.0,8.61,14,11,-1.0,0.41
5jxn,thermolysin in complex with jc240.,20,2902.2,10.15,19,17,0.5,0.50
2exm,human cdk2 in complex with isopentenyladenine,17,2268.7,10.00,5,10,-3.0,0.35
4ei4,jak1 kinase (jh1 domain) in complex with compound 20,18,2304.6,9.60,8,11,-3.0,0.39
2vpo,high resolution structure of the periplasmic binding protein teaa from teaabc trap transporter of halomonas elongata in complex with hydroxyectoine,15,2374.8,9.86,12,13,-3.0,0.53
6n7a,structure of the human jak1 kinase domain with compound 39,22,2762.0,8.88,14,11,-1.0,0.41
4k77,jak1 kinase (jh1 domain) in complex with compound 6,18,2226.3,9.61,8,9,-2.0,0.33
1e1v,human cyclin dependent kinase 2 complexed with the inhibitor nu2058,18,2454.6,9.49,9,12,-1.5,0.39
5jt9,thermolysin in complex with jc106.,21,3013.3,9.79,19,19,-0.5,0.52
6guk,cdk2 in complex with cgp74514a,19,2623.2,10.42,12,12,-0.5,0.42
5jvi,thermolysin in complex with jc148.,21,3013.3,9.80,19,19,-0.5,0.52
4ivd,jak1 kinase (jh1 domain) in complex with compound 34,23,2874.7,9.35,14,11,-1.0,0.39
4e5w,jak1 kinase (jh1 domain) in complex with compound 26,21,2629.0,9.52,10,15,-3.5,0.43
4ivb,"jak1 kinase (jh1 domain) in complex with the inhibitor trans-4-{2- [(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6h)- yl}cyclohexanecarbonitrile",19,2364.7,9.57,8,11,-3.0,0.37
4e4n,jak1 kinase (jh1 domain) in complex with compound 49,22,2762.0,8.66,14,11,-1.0,0.41
5jq5,crystal structure of cdk2 in complex with inhibitor icec0942,22,2986.8,8.31,14,18,-2.5,0.50
1pxp,"human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2, 4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-n',n'-dimethyl-benzene-1,4- diamine",19,2649.9,9.33,14,14,-0.5,0.47
1e1x,human cyclin dependent kinase 2 complexed with the inhibitor nu6027,18,2421.9,9.16,7,12,-2.5,0.39
6plf,crystal structure of human phgdh complexed with compound 1,23,3194.7,16.17,15,14,-0.5,0.43
4ivc,"jak1 kinase (jh1 domain) in complex with the inhibitor (trans-4-{2- [(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6h)- yl}cyclohexyl)acetonitrile",22,2762.0,8.46,14,11,-1.0,0.41
6q4e,cdk2 in complex with fraglite33,14,2052.2,10.22,7,8,-0.5,0.36
6q4g,cdk2 in complex with fraglite37,20,2764.8,9.09,14,12,0.5,0.45
4fk6,jak1 kinase (jh1 domain) in complex with compound 72,19,2450.7,8.64,13,11,-2.0,0.42
1jsv,the structure of cyclin-dependent kinase 2 (cdk2) in complex with 4- [(6-amino-4-pyrimidinyl)amino]benzenesulfonamide,16,2331.9,10.01,10,10,-0.5,0.44
1r9l,structure analysis of prox in complex with glycine betaine,11,1864.2,8.28,7,6,-0.5,0.45
1b38,human cyclin-dependent kinase 2,24,3200.9,9.44,15,16,-2.0,0.50
6guh,cdk2 in complex with azd5438,20,2710.0,9.06,14,14,-0.5,0.45
4rqv,crystal structure of pdk1 in complex with atp and the pif-pocket ligand rs2,25,3166.5,8.65,17,16,-1.0,0.56
1pxn,human cyclin dependent kinase 2 complexed with the inhibitor 4-[4-(4- methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol,18,2505.6,10.57,9,14,-2.5,0.44
5wbm,structure of human ketohexokinase complexed with hits from fragment screening,19,2156.4,13.20,2,3,-1.0,0.21
5lvl,human pdk1 kinase domain in complex with compound ps653 bound to the atp-binding site,16,2120.4,7.24,12,5,2.0,0.44
3nyd,crystal structure of kemp eliminase hg-2 complexed with transition state analog 5-nitro benzotriazole,14,1850.2,10.67,2,5,-2.0,0.21
4rqk,crystal structure of pdk1 in complex with atp and the pif-pocket ligand rs1,25,3166.5,8.60,17,16,-1.0,0.56
2vpn,high-resolution structure of the periplasmic ectoine-binding protein from teaabc trap-transporter of halomonas elongata,14,2285.8,10.32,11,12,-3.0,0.50
2xnb,discovery and characterisation of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional cdk inhibitors as anticancer agents,22,3015.1,10.73,14,16,-1.5,0.45
5wbo,structure of human ketohexokinase complexed with hits from fragment screening,21,2327.6,13.09,2,5,-2.0,0.24
2fvd,cyclin dependent kinase 2 (cdk2) with diaminopyrimidine inhibitor,19,2756.5,11.11,14,14,-0.5,0.47
6rih,crystal structure of phgdh in complex with compound 9,17,2291.6,12.32,6,8,-0.5,0.35
1pxo,human cyclin dependent kinase 2 complexed with the inhibitor [4-(2- amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine,18,2481.3,9.86,11,14,-1.5,0.44
3ppq,structures of the substrate-binding protein provide insights into the multiple compatible solutes binding specificities of bacillus subtilis abc transporter opuc,9,1427.4,1.54,10,10,0.0,0.89
3ppr,structures of the substrate-binding protein provide insights into the multiple compatible solutes binding specificities of bacillus subtilis abc transporter opuc,11,1714.9,1.54,17,12,1.0,0.91
2xmy,discovery and characterisation of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional cdk inhibitors as anticancer agents,19,2649.9,9.34,14,14,-0.5,0.47
2qw1,glucose/galactose binding protein bound to 3-o-methyl d-glucose,6,890.7,2.22,10,8,-0.5,0.83
4f9u,structure of glycosylated glutaminyl cyclase from drosophila melanogaster,15,2262.6,9.85,7,17,-5.0,0.60
3ppp,structures of the substrate-binding protein provide insights into the multiple compatible solutes binding specificities of bacillus subtilis abc transporter opuc,9,1427.4,1.48,10,10,0.0,0.89
1hdq,crystal structure of bovine pancreatic carboxypeptidase a complexed with d-n-hydroxyaminocarbonyl phenylalanine at 2.3 a,18,2642.2,7.64,21,17,0.0,0.72
4en4,crystal structure of the ternary human pl kinase-ginkgotoxin-mgatp complex,26,3486.8,14.44,15,15,-2.0,0.46
3kgq,carboxypeptidase a liganded to an organic small-molecule: conformational changes,15,2225.1,5.04,20,14,1.0,0.73
5vcw,crystal structure of human myt1 kinase domain in complex with pelitinib,22,2886.2,10.46,13,16,-1.5,0.50
3nzk,structure of lpxc from yersinia enterocolitica complexed with chir090 inhibitor,24,3321.8,12.89,15,16,1.0,0.50
1f57,carboxypeptidase a complex with d-cysteine at 1.75 a,9,1299.8,2.45,17,11,1.0,0.89
2z94,complex structure of sars-cov 3c-like protease with tdt,7,927.9,1.32,8,8,1.0,0.86
1iy7,crystal structure of cpa and sulfamide-based inhibitor complex,21,3015.3,7.75,26,17,1.0,0.67
5vd0,crystal structure of human myt1 kinase domain in complex with mk1775,27,3550.2,10.24,22,17,1.0,0.52
6o94,structure of the irak4 kinase domain with compound 17,27,3439.3,12.83,17,17,-2.0,0.48
5vcz,crystal structure of human myt1 kinase domain in complex with bosutinib isomer,25,3327.7,11.05,14,14,-0.5,0.44
1cps,structural comparison of sulfodiimine and sulfonamide inhibitors in their complexes with zinc enzymes,20,2904.2,8.04,26,15,2.0,0.65
6o95,structure of the irak4 kinase domain with compound 41,23,2982.3,12.44,14,14,-2.0,0.48
3cke,"crystal structure of aristolochene synthase in complex with 12,13- difluorofarnesyl diphosphate",17,2635.8,10.25,18,11,1.0,0.53
5vd3,crystal structure of human myt1 kinase domain (de-phosphorylated) in complex with saracatinib,29,3846.1,11.01,21,21,-0.5,0.55
5vcv,crystal structure of human myt1 kinase domain in complex with dasatinib,24,3161.0,10.03,14,14,-0.5,0.46
5vd1,crystal structure of human myt1 kinase domain in complex with pha- 848125,23,2999.8,8.50,17,15,-0.5,0.52
1cbx,crystal structure of the complex between carboxypeptidase a and the biproduct analog inhibitor l-benzylsuccinate at 2.0 angstroms resolution,19,2652.0,6.31,21,17,0.0,0.68
5vcy,crystal structure of human myt1 kinase domain in complex with bosutinib,29,3753.7,11.81,17,19,-1.5,0.48
4eoh,crystal structure of human pl kinase with bound theophylline,10,1207.0,2.39,7,9,-0.5,0.60
2rfh,crystal structure analysis of cpa-2-benzyl-3-nitropropanoic acid complex,17,2369.4,6.57,19,15,0.0,0.65
8cpa,comparison of the structures of three carboxypeptidase a-phosphonate complexes determined by x-ray crystallography,23,3247.7,7.72,28,19,1.0,0.70
6cpa,crystal structure of the complex of carboxypeptidase a with a strongly bound phosphonate in a new crystalline form: comparison with structures of other complexes,23,3247.7,7.73,28,19,1.0,0.70
5l2s,the x-ray co-crystal structure of human cdk6 and abemaciclib.,22,2962.3,7.81,13,22,-4.5,0.59
4pin,"ergothioneine-biosynthetic methyltransferase egtd in complex with n,n- dimethylhistidine",18,2549.6,10.15,12,11,0.0,0.56
4ih3,2.5 angstroms x-ray crystal structure of of human 2-amino-3- carboxymuconate-6-semialdehyde decarboxylase in complex with dipicolinic acid,16,2383.5,10.56,19,10,3.0,0.44
6fnr,ergothioneine-biosynthetic methyltransferase egtd in complex with chlorohistidine,23,2690.8,12.25,14,12,-1.5,0.35
3ga5,x-ray structure of glucose/galactose receptor from salmonella typhimurium in complex with (2r)-glyceryl-beta-d-galactopyranoside,23,3247.8,4.35,28,27,-1.5,0.78
6szp,high resolution crystal structure of human ddah-1 in complex with n- (4-aminobutyl)-n'-(2-methoxyethyl)guanidine,20,2551.2,4.90,19,16,-1.5,0.65
6f9g,ligand binding domain of p. putida kt2440 polyamine chemorecpetors mcpu in complex putrescine.,11,1746.9,6.78,5,10,-3.0,0.64
5os2,crystal structure of aurora-a kinase in complex with an allosterically binding fragment,21,2810.1,10.41,13,12,-1.0,0.48
5orv,crystal structure of aurora-a kinase in complex with an allosterically binding fragment,21,2810.1,10.33,13,12,-1.0,0.48
6fnq,"ergothioneine-biosynthetic methyltransferase egtd in complex with n,n, n-trimethylhistidine (hercynine)",18,2572.8,8.87,12,11,0.0,0.56
5os4,crystal structure of aurora-a kinase in complex with an allosterically binding fragment,21,2810.1,10.28,13,12,-1.0,0.48
5orw,crystal structure of aurora-a kinase in complex with an allosterically binding fragment,21,2810.1,10.42,13,12,-1.0,0.48
3uo4,aurora a in complex with rpm1680,22,2857.5,11.48,14,10,-1.0,0.36
4mmp,structure of sialic acid binding protein from pasturella multocida,18,2379.2,7.62,23,16,-1.0,0.61
3up2,aurora a in complex with rpm1686,22,2966.0,11.37,17,10,0.0,0.41
5ose,crystal structure of aurora-a kinase in complex with an allosterically binding fragment,21,2810.1,10.35,13,12,-1.0,0.48
6gw4,gii.22 human norovirus protruding domain in complex with glycochenodeoxycholate (gcdca),14,1918.0,7.85,14,7,2.5,0.50
2jew,"crystal structure of ((2s)-5-amino-2-((1-n-propyl-1h-imidazol-4-yl) methyl)pentanoic acid) uk396,082 a tafia inhibitor, bound to activated porcine pancreatic carboxypeptidaseb",19,2492.9,6.28,22,18,0.0,0.74
3uod,aurora a in complex with rpm1693,22,2966.0,10.72,17,10,0.0,0.41
5os5,crystal structure of aurora-a kinase in complex with an allosterically binding fragment,21,2810.1,10.34,13,12,-1.0,0.48
4bs0,"crystal structure of kemp eliminase hg3.17 e47n,n300d complexed with transition state analog 6-nitrobenzotriazole",18,2499.7,13.66,7,9,-2.0,0.33
4r74,structure of the periplasmic binding protein afua from actinobacillus pleuropneumoniae (exogenous fructose-6-phosphate bound),24,2596.4,4.27,16,17,-0.5,0.58
3e5a,crystal structure of aurora a in complex with vx-680 and tpx2,23,3152.5,11.64,15,12,-1.0,0.43
3k8o,crystal structure of human purine nucleoside phosphorylase in complex with datme-immh,21,2728.9,10.84,11,13,0.0,0.43
3myg,aurora a kinase complexed with sch 1473759,21,2853.8,10.17,18,8,1.0,0.43
5etj,"crystal structure of purine nucleoside phosphorylase (e258d, l261a) mutant from human complexed with dadme-immg and phosphate",20,2560.4,10.73,11,13,0.0,0.40
2q6f,crystal structure of infectious bronchitis virus (ibv) main protease in complex with a michael acceptor inhibitor n3,15,2016.0,7.48,9,11,1.0,0.47
2haw,crystal structure of family ii inorganic pyrophosphatase in complex with pnp,13,2107.3,13.07,7,6,0.0,0.38
6c2r,aurora a ligand complex,24,3324.5,12.69,20,10,1.0,0.42
5ia1,crystal structure of ephrin a2 (epha2) receptor protein kinase with mln8054,23,2947.9,8.30,23,13,1.0,0.52
5nka,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 2g,23,3274.1,13.30,12,11,-1.0,0.43
5ia4,crystal structure of ephrin a2 (epha2) receptor protein kinase with foretinib (xl880),31,4478.1,16.67,14,18,-2.5,0.42
3ime,crystal structure of mycobacterium tuberculosis pantothenate synthetase at 2.40 ang resolution in complex with fragment compound 1-benzofuran-2-carboxylic acid,14,1997.1,10.31,8,10,-0.5,0.43
5nk8,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 2f,25,3496.9,13.97,12,16,-3.0,0.48
6fnf,crystal structure of ephrin a2 (epha2) receptor protein kinase with nvp-bhg712,27,3918.6,17.53,9,12,-1.5,0.33
4ef6,crystal structure of mycobacterium tuberculosis pantothenate synthetase in complex with fragment 1,17,2139.6,7.88,10,11,0.0,0.47
5nk7,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 2a,24,3311.8,13.09,14,16,-3.0,0.50
4g5f,"pantothenate synthetase in complex with racemate (2s)-2,3-dihydro-1,4- benzodioxine-2-carboxylic acid and (2r)-2,3-dihydro-1,4-benzodioxine- 2-carboxylic acid",16,2330.5,12.03,8,10,-0.5,0.38
5nk3,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 1l,27,3783.1,15.15,14,15,-2.0,0.44
5nk6,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 2d,24,3283.5,11.84,13,15,-2.0,0.46
5nk9,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 2e,24,3283.5,12.09,13,15,-2.0,0.46
4efk,"pantothenate synthetase in complex with n,n-dimethylthiophene-3- sulfonamide",15,2071.9,12.66,6,6,0.0,0.27
5nkd,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 2i,23,3253.0,12.63,16,13,-1.0,0.48
3ioc,crystal structure of mycobacterium tuberculosis pantothenate synthetase at 2.50 ang resolution in complex with 5'-deoxy-5'- (benzyldisulfanyl)-adenosine,26,3552.6,18.87,12,13,0.0,0.35
4nxu,crystal structure of the cytosolic domain of human mid51,25,3494.2,14.29,27,13,3.5,0.52
5ia5,crystal structure of ephrin a2 (epha2) receptor protein kinase with golvatinib (e7050),29,4251.3,16.30,14,18,-2.5,0.45
4ddk,"pantothenate synthetase in complex with 1,3-benzodioxole-5-carboxylic acid",17,2139.6,7.92,10,11,0.0,0.47
3imc,"crystal structure of mycobacterium tuberculosis pantothenate synthetase at 1.6 ang resolution in complex with fragment compound 5- methoxyindole, sulfate and glycerol",14,1722.3,6.27,9,8,1.0,0.43
5ia3,crystal structure of ephrin a2 (epha2) receptor protein kinase with pd173955,20,2744.3,12.12,8,13,-3.0,0.45
5nk2,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 2b,25,3473.4,14.65,13,15,-2.0,0.44
4ddm,"pantothenate synthetase in complex with 2,1,3-benzothiadiazole-5- carboxylic acid",14,1973.9,9.51,8,10,-0.5,0.43
3p8p,crystal structure of human dimethylarginine dimethylaminohydrolase-1 (ddah-1) variant c274s bound with n5-(1-iminopentyl)-l-ornithine,21,2705.1,4.54,25,17,-0.5,0.67
4de5,pantothenate synthetase in complex with fragment 6,16,2330.5,12.14,8,10,-0.5,0.38
3coy,crystal structure of mycobacterium tuberculosis pantothenate synthetase at 2.05 ang resolution- in complex with sulphonamide inhibitor 3,27,3593.5,14.39,15,16,0.0,0.41
5i9z,crystal structure of ephrin a2 (epha2) receptor protein kinase with danusertib (pha739358),25,3251.7,9.74,21,18,-2.0,0.56
5nki,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 4b,23,3144.5,12.58,13,13,-2.0,0.43
5njz,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 1g,22,3084.4,13.02,13,13,-2.0,0.45
5i9x,crystal structure of ephrin a2 (epha2) receptor protein kinase with bosutinib (ski-606),24,3283.3,11.42,14,16,-3.0,0.50
5nkc,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 2h,24,3421.6,12.19,19,13,0.0,0.50
2vk2,crystal structure of a galactofuranose binding protein,16,2405.2,7.68,23,13,0.5,0.62
6fng,crystal structure of ephrin a2 (epha2) receptor protein kinase with an isomer of nvp-bhg712,26,3858.5,18.36,9,12,-1.5,0.35
4muf,crystal structure of pantothenate synthetase in complex with 2-(2-(4- tert-butylphenylsulfonylcarbamoyl)-5-methoxy-1h-indol-1-yl)acetic acid,30,3999.4,15.51,21,17,1.0,0.43
5ia2,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 66,23,3221.7,12.69,15,15,-2.0,0.48
3iod,crystal structure of mycobacterium tuberculosis pantothenate synthetase at 1.75 ang resolution in complex with 5'-deoxy-5'-((3- nitrobenzyl)disulfanyl)-adenosine,30,4039.5,16.98,17,18,0.0,0.40
3iob,crystal structure of mycobacterium tuberculosis pantothenate synthetase at 1.80 ang resolution in complex with 5'-deoxy-5'- thioadenosine,21,2776.0,11.98,12,13,0.0,0.43
5i9y,crystal structure of ephrin a2 (epha2) receptor protein kinase with dasatinib,26,3540.5,12.12,17,16,-2.0,0.50
3isj,crystal structure of pantothenate synthetase from mycobacterium tuberculosis in complex with 5-methoxy-n-(methylsulfonyl)-1h-indole- 2-carboxamide,20,2511.5,9.34,13,12,1.0,0.45
3ioe,"crystal structure of mycobacterium tuberculosis pantothenate synthetase at 1.95 ang resolution in complex with 5'-deoxy-5'-((r)-3, 4-dihydroxybutylthio)-adenosine",27,3643.8,15.99,16,17,0.0,0.41
5nkg,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 3d,24,3311.8,13.25,14,16,-3.0,0.50
4fzj,"pantothenate synthetase in complex with 1,3-dimethyl-1h-thieno[2,3- c]pyrazole-5-carboxylic acid",8,997.2,2.55,9,6,0.0,0.62
4ddh,pantothenate synthetase in complex with 6-methoxy-1-benzofuran-3-yl acetic acid,16,1984.7,6.25,15,9,2.0,0.50
3coz,crystal structure of mycobacterium tuberculosis pantothenate synthetase at 2.0 ang resolution- in complex with sulphonamide inhibitor 4,26,3453.5,13.30,15,16,0.0,0.42
5nkh,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 3e,25,3553.7,14.43,14,13,-1.0,0.44
3ivc,crystal structure of pantothenate synthetase in complex with 2-(2- ((benzofuran-2-ylmethoxy)carbonyl)-5-methoxy-1h-indol-1-yl)acetic acid,27,3605.9,13.51,21,17,1.0,0.48
3cow,crystal structure of mycobacterium tuberculosis pantothenate synthetase at 1.8 ang resolution- in complex with sulphonamide inhibitor 2,27,3593.5,14.11,15,16,0.0,0.41
3ivg,crystal structure of pantothenate synthetase in complex with 2-(2- ((benzofuran-2-sulfonamido)methyl)-5-methoxy-1h-indol-1-yl)acetic acid,26,3457.1,16.72,15,14,1.0,0.38
5nk4,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 2c,25,3371.9,13.20,14,16,-3.0,0.48
2h3e,structure of wild-type e. coli aspartate transcarbamoylase in the presence of n-phosphonacetyl-l-isoasparagine at 2.3a resolution,17,2364.2,4.46,35,12,4.5,0.76
5j7w,enterococcus faecalis thymidylate synthase complex with methotrexate,18,2774.9,17.89,7,6,-1.0,0.28
3iue,crystal structure of pantothenate synthetase in complex with 2-(5- methoxy-2-(5-methylpyridin-2-ylsulfonylcarbamoyl)-1h-indol-1-yl) acetic acid,25,3260.8,9.76,23,17,2.5,0.52
5nkb,crystal structure of ephrin a2 (epha2) receptor protein kinase with compound 4a,23,3144.5,12.64,13,13,-2.0,0.43
4zme,crystal structure of the alpha-kinase domain of myosin-ii heavy chain kinase a in complex with adenosine,14,1931.4,11.55,4,5,-1.0,0.29
4mq6,pantothenate synthase in complex with 2-(5-methoxy-2-(tosylcarbamoyl)- 1h-indol-1-yl)acetic acid,26,3380.9,13.60,16,15,1.0,0.42
4mul,crystal structure of pantothenate synthetase in complex with 2-(5- methoxy-2-(naphthalen-2-ylsulfonylcarbamoyl)-1h-indol-1-yl)acetic acid,28,3694.3,14.48,21,15,2.0,0.43
3ivx,crystal structure of pantothenate synthetase in complex with 2-(2- (benzofuran-2-ylsulfonylcarbamoyl)-5-methoxy-1h-indol-1-yl)acetic acid,28,3717.2,16.47,19,13,2.0,0.39
2fzc,the structure of wild-type e. coli aspartate transcarbamoylase in complex with novel t state inhibitors at 2.10 resolution,17,2492.6,5.54,17,14,1.0,0.65
4jyc,"meab, a bacterial homolog of mmaa, in its apo form",19,2294.2,6.86,19,10,2.5,0.53
4c1y,crystal structure of fucose binding lectin from aspergillus fumigatus (afl) in complex with b-methylfucoside,9,1565.3,6.80,8,6,-1.0,0.56
6nfy,"crystal structure of nonphosphorylated, hpk1 kinase domain in complex with sunitinib in the inactive state.",18,2167.5,14.57,3,4,-1.0,0.22
2mas,purine nucleoside hydrolase with a transition state inhibitor,20,2743.1,5.90,18,23,-3.0,0.70
4ehz,the jak1 kinase domain in complex with inhibitor,18,2304.6,9.53,8,11,-3.0,0.39
4e4l,jak1 kinase (jh1 domain) in complex with compound 30,21,2535.9,9.38,8,13,-4.0,0.38
2fzg,the structure of wild-type e. coli aspartate transcarbamoylase in complex with novel t state inhibitors at 2.25 resolution,20,2873.6,5.33,19,17,-0.5,0.70
3iub,crystal structure of pantothenate synthetase from mycobacterium tuberculosis in complex with 5-methoxy-n-(5-methylpyridin-2- ylsulfonyl)-1h-indole-2-carboxamide,23,2897.5,8.94,18,17,1.5,0.52
2fzk,the structure of wild-type e. coli aspartate transcarbamoylase in complex with novel t state inhibitors at 2.50 resolution,15,2175.6,5.12,18,10,2.5,0.67
1e5j,endoglucanase cel5a from bacillus agaradhaerens in the tetragonal crystal form in complex with methyl-4ii-s-alpha-cellobiosyl-4ii-thio- beta-cellobioside,8,1228.2,5.44,7,8,-0.5,0.62
4nxv,crystal structure of the cytosolic domain of human mid51,22,2993.9,12.59,26,12,3.5,0.55
3c56,"class ii fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with n-(3-hydroxypropyl)-glycolohydroxamic acid bisphosphate, a competitive inhibitor",22,2537.0,1.71,30,23,1.5,0.77
1d09,aspartate transcarbamoylase complexed with n-phosphonacetyl-l- aspartate (pala),16,2225.8,4.58,35,10,5.5,0.75
3po1,thrombin in complex with benzothiazole guanidine,18,2406.0,7.84,8,10,-1.5,0.50
1w3k,endoglucanase cel5a from bacillus agaradhaerens in complex with cellobio derived-tetrahydrooxazine,11,1630.3,7.18,11,8,0.5,0.64
1h5v,thiopentasaccharide complex of the endoglucanase cel5a from bacillus agaradharens at 1.1 a resolution in the tetragonal crystal form,6,923.7,4.63,7,6,0.5,0.67
5irr,crystal structure of septin gtpase domain from chlamydomonas reinhardtii,31,3819.6,5.64,33,23,2.0,0.68
1bcu,alpha-thrombin complexed with hirugen and proflavin,13,1471.1,4.82,3,6,-2.0,0.46
3c52,"class ii fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with phosphoglycolohydroxamic acid, a competitive inhibitor",17,1952.5,0.62,19,22,-0.5,0.82
1ocq,complex of the endoglucanase cel5a from bacillus agaradhearans at 1.08 angstrom resolution with cellobio-derived isofagomine,11,1630.3,7.20,11,8,0.5,0.64
3si4,human thrombin in complex with ubthr104,21,2770.0,9.58,9,15,-3.5,0.52
1w3l,endoglucanase cel5a from bacillus agaradhaerens in complex with cellotri derived-tetrahydrooxazine,10,1541.3,7.52,10,7,0.5,0.60
8a3h,cellobiose-derived imidazole complex of the endoglucanase cel5a from bacillus agaradhaerens at 0.97 a resolution,18,2684.4,9.39,17,17,-1.0,0.67
3f68,thrombin inhibition,22,2963.6,8.99,10,16,-3.5,0.55
3si3,human thrombin in complex with ubthr103,21,2770.0,9.57,9,15,-3.5,0.52
2bvs,human thrombin complexed with fragment-based small molecules occupying the s1 pocket,21,2879.7,9.58,11,12,-1.5,0.52
3qtv,thrombin inhibition by pyridin derivatives,20,2580.1,8.60,9,15,-3.5,0.55
3qto,thrombin inhibition by pyridin derivatives,21,2770.0,9.52,9,15,-3.5,0.52
3qwc,thrombin inhibition by pyridin derivatives,18,2408.9,9.54,9,13,-2.5,0.56
2bvr,human thrombin complexed with fragment-based small molecules occupying the s1 pocket,16,2030.9,7.38,5,9,-3.0,0.50
1w7g,alpha-thrombin complex with sulfated hirudin (residues 54-65) and l- arginine template inhibitor cs107,21,2794.6,10.34,10,11,-1.5,0.52
3sv2,human thrombin in complex with ubthr105,19,2520.0,8.85,9,15,-3.5,0.58
2zfp,thrombin inibition,20,2711.1,9.81,8,12,-2.5,0.50
3p17,thrombin inhibition by pyridin derivatives,19,2520.0,8.83,9,15,-3.5,0.58
2cex,structure of a sialic acid binding protein (siap) in the presence of the sialic acid acid analogue neu5ac2en,18,2405.0,7.55,25,18,-1.0,0.67
3qx5,thrombin inhibition by pyridin derivatives,22,2963.6,8.78,10,16,-3.5,0.55
1zgi,thrombin in complex with an oxazolopyridine inhibitor 21,20,2580.1,8.68,9,15,-3.5,0.55
1qbv,crystal structure of thrombin complexed with an guanidine-mimetic inhibitor,23,3157.2,8.60,11,17,-3.5,0.57
4eor,thr 160 phosphorylated cdk2 wt - human cyclin a3 complex with the inhibitor nu6102,20,2679.8,10.30,11,16,-2.5,0.45
3fvl,crystallogic studies on the complex of carboxypeptidase a with inhibitors using alpha-hydroxy ketone as zinc-binding group,18,2345.9,4.95,20,16,0.0,0.67
1d6w,structure of thrombin complexed with selective non-electrophilic inhibitors having cyclohexyl moieties at p1,23,3074.7,9.60,10,18,-4.5,0.57
1a4w,crystal structures of thrombin with thiazole-containing inhibitors: probes of the s1' binding site,21,2748.7,8.52,12,15,-2.5,0.57
2jh5,human thrombin hirugen inhibitor complex,19,2544.4,8.27,8,12,-2.5,0.53
3bv9,structure of thrombin bound to the inhibitor fm19,6,1004.3,2.84,14,2,3.5,0.67
1d4p,crystal structure of human alpha thrombin in complex with 5- amidinoindole-4-benzylpiperidine inhibitor,22,2881.1,9.89,9,17,-4.5,0.55
3da9,crystal structure of thrombin in complex with inhibitor,18,2467.5,9.16,10,16,-3.5,0.61
2zgx,thrombin inhibition,22,3015.8,9.67,9,15,-3.5,0.55
1g30,thrombin inhibitor complex,22,2881.1,9.67,9,17,-4.5,0.55
2zc9,thrombin in complex with inhibitor,22,2963.6,8.75,10,16,-3.5,0.55
3shc,human thrombin in complex with ubthr101,22,2963.6,8.91,10,16,-3.5,0.55
1sb1,"novel non-covalent thrombin inhibitors incorporating p1 4,5,6,7- tetrahydrobenzothiazole arginine side chain mimetics",24,3275.4,9.51,15,18,-3.5,0.58
3tu7,human alpha-thrombin complexed with n-(methylsulfonyl)-d-phenylalanyl- n-((1-carbamimidoyl-4-piperidinyl)methyl)-l-prolinamide (bms-189664),24,3163.7,8.80,11,19,-4.5,0.58
1g32,thrombin inhibitor complex,22,2881.1,9.74,9,17,-4.5,0.55
1fpc,active site mimetic inhibition of thrombin,21,2748.7,8.50,12,15,-2.5,0.57
2jh6,human thrombin hirugen inhibitor complex,20,2713.0,7.84,11,12,-1.5,0.55
1d3p,crystal structure of human aplha-thrombin in complex with benzo[b]thiophene inhibitor 3,23,3078.9,9.13,11,15,-2.5,0.52
3fx6,x-ray crystallographic studies on the complex of carboxypeptidase a with the inhibitor using alpha-nitro ketone as the zinc-binding group,17,2505.9,7.39,24,15,1.0,0.71
1ypj,thrombin inhibitor complex,27,3704.6,10.41,19,18,-2.5,0.56
2r2m,2-(2-chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors,22,2881.1,9.81,9,17,-4.5,0.55
1oyt,complex of recombinant human thrombin with a designed fluorinated inhibitor,25,3303.4,8.58,13,18,-3.5,0.56
1tom,alpha-thrombin complexed with hirugen,19,2520.0,9.05,9,15,-3.5,0.58
3sha,human thrombin in complex with ubthr97,19,2598.8,10.66,9,13,-2.5,0.53
1vzq,complex of thrombin with designed inhibitor 7165,27,3625.1,10.42,20,19,-2.5,0.56
1bhx,x-ray structure of the complex of human alpha thrombin with the inhibitor sdz 229-357,22,2881.1,9.85,9,17,-4.5,0.55
1mu8,"thrombin-hirugen_l-378,650",22,2963.6,9.02,10,16,-3.5,0.55
1ype,thrombin inhibitor complex,27,3704.6,10.22,19,18,-2.5,0.56
1ypg,thrombin inhibitor complex,26,3511.0,11.12,18,17,-2.5,0.54
4yes,thrombin in complex with (s)-(4-chloro-2-((1-(5-methyl-1h-pyrrole-2- carbonyl)pyrrolidine-2-carboxamido)methyl)phenyl)methanaminium,20,2711.1,9.67,8,12,-2.5,0.50
1mu6,"crystal structure of thrombin in complex with l-378,622",21,2770.0,9.80,9,15,-3.5,0.52
1nt1,thrombin in complex with selective macrocyclic inhibitor,23,3102.0,8.99,10,18,-4.5,0.57
1d3d,crystal structure of human alpha thrombin in complex with benzothiophene inhibitor 4,22,2885.3,9.25,10,14,-2.5,0.50
1k21,human thrombin-inhibitor complex,22,2963.6,9.44,10,16,-3.5,0.55
1d9i,structure of thrombin complexed with selective non-electophilic inhibitors having cyclohexyl moieties at p1,20,2636.1,8.62,10,16,-3.5,0.60
3fv3,secreted aspartic protease 1 from candida parapsilosis in complex with pepstatin a,8,1020.7,6.89,7,4,0.0,0.38
4i3z,structure of pcdk2/cyclina bound to adp and 2 magnesium ions,19,2601.2,10.01,10,14,-3.0,0.47
1mue,"thrombin-hirugen-l405,426",21,2770.0,9.75,9,15,-3.5,0.52
4bah,thrombin in complex with inhibitor,24,3185.8,8.47,10,20,-5.5,0.58
4bao,thrombin in complex with inhibitor,24,3185.8,8.36,10,20,-5.5,0.58
4bak,thrombin in complex with inhibitor,25,3324.2,8.30,10,22,-6.5,0.60
1c4u,selective non electrophilic thrombin inhibitors with cyclohexyl moieties.,23,3108.9,11.93,10,17,-4.5,0.52
2jh0,human thrombin hirugen inhibitor complex,19,2544.4,8.23,8,12,-2.5,0.53
4bcp,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,22,2964.5,9.45,15,17,-1.5,0.50
4bcm,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,20,2734.3,9.95,12,14,-1.5,0.45
4ban,thrombin in complex with inhibitor,24,3185.8,8.19,10,20,-5.5,0.58
1nm6,thrombin in complex with selective macrocyclic inhibitor at 1.8a,21,2770.0,9.61,9,15,-3.5,0.52
1ta6,crystal structure of thrombin in complex with compound 14b,23,3102.0,8.94,10,18,-4.5,0.57
1z71,thrombin and p2 pyridine n-oxide inhibitor complex structure,24,3134.8,8.57,10,18,-4.5,0.54
2cf9,complex of recombinant human thrombin with an inhibitor,24,3109.8,9.64,12,17,-3.5,0.54
1k22,human thrombin-inhibitor complex,24,3134.8,8.58,10,18,-4.5,0.54
4ax9,"human thrombin complexed with napsagatran, ro0466240",24,3302.5,11.33,11,18,-4.5,0.54
2zda,exploring thrombin s1 pocket,23,3074.7,8.84,10,18,-4.5,0.57
3utu,high affinity inhibitor of human thrombin,29,4070.4,10.71,26,22,-2.5,0.62
4bco,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,23,3211.4,8.57,18,19,-1.5,0.57
4baq,thrombin in complex with inhibitor,25,3324.2,8.20,10,22,-6.5,0.60
5l7e,mcr in complex with ligand,21,3286.6,19.05,12,6,1.0,0.29
4loy,"crystal structure analysis of thrombin in complex with compound d57, 5-chlorothiophene-2-carboxylic acid [(s)-2-[2-methyl-3-(2- oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1- yl)- 3-oxopropyl]amide (sar107375)",22,2963.6,8.93,10,16,-3.5,0.55
5mwy,the structure of mr in complex with eplerenone.,23,3457.4,17.85,13,7,1.0,0.35
5l7g,mcr in complex with ligand,24,3728.5,19.34,12,6,1.0,0.29
4bam,thrombin in complex with inhibitor,25,3324.2,8.54,10,22,-6.5,0.60
1pa9,"yersinia protein-tyrosine phosphatase complexed with pncs (yop51, pasteurella x,ptpase,yop51delta162) (catalytic domain, residues 163- 468) mutant with cys 235 replaced by arg (c235r)",16,2124.4,5.58,17,11,0.0,0.56
1h1s,structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6102,20,2679.8,10.18,11,16,-2.5,0.45
1sl3,crystal structue of thrombin in complex with a potent p1 heterocycle- aryl based inhibitor,22,2963.6,8.82,10,16,-3.5,0.55
5l7h,mcr in complex with ligand,24,3728.5,19.42,12,6,1.0,0.29
6gue,cdk2/cyclina in complex with azd5438,21,2981.9,8.75,15,17,-1.5,0.52
6guc,cdk2/cyclina in complex with su9516,16,2356.9,10.36,8,11,-1.5,0.44
1t4v,crystal structure analysis of a novel oxyguanidine bound to thrombin,25,3220.9,9.01,12,19,-4.5,0.56
5mwp,the structure of mr in complex with azd9977.,24,3624.1,18.81,13,7,1.0,0.33
4i9u,crystal structure of rabbit ldha in complex with a fragment inhibitor ap26256,14,1832.9,9.48,8,5,0.0,0.29
3r5t,crystal structure of holo-viup,22,3070.5,12.20,21,15,1.0,0.55
4bck,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,23,3077.2,11.80,13,15,-1.5,0.43
5ovx,x-ray characterization of striatal-enriched protein tyrosine phosphatase inhibitors,14,1991.5,1.24,24,13,1.0,0.86
4bcn,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,18,2589.8,9.91,14,14,-0.5,0.50
1o5g,dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa),30,3989.3,12.21,12,17,-3.5,0.53
4lch,crystal structure of the pseudomonas aeruginosa lpxc/lpc-051 complex,23,3076.5,12.96,17,15,0.5,0.48
4k9y,focal adhesion kinase catalytic domain in complex with 1-[4-(6-amino- purin-9-yl)-phenyl]-3-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-urea,27,3945.7,17.38,15,13,-0.5,0.41
4i8x,crystal structure of rabbit ldha in complex with ap27460,12,1575.0,7.02,12,9,0.5,0.58
5ovr,x-ray characterization of striatal-enriched protein tyrosine phosphatase inhibitors,14,1966.7,1.20,23,15,0.0,0.86
1c5o,"structural basis for selectivity of a small molecule, s1-binding, sub- micromolar inhibitor of urokinase type plasminogen activator",21,2492.3,3.21,7,16,-4.5,0.57
5drr,crystal structure of the pseudomonas aeruginosa lpxc/lpc-058 complex,21,2775.5,12.38,17,13,1.5,0.48
4w52,t4 lysozyme l99a with benzene bound,10,1356.4,6.11,7,6,0.5,0.40
4i9h,crystal structure of rabbit ldha in complex with ap28669,31,4036.7,17.21,25,14,1.5,0.39
5ia0,crystal structure of ephrin a2 (epha2) receptor protein kinase with alisertib (mln8237),23,2909.1,8.89,18,15,-1.0,0.52
1ghw,a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site,25,3105.7,6.45,11,16,-3.5,0.60
5aut,crystal structure of dapk1 in complex with ans.,18,2382.5,13.09,4,7,-2.0,0.28
1c5n,"structural basis for selectivity of a small molecule, s1-binding, sub- micromolar inhibitor of urokinase type plasminogen activator",22,2860.7,7.57,13,16,-3.5,0.59
1hee,crystal structure of bovine pancreatic carboxypeptidase a complexed with l-n-hydroxyaminocarbonyl phenylalanine at 2.3 a,18,2564.1,7.33,21,15,1.0,0.67
3zqe,prgi-sipd from salmonella typhimurium in complex with deoxycholate,17,2299.4,6.98,19,13,1.0,0.65
4auj,fimh lectin domain co-crystal with a alpha-d-mannoside o-linked to para hydroxypropargyl phenyl,15,2135.1,5.42,11,17,-2.5,0.67
6rot,thrombin in complex with mi2105,22,2963.6,8.92,10,16,-3.5,0.55
3u9q,ligand binding domain of ppargamma complexed with decanoic acid and pgc-1a peptide,17,2689.6,13.61,9,9,1.0,0.41
4att,fimh lectin domain co-crystal with a alpha-d-mannoside o-linked to a propynyl para methoxy phenyl,15,2133.1,5.36,12,18,-2.5,0.67
6gwe,crystal structure of thrombin bound to p2 macrocycle,26,3674.5,9.59,18,18,-2.5,0.58
1g7q,crystal structure of mhc class i h-2kb heavy chain complexed with beta-2 microglobulin and muc1 vntr peptide sapdtrpa,3,371.3,1.40,5,2,1.0,0.67
1uwf,1.7 a resolution structure of the receptor binding domain of the fimh adhesin from uropathogenic e. coli,15,2133.1,5.31,12,18,-2.5,0.67
3fur,crystal structure of pparg in complex with int131,23,3470.2,16.79,15,7,2.5,0.35
2cn0,complex of recombinant human thrombin with a designed inhibitor,31,4219.6,12.65,15,21,-4.5,0.58
6h77,e1 enzyme for ubiquitin like protein activation in complex with ubl,26,3328.8,9.90,23,16,0.0,0.54
4lov,crystal structure of fimh in complex with heptylmannoside,16,2249.2,5.35,13,19,-2.5,0.69
1fzo,mhc class i natural mutant h-2kbm8 heavy chain complexed with beta-2 microglobulin and sendai virus nucleoprotein,3,371.3,1.40,5,2,1.0,0.67
4pg9,mhc class i in complex with sendai virus nucleoprotein peptide fapgnypal,3,539.6,2.40,6,2,0.0,0.67
2cf8,complex of recombinant human thrombin with an inhibitor,32,4415.8,11.91,16,24,-5.5,0.59
4hfp,structure of thrombin mutant s195a bound to the active site inhibitor argatroban,24,3011.1,9.79,13,16,-2.5,0.50
3b1m,crystal structure of the ppargamma-lbd complexed with a cercosporamide derivative modulator cerco-a,22,3315.9,20.60,15,2,3.0,0.27
1fzm,mhc class i natural mutant h-2kbm8 heavy chain complexed with beta-2 microglobulin and vesicular stomatitis virus nucleoprotein,3,371.3,1.40,5,2,1.0,0.67
6fni,crystal structure of ephrin b4 (ephb4) receptor protein kinase with nvp-bhg712,30,4367.2,19.70,14,12,-0.5,0.33
4e7r,thrombin in complex with 3-amidinophenylalanine inhibitor,23,3049.7,9.30,12,17,-3.5,0.57
1ghv,a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site,24,2997.2,6.35,11,16,-3.5,0.58
1fzk,mhc class i natural mutant h-2kbm1 heavy chain complexed with beta-2 microglobulin and sendai virus nucleoprotein,3,371.3,1.40,5,2,1.0,0.67
4jpy,iron and phenylalanine bound crystal structure of phenylalanine hydroxylase from chromobacterium violaceum,5,644.5,0.96,4,8,-1.0,0.80
1fzj,mhc class i natural mutant h-2kbm1 heavy chain complexed with beta-2 microglobulin and vesicular stomatitis virus nucleoprotein,3,371.3,1.41,5,2,1.0,0.67
1br6,ricin a chain (recombinant) complex with pteroic acid,15,2194.4,8.84,13,11,-1.0,0.53
2dw7,crystal structure of d-tartrate dehydratase from bradyrhizobium japonicum complexed with mg++ and meso-tartrate,17,2525.3,2.75,20,21,-1.5,0.88
4gfo,"tyk2 kinase (jh1 domain) with 2,6-dichloro-n-(2-oxo-2,5- dihydropyridin-4-yl)benzamide",17,2220.9,10.36,8,9,-2.0,0.35
3dzt,aed7-leukotriene e4 complex,27,4222.4,12.44,28,14,5.0,0.52
5dfp,crystal structure of pak1 in complex with an inhibitor compound frax1036,25,3527.0,16.25,10,13,-3.0,0.40
1c1u,"recruiting zinc to mediate potent, specific inhibition of serine proteases",26,3272.4,8.44,11,16,-3.5,0.58
4jpx,crystal structure of phenylalanine hydroxylase s203p mutant from chromobacterium violaceum,5,644.5,0.88,4,8,-1.0,0.80
4av4,fimh lectin domain co-crystal with a alpha-d-mannoside o-linked to a propynyl pyridine,16,2249.2,5.05,13,19,-2.5,0.69
3acl,crystal structure of human pirin in complex with triphenyl compound,22,3134.9,14.18,14,12,0.0,0.36
4gu9,"focal adhesion kinase catalytic domain in complex with (2-fluoro- phenyl)-(1h-pyrazolo[3,4-d]pyrimidin-4-yl)-amine",15,1904.2,8.99,3,6,-2.0,0.33
4kao,focal adhesion kinase catalytic domain in complex with 1-(5-tert- butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-(4-pyridin-3- yl-phenyl)-urea,23,3402.5,18.41,8,11,-1.5,0.35
3p3g,crystal structure of the escherichia coli lpxc/lpc-009 complex,25,3389.4,12.91,14,15,0.5,0.52
3nyx,non-phosphorylated tyk2 jh1 domain with quinoline-thiadiazole- thiophene inhibitor,24,3403.3,17.99,5,6,-1.0,0.21
6n0j,the complex of ccg-222740 bound to pirin,23,3304.4,12.89,16,16,-1.0,0.43
5f9b,x-ray crystal structure of ppargamma in the complex with caulophyllogenin,20,2980.2,12.30,20,9,2.5,0.50
6n0k,the complex of ccg-257081 bound to pirin,25,3555.5,13.10,16,18,-2.0,0.44
5k8s,camp bound pfpka-r (297-441),22,3193.7,14.94,11,5,1.0,0.32
3tk2,crystallographic structure of phenylalanine hydroxylase from chromobacterium violaceum cocrystallized with phenylalanine in a site distal to the active site,5,644.5,0.94,4,8,-1.0,0.80
1c1v,"recruiting zinc to mediate potent, specific inhibition of serine proteases",27,3624.0,11.10,11,18,-4.5,0.59
6h8s,crystal structure of the mouse protein tyrosine phosphatase ptpn5 (step) in complex with compound bi-0314,13,1817.4,4.59,13,12,-0.5,0.69
3ps1,crystal structure of the escherichia coli lpxc/lpc-011 complex,24,3222.7,11.83,14,15,0.5,0.54
2wtv,aurora-a inhibitor structure,27,3531.2,10.50,23,12,1.0,0.44
3n1c,crystal structure of the phosphofructokinase-2 from escherichia coli in complex with fructose-6-phosphate,18,2061.8,4.55,24,10,2.0,0.56
3n9s,"class ii fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with n-(4-hydroxybutyl)- glycolohydroxamic acid bis- phosphate, a competitive inhibitor",24,2843.7,4.64,30,23,1.5,0.71
4buq,crystal structure of wild type fimh lectin domain in complex with heptyl alpha-d-mannopyrannoside,14,2019.0,5.38,10,16,-2.5,0.64
4avh,"structure of the fimh lectin domain in the trigonal space group, in complex with a thioalkyl alpha-d-mannoside at 2.1 a resolution",17,2365.3,5.08,14,20,-2.5,0.71
6gvz,gii.1 human norovirus protruding domain in complex with glycochenodeoxycholate (gcdca),19,2617.1,11.52,15,12,0.5,0.42
1ghy,a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site,24,3188.9,7.27,12,17,-3.5,0.58
5fs5,breaking down the wall: mutation of the tyrosine gate of the universal escherichia coli fimbrial adhesin fimh,18,2345.5,7.53,12,18,-2.5,0.56
5cep,dlk in complex with inhibitor n-(1-isopropyl-5-(piperidin-4-yl)-1h- pyrazol-3-yl)-4-(trifluoromethyl)pyridin-2-amine,19,2348.6,9.23,11,10,0.0,0.42
4x5p,crystal structure of fimh in complex with a benzoyl-amidophenyl alpha- d-mannopyranoside,20,2841.3,7.34,19,20,-1.5,0.65
6dgr,crystal structure of human ppargamma ligand binding domain in complex with cay10638,23,3637.5,21.07,14,9,2.0,0.35
4cst,crystal structure of fimh in complex with 3'-chloro-4'-(alpha-d- mannopyranosyloxy)-biphenyl-4-carbonitrile,18,2478.0,6.38,14,20,-2.5,0.67
5vo1,dlk in complex with compound 10 (5-(1-isopropyl-5-(3-(oxetan-3-yl)-3- azabicyclo[3.1.0]hexan-6-yl)-1h-pyrazol-3-yl)-3-(trifluoromethyl) pyridin-2-amine),20,2517.2,9.21,14,10,1.0,0.45
4gu6,"focal adhesion kinase catalytic domain in complex with n-{3-[(5-cyano- 2-phenyl-1h-pyrrolo[2,3-b]pyridin-4-ylamino)- methyl]-pyridin-2-yl}- n-methyl-methanesulfonamide",23,2872.8,11.95,9,12,-3.0,0.39
4css,crystal structure of fimh in complex with a sulfonamide biphenyl alpha d-mannoside,17,2365.3,5.14,14,20,-2.5,0.71
5lsg,ppargamma complex with the betulinic acid,24,3755.9,18.62,17,9,3.0,0.38
2p4y,crystal structure of human ppar-gamma-ligand binding domain complexed with an indole-based modulator,28,4243.3,20.53,15,11,0.5,0.36
4x5q,crystal structure of fimh in complex with 5-nitro-indolinylphenyl alpha-d-mannopyranoside,19,2594.1,6.03,15,21,-2.5,0.68
6dgq,crystal structure of human ppargamma ligand binding domain in complex with cay10506,26,4045.3,17.72,23,10,4.0,0.42
5ceq,dlk in complex with inhibitor 2-((1-cyclopentyl-5-(1-(oxetan-3-yl) piperidin-4-yl)-1h-pyrazol-3-yl)amino)isonicotinonitrile,20,2488.3,9.53,13,9,1.0,0.40
3b7i,crystal structure of the s228a mutant of the aminopeptidase from vibrio proteolyticus in complex with leucine phosphonic acid,17,2537.2,7.45,6,14,-3.0,0.59
3b3w,crystal structure of the s228a mutant of the aminopeptidase from vibrio proteolyticus in complex with leucine,7,882.1,2.44,6,8,-1.0,0.86
1txr,x-ray crystal structure of bestatin bound to aap,20,2826.3,10.58,7,15,-3.0,0.55
6qe0,structure of e.coli rlmj in complex with a bisubstrate analogue (ba2),27,3396.0,10.89,16,22,-2.5,0.52
3b3s,crystal structure of the m180a mutant of the aminopeptidase from vibrio proteolyticus in complex with leucine,7,882.1,2.40,6,8,-1.0,0.86
1ft7,aap complexed with l-leucinephosphonic acid,16,2370.9,7.05,7,15,-3.0,0.69
3b3c,crystal structure of the m180a mutant of the aminopeptidase from vibrio proteolyticus in complex with leucine phosphonic acid,15,2129.9,5.74,7,15,-3.0,0.73
4r06,crystal structure of sr2067 bound to ppargamma,26,3984.9,20.52,18,10,3.0,0.38
5hcv,identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists,22,3229.6,16.96,12,7,1.0,0.36
6dgl,crystal structure of human ppargamma ligand binding domain in complex with darglitazone,26,4045.3,19.44,23,10,4.0,0.42
4a4w,ligand binding domain of human ppar gamma in complex with amorfrutin b,24,3599.6,19.17,13,5,1.0,0.29
2i4z,crystal structure of the complex between ppargamma and the partial agonist lt127 (ureidofibrate derivative). this structure has been obtained from crystals soaked for 6 hours.,27,4279.4,22.90,17,11,2.0,0.37
1fm9,the 2.1 angstrom resolution crystal structure of the heterodimer of the human rxralpha and ppargamma ligand binding domains respectively bound with 9-cis retinoic acid and gi262570 and co-activator peptides.,30,4655.3,23.11,20,10,3.0,0.33
2yfe,ligand binding domain of human ppar gamma in complex with amorfrutin 1,21,3153.1,15.52,13,7,0.0,0.38
2i4j,crystal structure of the complex between ppargamma and the agonist lt160 (ureidofibrate derivative),29,4612.8,23.90,17,11,2.0,0.34
6md0,crystal structure of human ppargamma ligand binding domain in complex with oleic acid,22,3449.5,16.50,17,9,3.0,0.41
3vh9,crystal structure of aeromonas proteolytica aminopeptidase complexed with 8-quinolinol,16,2370.9,6.83,7,15,-3.0,0.69
4a4v,ligand binding domain of human ppar gamma in complex with amorfrutin 2,20,3014.7,16.82,13,5,1.0,0.35
6o5u,aac-via bound to kanamycin a,27,3337.3,8.81,12,24,-5.5,0.59
6fnj,crystal structure of ephrin b4 (ephb4) receptor protein kinase with an isomer of nvp-bhg712,27,4095.8,23.17,8,11,-1.5,0.30
6np3,aac-via bound to gentamicin,24,3084.4,11.70,12,21,-4.5,0.58
4xoe,crystal structure of a fimh*dsg complex from e.coli f18 with bound heptyl alpha-d-mannopyrannoside,19,2671.3,6.08,15,21,-2.5,0.68
6np5,aac-via bound to kanamycin b,29,3592.6,11.58,12,24,-5.5,0.55
5hu9,crystal structure of abl1 in complex with chmfl-074,30,4473.3,21.44,14,12,-0.5,0.30
6np4,aac-via bound to tobramycin,27,3478.1,13.89,12,23,-5.5,0.56
1kmy,"crystal structure of 2,3-dihydroxybiphenyl 1,2-dioxygenase complexed with 2,3-dihydroxybiphenyl under anaerobic condition",15,2285.3,9.90,13,17,0.5,0.60
1lgt,"crystal structure of 2,3-dihydroxybiphenyl 1,2-dioxygenase (dhbd) complexed with 2'-cl dihydroxybiphenyl (dhb)",16,2373.9,9.84,13,17,0.5,0.56
5his,crystal structure of pqs response protein pqse in complex with 3- methylthiophene-2-carboxylic acid,15,2180.7,6.83,12,18,-0.5,0.67
6ftf,regulatory subunit of a camp-independent protein kinase a from trypanosoma cruzi at 1.09 a resolution,24,3518.8,8.96,16,16,-1.0,0.54
2csn,binary complex of casein kinase-1 with cki7,17,2246.2,10.40,5,8,-2.0,0.35
6np2,aac-via bound to sisomicin,27,3455.2,12.57,13,22,-4.5,0.56
5oq8,structure of chk1 12-pt. mutant complex with arylbenzamide lrrk2 inhibitor,20,2309.1,10.17,6,12,-2.5,0.35
1k27,crystal structure of 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with a transition state analogue,20,2596.7,11.68,8,12,-1.5,0.45
5op4,structure of chk1 10-pt. mutant complex with aminopyrimidine lrrk2 inhibitor,20,2367.5,9.71,7,13,-2.5,0.40
1igb,aeromonas proteolytica aminopeptidase complexed with the inhibitor para-iodo-d-phenylalanine hydroxamate,19,2822.3,7.37,11,16,-2.0,0.68
6dz0,"crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with (3r,4s)-1-((4-amino-5h-pyrrolo[3,2- d]pyrimidin-7-yl)methyl)-4-((pent-4-yn-1-ylthio)methyl)pyrrolidin-3- ol",20,2633.8,12.14,9,13,-1.0,0.45
5op5,structure of chk1 10-pt. mutant complex with pyrrolopyrimidine lrrk2 inhibitor,19,2511.5,9.85,8,13,-2.5,0.42
3c2f,crystal structure of the quinolinate phosphoribosyl transferase (bna6) from saccharomyces cerevisiae complexed with prpp,12,1346.9,1.98,12,8,1.0,0.75
3c2o,crystal structure of the quinolinate phosphoribosyl transferase (bna6) from sachharomyces cerevisiae complexed with quinolinate,10,1324.1,2.09,18,7,2.5,0.80
5oot,structure of chk1 10-pt. mutant complex with aminopyrimido- benzodiazepinone lrrk2 inhibitor,20,2448.2,10.41,8,12,-1.5,0.35
6dyz,"crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with (3r,4s)-1-((4-amino-5h-pyrrolo[3,2- d]pyrimidin-7-yl)methyl)-4-((prop-2-yn-1-ylthio)methyl)pyrrolidin-3- ol",20,2633.8,12.24,9,13,-1.0,0.45
1ctt,transition-state selectivity for a single oh group during catalysis by cytidine deaminase,16,2117.6,5.77,9,13,-1.5,0.62
5dey,crystal structure of pak1 in complex with an inhibitor compound g-5555,24,3431.2,16.50,8,13,-3.0,0.38
1szd,structural basis for nicotinamide cleavage and adp-ribose transfer by nad+-dependent sir2 histone/protein deacetylases,27,3394.6,9.70,20,21,-1.5,0.59
6g14,crystal structure of ppgpp bound rbga from s. aureus,18,2354.1,6.49,20,12,2.5,0.61
5ime,crystal structure of p21-activated kinase 1 (pak1) in complex with compound 9,23,3317.1,16.43,6,11,-3.0,0.35
6g0z,crystal structure of gdp bound rbga from s. aureus,18,2354.1,6.53,20,12,2.5,0.61
4x50,crystal structure of fimh in complex with biphenyl alpha-d- mannopyranoside,18,2555.2,6.52,14,20,-2.5,0.67
4avj,"structure of the fimh lectin domain in the trigonal space group, in complex with a methanol triazol ethyl phenyl alpha-d-mannoside at 2.1 a resolution",16,2249.2,5.19,13,19,-2.5,0.69
5gj9,crystal structure of arabidopsis thaliana aco2 in complex with poa,16,2425.0,10.66,14,12,1.0,0.56
4avi,"structure of the fimh lectin domain in the trigonal space group, in complex with a methyl ester octyl alpha-d-mannoside at 2.4 a resolution",16,2249.2,5.18,13,19,-2.5,0.69
2uy4,sccts1_acetazolamide crystal structure,11,1524.1,7.91,5,8,-2.0,0.45
2uy3,sccts1_8-chlorotheophylline crystal structure,13,1726.8,8.42,7,10,-2.0,0.46
2uy5,sccts1_kinetin crystal structure,17,2388.3,12.42,7,10,-2.0,0.35
1ctu,transition-state selectivity for a single oh group during catalysis by cytidine deaminase,16,2032.5,6.50,8,12,-1.5,0.62
4xoc,crystal structure of the fimh lectin domain from e.coli f18 in complex with heptyl alpha-d-mannopyrannoside,18,2555.2,6.49,14,20,-2.5,0.67
4e9u,crystal structure of dehydrosqualene synthase (crtm) from s. aureus complexed with a thiocyanate inhibitor,21,3041.3,15.06,14,9,1.5,0.33
3tfp,crystal structure of dehydrosqualene synthase (crtm) from s. aureus complexed with bph-1162,21,2928.4,15.98,12,9,0.5,0.33
4ea2,crystal structure of dehydrosqualene synthase (crtm) aureus complexed with sq-109,20,2815.3,13.95,13,10,0.5,0.40
6g2r,crystal structure of fimh in complex with a tetraflourinated biphenyl alpha d-mannoside,23,3253.4,11.35,17,25,-3.5,0.65
1pb9,crystal structure of the nr1 ligand binding core in complex with d- cycloserine at 1.60 angstroms resolution,11,1605.6,8.99,9,5,0.0,0.45
3nhi,crystal structure of the anst-d7l1-leukotriene c4 complex,27,4302.6,12.13,30,15,4.0,0.56
1y1z,crystal structure of the nr1 ligand binding core in complex with acbc,11,1605.6,9.38,9,5,0.0,0.45
4xo8,crystal structure of the fimh lectin domain from e.coli k12 in complex with heptyl alpha-d-mannopyrannoside,18,2551.8,8.12,13,19,-2.5,0.61
3nht,crystal structure of the anst-d7l1-u46619 complex,22,3488.2,11.41,25,12,4.0,0.55
3tfn,crystal structure of dehydrosqualene synthase (crtm) from s. aureus complexed with bph-1183,23,3223.0,12.64,23,12,2.5,0.48
3acw,crystal structure of the c(30) carotenoid dehydrosqualene synthase from staphylococcus aureus complexed with bph-651,18,2589.0,15.04,8,8,0.5,0.28
2zcq,crystal structure of the c(30) carotenoid dehydrosqualene synthase from staphylococcus aureus complexed with bisphosphonate bph-652,22,3312.3,13.46,17,17,-3.0,0.59
2zcr,crystal structure of the c(30) carotenoid dehydrosqualene synthase from staphylococcus aureus complexed with bisphosphonate bph-698,26,3824.4,14.87,24,17,-0.5,0.50
2zcs,crystal structure of the c(30) carotenoid dehydrosqualene synthase from staphylococcus aureus complexed with bisphosphonate bph-700,22,3152.4,15.63,14,11,0.5,0.36
1y20,crystal structure of the nr1 ligand-binding core in complex with acpc,11,1605.6,9.28,9,5,0.0,0.45
3acx,crystal structure of the c(30) carotenoid dehydrosqualene synthase from staphylococcus aureus complexed with bph-673,22,3167.1,18.47,10,7,0.5,0.27
1rjk,crystal structure of the rat vitamin d receptor ligand binding domain complexed with 2md and a synthetic peptide containing the nr2 box of drip 205,29,4602.7,19.83,18,12,2.0,0.41
2o4r,crystal structure of rat vitamin d receptor ligand binding domain complexed with vitiii 17-20e and the nr2 box of drip 205,29,4602.7,19.85,18,12,2.0,0.41
2o4j,crystal structure of rat vitamin d receptor ligand binding domain complexed with vitiii 17-20z and the nr2 box of drip 205,29,4602.7,19.88,18,12,2.0,0.41
2oi2,streptococcus pneumoniae mevalonate kinase in complex with diphosphomevalonate,21,2453.2,9.23,11,12,-0.5,0.43
6rtw,crystal structure of the patched-1 (ptch1) ectodomain in complex with nanobody nb64 and cholesterol-hemisuccinate,23,3757.4,24.75,6,4,0.0,0.17
2reg,abc-transporter choline binding protein in complex with choline,11,1719.1,9.02,7,8,-2.0,0.45
2rin,abc-transporter choline binding protein in complex with acetylcholine,12,1857.5,8.47,7,10,-3.0,0.50
6eux,structure of the midlink and cap-binding domains of influenza b polymerase pb2 subunit with a bound azaindazole cap-binding inhibitor,19,2997.9,9.95,25,9,3.0,0.53
4daf,crystal structure of b. anthracis dhps with compound 19,16,2305.1,9.59,13,11,-0.5,0.50
2zy1,crystal structure of the c(30) carotenoid dehydrosqualene synthase from staphylococcus aureus complexed with bisphosphonate bph-830,18,2580.5,12.12,12,9,0.0,0.39
2e2p,crystal structure of sulfolobus tokodaii hexokinase in complex with adp,16,1671.6,5.13,11,5,1.0,0.38
4d8z,crystal structure of b. anthracis dhps with compound 24,15,2194.0,9.90,13,9,0.5,0.47
6mji,crystal structure of the mcd1d/xxs (jj304) /inktcr ternary complex,52,7632.7,39.43,24,20,-1.5,0.33
5c1m,crystal structure of active mu-opioid receptor bound to the agonist bu72,18,2972.5,16.44,15,11,1.0,0.44
2v7a,crystal structure of the t315i abl mutant in complex with the inhibitor pha-739358,24,3148.9,9.40,16,16,-2.0,0.50
4twp,the crystal structure of human abl1 t315i gatekeeper mutant kinase domain in complex with axitinib,21,2891.7,8.80,15,13,-1.0,0.48
4wa9,the crystal structure of human abl1 wild type kinase domain in complex with axitinib,22,3058.3,9.73,16,14,-1.0,0.50
4db7,crystal structure of b. anthracis dhps with compound 25,16,2278.0,10.00,13,11,-0.5,0.50
2ves,crystal structure of lpxc from pseudomonas aeruginosa complexed with the potent bb-78485 inhibitor,22,2851.4,12.48,12,18,-1.5,0.50
4nl1,crystal structure of b. anthracis dhps with compound 11: (e)-n-[4- (trifluoromethyl)benzyl]-1-[4-(trifluoromethyl)phenyl]methanimine,5,769.3,4.98,0,4,-2.0,0.40
6mja,crystal structure of the mcd1d/xxo (jj294) /inktcr ternary complex,55,8031.8,41.23,26,22,-1.5,0.33
3gvu,the crystal structure of human abl2 in complex with gleevec,27,4029.5,19.02,13,11,-0.5,0.33
3pyy,"discovery and characterization of a cell-permeable, small-molecule c- abl kinase activator that binds to the myristoyl binding site",27,3973.2,19.93,14,12,-0.5,0.33
6mll,crystal structure of kpc-2 with compound 7,16,2019.2,4.76,18,11,1.0,0.75
3ms9,abl kinase in complex with imatinib and a fragment (frag1) in the myristate pocket,28,4192.5,21.56,12,10,-0.5,0.29
5fol,crystal structure of the cryptosporidium muris cytosolic leucyl-trna synthetase editing domain complex with a post-transfer editing analogue of isoeucine (ile2aa),23,2892.9,9.20,17,13,0.0,0.57
3c2r,crystal structure of the quinolinate phosphoribosyl transferase (bna6) from sachharomyces cerevisiae complexed with the inhibitor phthalate,11,1497.5,2.15,23,7,3.5,0.82
6hd6,abl1 in complex with compound6 and imatinib (sti-571),28,4192.5,20.81,12,10,-0.5,0.29
6ift,ksga from bacillus subtilis in complex with sam,29,4029.5,17.38,9,17,-4.0,0.31
6mj4,crystal structure of mcd1d/inktcr ternary complex bound to glycolipid (xxw),52,7632.7,39.39,24,20,-1.5,0.33
3k5v,structure of abl kinase in complex with imatinib and gnf-2,28,4192.5,20.94,12,10,-0.5,0.29
6ssy,taurine abc transporter substrate binding protein taua from e. coli in complex with 2-aminoethylphosphonic acid,16,1939.9,8.25,9,12,-2.0,0.50
3tb6,structure of the effector-binding domain of arabinose repressor arar from bacillus subtilis,13,1996.6,2.62,16,17,-1.5,0.85
1u1w,structure and function of phenazine-biosynthesis protein phzf from pseudomonas fluorescens 2-79,19,2238.7,8.99,10,14,-1.0,0.47
6d16,crystal structure of kpc-2 complexed with compound 2,13,1702.9,5.66,18,9,2.5,0.69
6d15,crystal structure of kpc-2 complexed with compound 1,17,2179.9,4.13,23,13,2.5,0.76
1v48,"calf spleen purine nucleoside phosphorylase (pnp) binary complex with 9-(5,5-difluoro-5-phosphonopenthyl)guanine",22,2763.7,7.76,18,15,0.5,0.55
6d19,crystal structure of kpc-2 complexed with compound 9,14,1871.5,5.64,21,9,3.5,0.71
1b8n,purine nucleoside phosphorylase,20,2565.7,9.33,11,13,0.0,0.45
2qpq,structure of bug27 from bordetella pertussis,17,1998.4,3.73,13,13,0.5,0.65
6d18,crystal structure of kpc-2 complexed with compound 6,14,1871.5,5.63,21,9,3.5,0.71
6d17,crystal structure of kpc-2 complexed with compound 3,14,1871.5,5.67,21,9,3.5,0.71
4or6,structure of influenza b pb2 cap-binding domain with q325f mutation complex with gdp,13,2061.1,12.05,13,3,2.0,0.38
4or4,structure of influenza b pb2 cap-binding domain with q325f mutation complex with m7gdp,15,2428.1,10.74,19,4,3.0,0.47
6st0,taurine abc transporter substrate binding protein taua from e. coli in complex with n-(2-acetamido)-2-aminoethanesulfonic acid,18,2145.0,7.87,11,14,-2.0,0.56
1vfn,purine nucleoside phosphorylase,13,1582.7,9.45,6,5,0.0,0.31
4q46,the second structure of influenza b pb2 cap-binding domain complex with gdp,22,3271.9,8.94,36,10,4.0,0.59
4k6i,crystal structure of human retinoid x receptor alpha-ligand binding domain complex with targretin and the coactivator peptide grip-1,25,3785.1,21.09,12,6,1.5,0.24
5ad1,a complex of the synthetic siderophore analogue fe(iii)-8-licam with the ceue periplasmic protein from campylobacter jejuni,14,2109.8,4.82,26,8,4.5,0.64
1a9q,bovine purine nucleoside phosphorylase complexed with inosine,14,1694.1,12.38,3,5,-1.0,0.21
1b8o,purine nucleoside phosphorylase,20,2565.7,9.40,11,13,0.0,0.45
5vc4,crystal structure of human wee1 kinase domain in complex with bosutinib-isomer,21,2719.0,7.93,10,17,-4.0,0.52
4k4j,crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 9cuab30 and the coactivator peptide grip-1,22,3319.3,19.94,13,7,1.5,0.27
1rpj,crystal structure of d-allose binding protein from escherichia coli,15,2152.2,5.03,18,16,-2.0,0.73
6stl,taurine abc transporter substrate binding protein taua from e. coli in complex with taurine,15,1773.2,7.21,9,12,-2.0,0.53
3b92,"novel thio-based tace inhibitors part 2: rational design, synthesis and sar of thiol-contaning aryl sufones",19,2543.0,10.48,8,12,-0.5,0.37
4m8h,crystal structure of human retinoid x receptor alpha-ligand binding domain complex with (r)4-methyl 9cuab30 and coactivator peptide grip- 1,24,3618.4,19.71,12,6,1.5,0.25
5wij,jak2 pseudokinase in complex with nu6140,18,2556.6,9.92,15,8,2.0,0.44
1m1b,crystal structure of phosphoenolpyruvate mutase complexed with sulfopyruvate,15,1893.9,7.00,15,13,-0.5,0.60
5ut6,jak2 jh2 in complex with a diaminopyrimidine,17,2466.8,10.15,15,8,2.0,0.47
2oi0,crystal structure analysis 0f the tnf-a coverting enzyme (tace) in complexed with aryl-sulfonamide,19,2565.9,13.42,8,12,-0.5,0.37
4poh,crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 8-methyl uab30 and the coactivator peptide grip-1,21,3171.7,19.25,12,6,1.5,0.29
4pp5,crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 5-methyl uab30 and the coactivator peptide grip-1,22,3311.7,19.99,12,6,1.5,0.27
6nfh,"btk in complex with inhibitor 8-(2,3-dihydro-1h-inden-5-yl)-2-({4- [(2s)-3-(dimethylamino)-2-hydroxypropoxy]phenyl}amino)-5,8- dihydropteridine-6,7-dione",21,2596.3,6.68,12,12,-1.0,0.52
5g45,ligand complex of rorg lbd,11,1708.9,12.62,2,2,0.0,0.27
4pp3,crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 6-methyl uab30 and the coactivator peptide grip-1,24,3516.4,19.88,13,7,1.5,0.29
4m8e,crystal structure of human retinoid x receptor alpha-ligand binding domain complex with (s) 4-methyl 9cuab30 coactivator peptide grip-1,22,3369.9,20.06,12,6,1.5,0.23
3g3r,crystal structure of a eukaryotic polyphosphate polymerase in complex with appnhp-mn2+,15,2288.2,1.86,32,9,5.0,0.93
5g46,ligand complex of rorg lbd,10,1430.2,9.12,7,1,2.0,0.30
4poj,crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 7-methyl uab30 and the coactivator peptide grip-1,24,3594.5,18.59,13,7,1.5,0.29
1pbq,"crystal structure of the nr1 ligand binding core in complex with 5,7- dichlorokynurenic acid (dcka) at 1.90 angstroms resolution",12,1850.3,11.52,10,6,0.0,0.42
1xt8,crystal structure of cysteine-binding protein from campylobacter jejuni at 2.0 a resolution,8,1207.0,6.94,7,5,0.0,0.50
5dex,"crystal structure of glun1/glun2a nmda receptor agonist binding domains with glycine and antagonist, phenyl-acepc",20,2492.6,5.84,16,15,-0.5,0.65
6s5k,lxrbeta ligand binding domain in complex with small molecule inhibitors,27,4171.0,23.20,13,9,0.5,0.26
4ysl,crystal structure of sdoa from pseudomonas putida in complex with glutathione,21,3164.5,10.41,26,15,3.0,0.57
5vij,"crystal structure of glun1/glun2a nmda receptor agonist binding domains with glycine and antagonist, 4-bromophenyl-acepc",20,2593.9,5.95,16,15,-0.5,0.65
1f74,crystal structure analysis of n-acetylneuraminate lyase from haemophilus influenzae: crystal form ii complexed with 4-deoxy-sialic acid,20,2594.8,7.89,10,11,-1.0,0.50
4x5r,crystal structure of fimh in complex with a squaryl-phenyl alpha-d- mannopyranoside derivative,20,2863.6,7.17,18,21,-2.5,0.65
5u8c,crystal structure of glun1/glun2a ligand-binding domain in complex with glycine and nvp-aam077,21,2780.7,5.70,20,20,-1.5,0.71
6s4t,lxrbeta ligand binding domain in comlpex with small molecule inhibitors,30,4724.3,24.89,16,14,-0.5,0.33
5vih,"crystal structure of glun1/glun2a nmda receptor agonist binding domains with glycine and antagonist, 4-fluorophenyl-acepc",22,2820.9,6.96,16,17,-1.5,0.64
1phw,crystal structure of kdo8p synthase in its binary complex with substrate analog 1-deoxy-a5p,11,1480.8,6.96,12,6,1.5,0.45
3vje,crystal structure of the y248a mutant of c(30) carotenoid dehydrosqualene synthase from staphylococcus aureus in complex with zaragozic acid a,30,4337.6,21.45,27,13,2.5,0.43
4m12,crystal structure of itk in complex with compound 7 [4- (carbamoylamino)-1-(7-ethoxynaphthalen-1-yl)-1h-pyrazole-3- carboxamide],27,3989.7,16.24,14,11,-1.0,0.33
3ozj,crystal structure of human retinoic x receptor alpha complexed with bigelovin and coactivator src-1,15,2282.0,18.50,2,2,0.5,0.20
5ko5,crystal structure of isoform 2 of purine nucleoside phosphorylase from schistosoma mansoni in complex with cytosine,13,1608.8,8.88,4,6,-1.0,0.31
4fz3,crystal structure of sirt3 in complex with acetyl p53 peptide coupled with 4-amino-7-methylcoumarin,5,558.6,4.65,3,0,1.0,0.40
1g7v,crystal structures of kdo8p synthase in its binary complexes with the mechanism-based inhibitor,20,2656.2,7.09,24,18,1.0,0.65
4rfm,"itk kinase domain in complex with compound 1 n-{1-[(1,1-dioxo-1-thian- 2-yl)(phenyl)methyl]-1h- pyrazol-4-yl}-5,5-difluoro-5a-methyl-1h,4h, 4ah,5h,5ah,6h-cyclopropa[f]indazole-3-carboxamide",22,3107.0,14.04,9,10,-0.5,0.36
2rcb,crystal structure of the nr3b ligand binding core complex with d- serine at 1.62 angstrom resolution,6,759.8,0.75,12,4,1.5,0.67
4m0y,crystal structure of itk in complex with compound 1 [4- (carbamoylamino)-1-(naphthalen-1-yl)-1h-pyrazole-3-carboxamide],18,2394.5,9.73,11,7,0.5,0.39
4kfq,"crystal structure of the nmda receptor glun1 ligand binding domain in complex with 1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin- 4(5h)-one",13,1889.4,10.79,11,7,0.0,0.46
4q19,"human dck c4s-s74e mutant in complex with udp and the inhibitor 5 {5- (4-{[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl}-5-propyl-1,3- thiazol-2-yl)-2-methoxyphenol}",19,2905.5,12.49,15,11,-1.0,0.47
4m14,crystal structure of itk in complex with compound 9 [4- (carbamoylamino)-1-[7-(propan-2-yloxy)naphthalen-1-yl]-1h-pyrazole-3- carboxamide],17,2221.1,9.46,6,7,-0.5,0.35
5vc3,crystal structure of human wee1 kinase domain in complex with bosutinib,26,3185.0,7.29,16,20,-3.0,0.58
3ipq,x-ray structure of gw3965 synthetic agonist bound to the lxr-alpha,31,4916.9,24.36,14,12,-0.5,0.29
6dz3,"crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with (3r,4s)-1-((4-amino-5h-pyrrolo[3,2- d]pyrimidin-7-yl)methyl)-4-(((3-(1-butyl-1h-1,2,3-triazol-4-yl) propyl)thio)methyl)pyrrolidin-3-ol",27,3483.5,17.23,10,14,-1.0,0.37
4asj,pseudomonas aeruginosa rmla in complex with allosteric inhibitor,17,2483.8,4.17,17,11,1.5,0.65
3le9,crystal structure of the catalytic domain of tace with indazolinone- phenyl-hydantoin inhibitor,20,2713.2,11.60,11,10,1.5,0.35
4m13,crystal structure of itk in complex with compound 8 [4- (carbamoylamino)-1-(7-propoxynaphthalen-1-yl)-1h-pyrazole-3- carboxamide],28,4156.4,16.71,14,11,-1.0,0.32
6dz2,"crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with (3r,4s)-1-((4-amino-5h-pyrrolo[3,2- d]pyrimidin-7-yl)methyl)-4-(((3-(1-benzyl-1h-1,2,3-triazol-4-yl) propyl)thio)methyl)pyrrolidin-3-ol",27,3483.5,17.07,10,14,-1.0,0.37
1z95,crystal structure of the androgen receptor ligand-binding domain w741l mutant complex with r-bicalutamide,25,3898.5,21.07,14,9,1.5,0.24
2ihq,crystal structure of the rat androgen receptor ligand binding domian complex with an n-aryl-hydroxybicyclohydantoin,20,3166.0,19.29,11,5,1.0,0.20
3zll,pseudomonas aeruginosa rmla in complex with allosteric inhibitor,11,1637.8,6.87,12,6,1.5,0.55
3b66,crystal structure of the androgen receptor ligand binding domain in complex with sarm s-21,24,3769.7,19.57,15,9,1.5,0.25
2wuf,"crystal structure of s114a mutant of hsad from mycobacterium tuberculosis in complex with 4,9dsha",20,2601.5,16.94,8,7,0.5,0.20
5vd2,crystal structure of human wee1 kinase domain in complex with pf- 03814735,23,2789.0,6.75,14,16,-2.0,0.57
1e3g,human androgen receptor ligand binding in complex with the ligand metribolone (r1881),21,3355.9,20.13,11,5,1.0,0.19
3b68,crystal structure of the androgen receptor ligand binding domain in complex with sarm s-4,27,4273.8,19.91,18,12,1.5,0.30
3b65,crystal structure of the androgen receptor ligand binding domain in complex with sarm s-24,24,3769.7,19.49,15,9,1.5,0.25
3r6u,crystal structure of choline binding protein opubc from bacillus subtilis,9,1422.4,1.51,9,11,-1.0,0.89
5win,jak2 pseudokinase in complex with jnj7706621,19,2643.0,9.50,16,9,2.0,0.47
3ewj,crystal structure of catalytic domain of tace with carboxylate inhibitor,25,3335.1,11.42,15,16,0.5,0.44
3b67,crystal structure of the androgen receptor ligand binding domain in complex with sarm c-23,24,3769.7,19.69,15,9,1.5,0.25
3g0w,crystal structure of the rat androgen receptor ligand binding domain complex with an n-aryl-oxazolidin 2-imine inhibitor,23,3661.0,21.35,11,7,0.0,0.22
3l0v,crystal structure of catalytic domain of tace with the first hydantoin inhibitor occupying the s1' pocket,19,2543.0,10.42,8,12,-0.5,0.37
5cj6,crystal structure of a selective androgen receptor modulator bound to the ligand binding domain of the human androgen receptor,21,3355.9,20.28,11,5,1.0,0.19
1i37,crystal structure of the rat androgen receptor ligand binding domain complex with dihydrotestosterone,22,3522.6,21.17,11,5,1.0,0.18
1xow,"crystal structure of the human androgen receptor ligand binding domain bound with an androgen receptor nh2-terminal peptide, ar20-30, and r1881",21,3355.9,20.12,11,5,1.0,0.19
2ax9,crystal structure of the androgen receptor ligand binding domain in complex with r-3,18,2836.4,16.40,11,5,1.0,0.22
3kmc,crystal structure of catalytic domain of tace with tartrate-based inhibitor,21,2875.2,13.09,11,13,0.5,0.38
2oax,crystal structure of the s810l mutant mineralocorticoid receptor associated with sc9420,25,3868.5,20.47,12,6,1.0,0.28
3mhw,the complex crystal structure of urokianse and 2-aminobenzothiazole,17,1857.0,6.01,9,7,0.0,0.47
2bvd,"how family 26 glycoside hydrolases orchestrate catalysis on different polysaccharides. structure and activity of a clostridium thermocellum lichenase, ctlic26a",16,2803.1,10.99,11,16,-4.5,0.62
3b5r,crystal structure of the androgen receptor ligand binding domain in complex with sarm c-31,24,3769.7,19.59,15,9,1.5,0.25
4zji,pak1 in complex with 2-chloro-5-ethyl-8-fluoro-11-(4-methylpiperazin- 1-yl)-dibenzodiazepine,20,2889.6,11.57,12,16,-1.5,0.45
5ko1,pseudokinase domain of mlkl bound to compound 4.,21,2658.1,6.19,17,15,-1.0,0.62
4arw,pseudomonas aeruginosa rmla in complex with allosteric inhibitor,17,2483.8,4.16,17,11,1.5,0.65
3lea,crystal structure of the catalytic domain of tace with isoindolinone- biphenyl-hydantoin inhibitor,21,2824.3,11.46,11,12,0.5,0.38
5ufr,structure of rorgt bound to,28,4278.8,22.47,15,8,0.5,0.29
4h42,synthesis of a weak basic upa inhibitor and crystal structure of complex with upa,21,2499.8,6.19,10,13,-1.5,0.57
1gwv,"alpha-,1,3 galactosyltransferase - lactose complex",17,2622.9,10.61,19,9,1.5,0.53
1o7o,"roles of individual residues of alpha-1,3 galactosyltransferases in substrate binding and catalysis",18,2850.7,14.13,20,9,1.5,0.50
3mdz,"crystal structure of human carbonic anhydrase vii [isoform 1], ca7",17,2301.5,10.69,12,13,0.5,0.47
3kgp,crystal structures of urokinase-type plasminogen activator in complex with 4-(aminomethyl) benzoic acid and 4-(aminomethyl-phenyl)-methanol,15,1599.8,5.27,6,7,-1.0,0.47
3ml5,crystal structure of the c183s/c217s mutant of human ca vii in complex with acetazolamide,15,2208.7,8.91,15,13,1.5,0.60
2r2w,urokinase plasminogen activator b-chain-gppe complex,22,2641.5,4.83,19,14,1.0,0.59
1f5k,urokinase plasminogen activator b-chain-benzamidine complex,18,2163.9,5.23,15,8,1.0,0.56
2ews,crystal structure of s.aureus pantothenate kinase,24,2670.0,5.09,15,16,-0.5,0.50
3a1e,"crystal structure of the p- and n-domains of his462gln mutant copa, a copper-transporting p-type atpase, bound with amppcp-mg",25,2980.6,8.67,16,18,-2.0,0.52
2p15,crystal structure of the er alpha ligand binding domain with the agonist ortho-trifluoromethylphenylvinyl estradiol,23,3568.2,19.54,8,5,0.5,0.17
4qd6,itk kinase domain in complex with inhibitor compound,21,2845.0,9.28,14,12,-0.5,0.48
4rak,"crystal structure of nuclear receptor subfamily 1, group h, member 2 (lxrb) complexed with partial agonist",23,3497.6,18.21,12,11,-0.5,0.39
1f5l,urokinase plasminogen activator b-chain-amiloride complex,18,2163.9,5.23,15,8,1.0,0.56
1ejn,urokinase plasminogen activator b-chain inhibitor complex,25,3038.9,6.73,18,13,0.5,0.60
3a1c,"crystal structure of the p- and n-domains of copa, a copper- transporting p-type atpase, bound with amppcp-mg",25,2990.0,8.20,16,18,-1.5,0.52
1sqt,substituted 2-naphthamidine inhibitors of urokinase,20,2406.1,5.82,18,11,1.5,0.60
5za7,upa-hma,20,2470.3,4.91,19,12,2.0,0.60
3miy,x-ray crystal structure of itk complexed with sunitinib,18,2383.2,9.53,6,11,-2.5,0.44
5za8,upa-bb2-27f,20,2272.6,5.85,17,10,1.5,0.55
5zag,upa-bb2-94f,19,2317.1,5.24,17,10,1.5,0.58
4qij,crystal structure of menb from mycobacteria tuberculosis in complex with 1-hna-coa,35,4687.2,17.62,28,18,0.0,0.49
1owe,substituted 2-naphthamidine inhibitors of urokinase,20,2470.3,4.89,19,12,2.0,0.60
5za9,upa-bb2-50f,22,2675.2,4.57,20,10,2.0,0.59
5zaf,upa-bb2-28f,19,2183.6,5.84,16,9,1.5,0.53
4av5,"structure of a triclinic crystal of the fimh lectin domain in complex with a propynyl biphenyl alpha-d-mannoside, at 1.4 a resolution",20,2859.5,10.15,14,20,-2.5,0.60
5i3a,crystal structure of tyrosinase from bacillus megaterium with configuration a of hydroquinone inhibitor in the active site,11,1508.4,6.07,10,10,2.0,0.45
5v7a,"e. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 2-((2-amino-9-methyl-6-oxo-6,9-dihydro-1h-purin-8-yl) thio)acetic acid",20,2722.1,9.25,14,12,-0.5,0.50
1w0z,urokinase type plasminogen activator,24,2952.8,5.64,20,15,1.0,0.58
3a1d,"crystal structure of the p- and n-domains of copa, a copper- transporting p-type atpase, bound with adp-mg",23,2654.7,7.82,13,18,-2.5,0.52
5u11,"e. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 2-[(2-amino-6-oxo-6,9-dihydro-1h-purin-8-yl)sulfanyl]-n- methylacetamide",21,2906.0,8.46,24,12,1.5,0.57
5u13,"e. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 2-amino-8-{[2-(4-methoxyphenyl)-2-oxoethyl]sulfanyl}-1,7- dihydro-6h-purin-6-one",24,3281.1,9.98,30,13,2.5,0.58
1sqo,substituted 2-naphthamidine inhibitors of urokinase,19,2281.5,5.28,19,9,2.0,0.63
5zae,upa-6f-hma,21,2466.2,5.26,18,11,1.5,0.57
3qgy,crystal structure of itk inhibitor complex,22,2980.5,13.27,13,11,-0.5,0.45
5zaj,upa-31f,23,2788.0,4.91,23,13,3.0,0.61
5zc5,upa-nu-09f,23,2788.0,4.84,23,13,3.0,0.61
5u0w,e. coli dihydropteroate synthase complexed with 9-methylguanine,16,2150.3,7.42,11,9,-1.0,0.50
5u12,"e. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 2-azanyl-8-[(2-fluorophenyl)methylsulfanyl]-1,9- dihydropurin-6-one",19,2496.5,8.76,16,9,0.0,0.47
3mss,abl kinase in complex with imatinib and fragment (frag2) in the myristate site,26,3859.1,20.06,12,10,-0.5,0.31
1w11,urokinase type plasminogen activator,24,2901.8,5.92,20,13,2.0,0.54
5u14,"e. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 4-{2-[(2-amino-6-oxo-6,9-dihydro-1h-purin-8-yl) sulfanyl]ethyl}benzene-1-sulfonamide",24,3228.5,10.26,24,12,1.0,0.50
5v79,"e. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: 2-((2-amino-9-methyl-6-oxo-6,9-dihydro-1h-purin-8-yl) thio)-n-phenylacetamide",24,3270.6,10.69,25,13,1.5,0.54
1owh,substituted 2-naphthamidine inhibitors of urokinase,23,2941.7,6.31,20,15,1.0,0.61
3ipu,x-ray structure of benzisoxazole urea synthetic agonist bound to the lxr-alpha,29,4593.6,21.47,23,13,1.5,0.38
5u0z,e. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative,20,2732.6,8.65,19,12,0.5,0.55
1sqa,substituted 2-naphthamidine inhibitors of urokinase,22,2670.4,5.43,20,15,1.0,0.64
5u0y,"e. coli dihydropteroate synthase complexed with an 8-mercaptoguanine derivative: [(2-amino-6-oxo-6,9-dihydro-1h-purin-8-yl)sulfanyl]acetic acid",19,2559.2,8.57,14,12,-0.5,0.53
1nhz,crystal structure of the antagonist form of glucocorticoid receptor,22,3314.9,18.15,13,7,1.0,0.27
5tcy,"a complex of the synthetic siderophore analogue fe(iii)-5-licam with ceue (h227l variant), a periplasmic protein from campylobacter jejuni.",15,2286.2,9.48,24,6,4.0,0.53
1w13,urokinase type plasminogen activator,23,2870.7,5.12,24,14,3.0,0.65
6qas,crystal structure of ulk1 in complexed with pf-03814735,23,2953.3,10.31,15,15,0.0,0.48
5vsf,structure of human glp set-domain (ehmt1) in complex with inhibitor 17,18,2571.1,8.86,15,12,-2.0,0.61
3b3x,crystal structure of class a beta-lactamase of bacillus licheniformis bs3 with aminocitrate,17,2221.6,1.48,23,14,2.0,0.82
3qgw,crystal structure of itk kinase bound to an inhibitor,21,2860.0,12.80,13,9,0.0,0.43
5vb6,x-ray co-structure of nuclear receptor ror-gammat ligand binding domain with an inverse agonist and src2 peptide,31,4848.8,22.29,23,7,4.0,0.32
1i2s,beta-lactamase from bacillus licheniformis bs3,13,1684.9,0.77,21,10,3.0,0.85
5tuz,structure of human glp set-domain (ehmt1) in complex with inhibitor ms0124,16,2343.7,9.22,14,9,-1.0,0.56
5vb7,x-ray co-structure of nuclear receptor ror-gammat ligand binding domain with an agonist and src2 peptide,28,4368.7,21.82,18,7,3.0,0.32
4p6w,crystal structure of mometasone furoate-bound glucocorticoid receptor ligand binding domain,27,4114.7,20.09,14,8,1.0,0.33
5vb5,x-ray co-structure of nuclear receptor ror-gammat ligand binding domain with an inverse agonist and src2 peptide,32,5090.1,23.38,23,7,4.0,0.31
1n46,crystal structure of human tr beta ligand-binding domain complexed with a potent subtype-selective thyromimetic,28,3895.0,17.32,25,10,3.5,0.36
4ymq,x-ray co-structure of nuclear receptor ror-gammat + src2 peptide with a benzothiadiazole dioxide inverse agonist,29,4471.4,20.90,18,7,2.5,0.34
4nbn,tailoring small molecules for an allosteric site on procaspase-6,20,2555.0,10.34,10,14,-2.0,0.50
1p1o,crystal structure of the glur2 ligand-binding core (s1s2j) mutant l650t in complex with quisqualate,16,2179.1,4.83,16,10,1.0,0.69
5cbr,"crystal structure of the glua2 ligand-binding domain (s1s2j) in complex with the antagonist (s)-2-amino-3-(3,4-dichloro-5-(5- hydroxypyridin-3-yl)phenyl)propanoic acid at 2.0a resolution",19,2836.5,6.32,15,14,-1.0,0.68
3fuc,"recombinant calf purine nucleoside phosphorylase in a binary complex with multisubstrate analogue inhibitor 9-(5',5'-difluoro-5'- phosphonopentyl)-9-deazaguanine structure in a new space group with one full trimer in the asymmetric unit",26,3296.3,10.59,20,17,0.5,0.50
2wzm,crystal structure of a mycobacterium aldo-keto reductase in its apo and liganded form,24,2916.9,9.64,26,11,3.0,0.46
1p1n,glur2 ligand binding core (s1s2j) mutant l650t in complex with kainate,18,2484.2,6.10,16,12,0.0,0.67
4nbk,tailoring small molecules for an allosteric site on procaspase-6,14,1866.6,7.88,7,9,-1.0,0.50
1xhy,x-ray structure of the y702f mutant of the glur2 ligand-binding core (s1s2j) in complex with kainate at 1.85 a resolution,18,2534.8,7.59,15,11,0.0,0.61
4n6g,tailoring small molecules for an allosteric site on procaspase-6,6,948.8,3.53,6,6,0.0,0.67
4n5d,tailoring small molecules for an allosteric site on procaspase-6: cpd1,7,1092.6,3.41,8,8,0.0,0.71
1wvj,exploring the glur2 ligand-binding core in complex with the bicyclic ampa analogue (s)-4-ahcp,18,2534.8,7.96,15,11,0.0,0.61
1syh,x-ray structure of the glur2 ligand-binding core (s1s2j) in complex with (s)-cpw399 at 1.85 a resolution.,19,2755.3,5.06,17,13,0.0,0.68
4n7m,tailoring small molecules for an allosteric site on procaspase-6,10,1430.7,4.68,6,8,-1.0,0.60
6nsv,crystal structure of the human chip tpr domain in complex with a 5mer acetylated optimized peptide,14,2438.7,13.24,18,7,2.0,0.50
5f1v,biomimetic design results in a potent allosteric inhibitor of dihydrodipicolinate synthase from campylobacter jejuni,12,1497.0,5.09,10,3,2.0,0.50
4nbl,tailoring small molecules for an allosteric site on procaspase-6,13,1753.9,7.08,7,9,-1.0,0.54
5zni,plasmodium falciparum purine nucleoside phosphorylase in complex with mefloquine,17,2070.9,8.77,4,10,-3.0,0.53
4c2v,aurora b kinase in complex with the specific inhibitor barasertib,25,3640.4,17.01,15,10,-1.0,0.32
1f73,crystal structure analysis of n-acetylneuraminate lyase from haemophilus influenzae: crystal form iii in complex with sialic acid alditol,21,2710.9,7.53,11,12,-1.0,0.52
3rt8,chlorowillardiine bound to the ligand binding domain of glua3,16,2277.2,8.63,11,10,-1.0,0.56
5cjf,"the crystal structure of the human carbonic anhydrase xiv in complex with a 1,1'-biphenyl-4-sulfonamide inhibitor.",19,2667.5,10.09,14,15,0.5,0.53
3dp4,crystal structure of the binding domain of the ampa subunit glur3 bound to ampa,16,2199.5,6.44,12,11,-1.0,0.62
1o5c,dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa),30,3784.9,9.83,16,16,-1.5,0.53
4igt,crystal structure of the glua2 ligand-binding domain (s1s2j) in complex with the agonist za302 at 1.24a resolution,19,2677.8,5.91,17,13,0.0,0.68
5znc,plasmodium falciparum purine nucleoside phosphorylase in complex with quinine,15,2013.8,11.78,4,9,-3.0,0.47
6aqs,crystal structure of plasmodium falciparum purine nucleoside phosphorylase (v181d) mutant complexed with dadme-immg and phosphate,16,1907.1,3.78,8,11,-3.0,0.62
6maj,hbo1 is required for the maintenance of leukaemia stem cells,23,3376.1,10.77,19,12,1.0,0.52
4f39,kainate bound to the ligand binding domain of glua3,18,2534.8,7.73,15,11,0.0,0.61
1gi7,a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site,25,3170.4,5.22,23,15,2.0,0.60
3evd,crystal structure of gtp complex of yellow fever virus methyltransferase and s-adenosyl-l-homocysteine,16,2204.9,4.67,21,11,2.0,0.75
5fog,crystal structure of hte cryptosporidium muris cytosolic leucyl-trna synthetase editing domain complex with a post-transfer editing analogue of norvaline (nv2aa),24,3126.4,8.61,21,13,1.0,0.58
6efj,crystal structure of ndm-1 with compound 9,12,1713.8,6.34,12,10,1.0,0.58
1gjc,engineering inhibitors highly selective for the s1 sites of ser190 trypsin-like serine protease drug targets,28,3398.1,10.74,15,15,-1.5,0.54
4b8y,ferrichrome-bound fhud2,6,946.8,3.04,9,2,2.0,0.67
1sw2,crystal structure of prox from archeoglobus fulgidus in complex with glycine betaine,15,2287.0,1.27,14,18,-4.0,0.93
1o5a,dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa),26,3037.4,9.92,13,13,-1.5,0.50
6cn5,human retenoid-related orphan receptor-gamma ligand- binding domain in complex with indole ligand cp9b in inverse agonist conformation,27,4253.1,18.56,23,8,4.0,0.41
4keq,"crystal structure of 4-pyridoxolactonase, 5-pyridoxolactone bound",14,2157.2,10.41,5,11,-2.0,0.43
1drv,escherichia coli dhpr/acnadh complex,24,2945.0,7.47,27,11,2.5,0.46
6h36,the crystal structure of human carbonic anhydrase vii in complex with 4-(4-phenylpiperidine-1-carbonyl)benzenesulfonamide.,17,2301.5,10.68,12,13,0.5,0.47
4yb5,adenosine triphosphate phosphoribosyltransferase from campylobacter jejuni in complex with the allosteric inhibitor histidine,12,1625.3,12.51,5,2,1.0,0.25
6d1b,crystal structure of ndm-1 complexed with compound 2,11,1667.1,7.83,11,12,1.0,0.64
6h37,the crystal structure of human carbonic anhydrase vii in complex with 4-(4-phenyl)-4-hydroxy-1-piperidine-1-carbonyl)benzenesulfonamide,17,2301.5,10.80,12,13,0.5,0.47
6d1k,crystal structure of ndm-1 complexed with compound 14,11,1667.1,7.60,11,12,1.0,0.64
4dy6,crystal structure of nad kinase 1 from listeria monocytogenes in complex with 2'-phosphate bis(adenosine)-5'-diphosphate,20,2504.6,7.11,11,17,-2.0,0.55
3mam,a molecular switch changes the low to the high affinity state in the substrate binding protein afprox,11,1484.2,1.46,10,15,-3.0,0.91
6d1h,crystal structure of ndm-1 complexed with compound 11,11,1667.1,7.80,11,12,1.0,0.64
6h38,the crystal structure of human carbonic anhydrase vii in complex with 4-[(4-fluorophenyl)methyl]-1-piperazinyl]benzenesulfonamide.,18,2718.0,12.00,16,16,0.5,0.56
6d1a,crystal structure of ndm-1 complexed with compound 1,11,1667.1,7.85,11,12,1.0,0.64
2i2c,crystal structure of lmnadk1,17,2231.2,7.82,9,15,-2.5,0.59
6d1i,crystal structure of ndm-1 complexed with compound 12,11,1667.1,7.72,11,12,1.0,0.64
5dnu,crystal structure of striga kai2-like protein in complex with karrikin,14,2273.2,16.65,3,3,0.5,0.14
6mdu,crystal structure of ndm-1 with compound 7,17,2391.0,9.09,14,14,0.5,0.53
1syi,x-ray structure of the y702f mutant of the glur2 ligand-binding core (s1s2j) in complex with (s)-cpw399 at 2.1 a resolution.,19,2728.4,7.34,16,12,0.0,0.63
6d1j,crystal structure of ndm-1 complexed with compound 13,11,1621.0,5.49,13,14,1.0,0.73
6d1d,crystal structure of ndm-1 complexed with compound 6,11,1667.1,7.69,11,12,1.0,0.64
6d1g,crystal structure of ndm-1 complexed with compound 9,11,1667.1,7.54,11,12,1.0,0.64
2p2a,x-ray structure of the glur2 ligand binding core (s1s2j) in complex with 2-bn-tet-ampa at 2.26a resolution,24,3467.6,9.56,20,15,0.0,0.62
3pd9,x-ray structure of the ligand-binding core of glua2 in complex with (r)-5-hpca at 2.1 a resolution,15,2138.8,8.31,11,8,0.0,0.53
5jy3,"crystal structure of lxrbeta (nuclear receptor subfamily 1, group h, member 2) complexed with bms-852927",25,3932.6,22.97,10,9,-0.5,0.28
5fhn,crystal structure of the glua2 ligand-binding domain (s1s2j) in complex with (s)-2-amino-3-(5-(2-(3-methylbenzyl)-2h-tetrazol-5-yl)- 3-hydroxyisoxazol-4-yl)propanoic acid at 1.6 a resolution,30,4284.9,10.26,24,19,0.0,0.60
2ayr,a serm designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats,28,4252.9,20.62,15,9,0.5,0.29
3tza,crystal structure of the glua2 ligand-binding domain (s1s2j) in complex with the antagonist (s)-2-amino-3-(2-(2-carboxyethyl)-5- chloro-4-nitrophenyl)propionic acid at 1.9a resolution,19,2702.8,5.11,15,14,-1.0,0.68
2bt9,lectin from ralstonia solanacearum complexed with me-fucoside,15,2367.6,12.15,11,5,0.0,0.40
2yay,the crystal structure of leishmania major dutpase in complex with substrate analogue dupnpp,20,2988.3,7.87,24,22,-1.5,0.75
1qkt,mutant estrogen nuclear receptor ligand binding domain complexed with estradiol,18,2742.0,16.32,8,5,0.5,0.22
6s4n,lxrbeta ligand binding domain in comlpex with small molecule inhibitors,30,4623.4,22.59,17,15,-0.5,0.37
4g8m,crystal structure of the glua2 ligand-binding domain (s1s2j) in complex with the agonist cbg-iv at 2.05a resolution,16,2201.4,4.79,15,11,0.0,0.69
1drj,probing protein-protein interactions: the ribose-binding protein in bacterial transport and chemotaxis,17,2410.7,5.54,22,20,-2.0,0.71
5evk,crystal structure of the metallo-beta-lactamase l1 in complex with the bisthiazolidine inhibitor l-cs319,13,1945.8,7.88,14,15,1.5,0.69
5evd,crystal structure of the metallo-beta-lactamase l1 in complex with the bisthiazolidine inhibitor d-vc26,13,2050.4,7.71,14,15,1.5,0.69
2qdt,structural basis for the broad-spectrum inhibition of metallo-{beta}- lactamases: l1- is38 complex,12,1856.8,7.74,13,14,1.5,0.67
2dri,probing protein-protein interactions: the ribose binding protein in bacterial transport and chemotaxis,17,2410.7,5.56,22,20,-2.0,0.71
3i4y,"crystal structure determination of catechol 1,2-dioxygenase from rhodococcus opacus 1cp in complex with 3,5-dichlorocatechol",12,1610.0,16.04,2,2,0.0,0.17
5kva,crystal structure of sorghum caffeoyl-coa o-methyltransferase (ccoaomt),26,3344.0,10.74,11,19,-4.0,0.50
1drk,probing protein-protein interactions: the ribose-binding protein in bacterial transport and chemotaxis,17,2410.7,5.49,22,20,-2.0,0.71
3i51,"crystal structure determination of catechol 1,2-dioxygenase from rhodococcus opacus 1cp in complex with 4,5-dichlorocatechol",12,1632.5,15.75,2,4,-1.0,0.25
3mi2,crystal structure of human orotidine-5'-monophosphate decarboxylase complexed with pyrazofurin monophosphate,26,3372.8,7.65,22,19,-0.5,0.58
5evb,crystal structure of the metallo-beta-lactamase l1 in complex with the bisthiazolidine inhibitor d-cs319,13,2050.4,7.67,14,15,1.5,0.69
5nih,crystal structure of the glua2 ligand-binding domain (s1s2j) in complex with agonist lm-12b at 1.3 a resolution.,18,2534.8,7.58,15,11,0.0,0.61
5zg1,crystal structure of the glua2o lbd in complex with glutamate and compound-2,19,2474.6,11.47,17,8,3.0,0.47
2al5,crystal structure of the glur2 ligand binding core (s1s2j) in complex with fluoro-willardiine and aniracetam,15,1835.3,9.36,12,6,2.0,0.47
6j1l,crystal structure analysis of the ror gamma(c455e),29,4515.1,21.18,22,8,3.0,0.34
4exs,crystal structure of ndm-1 bound to l-captopril,10,1374.4,4.42,11,12,1.0,0.70
5xmx,co-crystal structure of inhibitor compound in complex with human ppardelta lbd,29,4730.5,24.96,18,9,3.0,0.31
4iuo,1.8 angstrom crystal structure of the salmonella enterica 3- dehydroquinate dehydratase (arod) k170m mutant in complex with quinate,17,2406.5,9.34,22,11,1.5,0.59
1xap,structure of the ligand binding domain of the retinoic acid receptor beta,25,3833.2,21.22,18,2,3.0,0.24
2b4l,crystal structure of the binding protein opuac in complex with glycine betaine,11,1662.6,8.70,8,7,-0.5,0.45
3o75,crystal structure of cra transcriptional dual regulator from pseudomonas putida in complex with fructose 1-phosphate',20,2778.5,6.57,26,17,0.5,0.70
6pve,structure of nicotinamide n-methyltransferase (nnmt) in complex with inhibitor ll319,36,4732.6,6.23,25,30,-3.0,0.72
1p1q,crystal structure of the glur2 ligand binding core (s1s2j) l650t mutant in complex with ampa,16,2148.9,4.74,13,12,-1.0,0.69
3hv8,crystal structure of fimx eal domain from pseudomonas aeruginosa bound to c-di-gmp,22,3048.6,14.83,14,15,-1.5,0.45
2pog,benzopyrans as selective estrogen receptor b agonists (serbas). part 2: structure activity relationship studies on the benzopyran scaffold.,19,3043.6,17.94,8,4,0.5,0.16
2qe4,estrogen receptor alpha ligand-binding domain in complex with a benzopyran agonist,21,3322.6,19.19,9,5,0.5,0.19
3axz,crystal structure of haemophilus influenzae trmd in complex with adenosine,21,2689.0,8.22,12,8,0.0,0.43
5ey0,crystal structure of cody from staphylococcus aureus with gtp and ile,19,2773.2,6.37,27,11,2.5,0.63
5fsy,crystal structure of trypanosoma brucei macrodomain in complex with adp-ribose,26,2874.1,10.42,12,11,-1.0,0.38
3eqr,crystal structure of ack1 with compound t74,29,3766.1,15.03,15,14,-2.0,0.38
6orr,co-crystal structure of human nicotinamiden-methyltransferase (nnmt) in complex with high-affinity alkynyl bisubstrate inhibitor ns1,35,4618.5,6.51,23,28,-3.0,0.71
6nmb,tranexamic acid is an active site inhibitor of urokinase plasminogen activator,16,1753.0,5.28,8,9,-0.5,0.50
4bup,a novel route to product specificity in the suv4-20 family of histone h4k20 methyltransferases,22,3058.2,10.69,12,18,-2.0,0.59
4mgd,crystal structure of hera-lbd (y537s) in complex with hpte,21,3442.7,21.99,7,3,0.0,0.14
1ftm,crystal structure of the glur2 ligand binding core (s1s2j) in complex with ampa at 1.7 resolution,16,2199.5,6.50,12,11,-1.0,0.62
1my4,crystal structure of glutamate receptor ligand-binding core in complex with iodo-willardiine in the zn crystal form,19,2728.4,6.76,16,12,0.0,0.63
3pd8,x-ray structure of the ligand-binding core of glua2 in complex with (s)-7-hpca at 2.5 a resolution,17,2423.3,5.58,16,10,1.0,0.65
3bft,structure of the ligand-binding core of glur2 in complex with the agonist (s)-tdpa at 2.25 a resolution,9,1183.9,5.53,7,4,0.0,0.44
2v2v,ispe in complex with ligand,15,1647.9,2.96,11,8,1.5,0.53
6qau,crystal structure of ulk2 in complexed with mrt67307,24,2863.4,9.05,12,17,-2.5,0.46
4csd,structure of monomeric ralstonia solanacearum lectin,13,2162.9,10.47,10,4,0.0,0.38
4n07,crystal structure of the glua2 ligand-binding domain (s1s2j-l483y- n754s) in complex with glutamate and bpam-344 at 1.87 a resolution,8,1145.5,8.08,5,2,1.0,0.38
3ujd,phosphoethanolamine methyltransferase mutant (y19f) from plasmodium falciparum in complex with phosphocholine,15,2490.3,8.23,17,10,1.0,0.67
6iht,crystal structure of bacterial serine phosphatase bound with phosphorylated peptide,7,801.7,2.66,2,6,-1.5,0.43
3ujc,phosphoethanolamine methyltransferase mutant (h132a) from plasmodium falciparum in complex with phosphocholine,15,2494.0,6.26,18,11,1.0,0.73
3uj9,phosphoethanolamine methyltransferase from plasmodium falciparum in complex with phosphocholine,16,2647.2,5.81,20,13,1.5,0.75
3juk,the crystal structure of udp-glucose pyrophosphorylase complexed with udp-glucose,32,4208.2,9.71,26,21,-1.0,0.53
2v2q,ispe in complex with ligand,15,1647.9,2.94,11,8,1.5,0.53
2v3u,structure of the ligand-binding core of the ionotropic glutamate receptor-like glurdelta2 in complex with d-serine,10,1211.6,3.87,11,7,0.0,0.60
5dpx,"1,2,4-triazole-3-thione compounds as inhibitors of l1, di-zinc metallo-beta-lactamases.",18,2515.3,7.26,16,19,0.5,0.67
5cc2,structure of the ligand-binding domain of the ionotropic glutamate receptor-like glud2 in complex with 7-cka,14,2056.8,8.97,10,8,-1.0,0.50
5vja,"crystal structure of human zipper-interacting protein kinase (zipk, alias dapk3) in complex with a pyrazolo[3,4-d]pyrimidinone ligand (hs38)",18,2356.6,12.98,6,9,-2.0,0.33
4x48,crystal structure of glur2 ligand-binding core,12,1628.3,8.16,10,4,2.0,0.42
3rtf,chlorowillardiine bound to the ligand binding domain of glua2,19,2728.4,6.56,16,12,0.0,0.63
4jsz,benzenesulfonamide bound to hcaii h94c,15,2116.9,4.52,20,14,2.0,0.60
2fu8,zinc-beta-lactamase l1 from stenotrophomonas maltophilia (d-captopril complex),14,2034.4,8.58,14,15,1.5,0.64
4xtw,mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 46 with azide in place of 2'oh,32,3933.0,8.55,36,21,2.5,0.50
5fng,"native state mass spectrometry, surface plasmon resonance and x-ray crystallography correlate strongly as a fragment screening combination",15,2260.8,10.13,12,13,0.5,0.53
4q7w,crystal structure of 1-hydroxy-6-methylpyridine-2(1h)-thione bound to human carbonic anhydrase ii,8,1042.5,5.27,4,6,-1.0,0.50
4q90,crystal structure of 4-methylpyridine-2(1h)-thione bound to human carbonic anhydrase ii,8,1127.3,4.26,9,6,0.0,0.62
4xtx,mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 57 with azide in place of ribose 2'oh,32,3930.0,8.75,34,21,1.5,0.50
4q8y,crystal structure of 2-hydroxyisoquinoline-1(2h)-thione bound to human carbonic anhydrase ii,13,2006.7,9.88,11,10,1.5,0.46
4xu3,mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 90 that has an acyclic ether in place of the ribose,32,3930.0,8.68,34,21,1.5,0.50
4q81,"crystal structure of 1-hydroxy-4,6-dimethylpyridine-2(1h)-thione bound to human carbonic anhydrase ii",12,1840.8,10.12,13,12,1.5,0.58
5flt,"native state mass spectrometry, surface plasmon resonance and x-ray crystallography correlate strongly as a fragment screening combination",12,1711.1,9.82,8,8,1.0,0.42
5th4,crystal structure of 1-hydroxypyridine-2(1h)-thione bound to human carbonic anhydrase 2 l198g,11,1541.9,4.66,11,12,0.5,0.64
5bw4,crystal structure of the 16s rrna (adenine(1408)-n(1))- methyltransferase w203a mutant with cosubstrate sam from catenulisporales acidiphilia,22,2777.5,11.44,12,9,-1.0,0.36
5fls,"native state mass spectrometry, surface plasmon resonance and x-ray crystallography correlate strongly as a fragment screening combination",10,1391.2,9.88,6,6,0.5,0.40
4q8x,crystal structure of 1-hydroxy-5-(trifluoromethyl)pyridine-2(1h)- thione bound to human carbonic anhydrase ii,10,1546.8,9.11,9,8,1.0,0.50
4xtz,mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 69 that has a fluorine in place of the ribose 2'oh,30,3665.7,8.58,32,17,2.0,0.47
5flq,"native state mass spectrometry, surface plasmon resonance and x-ray crystallography correlate strongly as a fragment screening combination",18,2626.2,12.74,12,13,0.5,0.44
4xty,mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 63 with fluorine in place of 2'oh,32,3933.0,8.58,36,21,2.5,0.50
4xu2,mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 87 with a 3'deoxy ribose,31,3779.8,8.40,34,19,2.0,0.48
4q7v,crystal structure of 1-hydroxy-5-methylpyridine-2(1h)-thione bound to human carbonic anhydrase ii,8,1042.5,5.24,4,6,-1.0,0.50
5l9o,crystal structure of agrobacterium tumefaciens c58 strain pbp soca in complex with glucopine,25,3165.1,15.00,12,9,0.0,0.28
6o5t,crystal structure of vim-2 with compound 16,15,2144.1,6.29,16,14,0.5,0.67
5ehw,human carbonic anhydrase ii in complex with ligand,14,2002.7,10.94,10,12,0.5,0.50
4jss,human carbonic anhydrase ii h94d bound to a bidentate inhibitor,8,1127.3,4.16,9,6,0.0,0.62
3rux,crystal structure of biotin-protein ligase bira from mycobacterium tuberculosis in complex with an acylsulfamide bisubstrate inhibitor,31,3779.8,8.44,34,19,2.0,0.48
4xtv,"mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 36 (n-({[(1r,3s)-3-(6-amino-9h-purin-9-yl) cyclopentyl]methyl}sulfamoyl)-5-[(3as,4s,6ar)-2-oxohexahydro-1h- thieno[3,4-d]imidazol-4-yl]pentanamide)",32,3890.9,8.60,34,21,1.0,0.50
5flo,"native state mass spectrometry, surface plasmon resonance and x-ray crystallography correlate strongly as a fragment screening combination",14,2041.5,8.45,14,15,0.5,0.64
3kwa,polyamines inhibit carbonic anhydrases,19,2740.3,12.24,14,15,0.5,0.47
2yz3,crystallographic investigation of inhibition mode of the vim-2 metallo-beta-lactamase from pseudomonas aeruginosa with mercaptocarboxylate inhibitor,11,1731.2,4.24,17,13,2.0,0.82
4jym,"crystal structure of kai2 in complex with 3-methyl-2h-furo[2,3- c]pyran-2-one",12,1950.8,14.79,4,4,0.5,0.25
4xu0,mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 73 that has a 2'-methyl on the ribose,32,3890.9,8.20,34,21,1.0,0.50
4xu1,mycobacterium tuberculosis biotin ligase complexed with bisubstrate inhibitor 82 that incorporates a morpholine in place of the ribose,32,3930.0,8.69,34,21,1.5,0.50
1rql,crystal structure of phosponoacetaldehyde hydrolase complexed with magnesium and the inhibitor vinyl sulfonate,15,1870.8,5.43,12,7,0.0,0.53
1ssq,serine acetyltransferase- complex with cysteine,2,251.1,2.18,0,2,-1.0,0.50
4q83,crystal structure of 1-hydroxy-3-(trifluoromethyl)pyridine-2(1h)- thione bound to human carbonic anhydrase ii,15,2234.1,9.27,12,13,0.5,0.53
5ehv,human carbonic anhydrase ii in complex with ligand,15,2230.5,12.58,11,12,0.5,0.47
5eh8,human carbonic anhydrase ii in complex with ligand,12,1724.6,11.19,6,6,0.5,0.33
5eh7,human carbonic anhydrase ii in complex with ligand,15,2208.2,9.27,14,15,0.5,0.60
2qtg,crystal structure of arabidopsis thaliana 5'-methylthioadenosine nucleosidase in complex with 5'-methylthiotubercidin,20,2601.9,11.01,6,11,-3.0,0.45
5lom,crystal structure of the pbp soca from agrobacterium tumefaciens c58 in complex with dfg at 1.5 a resolution,24,3051.0,15.12,10,7,0.0,0.25
2qtt,crystal structure of arabidopsis thaliana 5'-methylthioadenosine nucleosidase in complex with formycin a,20,2659.8,10.23,10,12,-2.0,0.55
4isu,crystal structure of the glua2 ligand-binding domain (s1s2j) in complex with the antagonist (2r)-ikm-159 at 2.3a resolution.,16,2096.7,5.44,12,11,-1.0,0.62
5ti0,"crystal structure of 2-hydroxycyclohepta-2,4,6-triene-1-thione bound to human carbonic anhydrase 2 l198g",14,2051.7,8.48,13,14,1.0,0.57
4q7p,crystal structure of 1-hydroxy-3-methylpyridine-2(1h)-thione bound to hcaii,8,1042.5,5.29,4,6,-1.0,0.50
1jcx,aquifex aeolicus kdo8p synthase in complex with api and cadmium,24,3242.0,4.20,38,22,2.5,0.83
6dd0,crystal structure of vim-2 complexed with compound 8,11,1731.2,4.79,17,13,2.0,0.82
2ez7,"carbonic anhydrase activators. activation of isozymes i, ii, iv, va, vii and xiv with l- and d-histidine and crystallographic analysis of their adducts with isoform ii: engineering proton transfer processes within the active site of an enzyme",7,953.9,4.48,4,6,-1.0,0.57
5ulp,structure of the ns5 methyltransferase from zika bound to ms2042,26,3133.1,6.69,19,15,-0.5,0.54
5vgy,identification of a new zinc binding chemotype by fragment screening,18,2730.8,13.57,12,13,0.5,0.44
4q7s,crystal structure of 1-hydroxy-4-methylpyridine-2(1h)-thione bound to human carbonic anhydrase ii,8,1042.5,5.25,4,6,-1.0,0.50
4jsa,benzenesulfonamide complexed with hcaii h94d,8,1127.3,4.28,9,6,0.0,0.62
3e12,cu2+ substituted aquifex aeolicus kdo8ps in complex with kdo8p,21,2767.1,1.38,36,20,2.5,0.90
5gmn,crystal structure of human carbonic anhydrase ii in complex with polmacoxib,20,3020.7,15.64,13,13,0.5,0.40
3tao,structure of mycobacterium tuberculosis triosephosphate isomerase bound to phosphoglycolohydroxamate,17,1920.3,5.01,9,10,-0.5,0.41
3s76,the origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase,12,1737.5,5.64,12,13,0.5,0.67
4q87,crystal structure of 1-hydroxy-4-(trifluoromethyl)pyridine-2(1h)- thione bound to human carbonic anhydrase ii,12,1866.7,9.98,11,10,1.5,0.50
4e3g,nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors,8,1127.3,4.32,9,6,0.0,0.62
3p4v,human carbonic anhydrase ii in complex with (+)-xylariamide a,19,2596.2,11.96,14,13,1.0,0.42
2x7u,structures of human carbonic anhydrase ii inhibitor complexes reveal a second binding site for steroidal and non-steroidal inhibitors.,17,2459.5,12.65,12,13,0.5,0.47
5u0d,identification of a new zinc binding chemotype by fragment screening,16,2319.5,11.68,12,13,0.5,0.50
3hkq,human carbonic anhydrase ii in complex with 1-s-d- galactopyranosylsulfonamide,16,2322.3,9.24,16,17,0.5,0.62
3hkt,human carbonic anhydrase ii in complex with alpha-d-glucopyranosyl-(1- >4)-1-thio-beta-d-glucopyranosylsulfonamide,16,2322.3,9.19,16,17,0.5,0.62
2q38,carbonic anhydrase ii in complex with saccharin at 1.95 angstrom,14,2094.1,9.18,12,13,0.5,0.57
5wgp,human carbonic anhydrase ix-mimic complexed with acek,13,1904.2,7.07,12,13,0.5,0.62
5tya,identification of a new zinc binding chemotype by fragment screening,14,2040.1,10.02,12,13,0.5,0.57
5fhm,crystal structure of the glua2 ligand-binding domain (s1s2j) in complex with (s)-2-amino-3-(5-(2-(3-(aminomethyl)benzyl)-2h-tetrazol- 5-yl)-3-hydroxyisoxazol-4-yl)propanoic acid at resolution 1.55 a resolution,30,4310.8,11.87,22,17,0.0,0.57
5u0g,identification of a new zinc binding chemotype by fragment screening,19,2854.0,14.84,13,13,0.5,0.42
3hkn,"human carbonic anhydrase ii in complex with (2,3,4,6-tetra-o-acetyl- beta-d-galactopyranosyl) -(1-4)-1,2,3,6-tetra-o-acetyl-1-thio-beta-d- glucopyranosylsulfonamide",20,2945.4,15.22,17,17,0.5,0.50
5ty9,identification of a new zinc binding chemotype by fragment screening,16,2319.5,11.71,12,13,0.5,0.50
5eij,carbonic anhydrase ii in complex with sulfonamide inhibitor,17,2513.5,11.79,12,13,0.5,0.47
5u0e,identification of a new zinc binding chemotype by fragment screening,15,2152.8,10.85,12,13,0.5,0.53
3bfu,structure of the ligand-binding core of glur2 in complex with the agonist (r)-tdpa at 1.95 a resolution,17,2366.2,7.67,12,11,-1.0,0.59
3bl1,carbonic anhydrase inhibitors. sulfonamide diuretics revisited old leads for new applications,18,2615.5,9.11,18,19,1.0,0.61
3m1k,carbonic anhydrase in complex with fragment,8,1127.3,4.15,9,6,0.0,0.62
6h29,human carbonic anhydrase ii in complex with benzyl carbamate,14,2094.1,9.22,12,13,0.5,0.57
2weh,thermodynamic optimisation of carbonic anhydrase fragment inhibitors,15,2234.1,9.12,12,13,0.5,0.53
2h15,carbonic anhydrase inhibitors: clashing with ala65 as a means of designing isozyme-selective inhibitors that show low affinity for the ubiquitous isozyme ii,22,3311.3,14.21,20,20,1.0,0.55
6qav,crystal structure of ulk2 in complexed with mrt68921,21,2549.2,8.52,10,15,-2.5,0.48
6q60,"structure of glua2 ligand-binding domain (s1s2j) in complex with the agonist (s)-2-amino-3-(2-methyl-5-hydroxy-2h-1,2,3-triazol-4-yl) propanoic acid at 1.55 a resolution",25,3415.5,6.33,19,18,-1.0,0.64
4q9y,crystal structure of 3-methylthiophenol bound to human carbonic anhydrase ii,8,1042.5,5.28,4,6,-1.0,0.50
5cbs,crystal structure of the glua2 ligand-binding domain (s1s2j) in complex with the antagonist (r)-2-amino-3-(3'-hydroxybiphenyl-3-yl) propanoic acid at 1.8a resolution,16,2278.8,5.94,14,10,0.0,0.62
1okl,carbonic anhydrase ii complex with the 1okl inhibitor 5-dimethylamino- naphthalene-1-sulfonamide,15,2234.1,9.22,12,13,0.5,0.53
5txy,identification of a new zinc binding chemotype of by fragment screening on human carbonic anhydrase,14,2040.1,9.97,12,13,0.5,0.57
6c7w,"carbonic anhydrase 2 in complex with [(2r,3s,4r,5r)-5-(6-amino-9h- purin-9-yl)-3,4-dihydroxytetrahydro-2-furanyl]methyl sulfamate inhibitor",18,2573.6,12.03,14,15,0.5,0.50
6q54,"structure of glua2 ligand-binding domain (s1s2j) in complex with the agonist (s)-2-amino-3-(1-ethyl-4-hydroxy-1h-1,2,3-triazol-5-yl) propanoic acid at 1.4 a resolution",23,3263.0,8.68,15,14,-1.0,0.57
1lvu,crystal structure of calf spleen purine nucleoside phosphorylase in a new space group with full trimer in the asymmetric unit,23,2951.6,8.33,19,16,0.5,0.52
5u0f,identification of a new zinc binding chemotype by fragment screening,18,2626.2,12.74,12,13,0.5,0.44
1n3i,crystal structure of mycobacterium tuberculosis pnp with transition state analog dadme-immh,19,2425.7,8.54,11,13,0.0,0.47
4yx4,human carbonic anhydrase ii complexed with an inhibitor with a benzenesulfonamide group (1).,8,1127.3,4.32,9,6,0.0,0.62
3oil,"human carbonic anhydrase ii mutant a65s, n67q (ca ix mimic) bound by 2-ethylestradiol 3-o-sulfamate",19,2899.7,13.31,19,19,1.0,0.58
1g2o,crystal structure of purine nucleoside phosphorylase from mycobacterium tuberculosis in complex with a transition-state inhibitor,20,2619.3,7.83,12,14,0.0,0.50
2wej,thermodynamic optimisation of carbonic anhydrase fragment inhibitors,14,2094.1,9.21,12,13,0.5,0.57
6ic2,polypharmacology of epacadostat: a potent and selective inhibitor of the tumor associated carbonic anhydrases ix and xii,19,2686.3,12.41,12,13,0.5,0.42
4q99,crystal structure of 2-mercapto-4-methylphenol bound to human carbonic anhydrase ii,8,1042.5,5.25,4,6,-1.0,0.50
5eh5,human carbonic anhydrase ii in complex with ligand,14,2040.1,9.90,12,13,0.5,0.57
6eeo,bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms ix and xii and show hypoxia-enhanced cytotoxicity against human cancer cell lines.,23,3217.4,12.27,20,21,1.0,0.57
2o4z,crystal structure of the carbonic anhydrase ii complexed with hydroxysulfamide inhibitor,12,1737.5,5.59,12,13,0.5,0.67
1c3x,purine nucleoside phosphorylase from cellulomonas sp. in complex with 8-iodo-guanine,13,1560.5,6.15,5,7,-0.5,0.46
1xq0,"structure of human carbonic anhydrase ii with 4-[(3-bromo-4-o- sulfamoylbenzyl)(4-cyanophenyl)amino]-4h-[1,2,4]-triazole",20,2878.7,12.51,14,17,-0.5,0.50
3s72,the origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase,15,2152.8,10.69,12,13,0.5,0.53
5ekm,human carbonic anhydrase ii complexed with a two-faced guest,17,2459.3,10.55,14,17,-0.5,0.59
4zx1,engineered carbonic anhydrase ix mimic in complex with a glucosyl sulfamate inhibitor,21,2987.4,13.64,18,19,1.0,0.52
3s78,the origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase,14,2094.1,9.03,12,13,0.5,0.57
4q6e,"crystal structure of human carbonic anhydrase isozyme ii with 4-{[3- (3,5-dimethyl-1h-pyrazol-1-yl)-3-oxopropyl]amino}benzene-1- sulfonamide",19,2686.3,12.01,12,13,0.5,0.42
4q08,crystal structure of chimeric carbonic anhydrase xii with inhibitor,22,3215.9,10.79,22,19,2.0,0.59
6equ,x-ray crystal structure of the human carbonic anhydrase ii adduct with a membrane-impermeant inhibitor,22,3054.2,12.25,20,21,1.5,0.55
1yda,structural basis of inhibitor affinity to variants of human carbonic anhydrase ii,14,2039.1,7.57,12,15,-0.5,0.64
6ecz,bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms ix and xii and show hypoxia-enhanced cytotoxicity against human cancer cell lines.,20,2762.8,12.88,18,19,1.0,0.55
3r17,hcarbonic anhydrase ii bound to n-(2-fluoro.4-sulfamoylphenyl)-2- (thiophen-2-yl) acetamide,18,2626.2,12.54,12,13,0.5,0.44
2weg,thermodynamic optimisation of carbonic anhydrase fragment inhibitors,14,2040.1,9.87,12,13,0.5,0.57
5nya,carbonic anhydrase ii inhibitor ra13,14,2094.1,9.01,12,13,0.5,0.57
4yyt,human carbonic anhydrase ii complexed with an inhibitor with a benzenesulfonamide group (5).,15,2154.2,9.87,14,15,0.5,0.60
2x7t,structures of human carbonic anhydrase ii inhibitor complexes reveal a second binding site for steroidal and non-steroidal inhibitors.,19,2747.4,13.58,13,13,0.5,0.42
6ql1,"crystal structure of chimeric carbonic anhydrase vi with 4-[(4,6- dimethylpyrimidin-2-yl)thio]-2,3,5,6-tetrafluorobenzenesulfonamide",21,2981.0,8.72,20,21,0.5,0.62
5dhu,crystal structure of nad kinase 1 from listeria monocytogenes in complex with a novel inhibitor,19,2329.3,9.61,12,13,-1.5,0.47
3oku,human carbonic anhydrase ii in complex with 2-ethylestrone-3-o- sulfamate,19,2779.4,12.65,14,15,1.0,0.47
4yxi,human carbonic anhydrase ii complexed with an inhibitor with a benzenesulfonamide group (2).,14,2040.1,9.87,12,13,0.5,0.57
6ebe,bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms ix and xii and show hypoxia-enhanced cytotoxicity against human cancer cell lines.,22,2989.6,12.27,18,19,1.0,0.50
3m67,"crystal structure of human carbonic anhydrase isozyme ii with 2- chloro-5-[(6,7-dihydro-1h-[1,4]dioxino[2,3-f]benzimidazol-2- ylsulfanyl)acetyl]benzenesulfonamide",23,3375.4,14.09,19,19,1.0,0.48
2weo,thermodynamic optimisation of carbonic anhydrase fragment inhibitors,15,2206.8,10.68,12,13,0.5,0.53
3mho,crystal structure of human carbonic anhydrase isozyme ii with 4-[n-(6- chloro-5-formyl-2-methylthiopyrimidin-4-yl)amino]benzenesulfonamide,20,2954.6,13.93,17,17,1.0,0.50
3mhi,"crystal structure of human carbonic anhydrase isozyme ii with 4-{[(5- nitro-6-oxo-1,6-dihydro-4-pyrimidinyl)amino]methyl}benzenesulfonamide",18,2626.2,12.63,12,13,0.5,0.44
4qtl,crystal structure of human carbonic anhydrase isozyme ii with inhibitor,21,3122.7,13.00,19,19,1.0,0.52
4qy3,the crystal structure of the complex of hcaii with an ortho- substituted benzoic acid,12,1525.3,3.77,9,9,-1.0,0.50
5ny1,carbonic anhydrase ii inhibitor ra10,18,2626.2,12.53,12,13,0.5,0.44
3m40,crystal structure of human carbonic anhydrase isozyme ii with 4-[n-(6- chloro-5-nitropyrimidin-4-yl)amino]benzenesulfonamide,16,2319.5,11.70,12,13,0.5,0.50
3bl0,"carbonic anhydrase inhibitors. interaction of 2-n,n-dimethylamino-1,3, 4-thiadiazole-5-methanesulfonamide with twelve mammalian isoforms: kinetic and x-ray crystallographic studies",15,2206.8,10.70,12,13,0.5,0.53
3oim,human carbonic anhydrase ii bound by 2-ethylestradiol 3-o-sulfamate,18,2626.2,12.81,12,13,0.5,0.44
5nxi,carbonic anhydrase ii inhibitor ra2,18,2519.6,11.89,12,13,0.5,0.44
3s75,the origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase,13,1927.4,8.28,12,13,0.5,0.62
3m3x,crystal structure of human carbonic anhydrase isozyme ii with 4-{2-[n- (6-methoxy-5-nitropyrimidin-4-yl)amino]ethyl}benzenesulfonamide,19,2686.3,12.01,12,13,0.5,0.42
3t82,human carbonic anhydrase ii in complex with acetylated carbohydrate sulfamates,19,2818.8,10.91,20,20,1.0,0.63
6bhv,human parp-1 bound to nad+ analog benzamide adenine dinucleotide (bad),23,3042.0,9.27,20,13,1.5,0.48
3t84,human carbonic anhydrase ii in complex with acetylated carbohydrate sulfamates,21,3175.4,13.22,20,20,1.0,0.57
4r5b,human carbonic anhydrase ii in complex with a carbohydrate-based sulfamate,19,2762.0,12.25,19,19,1.0,0.58
3t83,human carbonic anhydrase ii in complex with acetylated carbohydrate sulfamates,23,3400.8,15.63,20,20,1.0,0.52
4riv,a carbonic anhydrase ix mimic in complex with saccharin,14,2057.4,7.08,14,15,1.0,0.64
2yb0,the crystal structure of leishmania major dutpase in complex deoxyuridine,17,2725.8,9.83,25,13,1.5,0.59
1ydd,structural basis of inhibitor affinity to variants of human carbonic anhydrase ii,13,1934.1,7.05,17,13,1.5,0.69
4rn4,human carbonic anhydrases ii in complex with a acetazolamide derivative comprising one hydrophobic and one hydrophilic tail moiety,21,2911.5,11.99,14,17,-0.5,0.48
4omk,crystal structure of spf bound to squalene,40,6151.0,26.54,14,13,-0.5,0.30
5e2r,"the crystal structure of the human carbonic anhydrase ii in complex with a 1,1'-biphenyl-4-sulfonamide inhibitor",20,2830.1,11.61,14,15,0.5,0.45
4omj,"crystal structure of spf bound to 2,3-oxidosqualene",35,5390.9,27.73,12,8,1.5,0.26
3igp,structure of inhibitor binding to carbonic anhydrase ii,16,2380.6,12.88,13,13,0.5,0.50
3ffp,x ray structure of the complex between carbonic anhydrase ii and lc inhibitors,14,2094.1,9.15,12,13,0.5,0.57
1xpz,"structure of human carbonic anhydrase ii with 4-[4-o-sulfamoylbenzyl) (4-cyanophenyl)amino]-4h-[1,2,4]-triazole",18,2614.1,11.51,16,17,1.0,0.56
3mhm,crystal structure of human carbonic anhydrase isozyme ii with 4-{[n- (6-benzylamino-5-nitropyrimidin-4-yl)amino]methyl}benzenesulfonamide,19,2655.8,10.25,12,17,-1.5,0.53
3s77,the origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase,13,1927.4,8.22,12,13,0.5,0.62
6c7x,carbonic anhydrase 2 in complex with 2-chloro-5'-o-sulfamoyladenosine,19,2633.7,11.37,14,15,0.5,0.47
1z9y,carbonic anhydrase ii in complex with furosemide as sulfonamide inhibitor,21,3034.9,11.84,18,19,1.0,0.52
2pov,"the crystal structure of the human carbonic anhydrase ii in complex with 4-amino-6-chloro-benzene-1,3-disulfonamide",19,2728.2,10.59,18,19,1.0,0.58
2hnc,"crystal structure of the human carbonic anhydrase ii in complex with the 5-amino-1,3,4-thiadiazole-2-sulfonamide inhibitor.",13,1927.4,8.18,12,13,0.5,0.62
4bny,"crystal structure of 3-oxoacyl-(acyl-carrier-protein) reductase (fabg) from pseudomonas aeruginosa in complex with 4-(2-phenylthieno(3,2-d) pyrimidin-4-yl)morpholine at 1.8a resolution",22,2828.8,17.47,6,4,0.0,0.09
2yaz,the crystal structure of leishmania major dutpase in complex dump,22,3539.3,8.43,37,16,4.5,0.68
3f8e,coumarins are a novel class of suicide carbonic anhydrase inhibitors,12,1769.6,6.51,16,13,1.0,0.67
5gja,crystal structure of arabidopsis thaliana aco2 in complex with 2-pa,15,2286.6,10.74,14,10,2.0,0.53
3po6,"crystal structure of human carbonic anhydrase ii with 6,7-dimethoxy-1- methyl-3,4-dihydroisoquinoline-2(1h)-sulfonamide",17,2489.0,9.99,16,17,0.5,0.59
3k2f,nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma,22,3304.5,12.88,24,21,2.5,0.59
3ryv,carbonic anhydrase complexed with n-ethyl-4-sulfamoylbenzamide,16,2319.5,11.58,12,13,0.5,0.50
3m96,crystal structure of human carbonic anhydrase isozyme ii with 5-{[(5- bromo-1h-benzimidazol-2-yl)sulfanyl]acetyl}-2- chlorobenzenesulfonamide,23,3375.4,13.98,19,19,1.0,0.48
2pow,"the crystal structure of the human carbonic anhydrase ii in complex with 4-amino-6-trifluoromethyl-benzene-1,3-disulfonamide",19,2728.2,10.68,18,19,1.0,0.58
4itp,structure of human carbonic anhydrase ii bound to a benzene sulfonamide,17,2352.9,11.31,12,13,0.5,0.47
5wex,discovery of new selenoureido analogs of 4-(4-fluorophenylureido) benzenesulfonamides as carbonic anhydrase inhibitors,18,2573.6,12.12,14,15,0.5,0.50
3mhl,crystal structure of human carbonic anhydrase isozyme ii with 4-{[n- (6-methoxy-5-nitropyrimidin-4-yl)amino]methyl}benzenesulfonamide,17,2435.0,9.34,14,15,0.5,0.53
6cjv,carbonic anhydrase ix-mimic in complex with sucralose,13,1930.2,13.85,8,7,0.5,0.31
4l6t,gm1 bound form of the ecx ab5 holotoxin,8,1188.4,1.66,13,7,1.0,0.75
5tfx,new method for synthesis of benzoxazole amide inhibitors of carbonic anhydrase,16,2320.9,10.90,14,15,0.5,0.56
5nxw,carbonic anhydrase ii inhibitor ra9,18,2519.6,11.93,12,13,0.5,0.44
3lgs,a. thaliana mta nucleosidase in complex with s-adenosylhomocysteine,14,1656.2,5.35,7,8,-1.0,0.64
3r16,human caii bound to n-(4-sulfamoylphenyl)-2-(thiophen-2-yl) acetamide,17,2459.5,11.98,12,13,0.5,0.47
4iwz,structure of hcaii in complex with an acetazolamide derivative,17,2459.3,10.58,14,17,-0.5,0.59
1ttm,human carbonic anhydrase ii complexed with 667-coumate,17,2459.5,13.35,12,13,0.5,0.47
3m5e,crystal structure of human carbonic anhydrase isozyme ii with 4-{[n- (6-chloro-5-formyl-2-methylthiopyrimidin-4-yl) amino]methyl}benzenesulfonamide,19,2794.3,12.75,14,15,0.5,0.47
5fsx,crystal structure of trypanosoma brucei macrodomain in complex with adp,23,2638.8,8.51,11,10,-1.0,0.43
6ugp,human carbonic anhydrase 2 complexed with sb4-206,19,2793.1,12.37,13,14,0.5,0.47
6ugr,human carbonic anhydrase 2 complexed with sb4-208,19,2833.6,11.46,15,16,1.0,0.53
4riu,a carbonic anhydrase ix mimic in complex with a saccharin-based inhibitor,19,2764.0,10.81,17,18,1.0,0.58
1cnx,secondary interactions significantly removed from the sulfonamide binding pocket of carbonic anhydrase ii influence binding constants,18,2550.7,10.40,14,15,0.5,0.50
1zge,"carbonic anhydrase ii in complex with p-sulfonamido-o,o'- dichloroaniline as sulfonamide inhibitor",15,2152.8,10.86,12,13,0.5,0.53
6g3q,crystal structure of human carbonic anhydrase ii in complex with the inhibitor famotidine,18,2519.6,11.38,12,13,0.5,0.44
6ugn,human carbonic anhydrase 2 complexed with sb4-205,22,3243.5,13.61,16,16,0.5,0.50
3gdt,crystal structure of the d91n mutant of the orotidine 5'-monophosphate decarboxylase from saccharomyces cerevisiae complexed with 6- azauridine 5'-monophosphate,17,2116.4,4.25,19,10,2.5,0.59
6uh0,human carbonic anhydrase 2 in complex with sb4-202,21,3136.4,13.31,18,18,0.5,0.52
2vnt,urokinase-type plasminogen activator inhibitor complex with a 1-(7- sulphoamidoisoquinolinyl)guanidine,27,3250.6,8.76,19,16,-0.5,0.56
4q6d,crystal structure of human carbonic anhydrase isozyme ii with 4-[(z)- azepan-1-yldiazenyl]benzenesulfonamide,18,2626.2,12.59,12,13,0.5,0.44
6b4d,crystal structure of human carbonic anhydrase ii in complex with a heteroaryl-pyrazole carboxylic acid derivative.,18,2625.6,12.95,11,10,1.5,0.33
2pou,"the crystal structure of the human carbonic anhydrase ii in complex with 4,5-dichloro-benzene-1,3-disulfonamide",20,2956.0,12.42,19,19,1.0,0.55
5ny3,carbonic anhydrase ii inhibitor ra11,19,2686.3,11.98,12,13,0.5,0.42
3ni5,carbonic anhydrase inhibitor: c1 family,17,2433.6,11.86,14,15,0.5,0.53
5o07,the crystal structure of the human carbonic anhydrase ii in complex with a nitroimidazole sulfamate inhibitor,17,2433.6,11.67,14,15,0.5,0.53
1zfq,carbonic anhydrase ii in complex with ethoxzolamidphenole as sulfonamide inhibitor,15,2152.8,10.65,12,13,0.5,0.53
5fdc,"crystal structure of human carbonic anhydrase ii in complex with the anticonvulsant sulfamide jnj-26990990 and its s,s-dioxide analog.",15,2152.8,10.70,12,13,0.5,0.53
6gxb,carbonic anhydrase caix mimic in complex with inhibitor js13,21,3022.5,13.03,15,20,-1.5,0.57
3p5l,human carbonic anhydrase complexed with sodium 4-cyano-4- phenylpiperidine-1-carbodithioate,18,2585.2,12.63,17,18,1.0,0.56
5byi,human carbonic anhydrase ii with an azobenzene inhibitor (1d),17,2459.5,12.09,12,13,0.5,0.47
3ryy,fluoroalkyl and alkyl chains have similar hydrophobicities in binding to the hydrophobic wall of carbonic anhydrase,18,2626.2,12.69,12,13,0.5,0.44
1cnw,secondary interactions significantly removed from the sulfonamide binding pocket of carbonic anhydrase ii influence binding constants,17,2406.9,10.86,12,13,0.5,0.47
3rz0,fluoroalkyl and alkyl chains have similar hydrophobicities in binding to the hydrophobic wall of carbonic anhydrase,18,2626.2,12.78,12,13,0.5,0.44
3t5u,crystal structure of the human carbonic anhydrase ii in complex with n-hydroxy benzenesulfonamide,14,2094.1,9.21,12,13,0.5,0.57
6g2s,crystal structure of fimh in complex with a pentaflourinated biphenyl alpha d-mannoside,24,3338.7,12.88,15,23,-3.5,0.58
3p58,human carbonic anhydrase in complex with benzyl (methyl) carbamodithoic acid,17,2475.1,10.38,17,18,1.0,0.59
3ibn,the crystal structure of the human carbonic anhydrase ii in complex with an aliphatic bis-sulfamate inhibitor,18,2519.6,11.38,12,13,0.5,0.44
3myq,"crystal structure of human carbonic anhydrase isozyme ii with 2- chloro-5-[(1h-imidazo[4,5-c]quinolin-2-ylsulfanyl) acetyl]benzenesulfonamide",21,2994.4,12.38,16,17,0.5,0.48
3nb5,human carbonic anhydrase ii in complex with 2-(3-chloro-4- hydroxyphenyl)-n-(4-sulfamoylphenethyl)acetamide,20,2797.4,11.88,12,15,-0.5,0.45
4kni,"crystal structure of human carbonic anhydrase isozyme ii with 2- chloro-4-{[(4,6-dimethylpyrimidin-2-yl) sulfanyl]acetyl}benzenesulfonamide",18,2626.2,12.48,12,13,0.5,0.44
1cny,secondary interactions significantly removed from the sulfonamide binding pocket of carbonic anhydrase ii influence binding constants,18,2603.3,11.62,14,15,0.5,0.50
3dd8,carbonic anhydrase inhibitors. interaction of the antitumor sulfamate emd-486019 with twelve mammalian isoforms: kinetic and x-ray crystallographic studies,17,2459.5,12.05,12,13,0.5,0.47
5fdi,"crystal structure of human carbonic anhydrase ii with the anticonvulsant sulfamide jnj-26990990 and its s,s-dioxide analog.",16,2319.5,11.61,12,13,0.5,0.50
3mzc,human carbonic ahydrase ii in complex with a benzenesulfonamide inhibitor,20,2826.3,11.81,12,13,0.5,0.40
4ruz,crystal structure of human carbonic anhydrase ii in complex with 4- ethoxybenzenesulfonamide,17,2459.5,12.42,12,13,0.5,0.47
2hl4,crystal structure analysis of human carbonic anhydrase ii in complex with a benzenesulfonamide derivative,17,2433.6,11.47,14,15,0.5,0.53
3n4b,crystal structure of human carbonic anhydrase ii in complex with a benzenesulfonamide inhibitor,20,2880.3,12.40,14,15,0.5,0.45
1nw4,crystal structure of plasmodium falciparum purine nucleoside phosphorylase in complex with immh and sulfate,18,2302.8,6.29,15,10,-0.5,0.50
5n25,crystal structure of human carbonic anhydrase ii in complex with the inhibitor 4-pyridin-3-yl-benzenesulfonamide,16,2292.8,11.84,12,13,0.5,0.50
3ryj,"carbonic anhydrase complexed with 4-sulfamoyl-n-(2,2,2- trifluoroethyl)benzamide",18,2626.2,12.74,12,13,0.5,0.44
3eft,crystal structure of the complex between carbonic anhydrase ii and a spin-labeled sulfonamide incorporating tempo moiety,18,2519.6,11.50,12,13,0.5,0.44
3t85,human carbonic anhydrase ii in complex with acetylated carbohydrate sulfamates,19,2818.8,10.94,20,20,1.0,0.63
5e28,crystal structure of human carbonic anhydrase ii in complex with the 4-(4-aminophenyl)benzenesulfonamide inhibitor,17,2459.5,12.47,12,13,0.5,0.47
4knj,crystal structure of human carbonic anhydrase isozyme ii with 2- chloro-4-[(pyrimidin-2-ylsulfanyl)acetyl]benzenesulfonamide,19,2766.2,12.40,12,13,0.5,0.42
3daz,"use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties",15,2152.8,10.81,12,13,0.5,0.53
3mhc,crystal structure of human cabonic anhydrase ii in adduct with an adamantyl analogue of acetazolamide in a novel hydrophobic binding pocket,16,2346.6,8.93,14,17,-0.5,0.62
4p6x,crystal structure of cortisol-bound glucocorticoid receptor ligand binding domain,22,3401.4,17.09,14,8,1.0,0.32
3ibl,the crystal structure of the human carbonic anhydrase ii in complex with an aliphatic bis-sulfamate inhibitor,17,2406.9,10.46,12,13,0.5,0.47
6g6t,"crystal structure of human carbonic anhydrase isozyme ii with n-butyl- 2,4-dichloro-5-sulfamoyl-benzamide",21,3068.7,13.09,19,19,1.0,0.52
4ruy,crystal structure of human carbonic anhydrase ii in complex with 4- propoxybenzenesulfonamide,18,2626.2,12.49,12,13,0.5,0.44
6ql2,crystal structure of chimeric carbonic anhydrase vi with ethoxzolamide.,16,2300.3,7.92,15,16,0.5,0.62
1q1g,crystal structure of plasmodium falciparum pnp with 5'-methylthio- immucillin-h,19,2442.8,7.93,15,10,-0.5,0.47
5sz6,carbonic anhydrase ix-mimic in complex with 4-(3-formylphenyl)- benzenesulfonamide,21,2943.1,13.16,12,13,0.5,0.38
3rz5,fluoroalkyl and alkyl chains have similar hydrophobicities in binding to the hydrophobic wall of carbonic anhydrase,19,2686.3,12.13,12,13,0.5,0.42
4mo8,the crystal structure of the human carbonic anhydrase ii in complex with n-[2-(2-methyl-5-nitro-1h-imidazol-1-yl)ethyl]sulfamide,19,2814.6,13.24,17,17,1.0,0.53
5e2k,crystal structure of human carbonic anhydrase ii in complex with the 4-(3-aminophenyl)benzenesulfonamide inhibitor,17,2459.5,12.49,12,13,0.5,0.47
4rux,crystal structure of human carbonic anhydrase ii in complex with 4- (allyloxy)benzenesulfonamide,18,2626.2,12.50,12,13,0.5,0.44
4r59,a carbonic anhydrase ix mimic in complex with a carbohydrate-based sulfamate,18,2523.7,12.08,12,13,0.5,0.44
4ht0,crystal structure of human carbonic anhydrase isozyme ii with the inhibitor.,18,2626.2,12.24,12,13,0.5,0.44
5n1r,crystal structure of human carbonic anhydrase ii in complex with the inhibitor 4'-pyrazol-1-ylmethyl-biphenyl-4-sulfonamide,17,2352.9,11.34,12,13,0.5,0.47
3dbu,"use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties",18,2643.8,11.82,16,17,1.0,0.56
5n1s,crystal structure of human carbonic anhydrase ii in complex with the inhibitor 4-(1h-indol-2-yl)-benzenesulfonamide,17,2459.5,12.50,12,13,0.5,0.47
5nxp,carbonic anhydrase ii inhibitor ra7,17,2459.5,12.04,12,13,0.5,0.47
5uln,"synthesis of novel seleno ureido containing compounds as slc-0111 analogs. investigations on carbonic anhydrases activity, glutathione peroxidase and x-ray crystallography",18,2626.2,12.73,12,13,0.5,0.44
3oy0,"human carbonic anhydrase ii complexed with 1-(4-(4-(2- (isopropylsulfonyl)phenylamino)-1h-pyrrolo[2,3-b]pyridin-6-ylamino)- 3-methoxyphenyl)piperidin-4-ol",20,2840.9,12.00,18,19,1.0,0.55
6gxe,carbonic anhydrase caix mimic in complex with inhibitor js14,17,2409.6,12.44,12,13,0.5,0.47
3oyq,"structure of human carbonic anhydrase ii complexed with 5,6-dihydro- benzo[h]cinnolin-3-ylamine",17,2459.5,11.97,12,13,0.5,0.47
4zx0,human carbonic anhydrase ii in complex with a glucosyl sulfamate inhibitor,22,3184.0,14.78,19,19,1.0,0.50
2q1q,carbonic anhydrase inhibitors. interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and x-ray crystallographic studies,18,2534.2,10.62,18,19,1.0,0.61
3hs4,human carbonic anhydrase ii complexed with acetazolamide,13,1927.4,8.14,12,13,0.5,0.62
3b4f,carbonic anhydrase inhibitors. interaction of 2-(hydrazinocarbonyl)-3- phenyl-1h-indole-5-sulfonamide with twelve mammalian isoforms: kinetic and x-ray crystallographic studies,20,2985.5,11.98,20,20,1.0,0.60
4m2w,genetically engineered carbonic anhydrase ix in complex with dorzolamide,22,3211.4,15.07,17,17,1.0,0.45
4z1j,"carbonic anhydrase inhibitors: design and synthesis of new heteroaryl- n-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hca vii, hca ix, and hca xiv)",19,2740.3,12.56,14,15,0.5,0.47
3d8w,"use of a carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties",18,2614.1,11.86,16,17,1.0,0.56
3ryx,fluoroalkyl and alkyl chains have similar hydrophobicities in binding to the hydrophobic wall of carbonic anhydrase,18,2626.2,12.73,12,13,0.5,0.44
1ydb,structural basis of inhibitor affinity to variants of human carbonic anhydrase ii,14,2063.3,9.82,12,13,0.5,0.57
4z1e,"carbonic anhydrase inhibitors: design and synthesis of new heteroaryl- n-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hca vii, hca ix, and hca xiv)",18,2626.2,12.63,12,13,0.5,0.44
3vbd,"complex of human carbonic anhydrase ii with 4-(6-methoxy-3,4- dihydroisoquinolin-1-yl)benzenesulfonamide",17,2433.6,11.72,14,15,0.5,0.53
4rfc,human carbonic anhydrase ii in complex with tert-butyl 4-(4- sulfamoylphenoxy)butylcarbamate,19,2686.3,12.03,12,13,0.5,0.42
3dc3,"use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties",13,1927.4,8.34,12,13,0.5,0.62
1g4o,carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n- phenylmethylbenzamide,15,2156.9,10.03,12,13,0.5,0.53
1i9p,"carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 4,6-trifluorophenyl)methyl]-benzamide",18,2469.7,12.05,12,13,0.5,0.44
4z0q,"carbonic anhydrase inhibitors: design and synthesis of new heteroaryl- n-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hca vii, hca ix, and hca xiv)",19,2779.4,12.63,14,15,1.0,0.47
5j8z,human carbonic anhydrase ii in complex with ligand,18,2519.6,12.21,12,13,0.5,0.44
4m2v,genetically engineered carbonic anhydrase ix in complex with brinzolamide,23,3271.5,14.53,17,17,1.0,0.43
3rz8,fluoroalkyl and alkyl chains have similar hydrophobicities in binding to the hydrophobic wall of carbonic anhydrase,18,2519.6,12.08,12,13,0.5,0.44
1g48,"carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 6-difluorophenyl)methyl]-benzamide",16,2323.6,10.67,12,13,0.5,0.50
3hku,human carbonic anhydrase ii in complex with topiramate,20,2947.6,11.15,19,20,1.0,0.60
5amg,three dimensional structure of human carbonic anhydrase ii in complex with 2-(pentylsulfamoyl)-4-sulfamoylbenzoic acid,20,2894.9,11.85,18,19,1.0,0.55
4bf6,"three dimensional structure of human carbonic anhydrase ii in complex with 5-(1-(3-cyanophenyl)-1h-1,2,3-triazol-4-yl)thiophene-2- sulfonamide",14,2094.1,9.19,12,13,0.5,0.57
3n0n,crystal structure of human carbonic anhydrase ii in complex with a benzenesulfonamide inhibitor,20,2880.3,12.40,14,15,0.5,0.45
5n0e,"crystal structure of human carbonic anhydrase ii in complex with (s)- 4-(6,7-dihydroxy-1-phenyl-3,4-tetrahydroisoquinoline-1h-2-carbonyl) benzenesulfonamide.",21,3121.3,14.32,17,17,1.0,0.48
5n0d,"crystal structure of human carbonic anhydrase ii in complex with (r)- 4-(6,7-dihydroxy-1-phenyl-3,4-tetrahydroisoquinoline-1h-2-carbonyl) benzenesulfonamide.",23,3388.6,13.52,21,21,1.5,0.52
4q09,crystal structure of chimeric carbonic anhydrase xii with inhibitor,22,2993.9,11.98,20,17,1.5,0.55
4z1k,"carbonic anhydrase inhibitors: design and synthesis of new heteroaryl- n-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hca vii, hca ix, and hca xiv)",18,2519.6,11.89,12,13,0.5,0.44
3mna,"the crystal structure of human carbonic anhydrase ii in complex with a 1,3,5-triazine-substituted benzenesulfonamide inhibitor",19,2740.3,12.41,14,15,0.5,0.47
5nxo,carbonic anhydrase ii inhibitor ra6,18,2626.2,12.64,12,13,0.5,0.44
2h4n,h94n carbonic anhydrase ii complexed with acetazolamide,13,1888.3,8.32,12,13,0.0,0.62
3mmf,"crystal structure of human carbonic anhydrase ii in complex with a 1, 3,5-triazine-substituted benzenesulfonamide inhibitor",19,2740.3,12.39,14,15,0.5,0.47
6oe1,benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases ii and vii and show neuropathic pain attenuating effects,16,2346.8,11.97,12,13,0.5,0.50
1i9n,"carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 5-difluorophenyl)methyl]-benzamide",15,2156.9,9.98,12,13,0.5,0.53
1g45,carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2- fluorophenyl)methyl]-benzamide,16,2323.6,10.67,12,13,0.5,0.50
6mxc,crystal structure of trypanosoma brucei hypoxanthine-guanine-xanthine phosphoribosyltranferase in complex with gmp,17,2337.4,5.04,17,12,-1.0,0.65
3d9z,"use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties",15,2152.8,10.91,12,13,0.5,0.53
3s73,the origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase,15,2152.8,10.87,12,13,0.5,0.53
3ibi,the crystal structure of the human carbonic anhydrase ii in complex with an aliphatic sulfamate inhibitor,16,2346.8,11.13,12,13,0.5,0.50
5sz3,carbonic anhydrase ii in complex with 4-(3-quinolinyl)- benzenesulfonamide,19,2779.4,12.70,14,15,1.0,0.47
5zg3,crystal structure of the glua2o lbd in complex with glutamate and tak- 137,21,2808.0,14.31,17,8,3.0,0.43
3s71,the origin of the hydrophobic effect in the molecular recognition of arylsulfonamides by carbonic anhydrase,15,2152.8,10.71,12,13,0.5,0.53
1bcd,"x-ray crystallographic structure of a complex between human carbonic anhydrase ii and a new topical inhibitor, trifluoromethane sulphonamide",14,2044.2,7.14,12,13,0.5,0.57
4bf1,"three dimensional structure of human carbonic anhydrase ii in complex with 5-(1-naphthalen-1-yl-1,2,3-triazol-4-yl)thiophene-2-sulfonamide",18,2626.2,12.72,12,13,0.5,0.44
5mjn,three dimensional structure of human carbonic anhydrase ii in complex with 5-[(4chlorobenzyl)sulfanyl]thiophene-2-sulfonamide,17,2406.9,10.52,12,13,0.5,0.47
5amd,three dimensional structure of human carbonic anhydrase ii in complex with 2-((2-phenylethyl)sulfamoyl)-4-sulfamoylbenzoic acid,21,3007.6,12.69,18,19,1.0,0.52
1g46,"carbonic anhydrase ii (f131v) complexed with 4-(aminosulfonyl)-n-[(2, 3-difluorophenyl)methyl]-benzamide",16,2269.6,10.73,12,13,0.5,0.50
5nxg,carbonic anhydrase ii inhibitor ra1,16,2292.8,11.82,12,13,0.5,0.50
1g54,"carbonic anhydrase ii complexed with 4-(aminosulfonyl)-n-[(2,3,4,5,6- pentafluorophenyl)methyl]-benzamide",18,2519.6,11.69,12,13,0.5,0.44
6ugz,human carbonic anhydrase ix-mimic complexed with sb4-208,20,2923.1,12.85,15,16,1.0,0.50
5sz2,carbonic anhydrase ii in complex with 4-(3-formylphenyl)- benzenesulfonamide,15,2076.4,6.82,18,12,1.5,0.53
3v7x,"complex of human carbonic anhydrase ii with n-[2-(3,4- dimethoxyphenyl)ethyl]-4-sulfamoylbenzamide",18,2519.6,11.57,12,13,0.5,0.44
3ryz,fluoroalkyl and alkyl chains have similar hydrophobicities in binding to the hydrophobic wall of carbonic anhydrase,19,2686.3,12.19,12,13,0.5,0.42
4zwz,engineered carbonic anhydrase ix mimic in complex with a glucosyl sulfamate inhibitor,22,3051.1,10.37,19,20,1.0,0.55
5zg0,crystal structure of the glua2o lbd in complex with glutamate and compound-1,20,2641.3,12.91,17,8,3.0,0.45
5n24,crystal structure of human carbonic anhydrase ii in complex with the inhibitor b4'-cyano-biphenyl-4-sulfonic acid amide,17,2459.5,12.42,12,13,0.5,0.47
3rz1,fluoroalkyl and alkyl chains have similar hydrophobicities in binding to the hydrophobic wall of carbonic anhydrase,19,2686.3,12.18,12,13,0.5,0.42
3dd0,"use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties",16,2292.8,11.99,12,13,0.5,0.50
4zwx,engineered carbonic anhydrase ix mimic in complex with glucosyl sulfamate inhibitor,20,2887.4,15.69,13,13,0.5,0.40
4r5a,a carbonic anhydrase ix mimic in complex with a carbohydrate-based sulfamate,20,2844.0,9.04,22,22,1.5,0.65
1bnv,carbonic anhydrase ii inhibitor,21,3121.3,14.59,17,17,1.0,0.48
6oe0,benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases ii and vii and show neuropathic pain attenuating effects,19,2817.3,11.62,16,19,-0.5,0.58
3dcc,"use of carbonic anhydrase ii, ix active-site mimic, for the purpose of screening inhibitors for possible anti-cancer properties",15,2152.8,10.97,12,13,0.5,0.53
5sz1,carbonic anhydrase ii in complex with 4-(2-methylphenyl)- benzenesulfonamide,16,2292.8,11.89,12,13,0.5,0.50
5sz5,carbonic anhydrase ix-mimic in complex with 4-(2-methylphenyl)- benzenesulfonamide,23,3204.8,12.37,14,15,1.0,0.43
1g1d,carbonic anhydrase ii complexed with 4-(aminosulfonyl)-n-[(2- fluorophenyl)methyl]-benzamide,16,2346.8,11.62,12,13,0.5,0.50
3n2p,crystal structure of human carbonic anhydrase ii in complex with a benzenesulfonamide inhibitor,20,2878.7,12.21,14,17,-0.5,0.50
1g53,"carbonic anhydrase ii complexed with 4-(aminosulfonyl)-n-[(2,6- difluorophenyl)methyl]-benzamide",16,2346.8,11.45,12,13,0.5,0.50
6h2z,the crystal structure of human carbonic anhydrase ii in complex with 4-(4-phenylpiperidine-1-carbonyl)benzenesulfonamide.,18,2519.6,11.36,12,13,0.5,0.44
1bnu,carbonic anhydrase ii inhibitor,19,2779.4,13.02,14,15,1.0,0.47
4qxo,crystal structure of hsting(group2) in complex with dmxaa,10,1385.3,2.16,8,8,0.0,0.70
3rz7,fluoroalkyl and alkyl chains have similar hydrophobicities in binding to the hydrophobic wall of carbonic anhydrase,20,2830.1,11.61,14,15,0.5,0.45
5sz0,carbonic anhydrase ii in complex with 4-(phenyl)-benzenesulfonamide,18,2612.7,12.47,14,15,1.0,0.50
1g52,"carbonic anhydrase ii complexed with 4-(aminosulfonyl)-n-[(2,3- difluorophenyl)methyl]-benzamide",16,2346.8,11.39,12,13,0.5,0.50
6h34,the crystal structure of human carbonic anhydrase ii in complex with 4-[(4-fluorophenyl)methyl]-1-piperazinyl]benzenesulfonamide.,19,2890.4,14.61,15,15,1.0,0.47
4m2u,carbonic anhydrase ii in complex with dorzolamide,22,3261.3,15.26,17,17,1.0,0.45
3ml2,human carbonic anhydsase ii in complex with an aryl sulfonamide inhibitor,24,3437.5,15.54,12,15,-0.5,0.38
4ksy,crystal structure of sting in complex with cgamp,15,2227.0,5.53,17,9,1.0,0.67
1bnq,carbonic anhydrase ii inhibitor,21,3121.3,14.82,17,17,1.0,0.48
1bnw,carbonic anhydrase ii inhibitor,17,2459.5,12.25,12,13,0.5,0.47
5e2s,crystal structure of human carbonic anhydrase ii in complex with the 4-(2-iso-propylphenyl)benzenesulfonamide inhibitor,19,2740.3,13.38,14,15,0.5,0.47
6got,crystal structure of human carbonic anhydrase ii in complex with the inhibitor 4-(phenethylthio)benzenesulfonamide,18,2626.2,12.57,12,13,0.5,0.44
3ibu,the crystal structure of the human carbonic anhydrase ii in complex with an aliphatic sulfamate inhibitor,16,2346.8,11.19,12,13,0.5,0.50
1if8,carbonic anhydrase ii complexed with (s)-n-(3-indol-1-yl-2-methyl- propyl)-4-sulfamoyl-benzamide,17,2459.5,12.73,12,13,0.5,0.47
5aml,three dimensional structure of human carbonic anhydrase ii in complex with 2-(but-2-yn-1-ylsulfamoyl)-4-sulfamoylbenzoic acid,19,2741.7,11.81,16,17,0.5,0.53
6h33,the crystal structure of human carbonic anhydrase ii in complex with 4-(4-phenyl)-4-hydroxy-1-piperidine-1-carbonyl)benzenesulfonamide.,18,2519.6,11.44,12,13,0.5,0.44
6b59,carbonic anhydrase ii in complex with nitrogenous base-bearing benezenesulfonamide,21,2970.1,11.19,14,15,0.5,0.43
1bnt,carbonic anhydrase ii inhibitor,18,2626.2,12.98,12,13,0.5,0.44
2hoc,"crystal structure of the human carbonic anhydrase ii in complex with the 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole- 2-sulfonamide inhibitor",18,2627.6,11.96,14,15,0.5,0.50
1if7,carbonic anhydrase ii complexed with (r)-n-(3-indol-1-yl-2-methyl- propyl)-4-sulfamoyl-benzamide,18,2519.6,11.67,12,13,0.5,0.44
5llh,"crystal structure of human carbonic anhydrase isozyme ii with 4-(1,3- benzothiazol-2-ylthio)-2,3,5,6-tetrafluorobenzenesulfonamide",19,2767.6,11.63,14,15,0.5,0.47
6odz,benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases ii and vii and show neuropathic pain attenuating effects,15,2208.2,9.21,14,15,0.5,0.60
1bn1,carbonic anhydrase ii inhibitor,18,2626.2,12.68,12,13,0.5,0.44
5sz4,carbonic anhydrase ix-mimic in complex with 4-(phenyl)- benzenesulfonamide,17,2409.6,12.34,12,13,0.5,0.47
4rfd,human carbonic anhydrase ii in complex with 4-(4-sulfamoyl-phenoxy)- butylammonium,20,2826.3,11.79,12,13,0.5,0.40
5lle,"crystal structure of human carbonic anhydrase isozyme ii with 4-(1- adamantylamino)-2,3,5,6-tetrafluorobenzenesulfonamide",17,2459.5,12.48,12,13,0.5,0.47
1yvm,e. coli methionine aminopeptidase in complex with thiabendazole,10,1630.4,4.14,8,7,1.0,0.80
5sz7,carbonic anhydrase ix-mimic in complex with 4-(3-quinolinyl)- benzenesulfonamide,18,2469.7,11.93,12,13,0.5,0.44
1bn4,carbonic anhydrase ii inhibitor,19,2740.3,12.77,14,15,0.5,0.47
1bn3,carbonic anhydrase ii inhibitor,18,2626.2,12.78,12,13,0.5,0.44
5llc,"crystal structure of human carbonic anhydrase isozyme ii with 3- (methylamino)-2,5,6-trifluoro-4-[(2-phenylethyl) sulfonyl]benzenesulfonamide",20,2789.5,12.05,18,19,1.0,0.55
4cwo,human hsp90 alpha n-terminal domain in complex with an aminotriazoloquinazoline inhibitor,16,2273.3,15.40,6,7,-1.0,0.31
5nee,"crystal structure of human carbonic anhydrase ii in complex with the inhibitor 5-[2-(morpholine-4-carbonyl)1,3-oxazol-5-yl)]thiophene-2- sulfonammide",16,2320.9,10.69,14,15,0.5,0.56
5fnc,dynamic undocking and the quasi-bound state as tools for drug design,16,2080.9,13.36,5,7,-1.0,0.31
5nea,"crystal structure of human carbonic anhydrase ii in complex with the inhibitor 4-(2-methyl-1,3-oxazol-5-yl)benzene-1-sulfonammide",15,2152.8,10.71,12,13,0.5,0.53
5j82,"crystal structure of hsp90-alpha n-domain in complex 5-[4-(2-fluoro- phenyl)-5-oxo-4,5-dihydro-1h-[1,2,4]triazol-3-yl]-2,4-dihydroxy-n- isopropyl-n-methyl-benzenesulfonamide",17,2386.1,14.90,8,8,-1.0,0.35
5fnd,dynamic undocking and the quasi-bound state as tools for drug design,14,1684.4,4.24,10,11,-0.5,0.57
6ey8,estimation of relative drug-target residence times by random acceleration molecular dynamics simulation,18,2393.7,14.99,6,9,-2.0,0.33
1f4e,crystal structure of e. coli thymidylate synthase complexed with tosyl-d-proline,13,2080.2,12.49,7,7,-0.5,0.38
5llg,crystal structure of human carbonic anhydrase isozyme ii with 4- propylthiobenzenesulfonamide,18,2626.2,12.54,12,13,0.5,0.44
4lrr,"ternary complex between e. coli thymidylate synthase, dump, and f9",18,2694.2,10.96,10,14,-2.5,0.56
5fnf,dynamic undocking and the quasi-bound state as tools for drug design,13,1683.0,12.18,4,8,-2.0,0.38
4cwn,human hsp90 alpha n-terminal domain in complex with an aminotriazoloquinazoline inhibitor,19,2561.7,13.00,9,9,-1.0,0.37
2qg2,hsp90 complexed with a917985,20,2726.5,16.05,6,9,-2.0,0.30
4cwf,human hsp90 alpha n-terminal domain in complex with an aminotriazoloquinazoline inhibitor,11,1650.4,12.40,4,3,0.0,0.18
1bnn,carbonic anhydrase ii inhibitor,18,2626.2,12.82,12,13,0.5,0.44
3r4m,"optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. identification of development candidate 2-amino-4-{4-chloro-2-[2-(4- fluoro-1h-pyrazol-1-yl)ethoxy]-6-methylphenyl}-n-(2,2- difluoropropyl)-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine-6-carboxamide",13,1714.6,9.32,9,8,0.0,0.46
6eyb,estimation of relative drug-target residence times by random acceleration molecular dynamics simulation,19,2613.3,13.64,9,11,-2.0,0.42
3b27,hsp90 alpha n-terminal domain in complex with an inhibitor ro4919127,15,1994.6,11.28,9,8,0.0,0.40
4m2r,human carbonic anhydrase ii in complex with brinzolamide,25,3602.2,14.50,19,19,1.0,0.44
6ey9,estimation of relative drug-target residence times by random acceleration molecular dynamics simulation,20,2618.9,12.92,8,13,-3.0,0.40
4bqg,structure of hsp90 with an inhibitor bound,14,2073.2,13.91,6,7,-1.0,0.36
1yet,geldanamycin bound to the hsp90 geldanamycin-binding domain,20,2612.4,9.77,13,13,-1.0,0.50
4o04,identification of novel hsp90/isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating cns disorders such as huntington's disease,19,2453.2,13.41,6,9,-2.0,0.32
3b25,hsp90 alpha n-terminal domain in complex with an inhibitor ch4675194,14,1966.4,14.99,5,6,-1.0,0.29
4xip,discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors,20,2593.2,13.62,6,9,-2.0,0.30
6f1n,estimation of relative drug-target residence times by random acceleration molecular dynamics simulation,22,2735.3,10.22,11,14,-2.0,0.45
1yc1,crystal structures of human hsp90alpha complexed with dihydroxyphenylpyrazoles,17,2165.8,10.91,9,10,-1.0,0.41
6eln,estimation of relative drug-target residence times by random acceleration molecular dynamics simulation,17,2087.9,9.65,8,9,-1.0,0.41
6elo,estimation of relative drug-target residence times by random acceleration molecular dynamics simulation,18,2283.9,10.12,9,10,-1.0,0.44
4cwt,human hsp90 alpha n-terminal domain in complex with an aminotriazoloquinazoline inhibitor,18,2703.4,16.78,7,5,0.0,0.22
4loh,"crystal structure of hsting(h232) in complex with c[g(2',5')pa(3',5') p]",28,3924.9,7.42,25,19,0.0,0.68
6elp,estimation of relative drug-target residence times by random acceleration molecular dynamics simulation,16,2244.4,13.82,6,9,-2.0,0.38
4cwp,human hsp90 alpha n-terminal domain in complex with an aminotriazoloquinazoline inhibitor,17,2413.0,11.99,9,9,-1.0,0.41
1yc4,crystal structure of human hsp90alpha complexed with dihydroxyphenylpyrazoles,17,2221.8,10.40,10,11,-1.0,0.47
5odx,crystal structure of hsp90-alpha n-domain in complex with indazole derivative,20,2727.3,15.27,7,10,-2.0,0.35
3d0b,crystal structure of benzamide tetrahydro-4h-carbazol-4-one bound to hsp90,21,2868.4,15.46,9,9,-1.0,0.33
5j27,"hsp90 in complex with 5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1h-[1, 2,4]triazol-3-yl]-2,4-dihydroxy-n-methyl-n-propyl-benzenesulfonamide",17,2386.1,15.11,8,8,-1.0,0.35
4f5y,crystal structure of human sting ctd complex with c-di-gmp,22,3106.8,3.45,23,17,0.0,0.77
4fcq,"targeting conserved water molecules: design of 4-aryl-5- cyanopyrrolo[2,3-d]pyrimidine hsp90 inhibitors using fragment-based screening and structure-based optimization",17,2304.3,9.92,11,10,0.0,0.47
4xir,discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors,21,2761.8,13.18,9,9,-1.0,0.33
4cwq,human hsp90 alpha n-terminal domain in complex with an aminotriazoloquinazoline inhibitor,20,2849.0,12.34,12,12,-0.5,0.45
4xit,discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors,20,2701.7,14.36,9,9,-1.0,0.35
5j64,"crystal structure of hsp90-alpha n-domain in complex with 5-(2,4- dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3- one",16,2027.8,9.71,8,9,-1.0,0.44
3n3j,crystal structure of human carbonic anhydrase ii in complex with a benzenesulfonamide inhibitor,21,2993.0,12.32,12,13,0.5,0.38
6hhr,"hsp90 in complex with 5-(2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2, 4-dihydro-[1,2,4]triazole-3-thione",16,2027.8,9.89,8,9,-1.0,0.44
6fcj,estimation of protein-ligand unbinding kinetics using non-equilibrium targeted molecular dynamics simulations,17,2087.9,10.11,8,9,-1.0,0.41
6el5,estimation of relative drug-target residence times by random acceleration molecular dynamics simulation,20,2621.8,12.98,9,9,-1.0,0.35
4xiq,discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors,19,2426.5,12.72,6,9,-2.0,0.32
4o07,identification of novel hsp90/isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating cns disorders such as huntington's disease,23,3066.3,14.98,9,11,-2.0,0.35
4loi,"crystal structure of hsting(h232) in complex with c[g(2',5')pa(2',5') p]",28,3924.9,7.53,25,19,0.0,0.68
4o05,identification of novel hsp90/isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating cns disorders such as huntington's disease,22,2955.2,15.14,9,9,-1.0,0.32
6ei5,estimation of relative drug-target residence times by random acceleration molecular dynamics simulation,18,2527.1,11.53,11,11,-1.0,0.44
6eya,estimation of relative drug-target residence times by random acceleration molecular dynamics simulation,20,2649.7,11.14,12,14,-2.0,0.50
4few,"crystal structure of the aminoglycoside phosphotransferase aph(3')-ia, with substrate kanamycin and small molecule inhibitor pyrazolopyrimidine pp2",20,2613.0,3.00,23,26,-6.0,0.90
5nyh,crystal structure of hsp90-alpha n-domain in complex with indazole derivative,18,2393.7,14.91,6,9,-2.0,0.33
4fev,"crystal structure of the aminoglycoside phosphotransferase aph(3')-ia, with substrate kanamycin and small molecule inhibitor pyrazolopyrimidine pp1",18,2328.5,3.74,18,24,-6.0,0.89
4o09,identification of novel hsp90 / isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating cns disorders such as huntington s disease,23,3039.6,14.25,9,11,-2.0,0.35
3vha,hsp90 alpha n-terminal domain in complex with a macrocyclic inhibitor,17,2274.3,10.99,12,10,0.0,0.47
5ljt,"crystal structure of human carbonic anhydrase ii in complex with the 4-((1-phenyl-1h-1,2,3-triazol-4-yl)methoxy)benzenesulfonamide inhibitor",22,3146.2,12.14,14,15,1.0,0.41
4cws,human hsp90 alpha n-terminal domain in complex with an aminotriazoloquinazoline inhibitor,19,2693.8,13.18,11,11,-1.0,0.42
5lny,hsp90 with indazole derivative,19,2587.3,14.07,7,10,-2.0,0.37
5h85,crystal structure of the bromodomain of human crebbp in complex with uo37d,15,2356.0,13.15,12,8,0.0,0.40
5tb6,"structure of bromodomain of crebbp with a pyrazolo[4,3-c]pyridin fragment",11,1672.6,12.35,4,4,0.0,0.27
5j2x,"crystal structure of hsp90-alpha n-domain in complex with 5-(5-bromo- 2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol- 3-one",16,2027.8,9.82,8,9,-1.0,0.44
5mpz,crystal structure of crebbp bromodomain complexed with cbp007,10,1505.9,10.67,4,4,0.0,0.30
4tqn,crystal structure of the bromodomain of human crebbp in complex with ul04,14,2148.6,12.87,9,4,1.0,0.29
4egk,human hsp90-alpha atpase domain bound to radicicol,16,2081.8,9.87,10,11,-1.0,0.50
5j6n,"crystal structure of hsp90-alpha n-domain l107a mutant in complex with 5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1h-[1,2,4]triazol-3-yl]-2,4- dihydroxy-n-methyl-n-propyl-benzenesulfonamide",17,2333.5,12.23,10,10,-1.0,0.41
5nlk,crystal structure of crebbp bromodomain complexd with us13a,16,2459.1,14.05,11,6,1.0,0.31
5j86,"crystal structure of hsp90-alpha n-domain in complex with 2,4- dihydroxy-n-methyl-5-(5-oxo-4-o-tolyl-4,5-dihydro-1h-[1,2,4]triazol- 3-yl)-n-thiophen-2-ylmethyl-benzamide",19,2611.3,13.71,10,12,-2.0,0.42
4cwr,human hsp90 alpha n-terminal domain in complex with an aminotriazoloquinazoline inhibitor,17,2413.0,11.92,9,9,-1.0,0.41
5fho,crystal structure of the glua2 ligand-binding domain (s1s2j) in complex with (s)-2-amino-3-(5-(2-(3-chlorobenzyl)-2h-tetrazol-5-yl)- 3-hydroxyisoxazol-4-yl)propanoic acid at 2.3 a resolution,30,4337.5,12.62,22,17,0.0,0.57
5mmg,crystal structure of crebbp bromodomain complexed with ut07c,14,2179.7,12.04,11,6,1.0,0.36
5eng,crystal structure of the bromodomain of human crebbp in complex with up39,17,2631.3,15.57,12,8,0.0,0.35
5j0d,crystal structure of the bromodomain of human crebbp in complex with a benzoxazepine compound,14,2148.6,13.81,9,4,1.0,0.29
4o0b,identification of novel hsp90/isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating cns disorders such as huntington's disease,23,3039.6,14.22,9,11,-2.0,0.35
5ep7,crystal structure of the bromodomain of human crebbp in complex with un32,13,2073.8,13.86,10,4,1.0,0.31
5j6l,"crystal structure of hsp90-alpha n-domain in complex with n-butyl-5- [4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1h-[1,2,4]triazol-3-yl]-2,4- dihydroxy-n-methyl-benzamide",19,2615.7,12.32,11,11,-1.0,0.42
2yi0,"structural characterization of 5-aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole hsp90 inhibitors.",18,2204.0,9.38,9,10,-1.0,0.44
5j6m,"crystal structure of hsp90-alpha n-domain l107 mutant in complex with 5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1h-[1,2,4]triazol-3-yl]-n- furan-2-ylmethyl-2,4-dihydroxy-n-methyl-benzamide",18,2444.6,11.87,10,12,-2.0,0.44
5mpn,crystal structure of crebbp bromodomain complexed with fa26,12,1846.0,11.12,9,4,1.0,0.33
4nh8,correlation between chemotype-dependent binding conformations of hsp90 alpha/beta and isoform selectivity,22,2872.9,13.28,9,11,-2.0,0.36
2uwd,"inhibition of the hsp90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole, isoxazole amide analogs",20,2468.3,8.45,11,14,-1.5,0.50
2yki,tricyclic series of hsp90 inhibitors,25,3473.1,19.95,6,9,-2.0,0.24
4b7p,structure of hsp90 with nms-e973 inhibitor bound,20,2657.3,8.64,16,14,0.5,0.55
3qdd,hsp90a n-terminal domain in complex with biib021,15,2133.3,13.82,6,7,-1.0,0.33
2yi7,"structural characterization of 5-aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole hsp90 inhibitors.",17,2035.4,10.00,6,10,-2.0,0.41
3vhc,hsp90 alpha n-terminal domain in complex with a macrocyclic inhibitor,19,2528.0,10.08,13,11,0.0,0.47
5ljq,"crystal structure of human carbonic anhydrase ii in complex with the 4-(4-(phenoxymethyl)-1h-1,2,3-triazol-1-yl)benzenesulfonamide inhibitor",21,2993.0,12.23,12,13,0.5,0.38
5ot9,structure of the periplasmic binding protein (pbp) noct from a.tumefaciens c58 in complex with histopine.,22,2908.5,9.11,19,15,0.5,0.55
2we3,ebv dutpase inactive mutant deleted of motif v,21,2885.3,9.69,16,14,-1.5,0.48
5ot8,structure of the periplasmic binding protein (pbp) noct-g97s mutant from a. tumefaciens c58 in complex with octopine.,22,2991.4,8.96,22,18,0.5,0.64
5ota,structure of the periplasmic binding protein (pbp) noct from agrobacterium tumefaciens c58 in complex with octopinic acid,21,2764.7,8.90,17,13,0.5,0.52
5ito,structure of the periplasmic binding protein m117n-noct from a. tumefaciens in complex with octopine,24,3062.8,7.22,24,20,0.5,0.62
5otc,structure of the periplasmic binding protein (pbp) noct from agrobacterium tumefaciens c58 in complex with noroctopinic acid.,22,2908.5,8.98,19,15,0.5,0.55
5itp,structure of the periplasmic binding protein noct from a.tumefaciens in complex with octopine,24,3111.6,8.89,22,18,0.5,0.58
4qjx,crystal structure of human carbonic anhydrase isozyme xiii with inhibitor,22,3105.1,14.02,18,18,1.0,0.50
3b24,hsp90 alpha n-terminal domain in complex with an aminotriazine fragment molecule,14,1827.7,8.69,8,9,-1.0,0.50
5j8u,"crystal structure of hsp90-alpha n-domain l107a mutant in complex with 5-(2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2, 4]triazol-3-one",15,1833.6,9.74,7,8,-1.0,0.40
5i8g,"cbp in complex with cpd637 ((r)-4-methyl-6-(1-methyl-3-(1-methyl-1h- pyrazol-4-yl)-1h-indazol-5-yl)-1,3,4,5-tetrahydro-2h-benzo[b][1, 4]diazepin-2-one)",15,2292.4,12.79,11,6,1.0,0.33
5mpk,crystal structure of crebbp bromodomain complexed with dk19,16,2459.1,13.82,11,6,1.0,0.31
1f4f,crystal structure of e. coli thymidylate synthase complexed with sp- 722,17,2593.9,14.08,12,9,0.5,0.47
5mqe,crystal structure of crebbp bromodomain complexed with cbp006,10,1505.9,10.76,4,4,0.0,0.30
5j8m,"crystal structure of hsp90-alpha n-domain l107a mutant in complex with 5-(5-bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1, 2,4]triazol-3-one",16,1949.7,9.41,8,9,-1.0,0.44
4pp0,structure of the pbp noct-m117n in complex with pyronopaline,25,3252.7,8.97,24,20,0.5,0.60
1pzp,"tem-1 beta-lactamase in complex with a novel, core-disrupting, allosteric inhibitor",16,2193.2,17.58,0,2,-1.0,0.06
1f4g,crystal structure of e. coli thymidylate synthase complexed with sp- 876,23,3480.0,13.75,25,14,2.0,0.61
4pow,structure of the pbp noct in complex with pyronopaline,25,3301.5,10.29,22,18,0.5,0.56
3r4n,"optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. identification of development candidate 2-amino-4-{4-chloro-2-[2-(4- fluoro-1h-pyrazol-1-yl)ethoxy]-6-methylphenyl}-n-(2,2- difluoropropyl)-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine-6-carboxamide",16,2105.7,11.18,9,10,-1.0,0.44
3eko,dihydroxylphenyl amides as inhibitors of the hsp90 molecular chaperone,14,1801.0,9.15,8,9,-1.0,0.50
3b26,hsp90 alpha n-terminal domain in complex with an inhibitor ro1127850,14,1773.0,8.56,7,9,-1.0,0.43
2qg0,hsp90 complexed with a943037,18,2279.5,8.41,10,11,-1.0,0.44
1s19,crystal structure of vdr ligand binding domain complexed to calcipotriol.,27,4242.4,19.27,17,11,2.0,0.41
5mme,crystal structure of crebbp bromodomain complexd with us46c,14,2179.7,11.98,11,6,1.0,0.36
5j9x,"hsp90 in complex with n-butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5- dihydro-1h-[1,2,4]triazol-3-yl]-2,4-dihydroxy-n-methyl-benzamide",27,3692.6,15.86,13,15,-1.5,0.41
3ekr,dihydroxylphenyl amides as inhibitors of the hsp90 molecular chaperone,16,2081.8,9.82,10,11,-1.0,0.50
3rlp,"co-crystal structure of the hsp90 atp binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-6-methylpyrimidin-2-amine",16,2079.7,11.14,7,9,-1.0,0.38
3g30,ctx-m-9 class a beta-lactamase complexed with compound 3 (g30),15,1738.6,0.99,17,15,0.0,0.80
1ie9,crystal structure of the nuclear receptor for vitamin d ligand binding domain bound to mc1288,28,4409.1,20.68,17,11,2.0,0.39
3rlq,"co-crystal structure of the hsp90 atp binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2-methyl-7h-pyrrolo[2,3- d]pyrimidine-5- carbonitrile",16,2079.7,11.15,7,9,-1.0,0.38
3rlr,"co-crystal structure of the hsp90 atp binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2,6-dimethyl-7h-pyrrolo[2,3- d]pyrimidine-5-carbonitrile",17,2246.4,11.86,7,9,-1.0,0.35
5j20,"hsp90 in complex with 5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1h-[1, 2,4]triazol-3-yl]-n-furan-2-ylmethyl-2,4-dihydroxy-n-methyl-benzamide",20,2673.4,13.23,9,11,-2.0,0.40
3hek,"hsp90 n-terminal domain in complex with 1-{4-[(2r)-1-(5-chloro-2,4- dihydroxybenzoyl)pyrrolidin-2-yl]benzyl}-3,3-difluoropyrrolidinium",20,2535.6,9.67,11,12,-1.0,0.45
3ocp,crystal structure of camp bound cgmp-dependent protein kinase(92-227),17,2329.4,13.10,7,4,0.0,0.29
2a14,crystal structure of human indolethylamine n-methyltransferase with sah,8,1141.2,2.75,12,6,1.5,0.62
5nwi,14-3-3c in complex with cpp,5,730.3,2.24,11,1,2.0,0.80
4nh7,correlation between chemotype-dependent binding conformations of hsp90 alpha/beta and isoform selectivity,25,3399.9,15.88,10,12,-2.0,0.36
4e67,the structure of the polo-box domain (pbd) of polo-like kinase 1 (plk1) in complex with hydrocinnamoyl-derivatized plhspta peptide,9,1454.4,4.95,5,7,-0.5,0.56
3ocz,structure of recombinant haemophilus influenzae e(p4) acid phosphatase complexed with the inhibitor adenosine 5-o-thiomonophosphate,21,3135.5,9.12,23,23,-3.0,0.76
3r4p,"optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. identification of development candidate 2-amino-4-{4-chloro-2-[2-(4- fluoro-1h-pyrazol-1-yl)ethoxy]-6-methylphenyl}-n-(2,2- difluoropropyl)-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine-6-carboxamide",18,2410.4,9.78,10,13,-2.0,0.50
1azm,drug-protein interactions: structure of sulfonamide drug complexed with human carbonic anhydrase i,15,2215.4,12.54,11,12,1.0,0.47
4o9w,crystal structure of polo-like kinase(plk1)pbd in complex with phospho peptide,5,653.3,4.61,2,2,0.5,0.40
4o6w,peptide-based inhibitors of plk1 polo-box domain,14,2145.0,9.39,6,7,-1.0,0.50
5dbm,crystal structure of the cbp bromodomain in complex with cpi703,12,1786.7,11.89,6,6,0.0,0.33
3wha,hsp90 alpha n-terminal domain in complex with a tricyclic inhibitor,19,2499.4,11.08,10,11,-1.0,0.42
1n4h,characterization of ligands for the orphan nuclear receptor rorbeta,24,3606.6,17.58,17,7,2.0,0.38
3vhd,"hsp90 alpha n-terminal domain in complex with a macrocyclic inhibitor, ch5164840",18,2386.7,10.52,10,11,-1.0,0.44
6mkw,"crystal structure of the periplasmic lysine-, arginine-, ornithine- binding protein (lao) d11a mutant from salmonella typhimurium complexed with histidine",6,861.8,3.97,5,6,-1.0,0.67
6mli,"crystal structure of the periplasmic lysine-, arginine-, ornithine- binding protein (lao) r77a mutant from salmonella typhimurium complexed with histidine",6,897.0,5.18,3,4,-1.0,0.33
4yk0,crystal structure of the cbp bromodomain in complex with cpi098,10,1505.9,10.78,4,4,0.0,0.30
6mlp,"crystal structure of the periplasmic lysine-, arginine-, ornithine- binding protein (lao) y14a mutant from salmonella typhimurium complexed with histidine",6,863.7,1.75,8,6,0.0,0.83
1nq7,characterization of ligands for the orphan nuclear receptor rorbeta,27,4031.2,18.36,17,7,2.5,0.37
1uvt,bovine thrombin--bm14.1248 complex,24,3302.5,11.52,11,18,-4.5,0.54
6mku,"crystal structure of the periplasmic lysine-, arginine-, ornithine- binding protein (lao) d11a mutant from salmonella typhimurium complexed with arginine",5,646.1,3.70,3,4,-1.0,0.60
6mla,"crystal structure of the periplasmic lysine-, arginine-, ornithine- binding protein (lao) d161a mutant from salmonella typhimurium complexed with arginine",4,649.8,1.86,7,2,1.0,0.75
6mln,"crystal structure of the periplasmic lysine-, arginine-, ornithine- binding protein (lao) s72a mutant from salmonella typhimurium complexed with arginine",6,897.0,5.18,3,4,-1.0,0.33
3q2j,"crystal structure of 3',5""-aminoglycoside phosphotransferase type iiia protein kinase inhibitor cki-7 complex",15,2094.2,10.74,8,9,-1.0,0.47
6g5u,"crystal structure of human carbonic anhydrase isozyme xiii with n- butyl-2,4-dichloro-5-sulfamoyl-benzamide",20,2954.8,12.78,17,17,1.0,0.50
4knm,"crystal structure of human carbonic anhydrase isozyme xiii with 2- chloro-4-{[(4,6-dimethylpyrimidin-2-yl) sulfanyl]acetyl}benzenesulfonamide",20,2939.4,12.57,16,12,1.5,0.40
6mle,"crystal structure of the periplasmic lysine-, arginine-, ornithine- binding protein (lao) from salmonella typhimurium complexed with arginine",6,796.2,2.18,9,3,1.0,0.67
4hu1,crystal structure of human carbonic anhydrase isozyme xiii with the inhibitor.,19,2770.9,11.54,18,14,1.5,0.47
3czv,crystal structure of the human carbonic anhydrase xiii in complex with acetazolamide,16,2293.0,11.79,12,13,0.5,0.50
4knn,crystal structure of human carbonic anhydrase isozyme xiii with 2- chloro-4-[(pyrimidin-2-ylsulfanyl)acetyl]benzenesulfonamide,19,2825.2,9.86,21,16,1.5,0.58
1vso,crystal structure of the ligand-binding core of iglur5 in complex with the antagonist (s)-atpo at 1.85 a resolution,14,1896.8,1.46,13,12,-1.0,0.79
6fz4,"structure of gluk1 ligand-binding domain in complex with n-(7-fluoro- 2,3-dioxo-6-(trifluoromethyl)-3,4-dihydroquinoxalin-1(2h)-yl)-2- hydroxybenzamide at 1.85 a resolution",16,2176.5,1.49,16,14,-1.0,0.81
3e6y,structure of 14-3-3 in complex with the differentiation-inducing agent cotylenin a,15,2123.8,13.66,9,5,1.0,0.33
2w8y,ru486 bound to the progesterone receptor in a destabilized agonistic conformation,27,4219.6,20.76,12,8,0.0,0.26
1a28,hormone-bound human progesterone receptor ligand-binding domain,22,3449.0,18.22,12,6,1.0,0.27
1sr7,progesterone receptor hormone binding domain with bound mometasone furoate,24,3747.4,19.16,12,6,1.0,0.29
3g31,ctx-m-9 class a beta-lactamase complexed with compound 4 (gf1),7,988.3,2.96,6,5,0.0,0.57
3ai8,cathepsin b in complex with the nitroxoline,16,1907.9,2.06,12,15,-0.5,0.75
2e7f,5-methyltetrahydrofolate corrinoid/iron sulfur protein methyltransferase complexed with methyltetrahydrofolate to 2.2 angsrom resolution,22,2896.5,11.19,17,20,-3.0,0.55
6edr,crystal structure of human cd38 in complex with 4'-thioribose nad+,15,2096.7,8.53,12,13,-3.0,0.67
6faf,"crystal structure of human carbonic anhydrase i in complex with the 3- (2,5-dimethylphenyl)-1-(2-hydroxy-5-sulfamoylphenyl)urea inhibitor",20,2907.3,11.92,16,17,1.5,0.50
6g3v,crystal structure of human carbonic anhydrase i in complex with the inhibitor famotidine,22,3189.5,15.04,17,18,1.5,0.50
2ogy,asn199ala mutant of the 5-methyltetrahydrofolate corrinoid/iron sulfur protein methyltransferase complexed with methyltetrahydrofolate to 2.3 angstrom resolution,22,2844.3,11.62,15,18,-3.0,0.50
5org,structure of the periplasmic binding protein (pbp) occj from a. tumefaciens b6 in complex with octopine.,22,2954.2,11.58,20,15,0.0,0.50
4lar,crystal structure of a therapeutic single chain antibody in complex with amphetamine,11,1956.2,4.84,9,10,-0.5,0.73
2q89,crystal structure of ehub in complex with hydroxyectoine,16,2056.4,8.11,8,7,-1.0,0.38
3gm0,anti-methamphetamine single chain fv in complex with mdma,13,2235.1,6.47,10,11,-0.5,0.69
3g35,ctx-m-9 class a beta-lactamase complexed with compound 12 (f13),18,2086.9,0.63,20,18,0.0,0.83
3fvh,polo-like kinase 1 polo box domain in complex with ac-lhspta-nh2 peptide,5,575.2,4.04,2,2,0.5,0.40
4nwc,"crystal structure of the gluk3 ligand-binding domain (s1s2) in complex with the agonist (2s,4r)-4-(3-methoxy-3-oxopropyl)glutamic acid at 2.01 a resolution.",19,2661.4,9.88,12,13,-2.0,0.53
6fag,crystal structure of human carbonic anhydrase i in complex with the 1- (2-hydroxy-5-sulfamoylphenyl)-3-(2-methoxyphenyl)urea inhibitor,20,2866.9,13.11,17,18,2.0,0.50
4non,crystal structure of gdp-bound a143s mutant of the s. thermophilus feob g-domain,15,1736.5,5.48,14,13,0.0,0.67
4g8n,crystal structure of the kainate receptor gluk3 ligand-binding domain in complex with the agonist g8m,14,1914.7,5.61,11,10,-1.0,0.57
4de0,ctx-m-9 class a beta-lactamase complexed with compound 16,17,1970.8,0.97,19,17,0.0,0.82
3gkz,crystal structures of a therapeutic single chain antibody in complex methamphetamine,12,2122.9,6.65,9,10,-0.5,0.67
2q88,crystal structure of ehub in complex with ectoine,15,1967.4,8.59,7,6,-1.0,0.33
3hit,"crystal structure of saporin-l1 in complex with the dinucleotide inhibitor, a transition state analogue",26,3928.4,13.28,27,17,0.0,0.54
2nn1,structure of inhibitor binding to carbonic anhydrase i,16,2294.9,9.85,15,16,1.5,0.56
6f3b,crystal structure of human carbonic anhydrase i in complex with the 1- (2-hydroxy-5-sulfamoylphenyl)-3-[(4-methylphenyl)methyl]urea inhibitor,20,2842.7,12.82,14,15,1.0,0.45
6ex1,crystal structure of human carbonic anhydrase i in complex with the 4- [(3s)-3 benzyl-4-(4-sulfamoylbenzoyl)piperazine -1-carbonyl]benzene- 1-sulfonamide inhibitor,20,2907.3,12.08,16,17,1.5,0.50
5wcm,crystal structure of the complex between class b3 beta-lactamase bjp-1 and 4-nitrobenzene-sulfonamide - new refinement,13,1920.8,8.62,12,15,0.5,0.62
2vmd,structure of the complex of discoidin ii from dictyostelium discoideum with beta-methyl-galactose,4,605.1,2.26,8,2,1.0,0.50
2xxr,crystal structure of the gluk2 (glur6) wild-type lbd dimer in complex with glutamate,10,1518.2,4.47,18,6,2.0,0.80
6ml9,"crystal structure of the periplasmic lysine-, arginine-, ornithine- binding protein (lao) d30a mutant from salmonella typhimurium complexed with arginine",5,760.9,1.92,7,4,0.0,0.80
2nmx,structure of inhibitor binding to carbonic anhydrase i,20,2803.1,10.25,18,21,0.5,0.60
2nn7,structure of inhibitor binding to carbonic anhydrase i,20,2803.1,10.26,18,21,0.5,0.60
6evr,crystal structure of human carbonic anhydrase i in complex with the 4- (4 acetyl-3-benzylpiperazine-1 carbonyl)benzene-1-sulfonamide inhibitor,21,2969.2,12.72,16,17,1.5,0.48
4gqp,structure based design of sub-nanomolar affinity anti-methamphetamine single chain antibodies.,12,2122.9,6.61,9,10,-0.5,0.67
4de2,ctx-m-9 class a beta-lactamase complexed with compound 12,19,2260.3,0.61,25,18,1.0,0.84
3lxe,human carbonic anhydrase i in complex with topiramate,20,2944.7,11.49,19,20,2.0,0.60
2v25,"structure of the campylobacter jejuni antigen peb1a, an aspartate and glutamate receptor with bound aspartate",2,265.9,1.63,2,2,0.5,0.50
2xxt,crystal structure of the gluk2 (glur6) wild-type lbd dimer in complex with kainate,16,2216.8,9.43,10,9,-1.0,0.44
4de1,ctx-m-9 class a beta-lactamase complexed with compound 18,18,2086.9,0.66,20,18,0.0,0.83
4bi6,"crystal structure of a triple mutant (a198v, c202a and c222n) of triosephosphate isomerase from giardia lamblia. complexed with 2- phosphoglycolic acid",17,1841.8,4.66,9,10,-0.5,0.41
2vmc,structure of the complex of discoidin ii from dictyostelium discoideum with n-acetyl-galactosamine,10,1449.4,2.58,16,13,1.5,0.90
6mlj,"crystal structure of the periplasmic lysine-, arginine-, ornithine- binding protein (lao) s70a mutant from salmonella typhimurium complexed with arginine",6,773.9,2.45,10,2,2.0,0.67
4bi7,crystal structure of a mutant (c202a) of triosephosphate isomerase from giardia lamblia complexed with 2-phosphoglycolic acid,16,1809.2,3.88,10,11,-0.5,0.50
4bt3,"acetolactate decarboxylase with a bound (2r,3r)-2,3-dihydroxy-2- methylbutanoic acid",17,2449.5,10.83,12,11,0.5,0.41
4bt4,"acetolactate decarboxylase with a bound (2s,3s)-2,3-dihydroxy-2- methylbutanoic acid",15,2142.8,8.59,12,11,0.5,0.47
2xht,structure of hsp90 with small molecule inhibitor bound,16,2107.7,11.51,8,9,-1.0,0.44
5yas,hydroxynitrile lyase complexed with hexafluoroacetone,15,2313.1,13.18,7,6,1.0,0.40
2xdl,structure of hsp90 with small molecule inhibitor bound,18,2255.0,8.93,9,12,-2.0,0.50
4bt5,"acetolactate decarboxylase with a bound (2s,3r)-2,3-dihydroxy-2- methylbutanoic acid",16,2282.8,9.63,12,11,0.5,0.44
2xdk,structure of hsp90 with small molecule inhibitor bound,12,1546.0,9.87,6,8,-1.0,0.42
6olx,hsp90-alpha s52a bound to pu-11-trans,19,2611.5,18.89,5,6,-1.0,0.21
6n8x,hsp90-alpha bound to pu-11-trans,19,2611.9,17.95,6,7,-1.0,0.26
2xdx,structure of hsp90 with small molecule inhibitor bound,13,1686.0,11.03,6,8,-1.0,0.38
5ikb,crystal structure of the kainate receptor gluk4 ligand binding domain in complex with kainate,18,2476.5,8.33,12,11,-1.0,0.56
2xjg,structure of hsp90 with small molecule inhibitor bound,17,2274.4,12.30,8,9,-1.0,0.41
5z7j,crystal structure of a lactonase double mutant in complex with ligand l,24,3264.7,17.58,10,11,-0.5,0.33
3n9r,"class ii fructose-1,6-bisphosphate aldolase from helicobacter pylori in complex with n-(4-hydroxybutyl)-phosphoglycolohydroxamic acid, a competitive inhibitor",20,2381.2,3.69,24,22,0.5,0.75
5xo7,crystal structure of a novel zen lactonase mutant with ligand a,22,3094.5,15.52,11,12,-0.5,0.36
3fas,x-ray structure of iglur4 flip ligand-binding core (s1s2) in complex with (s)-glutamate at 1.40a resolution,3,574.6,2.04,11,0,2.0,0.67
4z07,co-crystal structure of the tandem cnb (cnb-a/b) domains of human pkg i beta with cgmp,22,3037.2,11.32,15,8,1.0,0.45
3udd,tankyrase-1 in complex with small molecule inhibitor,20,2666.1,8.38,11,10,1.0,0.40
6sbt,"structure of gluk1 ligand-binding domain (s1s2) in complex with n-(7- (1h-imidazol-1-yl)-2,3-dioxo-6-(trifluoromethyl)-3,4- dihydroquinoxalin-1(2h)-yl benzamide at 2.3 a resolution",16,2096.9,1.53,14,15,-2.0,0.81
2f35,crystal structure of the glur5 ligand binding core with ubp302 at 1.87 angstroms resolution,16,2141.9,6.69,12,11,-1.0,0.62
2yfa,x-ray structure of mcps ligand binding domain in complex with malate,9,1439.3,5.68,18,3,3.0,0.56
2xjx,structure of hsp90 with small molecule inhibitor bound,17,2221.8,10.80,10,11,-1.0,0.47
3gbb,x-ray structure of iglur5 ligand-binding core (s1s2) in complex with msviii-19 at 2.10a resolution,16,2141.9,7.09,12,11,-1.0,0.62
4dld,crystal structure of the gluk1 ligand-binding domain (s1s2) in complex with the antagonist (s)-2-amino-3-(2-(2-carboxyethyl)-5-chloro-4- nitrophenyl)propionic acid at 2.0 a resolution,18,2477.7,6.22,13,14,-2.0,0.67
2pbw,crystal structure of the ligand-binding core of iglur5 in complex with the partial agonist domoic acid at 2.5 a resolution,20,2626.2,6.36,19,12,0.0,0.60
2wky,crystal structure of the ligand-binding core of glur5 in complex with the agonist 4-ahcp,17,2256.8,6.49,12,13,-2.0,0.65
3re4,crystal structure of archaeoglobus fulgidus rio1 kinase bound to toyocamycin.,19,2652.0,11.26,6,11,-3.0,0.42
3s2v,"crystal structure of the ligand binding domain of gluk1 in complex with an antagonist (s)-1-(2'-amino-2'-carboxyethyl)-3-[(2- carboxythien-3-yl)methyl]thieno[3,4-d]pyrimidin-2,4-dione at 2.5 a resolution",20,2706.9,7.97,14,13,-1.0,0.60
2f34,crystal structure of the glur5 ligand binding core dimer with ubp310 at 1.74 angstroms resolution,17,2335.5,6.44,13,12,-1.0,0.65
5neb,structure of gluk1 ligand-binding domain (s1s2) in complex with lm-12b at 2.05 a resolution,18,2419.7,7.92,12,13,-2.0,0.61
3fvn,"crystal structure of the human glutamate receptor, glur5, ligand- binding core in complex with 9-deoxy-neodysiherbaine a in space group p1",19,2586.4,8.46,12,13,-2.0,0.58
3fuz,"crystal structure of the human glutamate receptor, glur5, ligand- binding core in complex with l-glutamate in space group p1",7,1205.6,4.39,14,1,3.0,0.57
6f28,"crystal structure of the kainate receptor gluk3 ligand binding domain in complex with (s)-1-[2'-amino-2'-carboxyethyl]-6-methyl-5,7- dihydropyrrolo[3,4-d]pyrimidin-2,4(1h,3h)-dione at resolution 2.4a",21,2837.6,9.86,13,14,-2.0,0.52
4e0x,crystal structure of the kainate receptor gluk1 ligand-binding domain in complex with kainate in the absence of glycerol,17,2330.7,8.14,11,12,-2.0,0.59
3fvk,"crystal structure of the human glutamate receptor, glur5, ligand- binding core in complex with 8-deoxy-neodysiherbaine a in space group p1",18,2419.7,7.98,12,13,-2.0,0.61
3fv2,"crystal structure of the human glutamate receptor, glur5, ligand- binding core in complex with neodysiherbaine a in space group p1",20,2673.4,7.58,13,14,-2.0,0.60
5o4f,structure of gluk3 ligand-binding domain (s1s2) in complex with the agonist lm-12b at 2.10 a resolution,15,2057.5,5.66,12,11,-1.0,0.60
3fv1,"crystal structure of the human glutamate receptor, glur5, ligand- binding core in complex with dysiherbaine in space group p1",20,2785.0,8.48,14,13,-1.0,0.60
5vyy,structure of human hsp90-alpha bound to resorcinylic inhibitor bnim,22,3036.7,11.96,12,12,-1.0,0.41
3v3q,"crystal structure of human nur77 ligand-binding domain in complex with ethyl 2-[2,3,4 trimethoxy-6(1-octanoyl)phenyl]acetate",19,2749.1,11.28,14,10,-1.0,0.53
3fat,x-ray structure of iglur4 flip ligand-binding core (s1s2) in complex with (s)-ampa at 1.90a resolution,16,2199.5,6.55,12,11,-1.0,0.62
1wht,structure of the complex of l-benzylsuccinate with wheat serine carboxypeptidase ii at 2.0 angstroms resolution,15,1918.1,2.60,8,14,-2.5,0.73
5avf,the ligand binding domain of mlp37 with taurine,15,2263.8,11.71,11,7,-1.0,0.40
4x8v,"factor viia in complex with the inhibitor (methyl {3-[(2r)-1-{(2r)-2- (3,4-dimethoxyphenyl)-2-[(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl) amino]acetyl}pyrrolidin-2-yl]-4-(propan-2-ylsulfonyl) phenyl}carbamate)",30,3783.9,10.72,18,17,-0.5,0.60
2j2u,crystal structure of a human factor xa inhibitor complex,22,2845.6,5.07,12,14,-2.0,0.59
2bok,factor xa - cation,23,2895.5,9.82,14,14,-0.5,0.52
5k0h,human factor xa in complex with synthetic inhibitor benzylsulfonyl- dser(benzyl)-gly-4-amidinobenzylamide,26,3399.2,6.33,19,18,-1.5,0.62
2xc0,"factor xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",25,3356.8,5.00,24,17,-1.0,0.68
1f0s,crystal structure of human coagulation factor xa complexed with rpr208707,17,2176.3,5.57,12,12,-2.0,0.65
1nfu,crystal structure of human coagulation factor xa complexed with rpr132747,20,2483.4,5.16,8,13,-3.0,0.55
2vwo,aminopyrrolidine factor xa inhibitor,23,3090.6,6.57,12,16,-3.0,0.61
1g2l,factor xa inhibitor complex,26,3397.9,7.71,16,18,-1.5,0.58
2j94,crystal structure of a human factor xa inhibitor complex,21,2652.0,5.17,11,13,-2.0,0.57
2xjj,structure of hsp90 with small molecule inhibitor bound,16,2107.7,11.39,8,9,-1.0,0.44
4x8u,factor viia in complex with the inhibitor 5-chloro-1h-indole-2- carboxylic acid,18,2220.9,6.65,12,10,0.5,0.56
2ra0,x-ray structure of fxa in complex with 7-fluoroindazole,25,3354.5,6.29,20,16,-1.0,0.64
4na9,"factor viia in complex with the inhibitor 3'-amino-5'-[(2s,4r)-6- carbamimidoyl-4-phenyl-1,2,3,4-tetrahydroquinolin-2-yl]biphenyl-2- carboxylic acid",27,3310.4,8.25,17,18,-1.5,0.63
4qf9,"structure of gluk1 ligand-binding domain (s1s2) in complex with (s)-2- amino-4-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-6-yl)butanoic acid at 2.28 a resolution",16,2337.3,6.35,12,12,-2.0,0.62
2vwl,aminopyrrolidine factor xa inhibitor,24,3264.0,6.52,17,16,-2.0,0.62
1f0r,crystal structure of human coagulation factor xa complexed with rpr208815,19,2380.2,5.43,14,14,-2.0,0.63
5u6j,"factor viia in complex with the inhibitor 3-{[(2r)-17-ethyl-4-methyl- 3,12-dioxo-7-[(propan-2-yl)sulfonyl]-13-oxa-4,11- diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-2- yl]amino}benzamide",28,3400.4,9.02,17,16,-0.5,0.61
1lpz,crystal structure of fxa in complex with 41.,23,3017.3,6.34,14,16,-3.0,0.61
3liw,factor xa in complex with (r)-2-(1-adamantylcarbamoylamino)-3-(3- carbamidoyl-phenyl)-n-phenethyl-propionic acid amide,23,2992.3,7.12,16,15,-2.0,0.61
4isi,"structure of factor viia in complex with the inhibitor (6s)-n-(4- carbamimidoylbenzyl)-1-chloro-3-(cyclobutylamino)-8,8-diethyl-4-oxo- 4,6,7,8-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide",23,2636.1,4.54,15,15,-0.5,0.61
2j34,crystal structure of a human factor xa inhibitor complex,21,2652.0,5.35,11,13,-2.0,0.57
4ish,"structure of factor viia in complex with the inhibitor bms-593214 also known as 2'-[(6r,6ar,11br)-2-carbamimidoyl-6,6a,7,11b-tetrahydro-5h- indeno[2,1-c]quinolin-6-yl]-5'-hydroxy-4'-methoxybiphenyl-4- carboxylic acid",24,2850.2,3.89,15,19,-2.5,0.67
1lpk,crystal structure of fxa in complex with 125.,24,3185.9,6.30,17,16,-2.0,0.62
1lpg,crystal structure of fxa in complex with 79.,26,3414.6,6.38,20,16,-1.0,0.62
1xka,"factor xa complexed with a synthetic inhibitor fx-2212a,(2s)-(3'- amidino-3-biphenylyl)-5-(4-pyridylamino)pentanoic acid",23,3016.0,7.23,11,16,-3.0,0.57
2xbx,"factor xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",22,2903.7,5.20,16,15,-2.0,0.64
2uwp,factor xa inhibitor complex,20,2591.9,5.18,11,13,-2.0,0.60
5l30,"factor viia in complex with the inhibitor (2r,15r)-2-[(1- aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1h-tetrazol-5- yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa- 1(18),6(21),7,9,16,19-hexaene-3,12-dione",31,3900.0,10.32,19,18,-0.5,0.61
2xbw,"factor xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",25,3419.1,5.11,22,18,-0.5,0.68
2vvu,aminopyrrolidine factor xa inhibitor,22,2952.2,6.37,12,14,-2.0,0.59
4y79,factor xa complex with gtc000406,20,2591.9,5.35,11,13,-2.0,0.60
2xab,structure of hsp90 with an inhibitor bound,17,2223.8,10.43,9,10,-1.0,0.47
2vwn,aminopyrrolidine factor xa inhibitor,24,3264.0,6.56,17,16,-2.0,0.62
2uwl,selective and dual action orally active inhibitors of thrombin and factor xa,21,2652.0,5.18,11,13,-2.0,0.57
2jkh,factor xa - cation inhibitor complex,21,2687.0,5.57,16,11,0.0,0.57
6iou,the ligand binding domain of mlp24 with serine,8,1091.0,2.11,4,9,-3.0,0.75
2vh0,structure and property based design of factor xa inhibitors:biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs,21,2729.7,7.04,10,12,-2.0,0.52
2y82,structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs,21,2652.0,5.26,11,13,-2.0,0.57
2j95,crystal structure of a human factor xa inhibitor complex,20,2591.9,5.30,11,13,-2.0,0.60
2y80,structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs,21,2652.0,5.37,11,13,-2.0,0.57
2vvv,aminopyrrolidine-related triazole factor xa inhibitor,22,2952.2,6.54,12,14,-2.0,0.59
2xbv,"factor xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",23,3056.9,5.27,18,17,-1.5,0.65
1nfx,crystal structure of human coagulation factor xa complexed with rpr208944,19,2423.3,5.28,8,13,-3.0,0.58
2xc4,"factor xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor",24,3239.0,6.63,19,15,-1.0,0.62
2y7z,structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs,21,2652.0,5.35,11,13,-2.0,0.57
2boh,"crystal structure of factor xa in complex with compound ""1""",24,3137.2,5.21,21,15,-1.0,0.62
4kp8,crystal structure of catalytic domain of human carbonic anhydrase isozyme xii with 3-[(pyrimidin-2-ylsulfanyl)acetyl]benzenesulfonamide,19,2537.4,9.47,16,17,0.5,0.58
2y81,structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine p4 motifs,22,2790.4,5.30,11,15,-3.0,0.59
4a7i,factor xa in complex with a potent 2-amino-ethane sulfonamide inhibitor,21,2652.0,5.19,11,13,-2.0,0.57
1mq5,crystal structure of 3-chloro-n-[4-chloro-2-[[(4-chlorophenyl) amino]carbonyl]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-2- thiophenecarboxamide complexed with human factor xa,22,2903.7,5.19,16,15,-2.0,0.64
2p95,"factor xa in complex with the inhibitor 5-chloro-n-((1r,2s)-2-(4-(2- oxopyridin-1(2h)-yl)benzamido) cyclopentyl)thiophene-2-carboxamide",22,2903.7,5.26,16,15,-2.0,0.64
2uwo,selective and dual action orally active inhibitors of thrombin and factor xa,21,2730.3,5.19,11,15,-3.0,0.62
2j4i,crystal structure of a human factor xa inhibitor complex,20,2591.9,5.23,11,13,-2.0,0.60
2wyg,structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with monoaryl p4 motifs,21,2652.0,5.28,11,13,-2.0,0.57
4qj0,crystal structure of catalytic domain of human carbonic anhydrase isozyme xii with inhibitor,26,3598.6,10.72,25,22,2.0,0.62
1nfw,crystal structure of human coagulation factor xa complexed with rpr209685,21,2790.3,5.05,14,14,-2.0,0.62
3m37,factor xa in complex with the inhibitor 1-[2-(aminomethyl)phenyl]-n- (3-fluoro-2'-sulfamoylbiphenyl-4-yl)-3-(trifluoromethyl)-1h-pyrazole- 5-carboxamide (dpc602),22,2743.1,6.67,15,16,-3.0,0.64
2wyj,structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with monoaryl p4 motifs,22,2845.6,5.23,12,14,-2.0,0.59
1ezq,crystal structure of human coagulation factor xa complexed with rpr128515,22,2823.7,7.22,13,15,-3.0,0.59
2w26,factor xa in complex with bay59-7939,21,2785.5,5.08,12,14,-2.0,0.62
2y7x,the discovery of potent and long-acting oral factor xa inhibitors with tetrahydroisoquinoline and benzazepine p4 motifs,21,2652.0,5.31,11,13,-2.0,0.57
2vh6,structure and property based design of factor xa inhibitors: pyrrolidin-2-ones with biaryl p4 motifs,23,3012.3,6.67,12,14,-2.0,0.57
1nfy,crystal structure of human coagulation factor xa complexed with rpr200095,20,2483.4,5.11,8,13,-3.0,0.55
4qjw,crystal structure of catalytic domain of human carbonic anhydrase isozyme xii with inhibitor,24,3305.4,11.23,23,20,1.5,0.62
5llo,"crystal structure of human carbonic anhydrase isozyme xii with 3- [(1s)-2,3-dihydro-1h-inden-1-ylamino]-2,5,6-trifluoro-4-[(2-hy- droxyethyl)sulfonyl]benzenesulfonamide",24,3291.9,9.88,25,22,2.0,0.67
3ffg,"factor xa in complex with the inhibitor (r)-6-(2'-((3- hydroxypyrrolidin-1-yl)methyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro- 1h-1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1h- pyrazolo[3,4-c]pyridin- 7(4h)-one",26,3476.2,8.22,23,17,-1.0,0.62
5llp,"crystal structure of human carbonic anhydrase isozyme xii with 3- [(1s)-1,2,3,4-tetrahydronapthalen-1-ylamino)-2,5,6-trifluoro-4-[(2- hydroxyethyl)sulfonyl]benzenesulfonamide",25,3458.6,10.72,25,22,2.0,0.64
1ksn,crystal structure of human coagulation factor xa complexed with fxv673,23,2997.1,6.79,18,15,-2.0,0.61
1z6e,"factor xa in complex with the inhibitor 1-(3'-amino-1,2-benzisoxazol- 5'-yl)-n-(4-(2'-((dimethylamino)methyl)-1h-imidazol-1-yl)-2- fluorophenyl)-3-(trifluoromethyl)-1h-pyrazole-5-carboxamide (razaxaban; dpc906; bms-561389)",23,3097.3,5.12,17,16,-2.0,0.65
3bxh,crystal structure of effector binding domain of central glycolytic gene regulator (cggr) from bacillus subtilis in complex with fructose-6-phosphate,21,2665.2,7.28,21,9,2.0,0.48
4kp5,crystal structure of catalytic domain of human carbonic anhydrase isozyme xii with 2-chloro-4-[(pyrimidin-2-ylsulfanyl) acetyl]benzenesulfonamide,19,2537.6,8.53,16,17,0.5,0.58
3bxg,crystal structure of effector binding domain of central glycolytic gene regulator (cggr) from bacillus subtilis in complex with glucose- 6-phosphate,22,2818.4,6.63,23,11,2.5,0.50
6g7a,crystal structure of human carbonic anhydrase isozyme xii 2- (benzylamino)-4-chloro-n-(2-hydroxyethyl)-5-sulfamoyl-benzamide,22,3007.6,10.68,20,20,1.0,0.59
4xxh,trehalose repressor from escherichia coli,17,2278.1,8.50,18,10,1.0,0.65
2flr,novel 5-azaindole factor viia inhibitors,21,2443.4,4.33,14,13,-0.5,0.67
3m36,factor xa in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-n- [3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1h- pyrazole-5-carboxamide (dpc423),24,3159.0,8.38,16,15,-2.0,0.58
3bxe,crystal structure of effector binding domain of central glycolytic gene regulator (cggr) from bacillus subtilis in complex with dihydroxyacetone phosphate,20,2498.5,5.66,21,9,2.0,0.50
4ht2,crystal structure of human carbonic anhydrase isozyme xii with the inhibitor.,19,2537.6,8.66,16,17,0.5,0.58
3bxf,"crystal structure of effector binding domain of central glycolytic gene regulator (cggr) from bacillus subtilis in complex with effector fructose-1,6-bisphosphate",21,2651.8,6.46,26,7,4.0,0.48
2jfz,crystal structure of helicobacter pylori glutamate racemase in complex with d-glutamate and an inhibitor,17,2548.9,12.84,12,11,-0.5,0.47
2b7d,"factor viia inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in a baboon thrombosis model",25,2925.7,6.07,15,14,-0.5,0.60
5fck,complement factor d in complex with compound 5,23,2887.2,7.75,23,11,3.0,0.65
6ftz,complement factor d complexed with compound 6,17,2013.8,3.11,14,10,0.0,0.71
5msb,"crystal structure of human carbonic anhydrase isozyme xii with 2,3,5, 6-tetrafluoro-4[(2-hydroxyethyl)sulfonyl]benzenesulfonamide",18,2426.9,6.87,15,16,0.5,0.61
5fbi,complement factor d in complex with compound 3b,11,1231.2,1.29,13,5,2.0,0.82
1fjs,crystal structure of the inhibitor zk-807834 (ci-1031) complexed with factor xa,24,3060.5,7.62,13,15,-1.5,0.54
2p16,"factor xa in complex with the inhibitor apixaban (bms-562247) aka 1- (4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-4,5,6,7- tetrahydro-1h-pyrazolo[3, 4-c]pyridine-3-carboxamide",22,2903.7,5.23,16,15,-2.0,0.64
1loq,crystal structure of orotidine monophosphate decarboxylase complexed with product ump,21,2713.0,8.99,16,11,0.0,0.48
2y5g,factor xa - cation inhibitor complex,26,3421.1,8.57,16,18,-1.5,0.58
3cs7,"factor xa in complex with the inhibitor 1-(4-methoxyphenyl)-6-(4-(1- (pyrrolidin-1-ylmethyl)cyclopropyl)phenyl)-3-(trifluoromethyl)-5,6- dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one",22,2903.7,5.13,16,15,-2.0,0.64
6fuh,complement factor d in complex with the inhibitor (4-((3- (aminomethyl)phenyl)amino)quinazolin-2-yl)-l-valine,21,2550.7,4.74,16,12,0.5,0.71
1km3,crystal structure of odcase mutant k42a complexed with 6-azaump,21,2697.6,9.25,15,13,-0.5,0.48
2y5h,factor xa - cation inhibitor complex,25,3231.2,6.28,16,18,-1.5,0.60
3ouj,phd2 with 2-oxoglutarate,15,2408.9,10.19,18,11,1.0,0.60
3wjw,wild-type orotidine 5'-monophosphate decarboxylase from m. thermoautotrophicus complexed with 6-methyl-ump,21,2790.7,10.20,15,10,0.0,0.43
6g5l,crystal structure of human carbonic anhydrase isozyme xii with 4- chloro-2-(cyclohexylamino)-n-(2-hydroxyethyl)-5-sulfamoyl-benzamide,23,3123.7,10.16,21,21,1.0,0.61
4ewn,structure of hisf-d130v+d176v with bound rcdrp,20,2178.5,9.34,10,7,0.0,0.40
1mq6,"crystal structure of 3-chloro-n-[4-chloro-2-[[(5-chloro-2-pyridinyl) amino]carbonyl]-6-methoxyphenyl]-4-[[(4,5-dihydro-2-oxazolyl) methylamino]methyl]-2-thiophenecarboxamide complexed with human factor xa",22,2903.7,5.32,16,15,-2.0,0.64
6fui,"complement factor d in complex with the inhibitor 3-((3-((3- (aminomethyl)phenyl)amino)-1h-pyrazolo[3,4-d]pyrimidin-4-yl)amino) phenol",19,2190.4,4.01,15,11,0.5,0.74
2p7a,crystal structure of estrogen related receptor g in complex with 3- methyl phenol,12,1920.3,12.51,6,3,0.0,0.25
4ymb,structure of the ligand-binding domain of gluk1 in complex with the antagonist cng10111,23,3126.1,9.37,16,17,-2.0,0.61
2p7z,estrogen related receptor gamma in complex with 4-hydroxy-tamoxifen,25,3862.2,17.01,11,11,-1.5,0.32
1amk,leishmania mexicana triose phosphate isomerase,17,1892.8,5.80,8,9,-0.5,0.35
2p7g,x-ray structure of estrogen related receptor g in complex with bisphenol a.,19,2982.6,15.90,9,5,0.0,0.26
6i65,crystal structure of human errg lbd in complex with 4-iso-propylphenol,12,1943.5,12.78,6,3,0.0,0.25
6i63,crystal structure of human errg lbd in complex with bisphenol-a,19,2982.6,16.14,9,5,0.0,0.26
2vwm,aminopyrrolidine factor xa inhibitor,25,3432.6,6.46,20,16,-1.0,0.64
6i61,crystal structure of human errg lbd in complex with bisphenol-b,19,2982.6,16.02,9,5,0.0,0.26
6i67,crystal structure of human errg lbd in complex with tetrahydro-2- naphtol,13,2008.9,13.17,6,3,0.0,0.23
2bz6,orally available factor7a inhibitor,27,3300.4,8.00,18,20,-1.5,0.63
6i62,crystal structure of human errg lbd in complex with hpte,19,2982.6,15.97,9,5,0.0,0.26
6i66,crystal structure of human errg lbd in complex with 4-sec-butylphenol,15,2307.3,13.95,6,3,0.0,0.27
3k97,"hsp90 n-terminal domain in complex with 4-chloro-6-{[(2r)-2-(2- methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol",16,2081.8,9.90,10,11,-1.0,0.50
1rtf,complex of benzamidine with the catalytic domain of human two chain tissue plasminogen activator [(tc)-t-pa],18,2046.5,6.56,6,7,-1.0,0.39
3w07,atomic resolution structure of orotidine 5'-monophosphate decarboxylase from methanothermobacter thermoautotrophicus bound with ump.,23,2978.9,9.28,18,13,0.5,0.48
2vxn,e65q-tim complexed with phosphoglycolohydroxamate at 0.82 a resolution,17,1892.8,5.81,8,9,-0.5,0.35
1o5e,dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa),30,3898.6,13.79,15,14,-0.5,0.50
6i64,crystal structure of human errg lbd in complex with bisphenol-e,17,2646.3,16.05,8,5,0.0,0.24
2e2r,crystal structure of human estrogen-related receptor gamma ligand binding domain complex with bisphenol a,19,2982.6,15.96,9,5,0.0,0.26
2y5f,factor xa - cation inhibitor complex,27,3523.8,7.14,17,18,-3.0,0.59
3pju,"structure of pseudomonas fluorescence lapd eal domain complexed with c-di-gmp, p6522",30,4168.1,13.75,40,18,3.0,0.53
2v2c,the a178l mutation in the c-terminal hinge of the flexible loop-6 of triosephosphate isomerase (tim) induces a more closed conformation of this hinge region in dimeric and monomeric tim,16,1804.2,5.03,8,9,-0.5,0.38
3s9e,crystal structure of the kainate receptor gluk3 ligand binding domain in complex with (s)-glutamate,4,600.8,2.46,6,3,1.5,0.75
1p57,extracellular domain of human hepsin,25,2986.4,4.89,14,14,-0.5,0.56
3g1d,crystal structure of orotidine 5'-monophosphate decarboxylase from methanobacterium thermoautotrophicum complexed with uridine 5'- monophosphate,24,3106.9,9.42,17,14,-1.0,0.50
3u93,crystal structure of the gluk3 ligand binding domain complex with glutamate and zinc: p2221 form,3,458.3,1.72,2,4,-0.5,0.67
2vvc,aminopyrrolidine factor xa inhibitor,25,3426.9,7.75,17,16,-2.0,0.60
1nli,complex of [e160a-e189a] trichosanthin and adenine,10,1487.1,6.06,10,5,1.0,0.50
3ip8,crystal structure of arylmalonate decarboxylase (amdase) from bordatella bronchiseptic in complex with benzylphosphonate,18,2320.8,12.66,5,5,0.0,0.33
1x1z,orotidine 5'-monophosphate decarboxylase (odcase) complexed with bmp (produced from 6-cyanoump),26,3426.8,9.85,19,16,-0.5,0.50
6g98,three dimensional structure of human carbonic anhydrase ix in complex with sulfonamide,23,3360.9,13.98,28,19,3.0,0.57
3g1v,crystal structure of the mutant d70g of orotidine 5'-monophosphate decarboxylase from methanobacterium thermoautotrophicum complexed with 5-fluorouridine 5'-monophosphate,23,2995.8,9.54,17,12,0.0,0.48
2bq7,crystal structure of factor xa in complex with 43,22,2903.7,6.03,16,15,-2.0,0.64
3u92,crystal structure of the gluk3 ligand binding domain complex with kainate and zinc: p2221 form,21,2734.3,8.48,14,15,-2.0,0.52
1lyx,plasmodium falciparum triosephosphate isomerase (pftim)- phosphoglycolate complex,18,2062.9,5.56,11,12,-0.5,0.44
6fe0,three dimensional structure of human carbonic anhydrase ix in complex with benzenesulfonamide.,20,2847.4,13.06,18,19,1.0,0.55
2zz2,orotidine monophosphate decarboxylase k72a mutant from m. thermoautotrophicum complexed with 6-cyano-ump,24,3105.0,10.81,14,14,-2.0,0.46
6g9u,three dimensional structure of human carbonic anhydrase ix in complex with sulfonamide,21,3135.5,11.73,28,19,3.0,0.62
6fe1,three dimensional structure of human carbonic anhydrase ix in complex with benzenesulfonamide.,24,3524.5,14.59,21,21,1.0,0.54
2zz1,snapshot of the reaction from 6-cn-ump to bmp catalyzed by orotidine monophosphate deacarboxylase from m. thermoautotrophicum,25,3273.6,10.24,17,14,-1.0,0.48
6nwl,structure of the ancestral glucocorticoid receptor 2 ligand binding domain in complex with hydrocortisone and pgc1a coregulator fragment,23,3537.7,19.18,13,7,1.0,0.26
1lbf,crystal structure of indole-3-glycerol phosphate syntase (igps)with reduced 1-(o-caboxyphenylamino)-1-deoxyribulose 5-phosphate (rcdrp),24,3325.6,13.66,19,13,0.0,0.50
3uzj,designed protein ke59 r13 3/11h with benzotriazole,10,1382.2,9.03,2,5,-2.0,0.30
4zt8,"structure of the complex of type 1 ribosome inactivating protein from momordica balsamina with a pyrimidine base, cytosine at 1.98 a resolution",5,575.3,2.10,5,5,0.0,0.80
5fl5,"three dimensional structure of human carbonic anhydrase ix in complex with 5-(1-(4-methoxyphenyl)-1h-1,2,3-triazol-4-yl)thiophene-2- sulfonamide",18,2554.1,10.84,17,15,0.5,0.56
3uz5,designed protein ke59 r13 3/11h,14,2018.5,14.38,2,5,-2.0,0.21
5cso,"structure of the complex of type 1 ribosome inactivating protein from momordica balsamina with a nucleoside, cytidine at 1.78 a resolution",14,2114.6,6.92,9,12,-3.0,0.57
5fl6,"three dimensional structure of human carbonic anhydrase ix in complex with 5-(1-(4-methylphenyl)-1h-1,2,3-triazol-4-yl)thiophene-2- sulfonamide",19,2665.2,10.79,17,17,-0.5,0.58
5cst,"structure of the complex of type 1 ribosome inactivating protein from momordica balsamina with a nucleotide, cytidine diphosphate at 1.78 a resolution",17,2580.1,9.04,17,12,-1.0,0.53
4emf,crystal structure of the complex of type i ribosome inactivating protein in complex with 7n-methyl-8-hydroguanosine-5-p-diphosphate at 1.77 a,17,2578.5,8.13,17,14,-2.0,0.59
5fl4,"three dimensional structure of human carbonic anhydrase ix in complex with 5-(1-naphthalen-1-yl-1,2,3-triazol-4-yl)thiophene-2-sulfonamide",18,2554.1,10.86,17,15,0.5,0.56
3gba,x-ray structure of iglur5 ligand-binding core (s1s2) in complex with dysiherbaine at 1.35a resolution,21,2789.5,7.65,14,15,-2.0,0.62
5f74,crystal structure of chrebp:14-3-3 complex bound with amp,19,2956.3,11.57,30,12,3.0,0.63
5zdb,crystal structure of poly(adp-ribose) glycohydrolase (parg) from deinococcus radiodurans in complex with adp-ribose (p21),28,3410.2,12.38,14,16,-3.0,0.43
3uxd,designed protein ke59 r1 7/10h with dichlorobenzotriazole (dbt),15,2053.7,13.63,3,6,-2.0,0.27
4yml,"crystal structure of escherichia coli 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with (3s,4r)- methylthio-dadme-immucillin-a",20,2560.2,11.42,8,11,-3.0,0.40
4emr,crystal structure determination of type1 ribosome inactivating protein complexed with 7-methylguanosine-triphosphate at 1.75a,20,2863.9,8.30,16,18,-3.0,0.60
4wko,crystal structure of helicobacter pylori 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with hydroxybutylthio-dadme-immucillin-a,21,2699.4,11.61,8,11,-3.0,0.33
1t7d,crystal structure of escherichia coli type i signal peptidase in complex with a lipopeptide inhibitor,8,899.8,3.86,3,5,-1.0,0.50
1iih,structure of trypanosoma brucei brucei triosephosphate isomerase complexed with 3-phosphoglycerate,16,1804.2,5.15,8,9,-0.5,0.38
6ior,the ligand binding domain of mlp24 with asparagine,6,840.9,1.79,3,10,-4.0,0.83
1trd,the influence of crystal packing on crystallographic binding studies: a new crystal form of trypanosomal tim,16,1804.2,5.22,8,9,-0.5,0.38
4ffs,crystal structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidase from helicobacter pylori with butyl-thio-dadme- immucillin-a,21,2699.4,11.64,8,11,-3.0,0.33
3h89,a combined crystallographic and molecular dynamics study of cathepsin- l retro-binding inhibitors(compound 4),29,3579.2,13.25,13,19,-3.0,0.41
4wkn,crystal structure of helicobacter pylori 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with methylthio- dadme-immucillin-a,21,2699.4,11.51,8,11,-3.0,0.33
4tim,crystallographic and molecular modeling studies on trypanosomal triosephosphate isomerase: a critical assessment of the predicted and observed structures of the complex with 2-phosphoglycerate,17,1920.3,4.93,9,10,-0.5,0.41
3fj7,crystal structure of l-phospholactate bound peb3,17,1846.7,11.08,10,8,0.0,0.35
4xmr,crystal structure of the sensory domain of the campylobacter jejuni chemoreceptor tlp3 (ccml) with isoleucine bound.,6,736.7,2.08,8,7,0.0,0.83
2h6b,crystal structure of oxidized cprk in complex with o- chlorophenolacetic acid,16,2332.1,10.67,11,5,2.0,0.38
4ynb,crystal structure of helicobacter pylori 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with pyrazinylthio-dadme-immucillin-a,21,2699.4,11.56,8,11,-3.0,0.33
1qan,the structure of the rrna methyltransferase ermc': implications for the reaction mechanism,6,986.2,4.77,11,1,2.0,0.50
5a2i,crystal structure of scfv-sm3 in complex with apd-sgalnac-rp,7,996.2,4.30,8,4,0.0,0.57
4f3k,crystal structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidase from salmonella enterica with homocysteine-dadme- immucillin-a,25,3307.5,13.03,9,14,-4.0,0.40
3h8b,a combined crystallographic and molecular dynamics study of cathepsin- l retro-binding inhibitors(compound 9),31,3831.5,13.25,15,21,-3.0,0.45
5qa8,oxa-48 in complex with compound 4c,15,2189.2,4.93,21,9,3.0,0.73
4f3c,crystal structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidase from salmonella enterica with butyl-thio-dadme- immucillin-a,25,3256.5,12.93,9,12,-3.0,0.36
4g4p,crystal structure of glutamine-binding protein from enterococcus faecalis at 1.5 a,8,1010.3,6.81,1,5,-2.0,0.38
4f2w,crystal structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidase from salmonella enterica with methyl-thio-dadme- immucillin-a,24,3062.9,14.11,8,11,-3.0,0.33
4b5t,"crystal structures of divalent metal dependent pyruvate aldolase, hpai, in complex with ketobutyrate",13,1899.1,10.54,10,8,-0.5,0.38
4b5s,"crystal structures of divalent metal dependent pyruvate aldolase, hpai, in complex with pyruvate",7,829.0,3.48,5,5,0.0,0.71
2j27,the functional role of the conserved active site proline of triosephosphate isomerase.,18,1981.8,5.90,9,10,-0.5,0.39
1kv5,structure of trypanosoma brucei brucei tim with the salt-bridge- forming residue arg191 mutated to ser,16,1804.2,4.98,8,9,-0.5,0.38
4ykk,mnemiopsis leidyi ml032222a iglur lbd d-serine complex,8,1071.2,2.70,10,8,-2.0,0.75
2bza,bovine pancreas beta-trypsin in complex with benzylamine,13,1427.0,3.86,6,7,-1.0,0.54
3aqt,crystal structure of rolr (ncgl1110) complex with ligand resorcinol,13,1882.2,11.67,11,3,1.0,0.31
2ypi,crystallographic analysis of the complex between triosephosphate isomerase and 2-phosphoglycolate at 2.5-angstroms resolution. implications for catalysis,16,1808.8,4.93,9,10,-0.5,0.44
3vx3,crystal structure of [nife] hydrogenase maturation protein hypb from thermococcus kodakarensis kod1,25,3315.5,11.07,19,11,2.0,0.48
1tpw,triosephosphate isomerase drinks water to keep healthy,17,1892.8,6.03,8,9,-0.5,0.35
1v2j,benzamidine in complex with bovine trypsin variant x(ssri)bt.c1,16,1798.2,4.33,8,9,-1.0,0.56
6nwk,structure of the ancestral glucocorticoid receptor 2 ligand binding domain in complex with dexamethasone and pgc1a coregulator fragment,24,3571.1,18.80,13,7,1.0,0.25
1nc3,crystal structure of e. coli mta/adohcy nucleosidase complexed with formycin a (fma),21,2751.7,14.38,8,9,-2.0,0.33
1jys,crystal structure of e. coli mta/adohcy nucleosidase,11,1324.3,7.58,2,6,-2.0,0.36
5qal,oxa-48 in complex with compound 11b,14,2129.1,4.98,21,9,3.0,0.79
1v2u,benzamidine in complex with bovine trypsin varinat x(ssai)bt.d1,16,1798.2,4.35,8,9,-1.0,0.56
1v2r,trypsin inhibitor in complex with bovine trypsin variant x(ssri)bt.b4,17,1971.6,3.96,13,9,0.0,0.59
1nc1,crystal structure of e. coli mta/adohcy nucleosidase complexed with 5'-methylthiotubercidin (mth),22,2890.1,13.51,8,11,-3.0,0.36
4u0w,crystal structure of yvoa from bacillus subtilis in complex with n- acetylglucosamine-6-phosphate,20,2728.2,4.23,26,17,0.0,0.80
5qay,oxa-48 in complex with compound 32,15,2189.2,4.89,21,9,3.0,0.73
2fx6,bovine trypsin complexed with 2-aminobenzamidazole,14,1488.7,4.84,7,8,-1.0,0.57
1y6r,crystal structure of mta/adohcy nucleosidase complexed with mt-imma.,22,2890.1,13.91,8,11,-3.0,0.36
1v2w,trypsin inhibitor in complex with bovine trypsin variant x(ssai)bt.b4,16,1798.2,4.36,8,9,-1.0,0.56
4abg,fragments bound to bovine trypsin for the sampl challenge,15,1604.6,4.99,7,8,-1.0,0.53
4yo8,"crystal structure of helicobacter pylori 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with (((4-amino- 5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)(hexyl)amino)methanol",25,3321.9,14.40,10,13,-2.5,0.32
4q9o,crystal structure of upps + inhibitor,28,4130.1,20.32,8,10,-1.0,0.25
1v2l,benzamidine in complex with bovine trypsin variant x(triple.glu)bt.d1,16,1847.2,4.58,6,9,-2.0,0.50
4abe,fragments bound to bovine trypsin for the sampl challenge,14,1515.6,5.10,6,7,-1.0,0.50
1y6q,cyrstal structure of mta/adohcy nucleosidase complexed with mt-dadme- imma,23,3002.8,14.80,8,11,-3.0,0.35
1v2s,benzamidine in complex with bovine trypsin variant x(ssfi.glu)bt.d1,16,1847.6,4.20,7,10,-2.0,0.56
1tx7,bovine trypsin complexed with p-amidinophenylmethylphosphinic acid (ampa),18,2118.1,5.98,10,11,-0.5,0.56
3dp9,crystal structure of vibrio cholerae 5'-methylthioadenosine/s-adenosyl homocysteine nucleosidase (mtan) complexed with butylthio-dadme- immucillin a,25,3205.7,13.11,9,12,-3.0,0.36
4ab9,fragments bound to bovine trypsin for the sampl challenge,18,1929.0,4.88,9,12,-1.5,0.56
1tng,prediction of novel serine protease inhibitors,19,2099.2,5.93,12,10,0.5,0.53
4aba,fragments bound to bovine trypsin for the sampl challenge,14,1515.6,5.05,6,7,-1.0,0.50
3aas,bovine beta-trypsin bound to meta-guanidino schiff base copper (ii) chelate,15,1641.9,4.84,9,10,-0.5,0.60
6dyu,"crystal structure of helicobacter pylori 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with (3r,4s)-1- ((4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-((prop-2-yn-1- ylthio)methyl)pyrrolidin-3-ol",21,2699.4,11.63,8,11,-3.0,0.33
6dyv,"crystal structure of helicobacter pylori 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with (3r,4s)-1- ((4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-((pent-4-yn-1- ylthio)methyl)pyrrolidin-3-ol",21,2699.4,11.62,8,11,-3.0,0.33
4abd,fragments bound to bovine trypsin for the sampl challenge,14,1515.6,5.04,6,7,-1.0,0.50
4abf,fragments bound to bovine trypsin for the sampl challenge,15,1680.7,3.25,7,8,-1.0,0.53
6dyw,"crystal structure of helicobacter pylori 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with (3r,4s)-1- ((4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(((3-(1-benzyl- 1h-1,2,3-triazol-4-yl)propyl)thio)methyl)pyrrolidin-3-ol",24,3150.7,11.66,16,13,-1.0,0.42
1v2t,trypsin inhibitor in complex with bovine trypsin variant x(ssfi.glu) bt.b4,17,1960.3,5.82,7,10,-2.0,0.53
4abh,fragments bound to bovine trypsin for the sampl challenge,15,1604.6,5.06,7,8,-1.0,0.53
4abb,fragments bound to bovine trypsin for the sampl challenge,14,1620.6,3.23,7,8,-1.0,0.57
1tnh,prediction of novel serine protease inhibitors,20,2210.3,5.84,12,12,-0.5,0.55
2tpi,on the disordered activation domain in trypsinogen. chemical labelling and low-temperature crystallography,8,932.6,1.62,8,5,1.0,0.75
3gy7,a comparative study on the inhibition of bovine beta-trypsin by bis- benzamidines diminazene and pentamidine by x-ray crystallography and itc,17,1910.9,5.82,8,9,-1.0,0.53
6qrc,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",21,2557.9,7.03,16,10,0.0,0.43
6qqq,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",23,2864.6,9.71,16,10,0.0,0.39
1v2o,trypsin inhibitor in complex with bovine trypsin variant x(ssyi)bt.b4,18,2079.5,5.28,11,9,0.0,0.56
6qqw,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",20,2417.9,6.02,16,10,0.0,0.45
1bju,beta-trypsin complexed with acpu,22,2682.0,6.33,15,13,0.5,0.59
3nkk,trypsin in complex with fluorine containing fragment,20,2292.8,5.24,13,11,0.5,0.55
1tni,prediction of novel serine protease inhibitors,17,2045.3,6.16,11,9,0.0,0.53
6qr7,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",22,2670.6,9.41,16,10,0.0,0.41
1ql7,factor xa specific inhibitor in complex with bovine trypsin,19,2250.3,3.57,13,14,-1.0,0.63
4x24,crystal structure of vibrio cholerae 5'-methylthioadenosine/s-adenosyl homocysteine nucleosidase (mtan) complexed with methylthio-dadme- immucillin-a,24,3062.9,14.30,8,11,-3.0,0.33
6qr9,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",22,2670.6,9.49,16,10,0.0,0.41
6qqv,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",21,2557.9,7.14,16,10,0.0,0.43
6qqu,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",19,2246.1,7.88,11,8,0.0,0.37
4wkb,crystal structure of vibrio cholerae 5'-methylthioadenosine/s-adenosyl homocysteine nucleosidase (mtan) complexed with methylthio-dadme- immucillin-a,24,3012.1,14.15,8,11,-3.0,0.33
3aau,bovine beta-trypsin bound to meta-diguanidino schiff base copper (ii) chelate,19,2298.3,4.94,13,11,0.5,0.68
5mn1,cationic trypsin in complex with 2-aminopyridine (deuterated sample at 100 k),16,1820.7,3.15,8,11,-2.0,0.62
6ueg,pseudomonas aeruginosa lpxa complex structure with ligand,18,2403.4,7.62,14,16,0.5,0.56
1y3x,trypsin inhibitor complex,24,2834.8,4.37,17,18,-0.5,0.62
6qr1,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",23,2833.1,9.04,16,10,0.0,0.43
6n95,methylmalonyl-coa decarboxylase in complex with 2-sulfonate-propionyl- coa,25,3492.6,14.94,21,8,4.0,0.36
6qr4,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",21,2557.9,7.35,16,10,0.0,0.43
1yp9,trypsin inhibitor complex,23,2664.9,6.14,15,16,-0.5,0.57
1uto,"trypsin specificity as elucidated by lie calculations, x-ray structures and association constant measurements",17,1945.0,3.22,9,12,-1.5,0.59
2v2h,the a178l mutation in the c-terminal hinge of the flexible loop-6 of triosephosphate isomerase (tim) induces a more closed conformation of this hinge region in dimeric and monomeric tim,16,1810.4,5.69,9,8,0.5,0.38
6qqz,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",21,2557.9,7.40,16,10,0.0,0.43
6qr2,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",21,2557.9,7.25,16,10,0.0,0.43
6qr3,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",21,2557.9,7.05,16,10,0.0,0.43
3gy4,a comparative study on the inhibition of bovine beta-trypsin by bis- benzamidines diminazene and pentamidine by x-ray crystallography and itc,19,2232.7,5.28,13,11,0.5,0.58
1g3e,bovine beta-trypsin bound to para-amidino schiff-base copper (ii) chelate,18,2118.1,5.96,10,11,-0.5,0.56
5mnn,cationic trypsin in complex with n-amidinopiperidine (deuterated sample at 100 k),18,1969.4,4.40,8,11,-2.0,0.56
1bjv,beta-trypsin complexed with appu,21,2488.4,6.57,14,12,0.5,0.57
1g3d,bovine beta-trypsin bound to meta-amidino schiff base copper (ii) chelate,18,2011.5,4.34,10,11,-0.5,0.56
1y3v,trypsin inhibitor complex,24,2834.8,4.33,17,18,-0.5,0.62
1qbn,"bovine trypsin 2-[amino(imino)methyl]-2-hydroxyphenoxy]-6-[3-(4,5- dihydro-1h-imidazol-2-yl)phenoxy]pyridine-4-carboxylic acid (zk- 806688) complex",20,2338.9,5.07,13,14,-1.0,0.60
6qr0,"crystal structure of trmd, a trna-(n1g37) methyltransferase, from mycobacterium abscessus in complex with inhibitor",21,2557.9,7.20,16,10,0.0,0.43
5ufc,crystal structure of variable lymphocyte receptor (vlr) tn4-22 with h- trisaccharide bound,10,1433.7,7.23,8,11,-2.0,0.70
3gy3,a comparative study on the inhibition of bovine beta-trypsin by bis- benzamidines diminazene and pentamidine by x-ray crystallography and itc,23,2749.7,4.27,19,17,0.5,0.65
1v2n,potent factor xa inhibitor in complex with bovine trypsin variant x(99/175/190)bt,21,2511.8,5.79,11,14,-1.5,0.57
1utn,"trypsin specificity as elucidated by lie calculations, x-ray structures and association constant measurements",17,1775.8,5.13,7,10,-2.0,0.53
1f0t,bovine trypsin complexed with rpr131247,23,2709.2,5.74,17,15,0.0,0.61
1pph,"geometry of binding of the nalpha-tosylated piperidides of m-amidino-, p-amidino-and p-guanidino phenylalanine to thrombin and trypsin: x- ray crystal structures of their trypsin complexes and modeling of their thrombin complexes",18,2118.1,6.00,10,11,-0.5,0.56
3gy2,a comparative study on the inhibition of bovine beta-trypsin by bis- benzamidines diminazene and pentamidine by x-ray crystallography and itc,23,2742.1,6.13,15,13,0.5,0.57
1ppc,"geometry of binding of the benzamidine-and arginine-based inhibitors n-alpha-(2-naphthyl-sulphonyl-glycyl)-dl-p-amidinophenylalanyl- piperidine (napap) and (2r,4r)-4-methyl-1-[n-alpha-(3-methyl-1,2,3,4- tetrahydro-8-quinolinesulphonyl)-l-arginyl]-2-piperidine carboxylic acid (mqpa) to human alpha-thrombin: x-ray crystallographic determination of the napap-trypsin complex and modeling of napap- thrombin and mqpa-thrombin",21,2437.3,5.13,14,15,-0.5,0.62
1qb6,"bovine trypsin 3,3'-[3,5-difluoro-4-methyl-2, 6-pyridinediylbis(oxy) ]bis(benzenecarboximidamide) (zk-805623) complex",21,2427.9,4.78,14,15,-1.0,0.62
1k1o,bovine trypsin-inhibitor complex,22,2605.2,4.77,16,17,-0.5,0.64
1v2k,factor xa specific inhibitor in complex with bovine trypsin variant x(triple.glu)bt.d2,20,2563.3,6.45,8,13,-3.0,0.55
1eb2,trypsin inhibitor complex (bpo),20,2338.9,5.00,13,14,-1.0,0.60
2zdl,exploring trypsin s3 pocket,23,2749.7,4.49,19,17,0.5,0.65
2zdm,exploring trypsin s3 pocket,24,2862.4,5.54,19,17,0.5,0.62
2zft,exploring trypsin s3 pocket,23,2693.8,6.02,16,17,-0.5,0.61
3fjg,crystal structure of 3pg bound peb3,19,2180.4,12.86,12,10,0.0,0.37
2zdk,exploring trypsin s3 pocket,23,2693.8,5.98,16,17,-0.5,0.61
1c5t,"structural basis for selectivity of a small molecule, s1-binding, sub- micromolar inhibitor of urokinase type plasminogen activator",22,2547.7,5.16,15,15,-0.5,0.59
2zdn,exploring trypsin s3 pocket,23,2693.8,6.02,16,17,-0.5,0.61
4gki,"crystal structure of the aminoglycoside phosphotransferase aph(3')-ia, with substrate kanamycin and small molecule inhibitor 1-nm-pp1",20,2489.1,3.46,15,27,-9.0,0.85
2zfs,exploring trypsin s3 pocket,22,2581.1,4.63,16,17,-0.5,0.64
1k1i,bovine trypsin-inhibitor complex,21,2459.5,6.88,13,11,0.5,0.52
1k1l,bovine trypsin-inhibitor complex,20,2321.2,5.48,13,14,-0.5,0.60
3ozg,crystal structure of plasmodium falciparum hypoxanthine-guanine- xanthine phosphoribosyltransferase in complex with s-serme-immh phosphonate,19,2596.0,6.29,13,15,-1.5,0.63
3ljo,bovine trypsin in complex with ub-thr 11,20,2399.4,6.90,13,11,0.5,0.55
1c5p,"structural basis for selectivity of a small molecule, s1-binding, sub- micromolar inhibitor of urokinase type plasminogen activator",22,2547.7,5.18,15,15,-0.5,0.59
2zq2,exploring trypsin s3 pocket,22,2604.8,6.21,15,16,-0.5,0.59
1oyq,trypsin inhibitor complex,23,2773.4,5.68,18,16,0.5,0.61
4gkh,"crystal structure of the aminoglycoside phosphotransferase aph(3')-ia, with substrate kanamycin and small molecule inhibitor 1-na-pp1",20,2570.7,3.59,21,27,-5.5,0.90
1k1n,bovine trypsin-inhibitor complex,21,2433.9,6.81,13,14,-0.5,0.57
1qb1,"bovine trypsin with 1-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-6- [3-(4,5-dihydro-1-methyl-1h-imidazol-2-yl)phenoxy]pyridin-4- yl]piperidine-3-carboxylic acid (zk-806974)",23,2641.2,4.60,16,17,-0.5,0.61
3m35,trypsin in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-n-[3- fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1h- pyrazole-5-carboxamide (dpc423),20,2259.8,4.40,15,16,-1.0,0.65
1bty,crystal structure of beta-trypsin in complex with benzamidine,20,2235.3,6.05,10,13,-1.5,0.55
3e5u,ocpa complexed cprk (c200s),15,2243.5,10.35,11,5,2.0,0.40
1g36,trypsin inhibitor complex,23,2773.4,5.71,18,16,0.5,0.61
1oau,fv structure of the ige spe-7 in complex with dnp-ser (immunising hapten),14,2402.5,8.40,20,9,2.5,0.57
1f0u,bovine trypsin complexed with rpr128515,20,2338.9,5.08,13,14,-1.0,0.60
1k1m,bovine trypsin-inhibitor complex,22,2627.5,6.68,14,15,-0.5,0.59
1qb9,bovine trypsin 7-[[2-[[1-(1-iminoethyl)piperidin-4-yl]oxy]-9h- carbozol-9-yl] methyl]naphthalene-2-carboximidamide (zk-806450) complex,21,2520.7,4.46,18,16,0.5,0.67
1k1j,bovine trypsin-inhibitor complex,21,2514.8,5.18,14,15,-0.5,0.62
5xpi,structure of uhrf1 ttd in complex with nv01,10,1518.7,5.51,6,12,-3.0,0.70
1utl,"trypsin specificity as elucidated by lie calculations, x-ray structures and association constant measurements",16,1940.5,4.72,9,10,-0.5,0.56
1ghz,a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site,22,2547.7,5.11,15,15,-0.5,0.59
1utm,"trypsin specificity as elucidated by lie calculations, x-ray structures and association constant measurements",15,1773.8,3.28,9,10,-0.5,0.60
1o35,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,22,2464.0,5.26,13,13,-0.5,0.55
1qbo,bovine trypsin 7-[[6-[[1-(1-iminoethyl)piperidin-4-yl]oxy]-2-methyl- benzimidazol-1-yl]methyl]naphthalene-2-carboximidamid zk-806711 inhibitor complex,20,2352.1,4.59,15,16,-0.5,0.65
5jop,crystal structure of anti-glycan antibody fab14.22 in complex with streptococcus pneumoniae serotype 14 tetrasaccharide at 1.75 a,5,906.6,2.98,5,6,-0.5,0.80
1o2r,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,28,3592.9,5.81,21,16,1.5,0.64
1bq4,saccharomyces cerevisiae phosphoglycerate mutase in complex with benzene hexacarboxylate,12,1899.8,1.79,35,9,5.0,0.92
4jzi,"crystal structure of matriptase in complex with inhibitor"".",27,3532.7,10.82,14,16,-1.5,0.56
3n35,erythrina corallodendron lectin mutant (y106g) with n- acetylgalactosamine,15,1769.3,8.05,7,8,-1.0,0.33
1utj,"trypsin specificity as elucidated by lie calculations, x-ray structures and association constant measurements",16,1820.3,4.76,7,10,-2.0,0.56
4jz1,crystal structure of matriptase in complex with inhibitor,28,3530.3,8.82,16,18,-1.5,0.61
1ax0,erythrina corallodendron lectin in complex with n-actylgalactosamine,14,1842.7,7.92,8,9,-1.0,0.43
4jyt,crystal structure of matriptase in complex with inhibitor,28,3668.6,11.10,15,16,-1.5,0.57
1gi1,a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site,22,2464.0,5.25,13,13,-0.5,0.55
1o2w,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,25,2824.8,4.92,15,15,-0.5,0.60
2gv6,crystal structure of matriptase with inhibitor cj-730,21,2638.3,7.08,13,13,-0.5,0.57
4io4,crystal structure of the avglur1 ligand binding domain complex with serine at 1.94 angstrom resolution,13,1940.1,4.66,13,10,0.0,0.69
3c79,crystal structure of aplysia californica achbp in complex with the neonicotinoid imidacloprid,17,2680.2,8.39,13,7,1.0,0.53
1o33,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,22,2547.7,5.05,15,15,-0.5,0.59
1o2z,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,28,3483.5,7.82,19,16,0.5,0.61
2gv7,structure of matriptase in complex with inhibitor cj-672,25,3241.6,7.23,12,19,-3.5,0.64
4o9v,crystal structure of matriptase in complex with inhibitor,23,2891.0,9.08,12,17,-2.5,0.57
4io7,crystal structure of the avglur1 ligand binding domain complex with phenylalanine at 1.9 angstrom resolution,7,915.2,2.83,12,3,2.0,0.71
4o97,crystal structure of matriptase in complex with inhibitor,24,3002.1,9.13,12,19,-3.5,0.58
4io3,crystal structure of the avglur1 ligand binding domain complex with aspartate at 1.66 angstrom resolution,6,826.2,2.84,11,2,2.0,0.67
1ele,structural analysis of the active site of porcine pancreatic elastase based on the x-ray crystal structures of complexes with trifluoroacetyl-dipeptide-anilide inhibitors,18,2211.8,5.68,16,12,0.5,0.61
4io6,crystal structure of the avglur1 ligand binding domain complex with methionine at 1.6 angstrom resolution,6,826.2,2.85,11,2,2.0,0.67
3c84,crystal structure of a complex of achbp from aplysia californica and the neonicotinoid thiacloprid,16,2506.8,9.08,8,7,0.0,0.50
4io5,crystal structure of the avglur1 ligand binding domain complex with alanine at 1.72 angstrom resolution,6,826.2,2.86,11,2,2.0,0.67
1o36,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,28,3376.9,6.64,19,16,0.5,0.61
1bma,benzyl methyl aminimide inhibitor complexed to porcine pancreatic elastase,23,2777.3,7.05,19,15,0.5,0.61
1ela,analogous inhibitors of elastase do not always bind analogously,20,2439.0,4.90,17,15,-0.5,0.65
1eld,structural analysis of the active site of porcine pancreatic elastase based on the x-ray crystal structures of complexes with trifluoroacetyl-dipeptide-anilide inhibitors,21,2659.2,7.60,17,14,-0.5,0.62
1c5s,"structural basis for selectivity of a small molecule, s1-binding, sub- micromolar inhibitor of urokinase type plasminogen activator",23,2741.3,4.47,16,16,-0.5,0.61
1o2n,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,27,3399.3,5.77,20,15,1.5,0.63
2weq,yeast hsp90 n-terminal domain li-iv mutant with geldanamycin,22,2815.1,10.27,13,13,-1.0,0.45
1elb,analogous inhibitors of elastase do not always bind analogously,19,2228.5,3.60,16,13,0.5,0.74
1o3j,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,25,2958.3,4.50,16,16,-0.5,0.64
2x00,crystal structure of a-achbp in complex with gymnodimine a,18,2725.4,6.98,20,11,2.0,0.72
1o2o,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,28,3510.4,5.61,20,17,0.5,0.64
6fuj,"complement factor d in complex with the inhibitor n-(3'-(aminomethyl)- [1,1'-biphenyl]-3-yl)-3-methylbutanamide",19,2190.4,4.05,15,11,0.5,0.74
1o3l,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,24,2849.8,4.43,16,16,-0.5,0.62
1elc,analogous inhibitors of elastase do not always bind analogously,26,3132.9,6.60,20,18,-0.5,0.69
5obg,crystal structure of glycine binding protein in complex with strychnine,16,2401.6,5.02,19,12,0.0,0.75
1o30,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,27,3316.8,6.17,19,16,0.5,0.63
2vwc,structure of the hsp90 inhibitor macbecin bound to the n-terminus of yeast hsp90.,20,2586.1,9.35,12,12,-1.0,0.45
2cgf,a radicicol analogue bound to the atp binding site of the n-terminal domain of the yeast hsp90 chaperone,15,1992.0,10.92,8,9,-1.0,0.40
1amw,adp binding site in the hsp90 molecular chaperone,19,2339.2,9.86,9,10,-1.0,0.37
4iue,"tankyrase in complex with 7-(2-fluorophenyl)-4-methyl-1,2- dihydroquinolin-2-one",19,2692.1,8.98,17,11,2.0,0.53
4a6l,beta-tryptase inhibitor,25,3096.4,6.98,17,17,-2.0,0.60
5ufs,x-ray crystal structure of the ancestral glucocorticoid receptor 2 ligand binding domain in complex with triamcinolone acetonide and shp coregulator fragment,26,3976.0,19.00,14,8,1.0,0.31
2wn9,crystal structure of aplysia achbp in complex with 4-0h-dmxba,14,2056.2,7.39,10,11,-1.0,0.64
4io2,crystal structure of the avglur1 ligand binding domain complex with glutamate at 1.37 angstrom resolution,6,826.2,2.86,11,2,2.0,0.67
1oar,fv ige spe-7 in complex with alizarin red,15,2517.1,11.40,19,8,2.5,0.47
4wkp,crystal structure of helicobacter pylori 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with 2-(2- hydroxyethoxy)ethylthiomethyl-dadme-immucillin-a,25,3321.9,14.17,10,13,-2.5,0.32
2wnc,crystal structure of aplysia achbp in complex with tropisetron,12,1897.7,5.60,9,8,0.0,0.75
1bgq,radicicol bound to the atp binding site of the n-terminal domain of the yeast hsp90 chaperone,15,1992.0,11.09,8,9,-1.0,0.40
2iwx,analogues of radicicol bound to the atp-binding site of hsp90.,15,1992.0,10.95,8,9,-1.0,0.40
1c5q,"structural basis for selectivity of a small molecule, s1-binding, sub- micromolar inhibitor of urokinase type plasminogen activator",23,2741.3,4.45,16,16,-0.5,0.61
2za5,crystal structure of human tryptase with potent non-peptide inhibitor,24,2980.3,7.09,16,16,-2.0,0.58
2fxs,yeast hsp82 in complex with the novel hsp90 inhibitor radamide,17,2252.6,10.97,14,10,1.0,0.47
2fpz,human tryptase with 2-amino benzimidazole,17,1993.7,5.16,12,10,-1.0,0.59
4j21,tankyrase 2 in complex with 7-(4-amino-2-chlorophenyl)-4- methylquinolin-2(1h)-one,19,2692.1,9.15,17,11,2.0,0.53
1o2h,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,28,3510.4,5.59,20,17,0.5,0.64
4j3l,"tankyrase 2 in complex with 3-chloro-n-(2-methoxyethyl)-4-(4-methyl-2- oxo-1,2-dihydroquinolin-7-yl)benzamide",20,2858.8,10.73,17,11,2.0,0.50
1o2j,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,28,3510.4,6.20,20,17,0.5,0.64
6dyy,"crystal structure of helicobacter pylori 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with (3r,4s)-1- ((4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(((3-(1-butyl-1h- 1,2,3-triazol-4-yl)propyl)thio)methyl)pyrrolidin-3-ol",26,3460.3,13.68,10,15,-3.5,0.35
1o3d,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,27,3316.8,6.13,19,16,0.5,0.63
2wnj,crystal structure of aplysia achbp in complex with dmxba,16,2303.9,6.29,11,12,-1.0,0.75
1o38,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,27,3183.3,6.63,18,15,0.5,0.59
5ei3,co-crystal structure of eif4e with nucleotide mimetic inhibitor.,11,1772.5,9.51,13,7,0.5,0.45
1xug,"trypsin-babim-zn+2, ph 8.2",28,3470.0,5.97,21,18,1.0,0.64
1o3i,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,24,2849.8,4.48,16,16,-0.5,0.62
1o3f,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,28,3376.9,6.59,19,16,0.5,0.61
1gj6,engineering inhibitors highly selective for the s1 sites of ser190 trypsin-like serine protease drug targets,26,3205.7,6.36,19,14,1.5,0.62
1c1r,"recruiting zinc to mediate potent, specific inhibition of serine proteases",27,3183.3,6.62,18,15,0.5,0.59
2buv,"crystal structure of protocatechuate 3,4-dioxygenase from acinetobacter sp. adp1 mutant r457s in complex with protocatechuate",13,2054.3,4.63,17,11,2.0,0.69
1o2q,elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors,28,3592.9,5.79,21,16,1.5,0.64
1eoc,"crystal structure of acinetobacter sp. adp1 protocatechuate 3,4- dioxygenase in complex with 4-nitrocatechol",16,2431.0,4.34,23,12,3.0,0.69
6jof,crystal structure of trmd from mycobacterium tuberculosis in complex with active-site inhibitor,18,2071.3,9.50,4,6,-1.0,0.28
4h75,crystal structure of human spindlin1 in complex with a histone h3k4(me3) peptide,8,1491.0,7.13,6,6,-0.5,0.50
1gi4,a novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site,23,2607.8,4.89,15,15,-0.5,0.57
5zhl,crystal structure of trmd from mycobacterium tuberculosis in complex with active-site inhibitor,20,2244.1,10.91,4,6,-1.0,0.25
4lps,crystal structure of hypb from helicobacter pylori in complex with nickel,28,3402.7,8.20,28,18,1.0,0.68
2xys,crystal structure of aplysia californica achbp in complex with strychnine,15,2237.8,6.33,10,11,-1.0,0.73
5j1r,structure of transcriptional regulatory repressor protein - ethr from mycobacterium tuberculosis in complex with 3-(furan-3-yl)-1- (pyrrolidin-1-yl)propan-1-one at 1.92a resolution,15,2500.5,15.18,10,8,-1.0,0.33
5j3l,structure of transcriptional regulatory repressor protein - ethr from mycobacterium tuberculosis in complex with 1-((2-cyclopentylethyl) sulfonyl)pyrrolidine at 1.66a resolution,18,3047.0,18.03,10,8,-1.0,0.28
5ioz,structure of transcriptional regulatory repressor protein - ethr from mycobacterium tuberculosis in complex with n-(cyclopentylmethyl) cyclopentanecarboxamide at 2.02a resolution,15,2500.5,15.17,10,8,-1.0,0.33
2ygf,"l89v, l93i and v136m mutant of n-term hsp90 complexed with geldanamycin",25,3124.9,10.22,13,13,-1.0,0.40
4kzq,crystal structure of human tankyrase 2 in complex with 4' -hydroxy flavone,17,2458.6,9.70,12,11,1.0,0.53
2wer,yeast hsp90 n-terminal domain li-iv mutant with radicicol,15,1992.0,11.40,8,9,-1.0,0.40
4kzu,crystal structure of human tankyrase 2 in complex with 4' -bromo flavone,17,2458.6,9.57,12,11,1.0,0.53
2yge,e88g-n92l mutant of n-term hsp90 complexed with geldanamycin,25,3158.9,10.95,14,15,-2.0,0.40
2v8w,crystallographic and mass spectrometric characterisation of eif4e with n7-cap derivatives,12,2006.6,9.95,21,6,2.0,0.58
5zyg,crystal structure of cert start domain in complex with compound b5,24,3451.9,18.88,19,12,1.5,0.42
6iez,crystal structure of cert start domain in complex with compound b16,29,4235.4,19.09,22,15,0.5,0.41
6if0,crystal structure of cert start domain in complex with compound d16,29,4235.4,19.26,22,15,0.5,0.41
6j0o,crystal structure of cert start domain in complex with compound sc1,24,3718.4,15.71,24,14,1.5,0.50
2cbz,structure of the human multidrug resistance protein 1 nucleotide binding domain 1,11,1346.8,4.27,11,7,1.0,0.64
5zym,crystal structure of cert start domain in complex with compound e25b,24,3689.2,17.54,21,14,0.5,0.46
4j22,"tankyrase 2 in complex with 3-chloro-4-(4-methyl-2-oxo-1,2- dihydroquinolin-7-yl)-n-[2-(morpholin-4-yl)ethyl]benzamide",19,2692.1,9.03,17,11,2.0,0.53
1fcy,isotype selectivity of the human retinoic acid nuclear receptor hrar: the complex with the rarbeta/gamma-selective retinoid cd564,13,2027.5,8.50,9,4,1.0,0.46
1fcz,isotype selectivity of the human retinoic acid nuclear receptor hrar: the complex with the panagonist retinoid bms181156,13,2027.5,8.64,9,4,1.0,0.46
3kr8,human tankyrase 2 - catalytic parp domain in complex with an inhibitor xav939,18,2632.0,9.44,17,11,2.0,0.56
1fd0,isotype selectivity of the human retinoic acid nuclear receptor hrar: the complex with the rargamma-selective retinoid sr11254,13,2027.5,8.71,9,4,1.0,0.46
5zyl,crystal structure of cert start domain in complex with compound e25a,25,3829.2,17.55,21,14,0.5,0.44
5jsg,crystal structure of spindlin1 bound to compound eml405,14,2652.1,14.93,10,9,-0.5,0.50
1fcx,isotype selectivity of the human retinoic acid nuclear receptor hrar: the complex with the rargamma-selective retinoid bms184394,13,2027.5,8.68,9,4,1.0,0.46
4myd,"1.37 angstrom crystal structure of e. coli 2-succinyl-6-hydroxy-2,4- cyclohexadiene-1-carboxylate synthase (menh) in complex with shchc",24,3517.6,11.23,28,12,4.0,0.46
6qpl,crystal structure of spindlin1 in complex with the inhibitor ms31,17,2596.3,7.59,8,19,-5.5,0.65
5jsj,crystal structure of spindlin1 bound to compound eml631,20,3518.8,14.36,19,15,0.5,0.60
6i8y,crystal structure of spindlin1 in complex with the methyltransferase inhibitor a366,9,1536.8,5.93,6,9,-1.5,0.67
4yc0,crystal structure of adp-ribosyltransferase vis in complex with m6 inhibitor,14,1840.3,3.49,13,12,-1.0,0.71
5h5f,the crystal structure of the yeast arginine methyltransferase sfm1 complexed with sam,29,3977.8,12.87,31,13,2.0,0.48
4ymg,crystal structure of sam-bound podospora anserina methyltransferase pamth1,23,3051.4,7.74,12,17,-3.0,0.61
2r0z,pfa1 fab complexed with gripi peptide fragment,13,1671.7,8.14,8,8,0.0,0.54
1hsl,refined 1.89 angstroms structure of the histidine-binding protein complexed with histidine and its relationship with many other active transport(slash)chemosensory receptors,3,393.7,3.36,0,2,-1.0,0.33
4p6c,structure of ribb complexed with inhibitor 4peh,19,2633.9,5.48,18,20,-3.0,0.74
6ayq,crystal structure of campylobacter jejuni 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with methylthio- dadme-immucillin-a,23,3045.8,12.94,6,11,-4.0,0.35
1zea,structure of the anti-cholera toxin antibody fab fragment te33 in complex with a d-peptide,6,1091.3,2.05,9,5,1.0,0.83
6ayo,crystal structure of campylobacter jejuni 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with 5'-deoxy-5'- propyl-dadme-immucillin-a,23,3045.8,13.11,6,11,-4.0,0.35
4b3c,humanised monomeric rada in complex with 5-hydroxy indole,9,1327.3,9.13,4,3,0.0,0.22
1flr,4-4-20 fab fragment,16,2408.0,6.07,19,16,-0.5,0.75
4qdk,crystal structure of magnesium protoporphyrin ix methyltransferase (chlm) from synechocystis pcc 6803 with bound sah,9,1450.2,10.98,4,5,-1.0,0.44
4m7j,crystal structure of s25-26 in complex with kdo(2.8)kdo(2.4)kdo trisaccharide,5,526.0,2.40,3,2,0.0,0.40
6idg,antibody 64m-5 fab in complex with dt(6-4)t,10,1354.8,3.75,15,9,2.5,0.70
4pf5,crystal structure of concanavalin a complexed with a synthetic derivative of high-mannose chain,11,1393.5,2.23,11,8,0.0,0.64
4j93,crystal structure of the n-terminal domain of hiv-1 capsid in complex with inhibitor bi-1,15,2254.4,10.04,16,6,2.0,0.33
3eeb,structure of the v. cholerae rtx cysteine protease domain,20,2843.0,0.98,43,15,7.0,0.85
1kel,catalytic antibody 28b4 fab fragment complexed with hapten (1-[n-4'- nitrobenzyl-n-4'-carboxybutylamino] methylphosphonic acid),19,2941.8,7.14,30,17,2.5,0.68
4b35,humanised monomeric rada in complex with 4-methylester indole,11,1620.5,9.70,6,5,0.5,0.27
4b34,humanised monomeric rada in complex with 2-amino benzothiazole,13,1950.1,12.38,6,5,0.5,0.23
4u0f,hexameric hiv-1 ca in complex with bi-2,12,1632.3,5.86,11,8,1.0,0.50
1lyb,crystal structures of native and inhibited forms of human cathepsin d: implications for lysosomal targeting and drug design,11,1524.2,6.18,12,9,1.0,0.55
5alb,ticagrelor antidote candidate medi2452 in complex with ticagrelor,27,3877.9,16.98,13,12,-0.5,0.37
1pr5,escherichia coli purine nucleoside phosphorylase complexed with 7- deazaadenosine and phosphate/sulfate,15,1850.5,8.32,7,8,-2.0,0.47
4oiv,structural basis for small molecule ndb as a selective antagonist of fxr,23,3574.9,18.03,15,9,2.0,0.35
4b2i,humanised monomeric rada in complex with indazole,10,1480.5,8.75,6,5,0.5,0.30
3bex,type iii pantothenate kinase from thermotoga maritima complexed with pantothenate,10,992.8,0.87,11,8,0.5,0.70
5fou,humanised monomeric rada in complex with fhpa tetrapeptide,7,822.2,2.10,5,4,0.0,0.57
3fzy,crystal structure of pre-cleavage form of cysteine protease domain from vibrio cholerae rtxa toxin,20,2843.0,1.05,43,15,7.0,0.85
3tif,dimeric structure of a post-hydrolysis state of the atp-binding cassette mj0796 bound to adp and pi,20,2457.0,8.05,17,14,1.5,0.55
4b2l,humanised monomeric rada in complex with l-methylester tryptophan,14,2059.6,10.53,6,9,-1.5,0.36
4b33,humanised monomeric rada in complex with napht-2-ol,11,1620.5,9.63,6,5,0.5,0.27
4duh,crystal structure of 24 kda domain of e. coli dna gyrase b in complex with small molecule inhibitor,19,2461.5,11.52,16,7,1.0,0.37
4b32,humanised monomeric rada in complex with napht-1-ol,11,1647.2,9.97,6,5,0.5,0.27
4qnb,disulfide stabilized hiv-1 ca hexamer in complex with phenyl-l- phenylalaninamide inhibitor,15,2059.9,6.12,15,12,1.0,0.53
1a69,purine nucleoside phosphorylase in complex with formycin b and sulphate (phosphate),19,2517.2,8.49,19,10,0.5,0.53
1upf,"structure of the uracil phosphoribosyltransferase, mutant c128v bound to the drug 5-fluorouracil",10,1393.3,7.80,2,4,-1.0,0.30
1jlr,structure of the uracil phosphoribosyltransferase gtp complex 2 mutant c128v,18,2832.7,7.58,26,9,3.0,0.67
4nja,crystal structure of fab 6c8 in complex with mpts,13,1812.1,3.13,20,5,3.0,0.54
4ucc,n-terminal globular domain of the rsv nucleoprotein in complex with the nucleoprotein phosphoprotein interaction inhibitor m76,11,1696.0,2.55,17,10,0.5,0.82
1hlk,metallo-beta-lactamase from bacteroides fragilis in complex with a tricyclic inhibitor,15,2044.6,8.48,15,13,1.5,0.60
5dqe,crystal structure of human transcription factor tead2 in complex with bromo-fenamic acid,21,3194.4,17.62,10,6,1.0,0.33
1np0,human lysosomal beta-hexosaminidase isoform b in complex with intermediate analogue nag-thiazoline,7,980.2,4.88,6,6,0.0,0.57
4yzu,rapid development of two factor ixa inhibitors from hit to lead,21,2635.2,5.29,12,19,-3.5,0.67
5ew0,crystal structure of the metallo-beta-lactamase sfh-i in complex with the bisthiazolidine inhibitor l-cs319,15,2222.5,8.14,16,14,1.5,0.67
4zae,development of a novel class of potent and selective fixa inhibitors,28,3703.0,7.79,22,21,-1.5,0.64
5dq8,crystal structure of human transcription factor tead2 in complex with flufenamic acid,22,3334.4,19.20,10,6,1.0,0.32
5egm,development of a novel tricyclic class of potent and selective fixa inhibitors,23,3071.8,5.94,24,18,1.0,0.70
4b3d,humanised monomeric rada in complex with 5-methyl indole,12,1802.6,10.55,7,3,1.0,0.25
4z0k,rapid development of two factor ixa inhibitors from hit to lead,21,2607.7,7.15,11,18,-3.5,0.62
4tpw,the co-complex structure of the translation initiation factor eif4e with the inhibitor 4egi-1 reveals an allosteric mechanism for dissociating eif4g,24,3526.8,12.59,36,16,3.0,0.67
5ucj,hsp90b n-terminal domain with inhibitors,17,2274.0,12.61,7,8,-1.0,0.35
5uc4,hsp90b n-terminal domain with inhibitors,17,2245.7,11.68,7,10,-2.0,0.41
5fox,humanised monomeric rada in complex with fhaa tetrapeptide,9,1221.1,4.33,10,9,0.5,0.78
5fov,humanised monomeric rada in complex with fhtg tetrapeptide,7,862.6,2.26,7,9,-0.5,0.86
5f08,structure of transcriptional regulatory repressor protein - ethr from mycobacterium tuberculosis in complex with compound 14 at 1.92a resolution,18,3020.0,19.66,10,8,-1.0,0.28
5g5f,crystallographic structure of the tau class glutathione s-transferase migstu in complex with reduced glutathione.,14,2025.8,7.52,17,7,2.0,0.64
5d1r,crystal structure of mycobacterium tuberculosis rv1816 transcriptional regulator.,22,3213.8,20.65,6,5,0.0,0.23
5f0f,structure of transcriptional regulatory repressor protein - ethr from mycobacterium tuberculosis in complex with compound 15 at 1.76a resolution,18,3020.0,19.29,10,8,-1.0,0.28
2vw5,structure of the hsp90 inhibitor 7-o-carbamoylpremacbecin bound to the n- terminus of yeast hsp90,20,2666.0,10.74,12,12,-1.0,0.45
5fot,humanised monomeric rada in complex with fhtu tetrapeptide,9,1132.7,4.08,7,6,0.0,0.56
4oct,crystal structure of human alkbh5 crystallized in the presence of mn^{2+} and 2-oxoglutarate,14,2136.4,6.53,21,10,3.0,0.64
5eyr,structure of transcriptional regulatory repressor protein - ethr from mycobacterium tuberculosis in complex with compound 5 at 1.57a resolution,21,3337.2,22.15,10,8,-1.0,0.24
5mrp,arabidopsis thaliana ispd glu258ala mutant in complex with azolopyrimidine (2),19,2596.2,14.84,10,9,-1.0,0.32
5fpk,monomeric rada in complex with fata tetrapeptide,10,1276.5,3.73,9,8,0.0,0.60
5mro,arabidopsis thaliana ispd glu258ala mutant in complex with azolopyrimidine (1),19,2596.2,14.91,10,9,-1.0,0.32
4b3b,humanised monomeric rada in complex with fhta tetrapeptide,9,1132.7,4.08,7,6,0.0,0.56
5mrm,arabidopsis thaliana ispd in complex with isoxazole (4),17,2422.3,13.51,10,7,0.0,0.29
3n3g,"4-(3-trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin s inhibitors: n3, not n1 is critically important",12,1802.0,5.99,13,7,1.0,0.50
4o61,structure of human alkbh5 crystallized in the presence of citrate,16,2463.3,10.20,17,11,2.0,0.56
4f0c,crystal structure of the glutathione transferase ure2p5 from phanerochaete chrysosporium,22,2856.3,13.39,20,11,1.5,0.41
1igj,26-10 fab:digoxin complex-affinity and specificity due to surface complementarity,17,2497.0,10.51,12,13,-1.0,0.59
1uj5,crystal structure of thermus thermophilus ribose-5-phosphate isomerase complexed with ribose-5-phosphate,19,2083.5,4.84,12,9,0.0,0.47
2gkl,"crystal structure of the zinc carbapenemase cpha in complex with the inhibitor pyridine-2,4-dicarboxylate",11,1570.0,8.22,10,8,1.0,0.55
1dqn,crystal structure of giardia guanine phosphoribosyltransferase complexed with a transition state analogue,16,2179.0,6.63,7,16,-4.5,0.62
2hhn,cathepsin s in complex with non covalent arylaminoethyl amide.,26,3313.2,16.95,17,12,1.5,0.35
3iof,crystal structure of cpha n220g mutant with inhibitor 10a,16,2226.7,9.39,11,12,0.5,0.50
5f1r,the transcriptional regulator prfa from listeria monocytogenes in complex with a ring-fused 2-pyridone (c10),24,3752.7,13.53,18,11,2.0,0.46
2f1g,cathepsin s in complex with non-covalent 2-(benzoxazol-2-ylamino)- acetamide,23,2866.5,12.32,17,12,1.5,0.39
6ayr,crystal structure of campylobacter jejuni 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with butylthio- dadme-immucillin-a,24,3251.6,14.25,8,13,-3.5,0.38
3uyr,structure of a monoclonal antibody complexed with its mhc-i antigen,12,1554.4,2.57,13,12,0.0,0.67
6cdo,structure of vaccine-elicited hiv-1 neutralizing antibody vfp16.02 in complex with hiv-1 fusion peptide residue 512-519,4,542.2,2.71,6,1,1.0,0.50
2doo,the structure of imp-1 complexed with the detecting reagent (dansylc4sh) by a fluorescent probe,21,2922.6,9.44,21,18,2.0,0.62
6cjs,candida albicans hsp90 nucleotide binding domain in complex with auy922,27,3421.1,13.09,13,16,-1.5,0.41
3iog,crystal structure of cpha n220g mutant with inhibitor 18,14,1922.6,7.31,13,11,1.5,0.57
3n7o,x-ray structure of human chymase in complex with small molecule inhibitor.,22,2826.1,5.82,23,16,2.0,0.68
6cvv,crystal structure of mycobacterium tuberculosis dethiobiotin synthetase in complex with adenosine triphosphate (atp) - promiscuous binding mode with disordered nucleoside,16,1772.5,3.70,13,8,0.0,0.50
2y7i,structural basis for high arginine specificity in salmonella typhimurium periplasmic binding protein stm4351.,11,1482.9,3.79,12,6,1.5,0.55
6ayt,crystal structure of campylobacter jejuni 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with pyrazinylthio-dadme-immucillin-a,25,3311.7,13.72,8,13,-3.5,0.36
6cze,crystal structure of mycobacterium tuberculosis dethiobiotin synthetase in complex with inosine triphosphate (itp) - promiscuous binding mode with disordered nucleoside,16,1799.8,3.47,13,8,0.0,0.50
5yjm,"human chymase in complex with 7-oxo-3-(phenoxyimino)-1,4-diazepane derivative",26,3479.2,9.64,27,13,3.5,0.62
5kbe,crystal structure of the aromatic sensor domain of mopr in complex with phenol,14,2138.7,9.41,7,6,0.5,0.36
2pcp,antibody fab complexed with phencyclidine,16,2519.7,7.04,13,15,-1.0,0.69
5mes,mcl1 fab complex in complex with compound 29,20,2903.8,14.56,11,8,1.0,0.30
6czb,crystal structure of mycobacterium tuberculosis dethiobiotin synthetase in complex with uridine triphosphate (utp) - promiscuous binding mode with disordered nucleoside,16,1750.0,5.14,13,6,1.0,0.44
6czc,crystal structure of mycobacterium tuberculosis dethiobiotin synthetase in complex with thymidine triphosphate (ttp) - promiscuous binding mode with disordered nucleoside,18,1918.9,4.56,10,10,-1.0,0.44
6fs0,induced myeloid leukemia cell differentiation protein fabcomplex in complex with azd5991,18,2740.4,17.78,8,3,1.5,0.17
6cvf,crystal structure of mycobacterium tuberculosis dethiobiotin synthetase in complex with cytidine diphosphate,20,2092.4,6.16,7,10,-2.0,0.40
4uin,crystal structure of quinine-dependent fab 314.3 with quinine,21,2799.7,8.09,20,17,-0.5,0.57
4wop,nucleotide triphosphate promiscuity in mycobacterium tuberculosis dethiobiotin synthetase,22,2320.7,7.53,9,9,-1.0,0.36
5kej,crystallographic structure of the tau class glutathione s-transferase migstu in complex with s-hexyl-glutathione,19,2903.0,12.20,21,10,2.5,0.58
4nj9,crystal structure of fab 8b10 in complex with mpts,12,1613.6,3.02,14,4,2.0,0.50
5oaj,"crystal structure of mutant achbp in complex with tropisetron (t53f, q74r, y110a, i135s, g162e)",10,1616.3,4.12,10,6,0.0,0.80
5c5t,the crystal structure of viral collagen prolyl hydroxylase vcph from paramecium bursaria chlorella virus-1 - 2og complex,17,2445.5,5.19,16,16,0.0,0.65
1j17,factor xa specific inhibitor in complex with rat trypsin mutant x99/175/190rt,21,2781.4,7.58,9,12,-2.0,0.52
1h4w,structure of human trypsin iv (brain trypsin),17,1975.1,5.62,9,10,-0.5,0.53
4czs,discovery of glycomimetic ligands via genetically-encoded library of phage displaying mannose-peptides,14,1681.4,4.55,12,8,0.0,0.57
1j14,benzamidine in complex with rat trypsin mutant x99rt,17,2015.5,5.77,8,9,-1.0,0.53
5tp0,human mesotrypsin in complex with diminazene,20,2475.1,5.24,21,12,2.0,0.60
1ql9,factor xa specific inhibitor in complex with rat trypsin mutant x99rt,19,2430.9,2.11,13,13,-1.0,0.68
1j16,benzamidine in complex with rat trypsin mutant x99/175/190rt,16,1902.4,4.68,7,8,-1.0,0.50
1oss,t190p streptomyces griseus trypsin in complex with benzamidine,16,1926.5,4.82,7,8,-1.0,0.50
3ozt,"rat catechol o-methyltransferase in complex with a catechol-type, 4- oxo-pyridinyl-containing inhibitor - humanized form",26,3531.5,13.30,20,20,-1.5,0.54
3ozr,"rat catechol o-methyltransferase in complex with a catechol-type, bisubstrate inhibitor, no substituent in the adenine site - humanized form",21,2987.1,11.42,17,17,-1.5,0.57
3ucj,coccomyxa beta-carbonic anhydrase in complex with acetazolamide,18,2312.5,8.40,11,12,0.0,0.50
3ozs,"rat catechol o-methyltransferase in complex with a catechol-type, trifluoromethyl-imidazolyl-containing inhibitor - humanized form",27,3665.5,14.30,18,20,-2.5,0.52
1qk4,toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase imp complex,18,2553.0,9.61,8,12,-3.0,0.50
3k99,"hsp90 n-terminal domain in complex with 4-(1,3-dihydro-2h-isoindol-2- ylcarbonyl)benzene-1,3-diol",17,2143.9,9.30,9,10,-1.0,0.47
2hxm,complex of ung2 and a small molecule synthetic inhibitor,16,1963.4,4.36,12,14,-0.5,0.69
4p58,crystal structure of mouse comt bound to an inhibitor,16,2220.6,6.73,15,11,0.5,0.50
5k03,"crystal structure of comt in complex with 2,6-dimethyl-3-(1h-pyrazol- 3-yl)imidazo[1,2-a]pyridine",18,2449.9,7.31,19,14,-0.5,0.56
3oe5,"rat catechol o-methyltransferase in complex with a catechol-type, pyridylsulfanyl-containing inhibitor - humanized form",25,3387.7,13.60,18,18,-1.5,0.52
1mh5,the structure of the complex of the fab fragment of the esterolytic antibody ms6-164 and a transition-state analog,24,4000.9,14.20,22,20,0.5,0.54
3oe4,"rat catechol o-methyltransferase in complex with a catechol-type, purine-containing bisubstrate inhibitor - humanized form",26,3561.1,13.41,23,18,-0.5,0.54
3hzm,crystal structure of s73-2 antibody in complex with antigen kdo,16,2527.5,4.60,27,11,3.0,0.75
5fsc,structure of tectonin 2 from laccaria bicolor in complex with allyl- alpha_4-methyl-mannoside,7,1017.6,5.94,4,3,0.0,0.29
1qk3,toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase gmp complex,17,2414.9,9.14,10,9,-1.0,0.47
6dyn,c-terminal condensation domain of ebony in complex with histamine,12,1680.4,11.11,4,6,-1.0,0.42
6dyr,c-terminal condensation domain of ebony in complex with carcinine,16,2368.4,11.44,8,10,-1.0,0.50
3hvi,"rat catechol o-methyltransferase in complex with a catechol-type, n6- ethyladenine-containing bisubstrate inhibitor",28,3897.3,13.21,26,23,-1.5,0.57
2byr,crystal structure of achbp from aplysia californica in complex with methyllycaconitine,21,3112.4,8.00,19,17,0.0,0.76
6dys,c-terminal condensation domain of ebony in complex with beta-alanyl- dopamine,18,2623.7,13.71,8,10,-1.0,0.44
3hzk,crystal structure of s73-2 antibody in complex with antigen kdo(2.4) kdo,8,1375.6,2.42,16,3,3.0,0.75
3bpc,"co-crystal structure of s25-2 fab in complex with 5-deoxy-4-epi-2,3- dehydro kdo (4.8) kdo",13,2007.1,2.63,22,14,1.5,0.85
6msy,anti-hiv-1 fab fab 2g12 + man4 re-refinement,0,0.0,0.00,0,0,0.0,0.00
3hzv,crystal structure of s73-2 antibody in complex with antigen kdo(2.8) kdo(2.4)kdo,6,988.4,3.15,14,1,3.0,0.67
2bys,crystal structure of achbp from aplysia californica in complex with lobeline,23,3437.5,11.80,15,8,1.0,0.48
6hai,"albam131a mutant in complex with albicidin , albicidin resistance protein",40,6478.3,33.08,29,16,2.5,0.33
6b5q,dcn1 bound to 38,19,2558.8,13.27,4,8,-2.0,0.42
4zb8,crystal structure of the glutathione transferase ure2p6 from phanerochaete chrysosporium in complex with oxidized glutathione.,21,2742.5,12.07,22,11,2.5,0.43
2xyt,crystal structure of aplysia californica achbp in complex with d- tubocurarine,21,2991.9,5.81,20,18,0.0,0.81
3q71,human parp14 (artd8) - macro domain 2 in complex with adenosine-5- diphosphoribose,28,3340.5,10.33,20,16,0.5,0.43
4xk9,crystal structure of a-achbp in complex with pinnatoxin g,21,3116.0,6.13,19,17,-1.0,0.76
6cjr,candida albicans hsp90 nucleotide binding domain in complex with snx- 2112,26,3645.1,17.69,13,12,-1.0,0.35
4nvp,structure of the cyclic nucleotide-binding domain of hcn4 channel complexed with 7-ch-camp,20,2985.1,11.58,23,5,3.0,0.45
2wf5,structure of beta-phosphoglucomutase inhibited with glucose-6- phosphate and trifluoromagnesate,19,2515.6,4.60,26,15,2.5,0.74
3kku,cruzain in complex with a non-covalent ligand,15,1797.1,6.14,6,9,-1.5,0.40
5ev8,crystal structure of the metallo-beta-lactamase imp-1 in complex with the bisthiazolidine inhibitor d-cs319,13,1849.7,7.01,14,12,2.0,0.62
1qyg,anti-cocaine antibody m82g2 complexed with benzoylecgonine,17,2526.9,7.97,16,14,0.0,0.53
2yme,crystal structure of a mutant binding protein (5htbp-achbp) in complex with granisetron,13,2072.6,6.78,12,7,0.0,0.69
3wgg,crystal structure of rsp in complex with alpha-nad+,29,3796.0,16.24,17,16,0.0,0.41
1q72,anti-cocaine antibody m82g2 complexed with cocaine,17,2474.3,6.18,18,16,0.0,0.59
1wc1,soluble adenylyl cyclase cyac from s. platensis in complex with rp- atpalphas,12,1631.8,6.92,11,5,0.0,0.42
1mfa,structure of a single-chain fv fragment complexed with a carbohydrate antigen at 1.7 angstroms resolution,4,631.0,5.83,3,2,0.5,0.25
1k9s,purine nucleoside phosphorylase from e. coli in complex with formycin a derivative and phosphate,20,2670.4,8.63,21,12,1.0,0.55
5ewa,crystal structure of the metallo-beta-lactamase imp-1 in complex with the bisthiazolidine inhibitor l-vc26,14,1988.1,6.81,14,14,1.0,0.64
5sym,"cocrystal structure of the human acyl protein thioesterase 1 with an isoform-selective inhibitor, ml348",27,3889.1,18.57,16,14,-0.5,0.37
3u81,crystal structure of a sah-bound semi-holo form of rat catechol-o- methyltransferase,8,988.3,2.61,7,4,0.0,0.62
4b5w,"crystal structures of divalent metal dependent pyruvate aldolase r70a mutant, hpai, in complex with pyruvate",15,2170.8,12.79,5,10,-2.5,0.33
3hvj,"rat catechol o-methyltransferase in complex with a catechol-type, n6- propyladenine-containing bisubstrate inhibitor",28,3897.3,13.10,26,23,-1.5,0.57
1yej,catalytic antibody complex,20,3330.8,14.19,17,14,1.0,0.50
4hj2,crystal structure analysis of gsta1-1 in complex with chlorambucil,24,3569.4,17.43,23,10,2.0,0.38
1yei,catalytic antibody d2.3 complex,21,3504.2,13.85,22,14,2.0,0.52
4yhm,reversal agent for dabigatran,21,3112.3,3.62,17,20,-2.5,0.71
1d6v,conformation effects in biological catalysis introduced by oxy-cope antibody maturation,18,2923.1,11.51,10,13,-2.5,0.50
1odi,purine nucleoside phosphorylase from thermus thermophilus,20,2709.0,10.23,16,12,-0.5,0.45
1odj,purine nucleoside phosphorylase from thermus thermophilus,20,2709.0,10.53,16,12,-0.5,0.45
4whs,"4-fluorocatechol bound to protocatechuate 3,4-dioxygenase (pseudomonas putida) at ph 8.5",10,1492.9,4.43,14,5,1.0,0.60
4yho,reversal agent for dabigatran,21,3146.5,5.51,17,19,-2.5,0.67
3i9g,crystal structure of the lt1009 (sonepcizumab) antibody fab fragment in complex with sphingosine-1-phosphate,24,3181.2,8.66,16,22,-3.0,0.62
3su5,crystal structure of ns3/4a protease variant d168a in complex with vaniprevir,24,3105.1,10.91,23,11,2.5,0.46
4dbm,aplysia californica-achbp in complex with triazole 18,16,2628.2,7.77,18,9,1.0,0.62
2vyt,the mbt repeats of human scml2 bind to peptides containing mono methylated lysine.,4,768.2,2.51,12,1,2.0,0.75
1z4o,structure of beta-phosphoglucomutase with inhibitor bound alpha- galactose 1-phosphate,19,2515.6,4.47,26,15,2.5,0.74
1ydk,crystal structure of the i219a mutant of human glutathione transferase a1-1 with s-hexylglutathione,20,3020.1,12.59,31,10,4.0,0.55
3sug,crystal structure of ns3/4a protease variant a156t in complex with mk- 5172,23,3069.0,9.58,22,13,1.5,0.52
3su6,crystal structure of ns3/4a protease variant a156t in complex with vaniprevir,24,3155.1,9.79,24,14,1.5,0.54
2ymd,crystal structure of a mutant binding protein (5htbp-achbp) in complex with serotonin (5-hydroxytryptamine),17,2683.3,10.41,11,4,1.0,0.41
6cdp,vaccine-elicited hiv-1 neutralizing antibody vfp20.01 in complex with hiv-1 fusion peptide residue 512-519,2,262.0,1.65,5,0,1.0,0.50
1m7i,crystal structure of a monoclonal fab specific for shigella flexneri y lipopolysaccharide complexed with a pentasaccharide,13,2043.9,6.11,16,13,0.5,0.69
1m7d,crystal structure of a monoclonal fab specific for shigella flexneri y lipopolysaccharide complexed with a trisaccharide,13,2043.9,6.12,16,13,0.5,0.69
3wto,crystal structure of lymnaea stagnalis acetylcholine-binding protein q55r mutant complexed with desnitro-imidacloprid,15,2410.4,7.96,13,6,1.0,0.60
4b5d,"capitella teleta achbp in complex with psychonicline (3-((2(s)- azetidinyl)methoxy)-5-((1s,2r)-2-(2-hydroxyethyl)cyclopropyl) pyridine)",16,2581.6,12.51,9,7,0.0,0.50
3su1,crystal structure of ns3/4a protease variant d168a in complex with danoprevir,23,3016.1,11.62,22,10,2.5,0.43
3su2,crystal structure of ns3/4a protease variant a156t in complex with danoprevir,22,2892.7,10.82,18,13,0.5,0.50
3su0,crystal structure of ns3/4a protease variant r155k in complex with danoprevir,23,3033.8,10.83,20,12,1.5,0.48
1mfd,the solution structure of a trisaccharide-antibody complex: comparison of nmr measurements with a crystal structure,5,691.1,5.58,3,2,0.5,0.20
2cgr,local and transmitted conformational changes on complexation of an anti-sweetener fab,18,2591.9,2.85,22,20,0.0,0.78
6nzv,crystal structure of hcv ns3/4a protease in complex with compound 12,23,3074.6,9.72,24,13,2.5,0.52
1mjj,high resolution crystal structure of the complex of the fab fragment of esterolytic antibody ms6-12 and a transition-state analog,21,3464.3,14.95,19,15,1.0,0.48
3wtj,crystal structure of lymnaea stagnalis acetylcholine binding protein complexed with thiacloprid,18,2804.9,8.63,14,9,0.0,0.61
3su3,crystal structure of ns3/4a protease in complex with vaniprevir,24,3127.6,10.28,23,13,1.5,0.50
2bmk,fab fragment of plp-dependent catalytic antibody 15a9 in complex with phosphopyridoxyl-d-alanine,15,2452.0,6.71,24,12,2.5,0.73
5aba,structure of the p53 cancer mutant y220c with bound small-molecule stabilizer phikan5149,14,1771.4,7.59,4,9,-3.0,0.57
2pgz,crystal structure of cocaine bound to an ach-binding protein,13,2037.7,6.24,9,8,0.0,0.69
3wtm,crystal structure of lymnaea stagnalis acetylcholine-binding protein q55r mutant complexed with nitromethylene analogue of imidacloprid,16,2668.9,7.22,19,7,2.0,0.62
3wtl,crystal structure of lymnaea stagnalis acetylcholine binding protein complexed with nitromethylene analogue of imidacloprid,17,2747.8,7.26,16,9,1.0,0.65
5aoi,structure of the p53 cancer mutant y220c in complex with an indole- based small molecule,15,1832.2,10.48,4,8,-2.0,0.47
1m5w,1.96 a crystal structure of pyridoxine 5'-phosphate synthase in complex with 1-deoxy-d-xylulose phosphate,18,2446.4,4.10,24,20,1.0,0.78
4afg,capitella teleta achbp in complex with varenicline,13,2084.7,11.44,6,5,0.0,0.46
3qqa,crystal structures of cmer-bile acid complexes from campylobacter jejuni,21,3339.3,16.03,12,10,1.0,0.38
3qps,crystal structures of cmer-bile acid complexes from campylobacter jejuni,18,2786.2,17.12,10,6,2.0,0.33
2vuk,structure of the p53 core domain mutant y220c bound to the stabilizing small-molecule drug phikan083,14,1927.9,10.69,3,6,-2.0,0.43
5aol,"structure of the p53 cancer mutant y220c with bound 3-bromo-5- (trifluoromethyl)benzene-1,2-diamine",15,2151.6,17.00,2,3,-1.0,0.20
5a7b,structure of the p53 cancer y220c bound to the stabilizing small molecule phikan5211,18,2173.0,9.08,5,10,-3.0,0.50
4agl,structure of the p53 core domain mutant y220c bound to the stabilizing small molecule phikan784,14,1771.4,7.69,4,9,-3.0,0.57
5g4m,crystal structure of the p53 cancer mutant y220c in complex with a monofluorinated derivative of the small molecule stabilizer phikan083,14,1850.2,9.56,4,7,-2.0,0.50
5o1f,p53 cancer mutant y220c in complex with compound mb582,19,2469.5,13.21,4,7,-2.0,0.37
4agn,structure of the p53 core domain mutant y220c bound to the stabilizing small molecule phikan5116,17,2112.9,9.20,5,10,-3.0,0.53
5o1h,p53 cancer mutant y220c in complex with compound mb539,19,2469.5,13.28,4,7,-2.0,0.37
4ago,structure of the p53 core domain mutant y220c bound to the stabilizing small molecule phikan5174,16,1996.8,9.87,4,9,-3.0,0.50
6gga,p53 cancer mutant y220c in complex with small-molecule stabilizer pk9284,13,1660.3,8.13,4,7,-2.0,0.54
3su4,crystal structure of ns3/4a protease variant r155k in complex with vaniprevir,27,3567.5,11.06,22,16,0.5,0.52
2vo4,glutathione transferase from glycine max,23,3667.3,14.20,29,7,5.0,0.52
5g4n,crystal structure of the p53 cancer mutant y220c in complex with a difluorinated derivative of the small molecule stabilizer phikan083,16,2156.9,11.37,4,7,-2.0,0.44
5o1d,p53 cancer mutant y220c in complex with compound mb481,19,2469.5,13.19,4,7,-2.0,0.37
4agm,structure of the p53 core domain mutant y220c bound to the stabilizing small molecule phikan5086,14,1771.4,7.60,4,9,-3.0,0.57
5aoj,"structure of the p53 cancer mutant y220c in complex with 2-hydroxy-3, 5-diiodo-4-(1h-pyrrol-1-yl)benzoic acid",15,2067.9,11.93,3,6,-2.0,0.40
4agq,structure of the p53 core domain mutant y220c bound to the stabilizing small molecule phikan5196,18,2173.0,9.11,5,10,-3.0,0.50
5uff,crystal structure of variable lymphocyte receptor (vlr) rbc36 with fucose(alpha-1-2)lactose bound,5,875.6,5.96,4,5,-0.5,0.60
1rbp,crystallographic refinement of human serum retinol binding protein at 2 angstroms resolution,27,4133.2,22.25,14,11,0.5,0.30
3ijh,structure of s67-27 in complex with ko,16,2475.3,4.60,28,12,3.0,0.75
4unp,mtb tmk in complex with compound 34,13,1971.7,7.89,21,6,3.0,0.62
5g4o,crystal structure of the p53 cancer mutant y220c in complex with a trifluorinated derivative of the small molecule stabilizer phikan083,16,2128.0,10.21,4,9,-3.0,0.50
6ggf,structure of the p53 cancer mutant y220c in complex with small- molecule stabilizer pk9328,15,1885.7,10.37,4,7,-2.0,0.47
6ggb,p53 cancer mutant y220c in complex with small-molecule stabilizer pk9318,16,1972.9,9.82,4,7,-2.0,0.44
3q6z,human parp14 (artd8)-macro domain 1 in complex with adenosine-5- diphosphoribose,23,2634.5,10.97,12,11,0.5,0.39
1mrs,crystal structure of mycobacterium tuberculosis thymidylate kinase complexed with 5-ch2oh deoxyuridine monophosphate,18,2767.0,5.09,22,17,-2.0,0.78
1mrn,crystal structure of mycobacterium tuberculosis thymidylate kinase complexed with bisubstrate inhibitor (tp5a),26,3782.7,6.44,34,21,-0.5,0.69
3gx0,crystal structure of gsh-dependent disulfide bond oxidoreductase,21,2759.2,10.92,19,14,1.5,0.48
4agp,structure of the p53 core domain mutant y220c bound to the stabilizing small molecule phikan5176,18,2173.0,9.05,5,10,-3.0,0.50
5voj,"crystal structure of hcv ns3/4a protease in complex with jz01-15, an analogue of 5172-mcp1p3",28,3637.4,10.09,26,16,1.5,0.54
5vp9,"crystal structure of hcv ns3/4a protease in complex with am-07, an analogue of 5172-mcp1p3",26,3410.6,8.81,26,16,1.5,0.58
5tmp,complex of e. coli thymidylate kinase with the bisubstrate inhibitor aztp5a,31,4420.9,12.13,42,19,2.5,0.61
5epn,crystal structure of hcv ns3/4a protease in complex with 5172-mcp1p3 (mk-5172 p1-p3 macrocyclic analogue),26,3410.6,8.95,26,16,1.5,0.58
2ca8,structure of sh28gst in complex with gsh at ph 6.0,12,1860.3,6.70,16,4,2.0,0.50
4tmk,complex of e. coli thymidylate kinase with the bisubstrate inhibitor tp5a,29,4012.6,8.90,42,19,2.5,0.66
3kdm,crystal structure of human anti-steroid fab 5f2 in complex with testosterone,15,2133.8,8.31,7,8,-1.0,0.47
3u10,tetramerization dynamics of the c-terminus underlies isoform-specific camp-gating in hcn channels,20,3031.9,12.70,22,4,3.0,0.40
1jgl,crystal structure of immunoglobulin fab fragment complexed with 17- beta-estradiol,16,2340.8,10.19,13,10,0.5,0.44
2yk1,structure of human anti-nicotine fab fragment in complex with nicotine,16,2486.5,13.35,7,5,-1.0,0.25
1m2x,crystal structure of the metallo-beta-lactamase blab of chryseobacterium meningosepticum in complex with the inhibitor d- captopril,12,1760.9,2.67,14,16,0.0,0.92
1f4x,crystal structure of an anti-carbohydrate antibody directed against vibrio cholerae o1 in complex with antigen,12,1974.2,8.48,9,9,-0.5,0.58
4ew3,the structure of human glycinamide ribonucleotide transformylase in complex with 10r-methylthio-ddathf.,17,2396.3,10.06,14,10,-0.5,0.41
1bzy,human hgprtase with transition state inhibitor,24,3334.7,10.19,15,14,-1.0,0.54
2euk,crystal structure of human glycolipid transfer protein complexed with 24:1 galactosylceramide,26,4015.6,29.90,3,4,-0.5,0.08
1ork,"tet repressor, class d in complex with 9-(n,n-dimethylglycylamido)-6- demethyl-6-deoxy-tetracycline",17,2374.4,10.24,19,14,2.0,0.59
2evl,crystal structure of human glycolipid transfer protein complexed with 18:2 galactosylceramide,8,1218.2,11.57,3,4,-0.5,0.25
6ajr,complex form of uracil dna glycosylase x and uracil,15,1934.8,7.27,12,3,2.5,0.47
4ew2,the structure of human glycinamide ribonucleotide transformylase in complex with 10s-methylthio-ddathf.,18,2485.3,10.72,15,11,-0.5,0.44
1aj7,immunoglobulin 48g7 germline fab antibody complexed with hapten 5- (para-nitrophenyl phosphonate)-pentanoic acid. affinity maturation of an esterolytic antibody,21,3448.8,9.81,30,12,3.5,0.62
5jsq,trypanosome brucei hypoxanthine-guanine phosphoribosyltranferase in complex with a 9-[7-(phosphonoheptyl]guanine,18,2653.7,13.22,6,9,-2.0,0.39
1kdk,the structure of the n-terminal lg domain of shbg in crystals soaked with edta,23,3340.8,17.17,15,11,0.0,0.43
1lhu,crystal structure of the n-terminal lg-domain of shbg in complex with estradiol,23,3364.7,16.91,14,10,0.0,0.39
6mg5,structure of full-length human lambda-6a light chain jto in complex with coumarin 1,14,2015.0,7.55,7,7,0.0,0.43
4rpn,pcpr inducer binding domain complex with pentachlorophenol,17,2393.4,11.40,6,8,0.0,0.29
6d2o,beta carbonic anhydrase in complex with 4-methylimidazole,11,1152.6,2.34,8,5,0.5,0.55
1ui0,crystal structure of uracil-dna glycosylase from thermus thermophilus hb8,16,2211.8,9.25,10,3,1.0,0.50
4jn2,an antidote for dabigatran,21,3064.1,8.85,14,16,-1.0,0.57
4kmz,human folate receptor beta (folr2) in complex with the folate,20,3382.1,10.99,30,12,2.5,0.60
4kn1,human folate receptor beta (folr2) in complex with the antifolate aminopterin,18,3015.1,12.67,24,11,1.5,0.56
1p19,"hypoxanthine phosphoribosyltransferase from trypanosoma cruzi, in complex with the product imp",16,2186.4,10.02,5,10,-3.0,0.44
4rfr,complex structure of alkb/rhein,18,2761.3,8.55,28,14,3.0,0.67
1nf8,crystal structure of phzd protein active site mutant with substrate,8,1220.8,8.09,5,5,1.0,0.38
2gst,"structure of the xenobiotic substrate binding site of a glutathione s- transferase as revealed by x-ray crystallographic analysis of product complexes with the diastereomers of 9-(s-glutathionyl)-10-hydroxy-9, 10-dihydrophenanthrene",25,3795.4,14.19,27,14,2.0,0.48
1aid,structure of a non-peptide inhibitor complexed with hiv-1 protease: developing a cycle of structure-based drug design,22,2761.0,20.58,2,6,-2.0,0.18
4kn0,human folate receptor beta (folr2) in complex with the antifolate methotrexate,18,3015.1,12.65,24,11,1.5,0.56
1xk5,crystal structure of the m3g-cap-binding domain of snurportin1 in complex with a m3gpppg-cap dinucleotide,13,2038.3,8.80,19,5,2.0,0.54
5el9,"a. thaliana igpd2 in complex with the triazole-phosphonate inhibitor, (s)-c348, to 1.1a resolution",8,1083.9,2.99,15,4,2.0,0.75
2vfk,akap18 delta central domain - amp,11,1633.6,3.15,18,9,3.0,0.82
4rpo,"pcpr inducer binding domain (complex with 2,4,6-trichlorophenol)",15,2108.5,12.18,8,5,0.5,0.27
3gst,"structure of the xenobiotic substrate binding site of a glutathione s- transferase as revealed by x-ray crystallographic analysis of product complexes with the diastereomers of 9-(s-glutathionyl)-10-hydroxy-9, 10-dihydrophenanthrene",25,3795.4,13.36,27,14,2.0,0.48
1xk9,pseudomanas exotoxin a in complex with the pj34 inhibitor,12,1703.0,3.64,8,10,-0.5,0.58
5elw,"a. thaliana igpd2 in complex with the triazole-phosphonate inhibitor, (r)-c348, to 1.36a resolution",7,972.8,2.98,15,2,3.0,0.71
3str,strep peptide deformylase with a time dependent thiazolidine hydroxamic acid,24,2937.9,8.54,11,17,-2.0,0.46
2vt3,structure and functional properties of the bacillus subtilis transcriptional repressor rex,18,2402.1,12.92,10,9,0.5,0.33
3sw8,strep peptide deformylase with a time dependent dichlorobenzamide- reverse hydroxamic acid,19,2260.4,8.42,7,11,-1.0,0.37
1c5c,decarboxylase catalytic antibody 21d8-hapten complex,17,2805.3,11.09,23,8,2.5,0.53
5nbw,crystal structure of the fab fragment 22f12 in complex with 3- hydroxybenzo[a]pyrene,17,2771.0,9.78,15,9,1.0,0.53
1gaf,48g7 hybridoma line fab complexed with hapten 5-(para-nitrophenyl phosphonate)-pentanoic acid,21,3509.9,11.46,28,10,3.5,0.57
2fgv,"x-ray crystal structure of hiv-1 protease t80n variant in complex with the inhibitor saquinavir used to explore the role of invariant thr80 in hiv-1 protease structure, function, and viral infectivity.",15,1638.8,8.77,4,8,-2.0,0.33
6ays,crystal structure of campylobacter jejuni 5'-methylthioadenosine/s- adenosyl homocysteine nucleosidase (mtan) complexed with hexylthio- dadme-immucillin-a,27,3586.9,15.87,8,13,-3.5,0.37
2qi0,"crystal structure of protease inhibitor, mit-1-kk80 in complex with wild type hiv-1 protease",32,3845.1,14.44,8,15,-5.0,0.31
1gar,towards structure-based drug design: crystal structure of a multisubstrate adduct complex of glycinamide ribonucleotide transformylase at 1.96 angstroms resolution,31,4069.4,13.88,30,21,1.0,0.48
2psv,crystal structure of wild type hiv-1 protease in complex with carb- kb45,29,3472.9,15.26,6,13,-5.0,0.28
3aid,"a new class of hiv-1 protease inhibitor: the crystallographic structure, inhibition and chemical synthesis of an aminimide peptide isostere",30,3622.2,18.13,10,8,-2.0,0.20
2qi1,"crystal structure of protease inhibitor, mit-1-kk81 in complex with wild type hiv-1 protease",31,3779.6,16.74,6,13,-5.0,0.26
2qhz,"crystal structure of protease inhibitor, mit-1-ac87 in complex with wild type hiv-1 protease",32,3889.0,18.10,2,14,-6.0,0.25
2psu,crystal structure of wild type hiv-1 protease in complex with carb- ad37,29,3472.9,15.12,6,13,-5.0,0.28
1kuk,crystal structure of a taiwan habu venom metalloproteinase complexed with pekw.,6,988.7,3.78,7,8,0.5,0.67
2uxi,phloretin in complex with ttgr,18,2489.9,16.38,8,5,0.0,0.28
2qhy,"crystal structure of protease inhibitor, mit-1-ac86 in complex with wild type hiv-1 protease",32,3895.7,16.01,7,14,-5.0,0.28
1kui,crystal structure of a taiwan habu venom metalloproteinase complexed with peqw.,6,988.7,3.75,7,8,0.5,0.67
1b6j,hiv-1 protease complexed with macrocyclic peptidomimetic inhibitor 1,19,2237.3,10.96,7,8,-2.0,0.26
1i7z,antibody gnc92h2 bound to ligand,18,2894.7,6.66,16,16,-1.5,0.72
1b6l,hiv-1 protease complexed with macrocyclic peptidomimetic inhibitor 4,31,3786.3,15.22,11,13,-4.0,0.29
2c80,structure of sh28gst in complex with s-hexyl glutathione,21,3127.0,10.20,20,12,0.5,0.52
5tuo,"crystal structure of the complex of helicobacter pylori alpha-carbonic anhydrase with 5-amino-1,3,4-thiadiazole-2-sulfonamide inhibitor.",17,2579.9,9.37,21,18,2.5,0.71
1oe8,28kda glutathione s-transferase from schistosoma haematobium (glutathione saturated),13,1841.6,5.56,16,6,1.0,0.54
3v78,crystal structure of transcriptional regulator,19,2919.4,16.44,9,9,-1.0,0.37
4trc,sulfolobus solfataricus adenine phosphoribosyltransferase with adenine,9,1483.3,8.20,3,5,-2.0,0.33
1z1h,hiv-1 protease complexed with macrocyclic peptidomimetic inhibitor 3,30,3612.9,15.99,6,13,-5.0,0.27
1mtr,hiv-1 protease complexed with a cyclic phe-ile-val peptidomimetic inhibitor,30,3670.2,16.34,10,12,-4.0,0.27
1kug,crystal structure of a taiwan habu venom metalloproteinase complexed with its endogenous inhibitor penw,6,988.7,3.75,7,8,0.5,0.67
2q55,crystal structure of kk44 bound to hiv-1 protease,32,4005.5,16.62,13,12,-3.0,0.28
6j0g,crystal structure of intracellular b30.2 domain of btn3a3 mutant in complex with hmbpp,11,1912.9,6.22,24,5,5.0,0.64
1a4k,diels alder catalytic antibody with transition state analogue,16,2349.0,10.59,19,9,1.0,0.50
4x8o,crystal structure of e. coli adenylate kinase y171w mutant in complex with inhibitor ap5a,46,6022.6,17.76,54,18,6.5,0.46
1b6k,hiv-1 protease complexed with macrocyclic peptidomimetic inhibitor 5,30,3670.2,16.74,10,12,-4.0,0.27
10gs,"human glutathione s-transferase p1-1, complex with ter117",17,2428.3,7.43,18,11,1.0,0.53
1lbk,"crystal structure of a recombinant glutathione transferase, created by replacing the last seven residues of each subunit of the human class pi isoenzyme with the additional c-terminal helix of human class alpha isoenzyme",14,2033.0,4.72,17,12,0.0,0.64
1d4l,hiv-1 protease complexed with a macrocyclic peptidomimetic inhibitor,32,3953.0,16.66,11,13,-4.0,0.28
2gss,human glutathione s-transferase p1-1 in complex with ethacrynic acid,11,1659.3,9.01,10,4,1.0,0.36
4yha,crystal structure of the complex of helicobacter pylori alpha-carbonic anhydrase with methazolamide,16,2185.4,8.39,14,14,0.5,0.56
4gah,human acyl-coa thioesterases 4 in complex with undecan-2-one-coa inhibitor,25,3502.9,14.34,24,10,3.5,0.40
3gss,human glutathione s-transferase p1-1 in complex with ethacrynic acid- glutathione conjugate,13,1894.6,4.94,17,10,1.0,0.62
1njs,"human gar tfase in complex with hydrolyzed form of 10-trifluoroacetyl- 5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid",22,3006.5,13.51,17,13,0.0,0.41
5tt3,crystal structure of the complex of helicobacter pylori alpha-carbonic anhydrase with ethoxzolamide,13,1791.6,9.19,9,10,0.5,0.46
2q54,crystal structure of kb73 bound to hiv-1 protease,30,3669.5,16.09,11,13,-4.0,0.30
4oak,"crystal structure of vancomycin resistance d,d-dipeptidase/d,d- pentapeptidase vanxyc d59s mutant in complex with d-alanine-d-alanine and copper (ii)",7,1051.8,8.87,7,2,1.5,0.29
4zb6,crystal structure of glutathione transferase ure2p4 from phanerochaete chrysosporium in complex with oxidized glutathione.,26,3440.2,10.40,31,17,3.0,0.54
1yfz,novel imp binding in feedback inhibition of hypoxanthine-guanine phosphoribosyltransferase from thermoanaerobacter tengcongensis,16,2191.3,8.72,14,6,1.0,0.44
1d4k,hiv-1 protease complexed with a macrocyclic peptidomimetic inhibitor,31,3786.3,16.39,11,13,-4.0,0.29
2fgu,"x-ray crystal structure of hiv-1 protease t80s variant in complex with the inhibitor saquinavir used to explore the role of invariant thr80 in hiv-1 protease structure, function, and viral infectivity.",15,1613.7,8.76,3,7,-2.0,0.33
3mxd,crystal structure of hiv-1 protease inhibitor kc53 in complex with wild-type protease,30,3639.6,16.37,6,13,-5.0,0.27
3ekx,"crystal structure of the wild-type hiv-1 protease with the inhibitor, nelfinavir",31,3779.6,17.32,6,13,-5.0,0.26
3suf,crystal structure of ns3/4a protease variant d168a in complex with mk- 5172,33,4251.5,13.68,29,17,1.5,0.55
1wuq,structure of gtp cyclohydrolase i complexed with 8-oxo-gtp,25,3438.7,10.27,24,13,3.5,0.48
3el1,"crystal structure of wild-type hiv protease in complex with the inhibitor, atazanavir",31,3786.3,15.87,11,13,-4.0,0.29
1wur,structure of gtp cyclohydrolase i complexed with 8-oxo-dgtp,24,3275.8,9.83,24,13,3.5,0.50
5j41,glutathione s-transferase bound with hydrolyzed piperlongumine,14,2033.0,4.90,17,12,0.0,0.64
2qi3,"crystal structure of protease inhibitor, mit-2-ad94 in complex with wild type hiv-1 protease",29,3528.5,17.39,6,11,-4.0,0.24
3ekv,"crystal structure of the wild type hiv-1 protease with the inhibitor, amprenavir",31,3755.7,16.43,7,14,-5.0,0.29
3mxe,"crystal structure of hiv-1 protease inhibitor, kc32 complexed with wild-type protease",31,3858.8,19.09,8,12,-4.0,0.26
2qi4,"crystal structure of protease inhibitor, mit-2-ad93 in complex with wild type hiv-1 protease",33,4062.4,17.17,7,14,-5.0,0.27
2qi7,"crystal structure of protease inhibitor, mit-2-ad86 in complex with wild type hiv-1 protease",29,3472.9,15.24,6,13,-5.0,0.28
4djq,crystal structure of wild-type hiv-1 protease in complex with mkp86,30,3639.6,16.84,6,13,-5.0,0.27
4ygf,crystal structure of the complex of helicobacter pylori alpha-carbonic anhydrase with acetazolamide,15,2072.7,7.49,14,14,0.5,0.60
3o9a,crystal structure of wild-type hiv-1 protease in complex with kd14,30,3663.5,17.74,5,12,-5.0,0.23
5ltn,crystal structure of lymphocytic choriomeningitis mammarenavirus endonuclease complexed with dpba,8,1089.3,2.05,7,7,-1.0,0.88
3gi4,"crystal structure of protease inhibitor, kb60 in complex with wild type hiv-1 protease",30,3662.8,17.88,6,13,-5.0,0.27
3i7e,co-crystal structure of hiv-1 protease bound to a mutant resistant inhibitor uic-98038,31,3838.8,15.94,13,12,-3.0,0.29
3o99,crystal structure of wild-type hiv-1 protease in complex with kd13,31,3836.9,17.25,10,12,-4.0,0.26
3gi5,"crystal structure of protease inhibitor, kb62 in complex with wild type hiv-1 protease",30,3662.8,17.86,6,13,-5.0,0.27
1atl,"structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin c (form-d)",20,2707.6,8.26,14,15,-0.5,0.55
2qi6,"crystal structure of protease inhibitor, mit-2-kb98 in complex with wild type hiv-1 protease",32,3895.7,16.02,7,14,-5.0,0.28
3o9d,crystal structure of wild-type hiv-1 protease in complex with kd19,31,3779.6,16.80,6,13,-5.0,0.26
2q5k,crystal structure of lopinavir bound to wild type hiv-1 protease,32,3953.0,17.14,11,13,-4.0,0.28
1uz8,anti-lewis x fab fragment in complex with lewis x,12,1937.1,6.00,10,12,-2.0,0.67
2v54,crystal structure of vaccinia virus thymidylate kinase bound to tdp,19,2807.1,4.41,25,15,0.0,0.74
2qi5,"crystal structure of protease inhibitor, mit-2-kc08 in complex with wild type hiv-1 protease",31,3779.6,16.92,6,13,-5.0,0.26
3o9e,crystal structure of wild-type hiv-1 protease in complex with af60,31,3779.6,16.91,6,13,-5.0,0.26
3gi6,"crystal structure of protease inhibitor, ad78 in complex with wild type hiv-1 protease",30,3662.8,17.78,6,13,-5.0,0.27
3sue,crystal structure of ns3/4a protease variant r155k in complex with mk- 5172,23,3037.1,9.69,20,13,1.5,0.52
5ngz,ube2t in complex with fragment em04,11,1495.4,10.54,3,4,-1.0,0.27
4djp,crystal structure of wild-type hiv-1 protease in complex with mkp73,33,4062.4,17.66,7,14,-5.0,0.27
4djr,crystal structure of wild-type hiv-1 protease in complex with mkp97,30,3639.6,16.91,6,13,-5.0,0.27
5w44,crystal structure of the influenza virus pa endonuclease in complex with inhibitor 7a (sri-29770),16,2389.0,6.83,15,12,-0.5,0.62
2i0a,crystal structure of kb-19 complexed with wild type hiv-1 protease,29,3546.7,18.29,5,12,-5.0,0.24
4zba,crystal structure of the glutathione transferase ure2p8 from phanerochaete chrysosporium with oxidized glutathione.,23,3105.8,6.23,33,18,4.0,0.70
4djo,crystal structure of wild-type hiv-1 protease in complex with mkp56,32,3895.7,16.23,7,14,-5.0,0.28
3o9i,crystal structure of wild-type hiv-1 protease in complex with af61,31,3779.6,16.70,6,13,-5.0,0.26
5we9,crystal structure of the influenza virus pa endonuclease in complex with inhibitor 7b (sri-29731),14,2087.7,6.41,15,10,0.5,0.64
1q91,crystal structure of human mitochondrial deoxyribonucleotidase in complex with the inhibitor dpb-t,16,2462.0,9.52,19,10,0.5,0.56
3kyq,lipid-induced conformational switch controls fusion activity of longin domain snare ykt6,15,2244.8,8.23,6,12,-3.0,0.60
5edl,crystal structure of an s-component of ecf transporter,11,1485.7,11.42,1,1,0.0,0.09
5dyo,fab43.1 complex with flourescein,17,2504.0,3.90,24,17,0.5,0.76
2bfr,the macro domain is an adp-ribose binding module,23,2590.8,11.08,4,8,-2.0,0.26
6g2m,crystal structure of human mitochondrial 5'(3')-deoxyribonucleotidase in complex with the inhibitor pb-pau,20,2948.7,12.10,21,11,0.0,0.60
6g2l,crystal structure of human mitochondrial 5'(3')-deoxyribonucleotidase in complex with the inhibitor pb-pmtmu,21,3117.3,11.54,24,11,1.0,0.62
3jrs,crystal structure of (+)-aba-bound pyl1,21,3006.8,14.35,11,12,-0.5,0.43
4jx9,crystal structure of the complex of peptidyl t-rna hydrolase from acinetobacter baumannii with uridine at 1.4a resolution,8,1212.3,2.86,10,10,0.5,0.75
4n7u,crystal structure of intracellular b30.2 domain of btn3a1 in complex with chdmapp,9,1550.7,7.53,20,4,4.0,0.56
4jwk,crystal structure of the complex of peptidyl-trna hydrolase from acinetobacter baumannii with cytidine at 1.87 a resolution,13,1714.7,2.94,13,13,1.0,0.62
2c1p,fab-fragment of enantioselective antibody complexed with finrozole,17,2564.9,16.45,10,11,-1.5,0.35
2bfq,macro domains are adp-ribose binding molecules,29,3318.6,10.93,13,14,-1.5,0.34
4w97,structure of ketosteroid transcriptional regulator kstr2 of mycobacterium tuberculosis,20,3290.4,7.92,32,15,2.0,0.65
3pn4,crystal structure of arabidopsis thaliana petide deformylase 1b (atpdf1b) in complex with actinonin (crystallized in peg-550-mme),22,2922.5,7.44,15,18,-2.0,0.59
1qji,structure of astacin with a transition-state analogue inhibitor,23,3177.1,7.81,16,21,-1.5,0.70
3w9r,crystal structure of the high-affinity abscisic acid receptor pyl9/rcar9 bound to aba,19,2782.8,13.45,10,11,-0.5,0.42
4dst,small-molecule ligands bind to a distinct pocket in ras and inhibit sos-mediated nucleotide exchange activity,30,3592.9,8.70,17,20,-3.0,0.57
6gj6,crystal structure of kras g12d (gppcp) in complex with 18,30,3592.9,8.84,17,20,-3.0,0.57
4epy,discovery of small molecules that bind to k-ras and inhibit sos- mediated activation,24,2943.6,9.33,16,15,-1.0,0.54
4dsu,small-molecule ligands bind to a distinct pocket in ras and inhibit sos-mediated nucleotide exchange activity,25,3045.3,7.77,15,18,-3.0,0.60
5fyx,crystal structure of drosophila ncs-1 bound to penothiazine fd16,16,2739.4,20.80,4,3,0.0,0.19
3spf,crystal structure of bcl-xl bound to bm501,13,1869.9,14.20,2,4,-1.0,0.23
3zln,crystal structure of bcl-xl in complex with inhibitor (compound 3),17,2318.3,8.28,20,9,1.0,0.53
6gj8,crystal structure of kras g12d (gppcp) in complex with bi 2852,14,1934.8,5.90,8,11,-2.0,0.57
1u71,understanding the role of leu22 variants in methotrexate resistance: comparison of wild-type and leu22arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and nadph,19,2666.7,10.55,12,11,-1.0,0.47
1kzk,je-2147-hiv protease complex,35,4351.9,17.12,13,15,-4.0,0.31
3p8o,crystal structure of hcv ns3/ns4a protease complexed with des-bromine analogue of bi 201335,20,2639.7,7.08,20,13,0.5,0.60
5ewk,scabin toxin from streptomyces scabies in complex with inhibitor pj34,22,3196.7,10.12,26,16,1.0,0.68
6ncn,fragment-based discovery of an apoe4 stabilizer,10,1497.7,8.60,4,6,-2.0,0.30
5ewy,scabin toxin from streptomyces scabies in complex with inhibitor p6e,19,2639.3,7.96,21,16,0.0,0.74
1lke,engineered lipocalin diga16 in complex with digoxigenin,19,2945.3,11.45,18,14,1.0,0.53
3oaf,"structural and kinetic data for antifolate interactions against pneumocystis jirovecii, pneumocystis carinii and human dihydrofolate reductase and thier active site mutants",17,2453.0,13.88,4,8,-2.0,0.35
1lnm,anticalin diga16 in complex with digitoxigenin,19,2945.3,11.37,18,14,1.0,0.53
6nco,fragment-based discovery of an apoe4 stabilizer,13,1948.9,9.38,9,8,-2.0,0.38
3p8n,crystal structure of hcv ns3/ns4a protease complexed with bi 201335,20,2639.7,7.18,20,13,0.5,0.60
4g95,hdhfr-oag binary complex,17,2377.2,11.52,6,10,-2.0,0.41
1fl3,crystal structure of the blue fluorescent antibody (19g2) in complex with stilbene hapten at 277k,20,2921.2,13.94,11,12,-1.0,0.40
2fxv,bacillus subtilis xanthine phosphoribosyltransferase in complex with guanosine 5'-monophosphate (gmp),21,2847.8,8.19,18,16,0.0,0.52
1erb,the interaction of n-ethyl retinamide with plasma retinol-binding protein (rbp) and the crystal structure of the retinoid-rbp complex at 1.9 angstroms resolution,27,4133.2,23.23,14,11,0.5,0.30
4qrh,molecular mechanism and evolution of guanylate kinase regulation by (p)ppgpp,25,3146.7,4.95,21,14,0.0,0.56
5z7b,crystal structure of the vanr transcription factor in complex with vanillate,17,2486.2,11.29,14,6,2.5,0.41
1a4r,g12v mutant of human placental cdc42 gtpase in the gdp form,19,2415.1,11.69,7,10,-2.0,0.47
4je8,crystal structure of a human-like mitochondrial peptide deformylase in complex with met-ala-ser,8,1058.5,1.68,6,10,-1.0,0.75
4je7,crystal structure of a human-like mitochondrial peptide deformylase in complex with actinonin,21,2907.9,6.58,24,14,1.0,0.62
5ymx,myxococcus xanthus mgla in gdp bound conformation,19,2245.5,9.15,15,6,2.0,0.42
3rlb,crystal structure at 2.0 a of the s-component for thiamin from an ecf- type abc transporter,8,1261.8,7.96,10,2,2.0,0.38
4aci,structure of the c. glutamicum acnr crystal form ii,14,1998.7,7.55,16,10,0.0,0.50
6pvz,e.coli dsba in complex with benzofuran compound 28 ((6-benzyl-1- benzofuran-3-yl)acetic acid),21,2790.2,11.20,15,14,-0.5,0.43
4pop,thit with lmg139 bound,8,1200.6,12.14,0,0,0.0,0.00
2qtn,crystal structure of nicotinate mononucleotide adenylyltransferase,16,2357.3,8.40,12,10,0.0,0.56
1qin,human glyoxalase i complexed with s-(n-hydroxy-n-p- iodophenylcarbamoyl) glutathione,27,4240.2,18.13,24,13,1.5,0.44
2wjg,structure and function of the feob g-domain from methanococcus jannaschii,18,2239.6,7.65,18,11,2.0,0.56
6quv,crystal structure of kras-g12d in complex with gmp-pcp and compound 15r,31,3630.1,7.16,19,22,-3.0,0.58
3qkd,crystal structure of bcl-xl in complex with a quinazoline sulfonamide inhibitor,25,3570.1,15.81,18,11,0.0,0.36
3zk6,crystal structure of bcl-xl in complex with inhibitor (compound 2).,26,3655.4,16.03,18,13,-1.0,0.42
2yxj,crystal structure of bcl-xl in complex with abt-737,24,3510.0,15.79,18,11,0.0,0.38
5c2o,crystal structure of streptococcus mutans deoxycytidylate deaminase complexed with dttp,16,1837.7,2.65,18,15,0.0,0.62
4i7k,t4 lysozyme l99a/m102h with toluene bound,11,1442.5,8.01,10,2,2.0,0.36
3juo,crystal structure of phza/b from burkholderia cepacia r18194 in complex with (r)-5-bromo-2-(piperidin-3-ylamino)benzoic acid,14,2406.2,13.75,17,6,1.5,0.43
3ao4,fragment-based approach to the design of ligands targeting a novel site on hiv-1 integrase,15,1917.4,7.43,12,10,-0.5,0.47
1y0l,catalytic elimination antibody 34e4 in complex with hapten,15,2448.7,11.59,11,11,-0.5,0.47
4i7j,t4 lysozyme l99a/m102h with benzene bound,8,1018.6,5.15,7,2,1.0,0.38
6poi,crystal structure of ecdsba in complex phenyl ether 25,17,2282.7,11.15,10,12,-0.5,0.41
5aan,crystal structure of drosophila ncs-1 bound to penothiazine fd44,17,2967.2,23.92,5,3,0.0,0.18
6epa,structure of dncs-1 bound to the ncs-1/ric8a protein/protein interaction regulator igs-1.76,17,2967.2,24.20,5,3,0.0,0.18
3jup,crystal structure of phza/b from burkholderia cepacia r18194 in complex with (s)-5-bromo-2-(piperidin-3-ylamino)benzoic acid,17,2871.4,16.35,14,8,0.5,0.35
4i7l,t4 lysozyme l99a/m102h with phenol bound,11,1442.5,7.91,10,2,2.0,0.36
3b4p,"crystal structure of phenazine biosynthesis protein phza/b from burkholderia cepacia r18194, complex with 2-(cyclohexylamino)benzoic acid",19,3207.7,16.61,19,8,1.5,0.37
4ahr,parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification,16,2164.1,7.31,15,10,0.5,0.50
4i7p,t4 lysozyme l99a/m102h with 4-bromoimidazole bound,9,1089.7,4.26,10,2,2.0,0.44
3ao5,fragment-based approach to the design of ligands targeting a novel site on hiv-1 integrase,17,2452.3,11.13,18,8,1.5,0.41
4kyk,crystal structure of mouse glyoxalase i complexed with indomethacin,18,2792.7,17.01,6,6,-1.0,0.28
4kyh,crystal structure of mouse glyoxalase i complexed with zopolrestat,14,2277.3,11.34,19,7,2.5,0.50
4pv5,crystal structure of mouse glyoxalase i in complexed with 18-beta- glycyrrhetinic acid,17,2643.5,11.93,25,7,4.5,0.53
1n0s,engineered lipocalin flua in complex with fluorescein,15,2439.8,7.81,22,10,3.0,0.67
4i7m,t4 lysozyme l99a/m102h with 2-allylphenol bound,15,2375.4,15.82,3,3,0.5,0.13
1sld,"streptavidin, ph 7.5, bound to cyclic disulfide-bonded peptide ligand ac-chpqfc-nh2",9,991.9,5.56,4,4,0.0,0.44
3dsz,engineered human lipocalin 2 in complex with y-dtpa,20,2903.3,10.48,20,12,1.0,0.55
3ovn,fragment-based approach to the design of ligands targeting a novel site on hiv-1 integrase,11,1695.3,6.86,7,7,-1.0,0.55
3zsy,small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design,16,2196.5,7.19,13,13,-0.5,0.56
4ahs,parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification,16,2278.9,10.84,13,8,0.5,0.38
4cgi,interrogating hiv integrase for compounds that bind- a sampl challenge,16,2196.5,7.23,13,13,-0.5,0.56
4cjp,interrogating hiv integrase for compounds that bind- a sampl challenge,18,2562.7,8.56,14,15,-1.5,0.56
3zt2,small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design,15,2085.4,7.39,13,11,0.5,0.53
5h1v,complex structure of trim24 phd-bromodomain and inhibitor 6,13,1861.0,12.68,5,5,0.0,0.31
2fw6,"structure of pure (n5-carboxyaminoimidazole ribonucleotide mutase) mutant h59n from the acidophilic bacterium acetobacter aceti, at ph 5.4",15,1571.2,5.19,11,8,0.5,0.40
3tf6,"crystal structure of neutrophil gelatinase-associated lipocalin (c87s mutant) in complex with europium and the siderophore analog tren(cam)(1,2-hopo)2",9,1528.1,6.28,11,2,3.0,0.56
1uv6,x-ray structure of acetylcholine binding protein (achbp) in complex with carbamylcholine,13,2128.2,8.05,12,5,1.0,0.62
3zt3,small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design,16,2223.8,7.37,13,13,-0.5,0.56
3zsx,small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design,16,2196.5,7.25,13,13,-0.5,0.56
1q54,structure and mechanism of action of isopentenylpyrophosphate- dimethylallylpyrophosphate isomerase: complex with the bromohydrine of ipp,18,2525.5,4.30,22,15,-0.5,0.72
4ceb,interrogating hiv integrase for compounds that bind- a sampl challenge,17,2223.2,6.50,13,16,-1.5,0.65
3ao2,fragment-based approach to the design of ligands targeting a novel site on hiv-1 integrase,17,2452.3,10.95,18,8,1.5,0.41
2vnp,monoclinic form of idi-1,18,2595.2,3.58,21,14,-0.5,0.78
4ahu,parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification,14,1884.4,8.62,12,8,0.5,0.43
2za0,crystal structure of mouse glyoxalase i complexed with methyl-gerfelin,17,2853.1,15.52,10,8,0.5,0.35
4cjr,interrogating hiv integrase for compounds that bind- a sampl challenge,15,1968.7,6.66,12,13,-0.5,0.60
4cj4,interrogating hiv integrase for compounds that bind- a sampl challenge,18,2562.7,8.53,14,15,-1.5,0.56
4ck3,interrogating hiv integrase for compounds that bind- a sampl challenge,18,2562.7,8.50,14,15,-1.5,0.56
6eq5,mth1 in complex with fragment 4,10,1691.2,14.52,4,6,-2.0,0.30
6cwn,"crystal structure of spaa-slh/g109a in complex with 4,6-pyr-beta-d- mannacome",13,1986.3,11.57,11,4,1.0,0.38
1srg,structure-based design of synthetic azobenzene ligands for streptavidin,20,2730.7,10.75,13,14,-2.0,0.50
3pcn,"structure of protocatechuate 3,4-dioxygenase complexed with 3,4- dihydroxyphenylacetate",16,2431.0,4.33,23,12,3.0,0.69
4cig,interrogating hiv integrase for compounds that bind- a sampl challenge,15,1968.7,6.67,12,13,-0.5,0.60
4cjq,interrogating hiv integrase for compounds that bind- a sampl challenge,19,2736.1,8.32,19,15,-0.5,0.58
4nyf,hiv integrase in complex with inhibitor,16,2174.0,8.82,13,11,0.5,0.50
4fxp,crystal structure of adenosine 5'-phosphosulfate kinase from arabidopsis thaliana in complex with sulfate and aps,20,2738.5,9.84,22,8,3.0,0.50
3pck,"structure of protocatechuate 3,4-dioxygenase complexed with 6- hydroxynicotinic acid n-oxide",15,2314.9,4.28,22,11,3.0,0.67
5fsn,mth1 substrate recognition: complex with a aminomethylpyrimidinyl oxypropanol.,15,2336.9,14.64,4,6,-2.0,0.27
3zsq,small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design,17,2424.3,8.77,14,13,-0.5,0.53
5fso,mth1 substrate recognition: complex with a methylaminopyrimidinedione.,11,1881.1,14.93,4,6,-2.0,0.27
1df8,s45a mutant of streptavidin in complex with biotin,19,2487.3,11.55,12,11,-1.0,0.42
3pce,"structure of protocatechuate 3,4-dioxygenase complexed with 3- hydroxyphenylacetate",15,2343.4,5.29,22,11,3.0,0.67
3f78,crystal structure of wild type lfa1 i domain complexed with isoflurane,12,2026.2,10.42,8,4,1.0,0.42
6eq2,mth1 in complex with fragment 6,11,1881.1,15.07,4,6,-2.0,0.27
4alx,crystal structure of ls-achbp complexed with the potent nachr antagonist dhbe,16,2658.8,7.31,15,8,1.0,0.62
3pcg,"structure of protocatechuate 3,4-dioxygenase complexed with the inhibitor 4-hydroxyphenylacetate",17,2519.6,5.18,23,12,3.0,0.65
3zso,small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based design,17,2424.3,8.79,14,13,-0.5,0.53
5anv,mth1 in complex with compound 15,23,3593.7,20.83,10,8,-1.0,0.26
6eq3,mth1 in complex with fragment 9,17,2619.6,14.24,9,8,-1.0,0.35
5anu,mth1 in complex with compound 15,23,3615.0,22.01,7,8,-2.0,0.22
6eq7,mth1 in complex with fragment 11,13,2214.7,14.96,5,7,-2.0,0.31
2xda,"structure of helicobacter pylori type ii dehydroquinase in complex with inhibitor compound (4r,6r,7s)-2-(2-cyclopropyl)ethyl-4,6,7- trihydroxy-4,5,6,7-tetrahydrobenzo(b)thiophene-4-carboxylic acid",20,2744.7,8.61,26,11,4.0,0.50
3zdh,"crystal structure of ls-achbp complexed with carbamoylcholine analogue n,n-dimethyl-4-(1-methyl-1h-imidazol-2-yloxy)butan-2-amine",15,2410.4,7.87,13,6,1.0,0.60
3pcj,"structure of protocatechuate 3,4-dioxygenase complexed with 2- hydroxyisonicotinic acid n-oxide",15,2314.9,4.33,22,11,3.0,0.67
4c9x,crystal structure of nudt1 (mth1) with s-crizotinib,17,2617.1,14.03,7,11,-3.0,0.35
1fzq,crystal structure of murine arl3-gdp,20,2544.9,7.25,18,15,0.0,0.65
5cs3,the structure of the nk1 fragment of hgf/sf complexed with (h)epps,10,1639.7,6.58,14,5,1.5,0.50
2nnd,the structural identification of the interaction site and functional state of rbp for its membrane receptor,14,2348.6,17.17,2,2,0.0,0.14
3pcf,"structure of protocatechuate 3,4-dioxygenase complexed with 3-fluro-4- hydroxybenzoate",17,2519.6,5.13,23,12,3.0,0.65
5ct2,the structure of the nk1 fragment of hgf/sf complexed with caps,11,1664.8,6.58,9,7,-0.5,0.45
6ayi,escherichia coli gusr,21,3118.0,12.17,19,10,1.0,0.48
3sio,ac-achbp ligand binding domain (not including beta 9-10 linker) mutated to human alpha-7 nachr,19,2763.8,6.86,17,14,0.0,0.74
6qgg,structure of human bcl-2 in complex with analogue of abt-737,26,3781.0,13.78,18,15,-2.0,0.42
1qy2,thermodynamics of binding of 2-methoxy-3-isopropylpyrazine and 2- methoxy-3-isobutylpyrazine to the major urinary protein,15,2462.7,16.02,4,4,0.0,0.20
3wtn,crystal structure of lymnaea stagnalis acetylcholine binding protein complexed with desnitro-imidacloprid,15,2410.4,7.84,13,6,1.0,0.60
1qy1,thermodynamics of binding of 2-methoxy-3-isopropylpyrazine and 2- methoxy-3-isobutylpyrazine to the major urinary protein,13,2181.9,16.35,2,2,0.0,0.15
6qgh,structure of human bcl-2 in complex with abt-263,27,3914.8,13.83,19,18,-3.0,0.44
5cp9,the structure of the nk1 fragment of hgf/sf complexed with mb605,8,1439.6,5.02,14,5,1.5,0.62
4qac,x-ray structure of acetylcholine binding protein (achbp) in complex with 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl) pyrimidin-2-amine,18,2830.8,9.74,14,7,1.0,0.56
3vw1,crystal strucuture of the crystal violet-bound form of ramr (transcriptional regurator of tetr family) from salmonella typhimurium,20,3023.4,16.66,7,6,0.0,0.40
3t1m,crystal structure of human galectin-3 carbohydrate recognition domain in complex with methyl 3-deoxy-2-o-toluoyl-3-n-toluoyl-beta-d- talopyranoside,13,1752.9,5.53,20,11,1.5,0.62
4k0o,f17b-g lectin domain with bound glcnac(beta1-3)gal,11,1430.0,5.19,13,9,0.0,0.64
3m6r,crystal structure of arabidopsis thaliana peptide deformylase 1b (atpdf1b) g41m mutant in complex with actinonin,21,2909.2,8.61,14,17,-2.0,0.57
3u8l,"crystal structure of the acetylcholine binding protein (achbp) from lymnaea stagnalis in complex with ns3570 (1-(5-phenylpyridin-3-yl)-1, 4-diazepane)",13,2163.5,9.50,14,7,1.0,0.62
2py4,"full length structure of the mycobacterium tuberculosis dutpase complexed with magnesium and alpha,beta-imido-dutp.",10,1375.4,3.50,7,8,-1.0,0.60
1kjr,crystal structure of the human galectin-3 crd in complex with a 3'- derivative of n-acetyllactosamine,6,991.4,4.83,11,4,0.0,0.67
5e89,"crystal structure of human galectin-3 crd in complex with 3- fluophenyl-1,2,3-triazolyl thiodigalactoside inhibitor",16,2231.4,7.86,25,13,1.5,0.62
3vw2,crystal strucuture of the berberine-bound form of ramr (transcriptional regurator of tetr family) from salmonella typhimurium,19,2806.1,12.18,14,7,1.0,0.47
3vvy,crystal strucuture of the ethidium-bound form of ramr (transcriptional regurator of tetr family) from salmonella typhimurium,19,2907.9,14.92,9,6,0.0,0.37
5ouh,humanized alpha-achbp (acetylcholine binding protein) in complex with lobeline.,16,2551.3,10.97,10,8,0.0,0.56
5edd,"crystal structure of mycobacterium tuberculosis dutpase r140k, h145w mutant",10,1375.4,3.59,7,8,-1.0,0.60
5ect,mycobacterium tuberculosis dutpase g143stop mutant,10,1375.4,3.57,7,8,-1.0,0.60
6f20,complex between mth1 and compound 1 (a 7-azaindole-4-ester derivative),16,2451.0,14.55,6,8,-2.0,0.31
6eol,human galectin-3c in complex with a galactose derivative,14,1865.6,7.92,18,9,1.5,0.50
4rhx,structures of mycobacterium tuberculosis 6-oxopurine phosphoribosyltransferase which is a potential target for drug development against this disease,26,3382.0,13.74,15,14,-2.0,0.46
1mmq,matrilysin complexed with hydroxamate inhibitor,17,2283.6,4.10,15,17,1.0,0.65
1mmr,matrilysin complexed with sulfodiimine inhibitor,17,2283.6,4.11,15,17,1.0,0.65
4cs9,crystal structure of the asymmetric human metapneumovirus m2-1 tetramer bound to adenosine monophosphate,9,1254.9,4.04,9,3,1.0,0.67
6eog,human galectin-3c in complex with a galactose derivative,13,1698.9,5.11,18,9,1.5,0.54
4p3h,crystal structure of kaposi's sarcoma-associated herpesvirus (kshv) protease in complex with dimer disruptor,18,2664.4,21.37,2,1,0.0,0.06
6n5x,crystal structure of the snx5 px domain in complex with the ci-mpr (space group p212121 - form 1),6,1035.8,5.68,7,3,0.0,0.50
3f34,"apoferritin: complex with 2,6-diethylphenol",8,1183.1,6.41,7,4,0.0,0.50
1rd4,an allosteric inhibitor of lfa-1 bound to its i-domain,25,4025.7,21.33,9,9,-1.0,0.32
1swr,core-streptavidin mutant w120a in complex with biotin at ph 7.5,19,2567.3,10.96,15,11,0.0,0.47
3f33,apoferritin: complex with propofol,8,1183.1,6.47,7,4,0.0,0.50
5efc,structure of influenza b lee pb2 cap-binding domain bound to gtp,13,2180.3,8.36,20,5,3.0,0.54
4ge1,structure of the tryptamine complex of the amine binding protein of rhodnius prolixus,17,2650.5,9.77,13,12,-1.0,0.53
2usn,crystal structure of the catalytic domain of human fibroblast stromelysin-1 inhibited with thiadiazole inhibitor pnu-141803,15,2123.5,8.01,12,14,1.0,0.53
3u90,apoferritin: complex with sds,9,1321.5,6.50,7,6,-1.0,0.56
2v57,crystal structure of the tetr-like transcriptional regulator lfrr from mycobacterium smegmatis in complex with proflavine,13,1900.5,6.78,14,12,-0.5,0.62
3f37,"apoferritin: complex with 2,6-dimethylphenol",7,1044.7,6.73,7,2,1.0,0.43
4f1l,"human artd8 (parp14, bal2) - catalytic domain in complex with inhibitor a16(z)",14,2159.5,6.69,10,10,0.5,0.57
1b8y,x-ray structure of human stromelysin catalytic domain complexed with non-peptide inhibitors: implications for inhibitor selectivity,22,3226.4,11.87,15,19,0.5,0.50
5efa,structure of influenza b lee pb2 cap-binding domain bound to m7gtp,16,2737.1,8.37,26,11,4.0,0.62
3k8c,complex of trypanosoma cruzi ribose 5-phosphate isomerase type b with 4-deoxy-4-phospho-d-erythronohydroxamic acid,16,2045.3,3.62,20,12,2.5,0.62
1ciz,x-ray structure of human stromelysin catalytic domain complexes with non-peptide inhibitors: implication for inhibitor selectivity,25,3694.8,16.31,15,19,0.5,0.44
5b5f,crystal structure of alis3-streptavidin complex,21,2882.2,12.59,14,12,-1.0,0.43
6qi4,ncs-1 bound to a ligand,16,2744.5,21.45,4,4,-1.0,0.19
3tvc,human mmp13 in complex with l-glutamate motif inhibitor,23,3246.7,13.39,12,14,1.0,0.39
1hfs,"crystal structure of the catalytic domain of human fibroblast stromelysin-1 inhibited with the n-carboxy-alkyl inhibitor l-764,004",25,3673.3,12.50,16,20,0.5,0.48
5b5g,crystal structure of alis4-streptavidin complex,15,2328.7,11.28,12,10,-1.0,0.53
1usn,crystal structure of the catalytic domain of human fibroblast stromelysin-1 inhibited with thiadiazole inhibitor pnu-142372,12,1784.0,6.37,10,12,1.0,0.58
1sln,"crystal structure of the catalytic domain of human fibroblast stromelysin-1 inhibited with the n-carboxy-alkyl inhibitor l-702,842",18,2613.9,8.53,14,16,1.5,0.50
4ciw,"crystal structure of mycobacterium tuberculosis type 2 dehydroquinase in complex with (1r,4r,5r)-1,4,5-trihydroxy-3-(2-hydroxy) ethylcyclohex-2-ene-1-carboxylic acid",16,2126.4,5.79,21,11,3.0,0.56
6hgs,crystal structure of human aprt wild type in complex with gmp,18,2474.3,9.59,13,9,-1.0,0.44
3pgl,crystal structure of human small c-terminal domain phosphatase 1 (scp1) bound to rabeprazole,15,2152.4,7.22,15,9,1.5,0.60
2std,scytalone dehydratase complexed with tight-binding inhibitor carpropamid,24,3789.7,20.31,11,9,1.0,0.25
3n76,crystal structure of 3-dehydroquinate dehydratase from mycobacterium tuberculosis in complex with compound 5,21,2838.4,6.07,31,13,4.0,0.57
6qlq,galectin-3c in complex with fluoroaryltriazole monothiogalactoside derivative 4,15,1971.1,5.75,18,11,0.5,0.60
6qln,galectin-3c in complex with fluoroaryl triazole monothiogalactoside derivative 2,14,1858.4,5.20,18,11,0.5,0.64
6qlt,galectin-3c in complex with fluoroaryltriazole monothiogalactoside derivative-7,15,1971.1,7.32,18,11,0.5,0.60
2xb8,structure of mycobacterium tuberculosis type ii dehydroquinase in complex with inhibitor compound (2r)-2-(4-methoxybenzyl)-3- dehydroquinic acid,19,2639.9,6.50,31,11,5.0,0.58
6qlu,galectin-3c in complex with fluoroaryltriazole monothiogalactoside derivative-8,17,2143.9,7.46,18,11,0.5,0.53
4b6p,structure of mycobacterium tuberculosis type ii dehydroquinase inhibited by (2s)-2-perfluorobenzyl-3-dehydroquinic acid,19,2639.9,6.62,31,11,5.0,0.58
2izl,streptavidin-2-iminobiotin ph 7.3 i222 complex,23,3153.4,11.85,16,17,-2.0,0.52
6qge,galectin-3c in complex with a pair of enantiomeric ligands: s enantiomer,18,2507.8,10.43,23,13,0.5,0.56
6qgf,galectin-3c in complex with a pair of enantiomeric ligands: r enantiomer,17,2396.7,10.81,23,11,1.5,0.53
4y5d,crystal structure of alis2-streptavidin complex,16,2217.2,4.39,30,14,3.0,0.81
4km0,crystal structure of dihydrofolate reductase from mycobacterium tuberculosis in complex with pyrimethamine,16,1875.8,3.77,22,7,3.0,0.50
6qlr,galectin-3c in complex with fluoroaryltriazole monothiogalactoside derivative 5,14,1858.4,5.16,18,11,0.5,0.64
4b6o,structure of mycobacterium tuberculosis type ii dehydroquinase inhibited by (2s)-2-(4-methoxy)benzyl-3-dehydroquinic acid,19,2639.9,6.78,31,11,5.0,0.58
6qlo,galectin-3c in complex with substituted fluoroaryltriazole monothiogalactoside derivative 1,13,1749.9,5.41,18,11,0.5,0.62
6qlp,galectin-3c in complex with substituted polyfluoroaryl monothiogalactoside derivative 3,16,2031.2,6.97,18,11,0.5,0.56
6hgr,crystal structure of human aprt wild type in complex with imp,17,2307.6,8.12,13,9,-1.0,0.47
4y0a,shikimate kinase from acinetobacter baumannii in complex with shikimate,21,3003.0,9.24,22,10,1.0,0.48
6gl8,crystal structure of bcl-2 in complex with the novel orally active inhibitor s55746,19,2781.2,12.43,10,13,-3.0,0.42
2y8c,plasmodium falciparum dutpase in complex with a trityl ligand,17,2315.8,10.02,14,8,1.0,0.47
4y59,crystal structure of alis1-streptavidin complex,17,2371.2,11.11,13,11,-1.0,0.47
3t60,5'-diphenyl nucleoside inhibitors of plasmodium falciparum dutpase,16,2142.4,10.10,9,8,0.0,0.44
6qls,galectin-3c in complex with fluoroaryltriazole monothiogalactoside derivative 6,14,1950.6,5.17,23,11,1.5,0.64
2aac,escherchia coli gene regulatory protein arac complexed with d-fucose,15,2457.3,11.19,15,9,2.0,0.47
4km2,crystal structure of dihydrofolate reductase from mycobacterium tuberculosis in an open conformation in complex with trimethoprim,18,2182.5,5.75,22,7,3.0,0.44
5h1t,complex structure of trim24 phd-bromodomain and inhibitor 1,10,1417.3,9.82,3,3,0.0,0.30
3t70,5'-diphenyl nucleoside inhibitors of plasmodium falciparum dutpase,16,2142.4,10.16,9,8,0.0,0.44
5h1u,complex structure of trim24 phd-bromodomain and inhibitor 2,10,1417.3,9.84,3,3,0.0,0.30
2xd9,"structure of helicobacter pylori type ii dehydroquinase in complex with inhibitor compound (4r,6r,7s)-4,6,7-trihydroxy-2-((e)-prop-1- enyl)-4,5,6,7-tetrahydrobenzo(b)thiophene-4-carboxylic acid",19,2700.0,10.84,20,12,2.0,0.47
5ldp,crystal structure of e.coli ligt complexed with atp,11,1757.9,6.01,21,6,3.5,0.73
1alw,inhibitor and calcium bound domain vi of porcine calpain,12,2026.7,10.98,13,4,2.5,0.33
3t64,5'-diphenyl nucleoside inhibitors of plasmodium falciparum dutpase,16,2142.4,10.03,9,8,0.0,0.44
4b6s,structure of helicobacter pylori type ii dehydroquinase inhibited by (2s)-2-perfluorobenzyl-3-dehydroquinic acid,21,2955.7,12.18,21,13,2.0,0.48
4b6r,structure of helicobacter pylori type ii dehydroquinase inhibited by (2s)-2-(4-methoxy)benzyl-3-dehydroquinic acid,23,3240.2,11.13,26,15,2.0,0.52
2d1n,collagenase-3 (mmp-13) complexed to a hydroxamic acid inhibitor,24,3409.6,13.21,12,14,1.0,0.38
4bqs,crystal structure of mycobacterium tuberculosis shikimate kinase in complex with adp and a shikimic acid derivative.,18,2343.9,5.74,29,8,4.0,0.61
6qz5,structure of mcl-1 in complex with compound 8a,14,2180.2,14.53,8,3,1.5,0.21
1qft,histamine binding protein from female brown ear rhipicephalus appendiculatus,12,1868.0,10.31,4,7,-2.0,0.42
6udu,x-ray co-crystal structure of compound 8 bound to human mcl-1,20,2940.5,18.29,8,3,1.5,0.15
4l19,matrix metalloproteinase-13 complexed with selective inhibitor compound q1,18,2634.6,14.40,6,8,-0.5,0.33
2d1o,stromelysin-1 (mmp-3) complexed to a hydroxamic acid inhibitor,27,3901.9,14.62,18,22,0.5,0.48
3lzz,crystal structures of cupin superfamily bbduf985 from branchiostoma belcheri tsingtauense in apo and gdp-bound forms,12,1821.6,10.04,8,7,-0.5,0.42
6udi,x-ray co-crystal structure of compound 20 with mcl-1,18,2740.4,17.19,8,3,1.5,0.17
6b4u,crystal structure of mcl-1 in complex with a bim competitive inhibitor,19,2851.5,16.49,8,5,0.5,0.21
2nsl,e. coli pure h45n mutant complexed with cair,17,1720.3,5.05,12,9,0.5,0.41
4lhv,crystal structure of rab8 in its inactive gdp-bound form,24,2971.9,5.41,25,16,1.0,0.67
6oqd,crystal structure of mcl1 with inhibitor 8,19,2800.5,17.15,8,3,1.5,0.16
6ud2,co-crystal structure of compound 1 bound to human mcl-1,20,2969.1,15.98,11,3,2.5,0.20
5ant,potent and selective inhibitors of mth1 probe its role in cancer cell survival,24,3753.4,21.62,7,10,-3.0,0.25
2nsj,e. coli pure h45q mutant complexed with cair,16,1689.9,5.34,12,9,0.5,0.44
6udv,x-ray co-crystal structure of compound 3 bound to human mcl-1,18,2740.4,17.09,8,3,1.5,0.17
6udt,x-ray co-crystal structure of compound 10 bound to human mcl-1,18,2740.4,17.10,8,3,1.5,0.17
6o0p,crystal structure of bcl-2 g101a mutation with venetoclax,25,3777.0,12.58,22,16,-2.0,0.48
6o0m,crystal structure of bcl-2 f104l mutation with venetoclax,24,3615.4,12.62,22,14,-1.0,0.46
456c,crystal structure of collagenase-3 (mmp-13) complexed to a diphenyl- ether sulphone based hydroxamic acid,21,3019.4,11.85,11,13,1.0,0.38
3kek,crystal structure of human mmp-13 complexed with a (pyridin-4-yl)-2h- tetrazole compound,26,3696.0,13.13,19,15,2.0,0.50
4ieh,crystal structure of human bcl-2 in complex with a small molecule inhibitor targeting bcl-2 bh3 domain interactions,23,3465.2,13.11,17,14,-2.0,0.43
2xp7,discovery of cell-active phenyl-imidazole pin1 inhibitors by structure-guided fragment evolution,12,1616.9,8.05,11,7,1.0,0.50
4lxd,bcl_2-navitoclax analog (without thiophenyl) complex,21,3148.0,13.70,10,12,-3.0,0.38
3g5k,"structure and activity of human mitochondrial peptide deformylase, a novel cancer target",21,2881.4,7.84,24,14,1.0,0.62
6o0k,crystal structure of bcl-2 with venetoclax,25,3727.6,12.62,23,15,-1.0,0.48
5dus,crystal structure of mers-cov macro domain in complex with adp-ribose,28,3091.8,13.64,10,9,0.5,0.21
6cwh,"crystal structure of spaa-slh in complex with 4,6-pyr-beta-d-mannacome (p1)",13,1994.1,8.62,15,7,1.0,0.54
6d9s,the (p)ppgpp-bound crystal structure of hprt (hypoxanthine phosphoribosyltransferase),25,3398.4,11.62,14,13,-2.0,0.44
6fa4,antibody derived (abd-7) small molecule binding to kras.,30,3435.3,7.81,17,18,-2.0,0.53
966c,crystal structure of fibroblast collagenase-1 complexed to a diphenyl- ether sulphone based hydroxamic acid,21,2895.8,8.86,19,16,2.0,0.52
5mg2,crystal structure of the second bromodomain of human taf1 in complex with bay-299 chemical probe,14,2164.2,9.55,11,10,0.5,0.50
4b0b,crystal structure of 3-hydroxydecanoyl-acyl carrier protein dehydratase (faba) from pseudomonas aeruginosa in complex with 3- (pyridin-2-yloxy)aniline,19,2601.0,10.82,13,9,0.5,0.32
4ai5,crystal structure of y16f of 3-methyladenine dna glycosylase i (tag) in complex with 3-methyladenine,9,1498.2,8.98,6,6,-0.5,0.44
5i1q,second bromodomain of taf1 bound to a pyrrolopyridone compound,16,2438.2,11.04,11,12,-0.5,0.50
3lka,catalytic domain of human mmp-12 complexed with hydroxamic acid and paramethoxy-sulfonyl amide,14,1962.0,9.13,7,9,0.0,0.43
3ehy,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor (r)-2-(4-methoxyphenylsulfonamido)propanoic acid,16,2268.4,8.55,11,13,1.0,0.50
5i29,taf1(2) bound to a pyrrolopyridone compound,14,2164.2,9.23,11,10,0.5,0.50
6b4l,crystal structure of mcl-1 in complex with a bim competitive inhibitor,17,2587.2,17.52,6,1,1.0,0.12
5vkc,crystal structure of mcl-1 in complex with a bim competitive inhibitor,26,3981.3,27.37,11,5,2.0,0.15
4aia,the structural basis of 3-methyladenine recognition by 3- methyladenine dna glycosylase i (tag) from staphylococcus aureus,9,1501.9,7.33,7,7,-0.5,0.56
3ikg,structure-based design of novel pin1 inhibitors (i),16,2254.5,5.35,23,12,3.0,0.75
3lir,human mmp12 in complex with non-zinc chelating inhibitor,20,2603.6,9.79,9,10,-0.5,0.40
2hu6,crystal structure of human mmp-12 in complex with acetohydroxamic acid and a bicyclic inhibitor,18,2456.0,13.08,8,7,0.5,0.33
3tsk,human mmp12 in complex with l-glutamate motif inhibitor,21,2930.9,12.36,12,8,1.5,0.38
4std,high resolution structures of scytalone dehydratase-inhibitor complexes crystallized at physiological ph,24,3735.3,18.28,15,9,2.0,0.29
5std,scytalone dehydratase plus inhibitor 2,25,3888.5,18.95,17,11,2.5,0.32
3n2u,"crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor n-hydroxy-2-(4-methoxy-n(2-(3,4,5-trihydroxy-6- (hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)ethyl)phenylsulfonamido) acetamide",17,2357.0,9.75,11,13,1.0,0.47
7std,scytalone dehydratase plus inhibitor 4,24,3735.3,18.58,15,9,2.0,0.29
1b55,"ph domain from bruton's tyrosine kinase in complex with inositol 1,3, 4,5-tetrakisphosphate",14,2075.8,0.95,34,9,7.0,0.93
6oqb,co-crystal structure of mcl1 with inhibitor 10,23,3440.6,21.12,8,3,1.5,0.13
6o0o,crystal structure of bcl-2 g101v mutation with s55746,15,2306.2,10.01,11,7,-1.0,0.40
3ehx,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor (r)-2-(biphenyl-4-ylsulfonamido)-4-methylpentanoic acid,20,2841.7,9.47,16,15,2.5,0.50
3f15,"crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor (s)-n-(2,3-dihydroxypropyl)-4-methoxy-n-(2- nitroso-2-oxoethyl)benzenesulfonamide",17,2357.0,9.75,11,13,1.0,0.47
3lk8,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor paramethoxy-sulfonyl-glycine hydroxamate,17,2357.0,9.69,11,13,1.0,0.47
4lvt,bcl_2-navitoclax (abt-263) complex,24,3548.2,14.54,15,12,-2.0,0.38
4gr8,crystal structure of the catalytic domain of human mmp12 in complex with selective phosphinic inhibitor rxp470c,22,2990.4,10.27,16,15,2.5,0.45
3n2v,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor n-hydroxy-2-(n-hydroxyethyl)biphenyl-4- ylsulfonamido)acetamide,18,2525.6,9.66,14,13,2.0,0.50
6oqc,crystal structure of mcl1 with inhibitor 9,20,2953.7,17.03,10,5,2.0,0.20
3f19,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor 4-fluoro-n-(2-nitroso-2-oxoethyl) benzenesulfonamide,17,2357.0,9.73,11,13,1.0,0.47
6std,scytalone dehydratase plus inhibitor 3,24,3735.3,18.61,15,9,2.0,0.29
5ldm,crystal structure of e.coli ligt complexed with 2'-amp,17,2466.7,7.95,26,12,3.0,0.71
3f1a,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor n-(2-nitroso-2-oxoethyl)benzenesulfonamide,16,2190.3,8.08,11,13,1.0,0.50
3f18,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor 4-fluoro-n-(2-hydroxyethyl)-n-(2-nitroso-2- oxoethyl)benzenesulfonamide,17,2357.0,9.71,11,13,1.0,0.47
4gr3,crystal structure of the catalytic domain of human mmp12 in complex with selective phosphinic inhibitor rxp470a,23,3106.5,9.67,17,16,2.5,0.48
3std,scytalone dehydratase and cyanocinnoline inhibitor,25,3925.2,19.92,15,9,2.0,0.28
3ljg,human mmp12 in complex with non-zinc chelating inhibitor,19,2516.1,12.81,8,7,0.5,0.32
4efs,human mmp12 in complex with l-glutamate motif inhibitor,23,3225.4,13.17,17,13,3.0,0.43
3tmk,crystal structure of yeast thymidylate kinase complexed with the bisubstrate inhibitor tp5a at 2.0 a resolution: implications for catalysis and azt activation,34,4801.6,9.85,44,22,3.0,0.68
3ikd,structure-based design of novel pin1 inhibitors (i),19,2594.3,4.78,26,14,3.0,0.74
3nx7,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor n-hydroxy-2-(n-(2-hydroxyethyl)4- methoxyphenylsulfonamido)acetamide,17,2357.0,9.69,11,13,1.0,0.47
3m3c,crystal structure of agrocybe aegerita lectin aal complexed with p- nitrophenyl tf disaccharide,7,1046.8,3.00,12,6,0.0,0.71
4jal,crystal structure of trna (um34/cm34) methyltransferase trml from escherichia coli with sah,12,1477.9,4.81,12,6,1.0,0.67
5d3x,"crystal structure of the p-rex1 ph domain with inositol-(1,3,4,5)- tetrakisphosphate bound",12,1731.7,3.03,25,6,5.0,0.75
1rmz,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor nngh at 1.3 a resolution,17,2357.0,9.73,11,13,1.0,0.47
5czm,crystal structure of a mutated catalytic domain of human mmp12 in complex with rxp470,28,3786.6,12.63,22,18,2.5,0.46
3f17,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor n-(2-nitroso-2-oxoethyl)biphenyl-4-sulfonamide,17,2357.0,9.76,11,13,1.0,0.47
5cxa,crystal structure of the catalytic domain of human mmp12 in complex with a carboxylate inhibitor related to rxp470,25,3378.9,13.59,19,13,3.0,0.40
3f16,crystal structure of the catalytic domain of human mmp12 complexed with the inhibitor (r)-n-(3-hydroxy-1-nitroso-1-oxopropan-2-yl)-4- methoxybenzenesulfonamide,17,2357.0,9.76,11,13,1.0,0.47
4rdn,structure of yth-ythdf2 in complex with m6a,15,2185.9,4.66,18,13,0.0,0.80
4kax,crystal structure of the grp1 ph domain in complex with arf6-gtp,28,3272.1,12.10,16,16,-1.0,0.50
3ts4,human mmp12 in complex with l-glutamate motif inhibitor,22,3136.8,12.32,17,13,3.0,0.45
4gr0,crystal structure of the catalytic domain of human mmp12 in complex with selective phosphinic inhibitor rxp470b,26,3612.1,12.20,24,15,4.5,0.46
5d3c,crystal structure of a double mutant catalytic domain of human mmp12 in complex with an hydroxamate analogue of rxp470,28,3796.3,12.99,20,16,2.0,0.43
6b7b,crystal structure of e.coli phosphopantetheine adenylyltransferase (ppat/coad) in complex with 5-methoxy-2-methyl-1h-indole,11,1489.6,8.65,8,5,0.0,0.36
1cgl,structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor,33,4284.8,9.14,27,30,-1.0,0.64
4in9,structure of karilysin mmp-like catalytic domain in complex with inhibitory tetrapeptide swfp,5,701.3,5.33,2,2,0.0,0.40
6chp,"phosphopantetheine adenylyltransferase (coad) in complex with methyl (r)-4-(3-(2-cyano-1-((5-methyl-1h-imidazo[4,5-b]pyridin-2-yl)amino) ethyl)benzyl)piperidine-1-carboxylate",23,3016.1,13.34,15,11,0.0,0.43
1zvx,crystal structure of the complex between mmp-8 and a phosphonate inhibitor (r-enantiomer),22,3069.6,9.35,19,16,2.0,0.50
6ckw,"phosphopantetheine adenylyltransferase (coad) in complex with (r)-3- ((7-(((s)-2-amino-2-(2-methoxyphenyl)ethyl)amino)-5-methyl-[1,2, 4]triazolo[1,5-a]pyrimidin-2-yl)amino)-3-(3-chlorophenyl) propanenitrile",19,2508.6,11.73,13,10,0.0,0.42
6b7a,crystal structure of e.coli phosphopantetheine adenylyltransferase (ppat/coad) in complex with 2-methyl-1h-benzo[d]imidazol-4-ol,8,1139.7,8.68,2,4,-1.0,0.25
1zs0,crystal structure of the complex between mmp-8 and a phosphonate inhibitor (s-enantiomer),23,3243.0,9.40,24,16,3.0,0.52
3tt4,human mmp8 in complex with l-glutamate motif inhibitor,25,3600.1,10.50,25,17,3.0,0.52
4k7n,human peroxiredoxin 5 with a fragment,14,1808.8,7.53,13,2,3.0,0.43
6gjr,cyclophilin a complexed with tri-vector ligand 9.,20,2544.6,8.24,21,16,2.0,0.50
5lud,"structure of cyclophilin a in complex with 2,3-diaminopyridine",12,1194.5,1.81,11,11,0.0,0.58
1jaq,complex of 1-hydroxylamine-2-isobutylmalonyl-ala-gly-nh2 with the catalytic domain of matrix metallo proteinase-8 (met80 form),19,2614.0,9.72,13,15,1.0,0.47
4zcs,crystal structure of the c-terminal catalytic domain of plasmodium falciparum ctp:phosphocholine cytidylyltransferase in complex with cdp-choline,25,3454.5,5.71,25,24,-0.5,0.72
6gjm,cyclophilin a complexed with tri-vector ligand 4.,18,2230.5,7.50,18,13,1.5,0.50
6gjj,cyclophilin a complexed with tri-vector ligand 2.,17,2141.5,7.60,17,12,1.5,0.47
2gzl,"structure of 2c-methyl-d-erythritol 2,4-clycodiphosphate synthase complexed with a cdp derived fluorescent inhibitor",18,2367.0,5.84,12,19,-2.5,0.67
3ljz,crystal structure of human mmp-13 complexed with an amino-2-indanol compound,25,3473.5,17.97,11,15,0.0,0.36
3q7q,crystal structure of rad g-domain q148a-gtp analog complex,20,2211.4,7.08,17,10,1.0,0.50
6gjl,cyclophilin a complexed with tri-vector ligand 10.,20,2544.6,8.42,21,16,2.0,0.50
4k7i,human peroxiredoxin 5 with a fragment,13,1642.1,7.03,13,2,3.0,0.46
5t9w,discovery of a potent cyclophilin inhibitor (compound 5) based on structural simplification of sanglifehrin a,17,2349.4,9.80,17,9,2.5,0.41
6gji,cyclophilin a complexed with the tri-vector ligand 8.,19,2393.4,8.21,18,13,1.5,0.47
5t9z,discovery of a potent cyclophilin inhibitor (compound 6) based on structural simplification of sanglifehrin a,18,2502.1,9.83,20,15,2.0,0.50
4k7o,human peroxiredoxin 5 with a fragment,16,1957.9,6.89,14,3,3.0,0.44
6gjn,cyclophilin a complexed with tri-vector ligand 15.,22,2879.9,8.87,24,16,3.0,0.50
1jao,complex of 3-mercapto-2-benzylpropanoyl-ala-gly-nh2 with the catalytic domain of matrix metallo proteinase-8 (met80 form),24,3377.8,9.07,26,20,3.0,0.58
5ta4,discovery of a potent cyclophilin inhibitor (compound 8) based on structural simplification of sanglifehrin a,18,2448.1,9.71,18,13,2.0,0.44
5ta2,discovery of a potent cyclophilin inhibitor (compound 7) based on structural simplification of sanglifehrin a,18,2502.1,9.79,20,15,2.0,0.50
3nq9,bovine beta-lactoglobulin complex with caprylic acid,13,2054.6,15.39,6,2,1.0,0.23
3ueu,bovine beta-lactoglobulin complex with lauric acid,17,2750.3,21.31,6,0,2.0,0.12
3nq3,bovine beta-lactoglobulin complex with capric acid,16,2525.8,22.95,0,0,0.0,0.00
3uev,bovine beta-lactoglobulin complex with myristic acid,19,3001.4,21.64,6,2,1.0,0.16
6r8l,"human cyclophilin d in complex with 1-((1s,9s,10s)-10-hydroxy-12-oxa- 8-aza-tricyclo[7.3.1.02,7]trideca-2,4,6-trien-4-ylmethyl)-3- {2-[(r)- 2-(2-methylsulfanyl-phenyl)-pyrrolidin-1-yl]-2-oxo-ethyl}-urea",23,2888.3,8.39,27,14,3.5,0.52
3nw3,crystal structure of the complex of peptidoglycan recognition protein (pgrp-s) with the pgn fragment at 2.5 a resolution,18,2080.2,10.61,13,9,1.5,0.33
6r9u,human cyclophilin d in complex with fragment,15,1596.6,1.83,19,11,2.0,0.60
6r8w,"human cyclophilin d in complex with 2-(exo-3,5-dioxo-4-aza- tricyclo[5.2.1.02,6]dec-4-yl)-n-((1r,9r,10s)-10-hydroxy-12-oxa-8-aza- tricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ylmethyl)-acetamide",22,2715.9,8.51,24,14,2.5,0.50
6ge7,"thermodynamic, crystallographic and computational studies of non mammalian fatty acid binding to bovine b-lactoglobulin",22,3528.2,24.04,9,0,3.0,0.14
6r8o,"human cyclophilin d in complex with 1-(((2r,3s,6r)-3-hydroxy-2,3,4,6- tetrahydro-1h-2,6-methanobenzo[c][1,5]oxazocin-8-yl)methyl)-3-(2- ((r)-2-(2-(methylthio)phenyl)pyrrolidin-1-yl)-2-oxoethyl)urea",23,2882.6,9.06,24,14,2.5,0.48
3umq,crystal structure of peptidoglycan recognition protein-s complexed with butyric acid at 2.2 a resolution,6,669.4,5.06,0,0,0.0,0.50
4gny,bovine beta-lactoglobulin complex with dodecyl sulfate,19,3001.4,21.30,6,2,1.0,0.16
6qi7,engineered beta-lactoglobulin: variant l39y in complex with endogenous ligand,17,2722.0,19.52,6,2,1.0,0.18
3usx,crystal structure of pgrp-s complexed with myristic acid at 2.28 a resolution,10,1229.1,10.74,10,0,2.0,0.30
6euw,crystal structure of the cap-binding domain of the pb2 subunit of influenza a/h5n1 polymerase bound to an azaindazole inhibitor,17,2574.3,8.25,24,13,3.0,0.65
1gx8,"bovine beta-lactoglobulin complexed with retinol, trigonal lattice z",16,2422.8,14.10,8,4,1.0,0.31
5lne,e. coli f9 pilus adhesin fmlh bound to the thomsen-friedenreich (tf) antigen,7,954.2,3.93,6,8,-1.0,0.71
4gql,crystal structure of the catalytic domain of human mmp12 in complex with selective phosphinic inhibitor rxp470.1,29,3967.2,12.10,20,20,1.5,0.48
6ghh,"thermodynamic, crystallographic and computational studies of non mammalian fatty acid binding to bovine b-lactoglobulin",19,3001.4,21.53,6,2,1.0,0.16
6r9x,human cyclophilin d in complex with n-cyclopentyl-n'-pyridin-2- ylmethyl-oxalamide,14,1851.2,8.02,14,9,1.5,0.43
3uex,bovine beta-lactoglobulin complex with stearic acid,22,3498.0,24.57,6,2,1.0,0.14
6gfs,"thermodynamic, crystallographic and computational studies of non mammalian fatty acid binding to bovine b-lactoglobulin",19,3001.4,21.65,6,2,1.0,0.16
3uew,bovine beta-lactoglobulin complex with palmitic acid,18,2834.7,22.19,6,2,1.0,0.17
2gj5,crystal structure of a secondary vitamin d3 binding site of milk beta- lactoglobulin,19,2741.6,18.79,9,5,1.0,0.26
6gf9,"thermodynamic, crystallographic and computational studies of non mammalian fatty acid binding to bovine b-lactoglobulin",22,3473.7,23.28,8,2,2.0,0.14
6arn,f9 pilus adhesin fmlh lectin domain from e. coli uti89 co-crystallized with o-methoxyphenyl beta-galactoside (ompg),17,2291.8,7.27,18,15,-1.0,0.65
6arm,f9 pilus adhesin fmlh lectin domain from e. coli uti89 co-crystallized with o-nitrophenyl beta-galactoside (onpg),17,2281.3,9.67,13,15,-2.0,0.59
2bet,"structure of mycobacterium tuberculosis ribose-5-phosphate isomerase, rpib, rv2465c, in complex with 4-phospho-d-erythronate.",18,2157.7,2.03,27,16,2.5,0.67
2bes,"structure of mycobacterium tuberculosis ribose-5-phosphate isomerase, rpib, rv2465c, in complex with 4-phospho-d-erythronohydroxamic acid.",18,2157.7,1.99,27,16,2.5,0.67
6aro,f9 pilus adhesin fmlh lectin domain from e. coli uti89 co-crystallized with 8-hydroxyquinoline beta-galactoside,16,2125.1,5.46,18,15,-1.0,0.69
1ex8,"crystal structure of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase complexed with hp4a, the two-substrate-mimicking inhibitor",29,4197.7,13.18,40,15,3.5,0.52
4f7v,crystal structure of e. coli hppk in complex with bisubstrate analogue inhibitor j1d (hp26),29,4281.7,12.13,36,20,2.0,0.59
3ng4,ternary complex of peptidoglycan recognition protein (pgrp-s) with maltose and n-acetylglucosamine at 1.7 a resolution,15,1718.5,8.37,11,9,0.0,0.40
4fnn,crystal structure of the complex of cpgrp-s with stearic acid at 2.2 a resolution,15,1809.7,9.12,12,6,0.0,0.53
4kow,crystal structure of a gnat superfamily acetyltransferase pa4794 in complex with cefoxitin,20,3053.9,8.49,21,11,2.5,0.60
3o4k,crystal structure of the complex of peptidoglycan recognition protein (pgrp-s) and lipoteichoic acid at 2.1 a resolution,39,5095.3,10.73,47,29,3.5,0.62
2p3i,crystal structure of rhesus rotavirus vp8* at 295k,9,1328.0,1.46,13,5,2.0,0.78
4q0k,crystal structure of phytohormone binding protein from medicago truncatula in complex with gibberellic acid (ga3),19,3034.4,13.10,10,12,-1.0,0.47
3uil,crystal structure of the complex of pgrp-s with lauric acid at 2.2 a resolution,8,998.9,7.05,10,2,1.0,0.50
1hi5,eosinophil-derived neurotoxin (edn) - adenosine-5'-diphosphate complex,15,2324.6,8.36,24,15,3.5,0.67
5e13,crystal structure of eosinophil-derived neurotoxin in complex with the triazole double-headed ribonucleoside 11c,14,1900.6,6.21,16,11,0.5,0.71
1hi3,eosinophil-derived neurotoxin (edn) - adenosine 2'-5'-diphosphate complex,13,1939.3,6.87,22,11,3.0,0.69
1hi4,eosinophil-derived neurotoxin (edn) - adenosien-3'-5'-diphosphate complex,20,2920.9,8.58,24,15,2.0,0.65
5u49,"wild-type transthyretin in complex with 5-[(1e)-2-(2-chloro-4- hydroxyphenyl)ethenyl]-1,3-benzenediol",9,1167.9,5.66,7,4,1.0,0.56
5kcb,the structure of sav2435 bound to ethidium bromide,15,2201.6,6.71,10,11,-1.0,0.53
4mmm,human pdrx5 complex with a ligand bp7,12,1625.5,10.02,7,2,1.0,0.33
2w9h,wild-type staphylococcus aureus dhfr in complex with trimethoprim,19,2652.1,15.03,9,11,-0.5,0.37
6ne5,discovery of potent myeloid cell leukemia-1 (mcl-1) inhibitors that demonstrate in vivo activity in mouse xenograft models of human cancer,25,3532.2,17.36,14,11,1.5,0.28
5kat,the structure of sav2435 bound to tetraphenylphosphonium,18,2580.1,14.98,12,9,2.5,0.33
6sge,crystal structure of human rhob-gtp in complex with nanobody b6,36,4544.0,11.65,25,21,0.0,0.56
3tay,crystal structure of porcine rotavirus crw-8 vp8* in complex with n- glycolylneuraminic acid,14,1803.4,1.53,17,14,0.5,0.79
6f05,"arabidopsis thaliana gstf9, gso3 bound",19,2560.6,10.38,20,9,2.5,0.53
3cft,crystal structure of human transthyretin in complex with 1-amino-5- naphthalene sulfonate,6,768.2,5.02,4,1,1.0,0.33
3ed0,crystal structure of (3r)-hydroxyacyl-acyl carrier protein dehydratase (fabz) from helicobacter pylori in complex with emodin,12,2009.7,11.97,11,5,1.5,0.42
3cfn,crystal structure of human transthyretin in complex with 1-anilino-8- naphthalene sulfonate,7,962.8,6.50,5,2,1.0,0.43
5u4b,wild-type transthyretin in complex with 3-[(1e)-2-(4-hydroxyphenyl) ethenyl]benzoic acid,8,1000.4,4.36,6,3,1.0,0.50
4des,crystal structure of the wild type ttr binding chrysin (ttrwt:chr),8,1051.8,5.49,6,3,1.0,0.50
3cf8,crystal structure of (3r)-hydroxyacyl-acyl carrier protein dehydratase (fabz) from helicobacter pylori in complex with quercetin,15,2424.2,16.10,14,1,3.0,0.27
3kgt,v30m mutant human transthyretin (ttr) complexed with genistein (v30m:gen) ph 7.5,10,1278.8,6.09,6,5,0.0,0.50
4ad6,synthesis and sar of guanine based analogues for hppk inhibitors,15,1885.5,7.75,8,9,-1.0,0.40
4cl6,"crystal structure of 3-hydroxydecanoyl-acyl carrier protein dehydratase (faba) from pseudomonas aeruginosa in complex with n-(4- chlorobenzyl)-3-(2-furyl)-1h-1,2,4-triazol-5-amine",24,3298.5,14.40,15,11,0.5,0.33
6fs1,mcl1 in complex with an indole acid ligand,18,2740.4,17.62,8,3,1.5,0.17
4det,crystal structure of the wild type ttr binding kaempferol (ttrwt:kae),9,1140.4,5.88,6,3,1.0,0.44
6aox,f9 pilus adhesin fmlh lectin domain from e. coli uti89 co-crystallized with tf antigen,6,871.1,2.19,9,6,0.0,0.83
4der,crystal structure of the wild type ttr binding apigenin (ttrwt:api),9,1140.4,5.72,6,3,1.0,0.44
3nee,wild type human transthyretin (ttr) complexed with gc-1 (ttrwt:gc-1),10,1278.8,6.01,6,5,0.0,0.50
3b7j,crystal structure of (3r)-hydroxyacyl-acyl carrier protein dehydratase(fabz) from helicobacter pylori complexed with juglone,7,1143.0,8.84,6,1,1.0,0.29
3kgu,wild type human transthyretin (ttr) complexed with genistein (ttrwt:gen) ph 7.5,9,1190.2,5.85,6,5,0.0,0.56
4dew,crystal structure of the wild type ttr binding luteolin (ttrwt:lut),10,1256.5,5.70,7,4,1.0,0.50
1e4h,structure of human transthyretin complexed with bromophenols: a new mode of binding,8,1051.8,5.60,6,3,1.0,0.50
3neo,wild type human transthyretin (ttr) complexed with gc-24 (ttrwt:gc-24),12,1594.9,7.28,8,7,0.5,0.50
5u4d,wild-type transthyretin in complex with 3-[(1e)-2-(2-chloro-4- hydroxyphenyl)ethenyl]benzoic acid,11,1394.9,5.85,7,6,0.0,0.55
2glp,crystal structure of (3r)-hydroxyacyl-acyl carrier protein dehydratase(fabz) from helicobacter pylori complexed with compound 1,12,1952.7,11.75,14,3,2.0,0.42
2b9a,"human transthyretin (ttr) complexed with diflunisal analogues- ttr.3', 5'-difluorobiphenyl-4-carboxylic acid",8,1051.8,5.70,6,3,1.0,0.50
5h9r,crystal structure of human galectin-3 crd in complex with taztdg,14,1950.6,5.13,23,11,1.5,0.64
2f7i,"human transthyretin (ttr) complexed with diflunisal analogues- ttr. 2',6'-difluorobiphenyl-4-carboxylic acid",8,1000.4,4.40,6,3,1.0,0.50
1bm7,human transthyretin (prealbumin) complex with flufenamic acid (2-[[3- (trifluoromethyl)phenyl]amino] benzoic acid),11,1345.5,5.75,8,5,1.0,0.55
3nes,v30m mutant human transthyretin (ttr) complexed with gc-1 (v30m:gc-1),11,1441.7,7.56,6,5,0.0,0.45
2drc,investigation of the functional role of tryptophan-22 in escherichia coli dihydrofolate reductase by site-directed mutagenesis,20,2858.6,10.22,19,7,2.0,0.45
2g5u,"human transthyretin (ttr) complexed with hydroxylated polychlorinated biphenyl-4,4'-dihydroxy-3,3',5,5'-tetrachlorobiphenyl",9,1116.5,4.04,7,4,1.0,0.56
3qbc,structure and design of a new pterin site inhibitor of s. aureus hppk,13,1714.3,8.51,8,7,0.0,0.38
2ra6,crystal structure of the possum milk whey lipocalin trichosurin at ph 4.6 with bound 4-ethylphenol,13,1945.3,16.04,3,3,0.0,0.15
2fqo,"crystal structure of b. subtilis luxs in complex with (2s)-2-amino-4- [(2r,3r)-2,3-dihydroxy-3-n- hydroxycarbamoyl-propylmercapto]butyric acid",12,1523.1,4.75,9,13,-1.0,0.67
4deu,crystal structure of the wild type ttr binding naringenin (ttrwt:nar),12,1539.1,5.70,9,6,1.0,0.58
3elc,"crystal structure of 2c-methyl-d-erythritol 2,4-clycodiphosphate synthase complexed with ligand",19,2648.2,15.56,19,4,3.0,0.37
3p3r,"transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)(2- fluorophenyl)methanone",10,1256.5,5.87,7,4,1.0,0.50
5kax,the structure of ctr107 protein bound to rhodamine 6g,19,2796.3,12.01,8,14,-2.5,0.47
3p3t,"human transthyretin (ttr) complexed with 4-(3-(2-flourophenoxy) propyl)-3,5-dimethyl-1h-pyrazole",10,1256.5,5.87,7,4,1.0,0.50
3nex,v30m mutant human transthyretin (ttr) complexed with gc-24 (v30m:gc- 24),11,1441.7,7.71,6,5,0.0,0.45
2fqt,"crystal structure of b.subtilis luxs in complex with (2s)-2-amino-4- [(2r,3s)-2,3-dihydroxy-3-n-hydroxycarbamoyl-propylmercapto]butyric acid",12,1523.1,4.70,9,13,-1.0,0.67
3p3s,"human transthyretin (ttr) complexed with (z)-5-(3,5-dibromo-4- hydroxybenzylidene)-imino-1-methylimidazolidin-4-one",10,1256.5,5.80,7,4,1.0,0.50
5ayt,crystal structure of transthyretin in complex with l6,9,1190.2,5.82,6,5,0.0,0.56
6as8,f9 pilus adhesin fmlh lectin domain from e. coli uti89 co-crystallized with ortho-biphenyl-2'-carboxyl n-acetyl-beta-galactosaminoside,25,3146.1,12.18,19,16,-1.0,0.48
1g85,crystal structure of bovine odorant binding protein complexed with is natural ligand,15,2326.9,13.74,7,7,0.0,0.33
4qew,"crystal structure of brd2(bd2) mutant with ligand et bound (methyl (2r)- 2-[(4s)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4h-[1,2, 4]triazolo[4,3-a][1, 4]benzodiazepin-4-yl]butanoate)",13,1949.5,11.70,5,6,-1.0,0.38
4d7b,structure of human transthyretin in complex with tolcapone,11,1345.5,5.81,8,5,1.0,0.55
6fmc,"neuropilin1-b1 domain in complex with eg01377, 0.9 angstrom structure",11,1581.1,3.18,9,9,-1.0,0.73
1dhi,long-range structural effects in a second-site revertant of a mutant dihydrofolate reductase,19,2720.4,10.85,19,5,3.0,0.42
4mr6,crystal structure of the second bromodomain of human brd2 in complex with a quinazolinone ligand (rvx-208),13,2019.5,12.48,7,6,0.5,0.38
2d0k,methionine-free mutant of escherichia coli dihydrofolate reductase,18,2682.4,10.90,18,6,2.0,0.44
4qev,"crystal structure of brd2(bd2) mutant with ligand me bound (methyl (2r)- 2-[(4s)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4h-[1,2, 4]triazolo[4,3-a][1, 4]benzodiazepin-4-yl]propanoate)",13,1949.5,11.76,5,6,-1.0,0.38
6k04,crystal structure of brd2(bd2)with ligand by27 bound,16,2462.1,11.89,10,8,0.5,0.44
1dhj,long-range structural effects in a second-site revertant of a mutant dihydrofolate reductase,19,2720.4,10.66,19,5,3.0,0.42
1ws1,structure analysis of peptide deformylase from bacillus cereus,21,2624.7,9.09,13,14,-1.0,0.48
4rlw,crystal structure of (3r)-hydroxyacyl-acp dehydratase hadab hetero- dimer from mycobacterium tuberculosis complexed with butein,17,2334.8,10.43,13,15,-1.0,0.59
4rlu,"crystal structure of (3r)-hydroxyacyl-acp dehydratase hadab hetero- dimer from mycobacterium tuberculosis complexed with 2',4,4'- trihydroxychalcone",16,2220.7,10.41,11,13,-1.0,0.56
5ijr,x-ray structure of neuropilin-1 b1 domain complexed with arg-1 ligand.,4,731.1,2.39,4,3,0.0,0.75
4c5d,crystal structure of bcl-xl in complex with benzoylurea compound (42),22,3263.4,15.97,10,7,0.0,0.23
1adl,adipocyte lipid binding protein complexed with arachidonic acid: x-ray crystallographic and titration calorimetry studies,21,2625.8,11.61,18,7,2.0,0.52
1g74,"toward changing specificity: adipocyte lipid binding protein mutant, oleic acid bound form",21,2998.5,13.52,18,7,2.0,0.48
4c52,crystal structure of bcl-xl in complex with benzoylurea compound (39b),21,3149.3,16.20,8,5,0.0,0.19
3zlr,crystal structure of bcl-xl in complex with inhibitor (wehi-539),22,3072.5,8.38,22,13,0.0,0.55
3hk1,identification and characterization of a small molecule inhibitor of fatty acid binding proteins,21,3032.1,12.75,22,6,3.0,0.48
5jhk,x-ray structure of neuropilin-1 b1 domain complexed with arg-6 ligand.,17,2391.8,8.40,12,12,-1.0,0.59
4psb,crystal structure of phytohormone binding protein from vigna radiata in complex with gibberellic acid (ga3),19,3053.5,14.76,8,10,-1.0,0.42
5jgi,x-ray structure of neuropilin-1 b1 domain complexed with m45 compound,14,2024.0,9.76,9,9,-1.0,0.57
1dzk,porcine odorant binding protein complexed with pyrazine (2-isobutyl-3- metoxypyrazine),15,2273.6,14.44,6,6,0.0,0.27
5jgq,x-ray structure of neuropilin-1 b1 domain complexed with arg-7 ligand.,19,2590.9,9.27,11,11,-1.0,0.58
6t1j,crystal structure of mllt1 (enl) yeats domain in complexed with piperazine-urea derivative 2,20,2724.7,11.08,15,14,-0.5,0.55
6t1l,crystal structure of mllt1 (enl) yeats domain in complexed with piperazine-urea derivative 3,19,2613.6,10.86,15,12,0.5,0.53
4rlt,crystal structure of (3r)-hydroxyacyl-acp dehydratase hadab hetero- dimer from mycobacterium tuberculosis complexed with fisetin,18,2456.7,7.94,15,17,-1.0,0.67
3rdq,crystal structure of r7-2 streptavidin complexed with desthiobiotin,18,2233.6,8.66,13,13,-1.0,0.56
3brn,crystal structure of am182 serotonin complex,15,2288.9,13.34,4,7,-2.0,0.33
1dud,deoxyuridine 5'-triphosphate nucleotide hydrolase (d-utpase) complexed with the substrate analogue deoxyuridine 5'-diphosphate (d-udp),12,1704.3,7.62,6,8,-1.0,0.42
3rdo,crystal structure of r7-2 streptavidin complexed with biotin,17,2144.6,8.73,12,12,-1.0,0.53
6hax,crystal structure of protac 2 in complex with the bromodomain of human smarca2 and pvhl:elonginc:elonginb,34,5291.8,24.52,29,19,2.0,0.41
5t7s,crystal structure of galectin-8n in complex with lactose,4,713.0,3.55,11,2,1.0,0.75
6hpw,crystal structure of enl (mllt1) in complex with compound 20,16,2172.6,9.10,15,7,1.5,0.50
6t1i,crystal structure of mllt1 (enl) yeats domain in complexed with piperazine-urea derivative 1,18,2423.4,9.87,15,12,0.5,0.56
5y13,crystal structure of human fabp4 complexed with ligand 5-((4- bromonaphthalene)-1-sulfonamido)pentanoic acid,22,3222.8,14.69,20,9,1.0,0.45
5iyy,x-ray structure of neuropilin-1 b1 domain complexed with arg-4 ligand.,16,2333.7,8.86,11,11,-1.0,0.62
6ht1,crystal structure of mllt1 (enl) yeats domain in complexed with sgc- imllt (compound 92),16,2172.6,9.01,15,7,1.5,0.50
6t1n,crystal structure of mllt1 (enl) yeats domain in complexed with benzimidazole-amide derivative 5,14,1901.2,6.64,15,7,1.5,0.50
6t1m,crystal structure of mllt1 (enl) yeats domain in complexed with benzimidazole-amide derivative 4,15,2015.3,6.60,17,9,1.5,0.53
5y12,crystal structure of human fabp4 complexed with ligand 5-((4- methoxynaphthalene)-1-sulfonamido)pentanoic acid,23,3362.8,15.42,20,9,1.0,0.43
6t1o,crystal structure of mllt1 (enl) yeats domain in complexed with benzimidazole-amide derivative 6,15,2039.6,6.67,15,9,0.5,0.53
5d45,"crystal structure of fabp4 in complex with 3-(5-cyclopropyl-2,3- diphenyl-1h-indol-1-yl)propanoic acid",26,3709.9,14.23,28,9,4.0,0.50
5d47,crystal structure of fabp4 in complex with 3-[5-cyclopropyl-3-(3- methoxypyridin-4-yl)-2-phenyl-1h-indol-1-yl] propanoic acid,27,3768.4,12.56,28,11,3.0,0.52
6hay,crystal structure of protac 1 in complex with the bromodomain of human smarca2 and pvhl:elonginc:elonginb,35,5404.5,25.72,29,19,2.0,0.40
6ajv,crystal structure of brd4 in complex with isoliquiritigenin and dmso (cocktail no. 3),11,1624.1,10.47,6,6,-1.0,0.36
5x74,"the crystal structure pde delta in complex with compound (r, r)-1g",33,4991.2,27.74,16,8,1.0,0.27
6ajy,"crystal structure of brd4 in complex with 2',4'-dihydroxy-2- methoxychalcone",13,1904.9,11.42,8,8,-1.0,0.38
5l4m,"crystal structure of human transthyretin in complex with 3,5,6- trichloro-2-pyridinyloxyacetic acid (triclopyr)",10,1280.4,6.90,6,3,1.0,0.40
5l4j,"crystal structure of human transthyretin in complex with 4,4'- dihydroxydiphenyl sulfone (bisphenol s, bps)",11,1340.5,6.00,7,6,0.0,0.55
5boj,crystal structure of human transthyretin in complex with gemfibrozil,11,1345.5,6.14,8,5,1.0,0.55
5d48,"crystal structure of fabp4 in complex with 3-{5-cyclopropyl-3-(3,5- dimethyl-1h-pyrazol-4-yl)-2-[3-(propan-2-yloxy) phenyl]-1h-indol-1- yl}propanoic acid",31,4396.8,12.36,33,18,2.5,0.58
4fht,crystal structure of the pcav transcriptional regulator from streptomyces coelicolor in complex with its natural ligand,15,2155.2,8.45,16,10,2.5,0.47
5l4i,crystal structure of human transthyretin in complex with clonixin,9,1089.4,4.39,7,4,1.0,0.56
5en3,crystal structure of human transthyretin in complex with luteolin-cl at 1.25 a resolution,13,1646.8,7.64,8,7,0.0,0.54
2gl0,structure of pae2307 in complex with adenosine,16,2304.2,12.03,12,11,1.0,0.44
5t9u,discovery of a potent cyclophilin inhibitor (compound 3) based on structural simplification of sanglifehrin a,22,3255.6,14.97,23,11,4.0,0.41
5hz6,fabp4 in complex with 6-chloro-2-isopropyl-4-(3-isopropyl-phenyl)- quinoline-3-carboxylic acid,25,3470.0,10.11,28,14,2.0,0.60
5edc,human fabp4 in complex with 6-chloro-4-phenyl-2-piperidin-1-yl- quinoline-3-carboxylic acid at 1.29a,22,3073.7,10.39,24,8,3.0,0.55
6p9e,crystal structure of il-36gamma complexed to a-552,16,2416.2,12.56,16,7,1.0,0.50
2hnx,crystal structure of ap2,21,2955.7,12.44,20,7,2.0,0.48
6o5g,calmodulin in complex with isomalbrancheamide d,11,1760.1,15.72,0,0,0.0,0.00
5edb,human fatty acid binding protein 4 in complex with 6-chloro-2-methyl- 4-phenyl-quinoline-3-carboxylic acid at 1.18a,20,2817.6,9.63,23,7,3.0,0.55
6ooy,asymmetric htnf-alpha,20,2941.7,11.19,9,9,0.0,0.40
1lrh,crystal structure of auxin-binding protein 1 in complex with 1- naphthalene acetic acid,10,1469.9,6.59,12,9,1.0,0.60
5ihh,crystal structure of human transthyretin in complex with luteolin-meo at 1.35 a resolution,12,1407.2,5.81,9,6,1.0,0.58
6eeb,calmodulin in complex with malbrancheamide,11,1760.1,15.88,0,0,0.0,0.00
2ans,adipocyte lipid binding protein complexed with 1-anilino-8-naphthalene sulfonate,20,2891.0,12.73,21,8,2.0,0.50
3kqr,the structure of serum amyloid p component bound to phosphoethanolamine,6,793.9,1.91,8,7,0.0,0.83
5hbn,clpc n-terminal domain with bound phospho-arginine,21,2573.1,9.72,17,15,-0.5,0.52
2qm9,troglitazone bound to fatty acid binding protein 4,25,3513.0,13.10,25,11,2.0,0.52
3oyw,crystal structure of human galectin-1 in complex with thiodigalactoside,8,1214.2,3.65,14,10,1.0,0.75
3oy8,crystal structure of human galectin-1 in complex with lactobionic acid,7,1005.6,1.30,13,7,0.5,0.86
5twj,crystal structure of rlmh in complex with s-adenosylmethionine,23,3061.1,14.38,9,9,-0.5,0.30
4mre,crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule,8,1047.2,2.11,10,9,-1.0,0.75
4np2,crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule,10,1280.7,2.12,15,9,0.0,0.70
6dl2,brd4 bromodomain 1 in complex with hyb157,13,2054.3,12.09,5,6,-1.0,0.38
4np3,crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule,10,1280.7,2.12,15,9,0.0,0.70
3bu1,crystal structure of monomine-histamine complex,11,1655.9,6.38,5,8,-2.0,0.55
4ozj,glnk2 from haloferax mediterranei complexed with adp,13,1565.3,3.89,16,4,3.0,0.54
5f8y,crystal structure of a crenomytilus grayanus lectin in complex with galactosamine,11,1424.7,1.71,14,11,1.5,0.64
4mrg,crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule,9,1200.4,2.07,12,11,-0.5,0.78
4g0z,crystal structure of arabidopsis thaliana ago1 mid domain in complex with gmp,12,1749.9,2.47,17,8,3.5,0.83
4g0y,crystal structure of arabidopsis ago1 in complex with amp,12,1701.5,2.87,17,8,3.5,0.75
2pql,crystal structure of anopheles gambiae d7r4-tryptamine complex,15,2352.4,7.66,14,12,-1.5,0.60
4g0q,crystal structure of arabidopsis thaliana ago1 mid domain in complex with cmp,12,1752.5,2.25,17,10,2.5,0.83
5xg5,crystal structure of mitsuba-1 with bound nacgal,11,1396.7,1.65,14,10,1.5,0.64
5f2u,structure of fully modified farnesylated inpp5e peptide in complex with pde6d,24,3699.9,22.33,12,5,1.0,0.25
5y94,crystal structure analysis of the brd4,13,2054.3,12.05,5,6,-1.0,0.38
4g0p,crystal structure of arabidopsis thaliana ago1 mid domain in complex with ump,12,1752.5,2.21,17,10,2.5,0.83
2w47,"clostridium thermocellum cbm35 in complex with delta-4,5- anhydrogalacturonic acid",2,341.9,3.54,3,2,0.0,0.50
5d0c,crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand,13,2054.3,12.11,5,6,-1.0,0.38
5yqx,crystal structure analysis of the brd4,13,2054.3,12.24,5,6,-1.0,0.38
5e8f,structure of fully modified geranylgeranylated pde6c peptide in complex with pde6d,27,3979.3,22.92,14,8,1.0,0.33
4p5d,crystal structure of rat dnph1 (rcl) with 6-naphthyl-purine-riboside- monophosphate,24,3030.5,11.23,13,14,-1.5,0.46
5cy9,crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand,13,2054.3,12.06,5,6,-1.0,0.38
5cp5,crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand,13,2054.3,12.17,5,6,-1.0,0.38
5n1z,crystal structure of the bcl6 btb domain in complex with pyrazolo- pyrimidine macrocyclic ligand,13,1642.5,4.09,9,13,-1.5,0.69
1h6h,structure of the px domain from p40phox bound to phosphatidylinositol 3-phosphate,17,2641.7,7.20,28,14,3.0,0.71
5y8y,crystal structure analysis of the brd4,13,2054.3,12.12,5,6,-1.0,0.38
5cqt,crystal structure of the first bromodomain of human brd4 in complex with benzo[cd]indol-2(1h)-one ligand,13,2054.3,11.91,5,6,-1.0,0.38
2c94,"lumazine synthase from mycobacterium tuberculosis bound to 3-(1,3,7- trihydro-9-d-ribityl-2,6,8-purinetrione-7-yl) 1,1 difluoropentane-1- phosphate",28,3713.5,15.13,24,14,2.0,0.39
2c92,"lumazine synthase from mycobacterium tuberculosis bound to 3-(1,3,7- trihydro-9-d-ribityl-2,6,8-purinetrione-7-yl) pentane 1 phosphate",29,3857.3,14.38,26,16,2.0,0.41
3w9k,crystal structure of thermoacidophile-specific protein stk_08120 complexed with myristic acid,19,2707.0,11.06,17,6,3.5,0.42
2yek,crystal structure of the first bromodomain of human brd2 with the inhibitor gsk525762 (ibet),14,2222.9,11.26,8,6,0.0,0.43
2ydw,crystal structure of the first bromodomain of human brd2 with the inhibitor gw841819x,15,2309.2,11.03,7,10,-2.0,0.47
1kyv,lumazine synthase from s.pombe bound to riboflavin,21,3111.0,17.76,16,10,1.0,0.33
2c97,"lumazine synthase from mycobacterium tuberculosis bound to 4-(6- chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)butyl phosphate",20,2803.1,8.88,24,12,3.0,0.50
2amt,"structure of 2c-methyl-d-erythritol 2,4-clycodiphosphate synthase complexed with a cdp derived fluorescent inhibitor",29,3813.4,14.19,20,19,0.5,0.48
3wzn,crystal structure of the core streptavidin mutant v21 (y22s/n23d/s27d/y83s/r84k/e101d/r103k/e116n) complexed with biotin at 1.3 a resolution,18,2389.9,9.72,10,15,-4.0,0.56
3alt,crystal structure of cel-iv complexed with melibiose,9,1245.0,5.53,8,7,0.0,0.56
6bbx,crystal structure of tnms3 in complex with tnm c,24,3494.2,16.08,21,13,1.5,0.33
5hz5,fabp5 in complex with 6-chloro-4-phenyl-2-piperidin-1-yl-3-(1h- tetrazol-5-yl)-quinoline,22,3089.2,12.27,18,7,2.0,0.45
5km9,human histidine triad nucleotide binding protein 2 (hhint2) adenosine complex,17,2619.9,13.89,15,11,1.5,0.41
4w9f,"pvhl:elob:eloc in complex with (2s,4r)-1-(3,3-dimethylbutanoyl)-4- hydroxy-n-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 5)",16,2610.1,10.68,17,10,2.0,0.50
4w9l,"pvhl:elob:eloc in complex with (2s,4r)-1-((s)-2-((s)-2-acetamido-3,3- dimethylbutanamido)-3,3-dimethylbutanoyl)-4-hydroxy-n-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 15)",18,2921.5,13.22,23,11,3.0,0.50
4uyf,n-terminal bromodomain of human brd2 with i-bet726 (gsk1324726a),13,2111.8,12.08,8,4,1.0,0.38
5btx,structure of the n-terminal domain of lpg1496 from legionella pneumophila in complex with nucleotide,10,1336.4,3.54,10,10,0.5,0.70
5ogb,human cellular retinoic acid binding protein ii (crabpii) with bound synthetic retinoid dc360.,21,2986.7,16.50,18,5,2.0,0.33
5umy,crystal structure of tnms3 in complex with tiancimycin,22,3180.8,15.26,16,13,0.5,0.32
4w9d,"pvhl:elob:eloc in complex with (2s,4r)-1-(3,3-dimethylbutanoyl)-4- hydroxy-n-(4-(4-methyloxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 3)",16,2634.0,13.68,16,9,2.0,0.44
5umx,crystal structure of tnms3 in complex with riboflavin,14,2211.1,12.81,14,12,0.5,0.43
2hmu,diamond-shaped octameric ring structure of an rck domain with atp bound,25,3014.7,9.40,19,12,1.0,0.40
4rra,n-terminal editing domain of threonyl-trna synthetase from aeropyrum pernix with l-thr3aa (snapshot 1),22,3113.8,12.68,14,7,2.5,0.36
2xde,crystal structure of the complex of pf-3450074 with an engineered hiv capsid n terminal domain,16,2211.5,5.10,17,16,0.5,0.62
6j3o,crystal structure of the human pcaf bromodomain in complex with compound 12,14,2120.5,6.81,9,9,-1.0,0.57
2hmv,diamond-shaped octameric ring structure of an rck domain with adp bound,23,2816.2,9.87,19,10,2.0,0.39
6g24,x-ray structure of nsd3-pwwp1 in complex with compound 3,12,1777.8,6.44,12,12,0.5,0.58
5j1x,x-ray structure of neuropilin-1 b1 domain complexed with arg-5 ligand.,15,2140.1,9.74,10,10,-1.0,0.60
5ovc,pdz domain from rat shank3 bound to the c terminus of gkap,8,1009.9,2.06,10,6,1.5,0.62
4rr6,n-terminal editing domain of threonyl-trna synthetase from aeropyrum pernix with l-ser3aa (snapshot 1),21,2945.2,13.32,11,7,1.5,0.33
6g2e,x-ray structure of nsd3-pwwp1 in complex with compound 13,11,1641.0,6.97,12,8,0.0,0.55
1ucn,x-ray structure of human nucleoside diphosphate kinase a complexed with adp at 2 a resolution,18,2568.9,7.88,19,11,0.0,0.56
6g27,x-ray structure of nsd3-pwwp1 in complex with compound 5,12,1830.9,8.67,12,8,0.0,0.50
6g29,x-ray structure of nsd3-pwwp1 in complex with compound 6,11,1641.0,7.06,12,8,0.0,0.55
4w9j,"pvhl:elob:eloc in complex with (2s,4r)-1-((s)-2-((s)-2-acetamido-4- methylpentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-n-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 13)",18,2921.5,13.27,23,11,3.0,0.50
6g2f,x-ray structure of nsd3-pwwp1 in complex with compound 16,13,1952.8,6.66,17,10,0.0,0.62
4bkt,"von hippel lindau protein:elonginb:elonginc complex, in complex with (2s,4r)-n-methyl-1-[2-(3-methyl-1,2-oxazol-5-yl)ethanoyl]-4-oxidanyl- pyrrolidine-2-carboxamide",10,1715.6,5.79,16,9,2.0,0.70
6g2b,x-ray structure of nsd3-pwwp1 in complex with compound 8,10,1552.4,6.02,12,8,0.0,0.60
4w9i,"pvhl:elob:eloc in complex with (2s,4r)-1-((2s,4r)-1-acetyl-4- hydroxypyrrolidine-2-carbonyl)-4-hydroxy-n-(4-(4-methylthiazol-5-yl) benzyl)pyrrolidine-2-carboxamide (ligand 10)",17,2750.1,12.95,17,10,2.0,0.47
5fe9,crystal structure of human pcaf bromodomain in complex with compound sl1122 (compound 13),13,1892.7,5.32,8,9,-1.0,0.62
6g2c,x-ray structure of nsd3-pwwp1 in complex with compound 9,11,1641.0,6.90,12,8,0.0,0.55
5yz2,the cystathionine-beta-synthase (cbs) domain of magnesium and cobalt efflux protein corc in complex with both c2'- and c3'-endo amp,16,2258.2,8.90,12,11,-0.5,0.50
5lvr,crystal structure of human pcaf bromodomain in complex with compound-e (cpd-e),11,1700.8,7.12,6,7,-1.0,0.55
4w9c,"pvhl:elob:eloc in complex with (2s,4r)-1-(3,3-dimethylbutanoyl)-4- hydroxy-n-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 2)",15,2494.0,11.18,16,9,2.0,0.47
1vyg,schistosoma mansoni fatty acid binding protein in complex with arachidonic acid,28,4024.9,15.78,27,11,3.0,0.46
6g2o,x-ray structure of nsd3-pwwp1 in complex with compound bi-9321,13,1952.8,6.73,17,10,0.0,0.62
5fe7,crystal structure of human pcaf bromodomain in complex with fragment zb2216 (fragment 11),12,1754.3,6.28,8,7,0.0,0.58
5fe6,crystal structure of human pcaf bromodomain in complex with fragment zb1916 (fragment 10),10,1473.0,5.56,5,7,-1.0,0.60
6g25,x-ray structure of nsd3-pwwp1 in complex with compound 4,10,1528.3,6.17,12,8,0.0,0.60
5lvq,"crystal structure of human pcaf bromodomain in complex with compound-d (cpd-d), n-methyl-2-(tetrahydro-2h-pyran-4-yloxy)benzamide",13,1951.9,7.32,6,9,-2.0,0.54
4w9k,"pvhl:elob:eloc in complex with (2s,4r)-1-((s)-2-((s)-2-acetamido-3- phenylpropanamido)-3,3-dimethylbutanoyl)-4-hydroxy-n-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 14)",19,3037.6,12.45,24,12,3.0,0.53
1hmt,1.4 angstroms structural studies on human muscle fatty acid binding protein: binding interactions with three saturated and unsaturated c18 fatty acids,26,3776.8,12.68,28,12,3.0,0.54
1vyf,schistosoma mansoni fatty acid binding protein in complex with oleic acid,23,3297.7,13.22,23,10,2.0,0.48
5hz8,"fabp4_3 in complex with 6,8-dichloro-4-phenyl-2-piperidin-1-yl- quinoline-3-carboxylic acid",22,3236.3,12.89,23,7,3.0,0.45
5htl,structure of mshe with cdg,21,2947.8,9.34,28,11,2.0,0.52
6e5t,crystal structure of human cellular retinol binding protein 1 in complex with abnormal-cannabidiorcin (abn-cbdo),25,3697.3,15.72,24,11,3.0,0.40
4tkb,the 0.86 angstrom x-ray structure of the human heart fatty acid- binding protein complexed with lauric acid,10,1219.6,4.48,7,6,0.0,0.60
3wvm,the 0.88 angstrom x-ray structure of the human heart fatty acid- binding protein complexed with stearic acid,25,3610.1,11.18,28,12,3.0,0.56
1hms,1.4 angstroms structural studies on human muscle fatty acid binding protein: binding interactions with three saturated and unsaturated c18 fatty acids,26,3776.8,12.97,28,12,3.0,0.54
4tjz,the 0.87 angstrom x-ray structure of the human heart fatty acid- binding protein complexed with capric acid,10,1219.6,4.49,7,6,0.0,0.60
4bks,"von hippel lindau protein:elonginb:elonginc complex, in complex with (2s,4r)-1-ethanoyl-n-[[4-(1,3-oxazol-5-yl)phenyl]methyl]-4-oxidanyl- pyrrolidine-2-carboxamide",14,2350.2,11.77,14,7,2.0,0.43
4tkh,the 0.93 angstrom x-ray structure of the human heart fatty acid- binding protein complexed with myristic acid,10,1219.6,4.50,7,6,0.0,0.60
5yyf,"crystal structure of af9 yeats domain in complex with a peptide inhibitor ""phq-h3(q5-k9)"" modified at k9 with 2-furancarboyl group",7,1012.4,4.32,7,7,1.0,0.57
5hwu,crystal structure of dr2231_e46a mutant in complex with dumpnpp and manganese,20,3014.1,10.09,22,15,0.5,0.60
1hmr,1.4 angstroms structural studies on human muscle fatty acid binding protein: binding interactions with three saturated and unsaturated c18 fatty acids,26,3813.9,13.80,29,13,3.5,0.54
5hbs,crystal structure of human cellular retinol binding protein 1 in complex with all-trans-retinol at 0.89 angstrom.,32,4946.7,22.74,21,12,2.0,0.34
4w9h,"pvhl:elob:eloc in complex with (2s,4r)-1-((s)-2-acetamido-3,3- dimethylbutanoyl)-4-hydroxy-n-(4-(4-methylthiazol-5-yl)benzyl) pyrrolidine-2-carboxamide (ligand 7)",19,3037.6,12.53,24,12,3.0,0.53
5ha1,crystal structure of human cellular retinol binding protein 1 in complex with retinylamine,30,4590.1,20.33,21,12,2.0,0.37
4tkj,the 0.87 angstrom x-ray structure of the human heart fatty acid- binding protein complexed with palmitic acid,26,3813.9,13.31,29,13,3.5,0.54
6gfz,"pvhl:elob:eloc in complex with modified vh032 containing (3s,4s)-3- fluoro-4-hydroxyproline (ligand 14b)",19,3037.6,12.55,24,12,3.0,0.53
6e5l,crystal structure of human cellular retinol binding protein 1 in complex with abnormal-cannabidiol (abn-cbd),28,4231.0,15.00,30,12,4.0,0.43
5duw,crystal structure of the human galectin-4 n-terminal carbohydrate recognition domain in complex with lactose-3'-sulfate,15,2167.7,9.49,21,8,2.5,0.47
3ap4,crystal structure of the galectin-8 n-terminal carbohydrate recognition domain in complex with lactose,3,539.6,3.56,6,2,0.0,0.67
5lli,pvhl:elob:eloc in complex with vh298,19,3037.6,12.80,24,12,3.0,0.53
1ugx,crystal structure of jacalin- me-alpha-t-antigen (gal-beta(1-3)- galnac-alpha-o-me) complex,10,1509.6,7.30,3,4,-1.0,0.30
5n17,first bromodomain (bd1) from candida albicans bdf1 bound to a dibenzothiazepinone (compound 3),14,2096.6,12.18,8,5,1.5,0.36
5nvv,"pvhl:elob:eloc in complex with (2s,4r)-4-hydroxy-1-((s)-2-(2- hydroxyacetamido)-3,3-dimethylbutanoyl)-n-(4-(4-methylthiazol-5-yl) benzyl)pyrrolidine-2-carboxamide (ligand 3)",19,3037.6,12.47,24,12,3.0,0.53
4np9,structure of rabphilin c2a domain bound to ip3,11,1598.4,1.49,18,9,3.0,0.82
4uoh,crystallographic structure of nucleoside diphosphate kinase from litopenaeus vannamei complexed with adp,17,2465.5,7.94,24,10,2.5,0.59
5nw0,"pvhl:elob:eloc in complex with (2s,4r)-1-((s)-2-(1- acetamidocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-n- (4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 17)",19,3037.6,12.87,24,12,3.0,0.53
4b9k,"pvhl-elob-eloc complex_(2s,4r)-1-(3-amino-2-methylbenzoyl)-4-hydroxy- n-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide bound",17,2800.0,13.15,17,10,2.0,0.47
5nvw,"pvhl:elob:eloc in complex with (2s,4r)-1-((s)-2- (cyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-n-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 6)",19,3037.6,12.55,24,12,3.0,0.53
4nnr,fkbp13-fk506 complex,20,3048.3,15.75,13,8,0.0,0.35
6fmj,"pvhl:elob:eloc in complex with (2s,4r)-1-((s)-2- acetamidopropanethioyl)-4-hydroxy-n-(4-(4-methylthiazol-5-yl) benzyl)pyrrolidine-2-carboxamide (ligand 3)",16,2634.0,13.56,16,9,2.0,0.44
4kxn,crystal structure of dnph1 (rcl) with kinetine riboside monophosphate,26,3509.8,12.65,18,14,0.5,0.46
5nw2,"pvhl:elob:eloc in complex with (2s,4r)-1-((s)-3,3-dimethyl-2-(oxetane- 3-carboxamido)butanoyl)-4-hydroxy-n-(4-(4-methylthiazol-5-yl)benzyl) pyrrolidine-2-carboxamide (ligand 19)",19,3037.6,12.83,24,12,3.0,0.53
2vsl,crystal structure of xiap bir3 with a bivalent smac mimetic,4,662.3,4.09,6,2,1.5,0.50
5nvx,"pvhl:elob:eloc in complex with (2s,4r)-1-((s)-2-(1- fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-n-(4- (4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 10)",19,3037.6,12.56,24,12,3.0,0.53
3qlm,crystal structure of porcine pancreatic phospholipase a2 in complex with n-hexadecanoic acid,15,2221.5,11.69,10,5,1.0,0.40
5nw1,"pvhl:elob:eloc in complex with (2s,4r)-1-((s)-2- (cyclobutanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-n-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 18)",19,3037.6,12.79,24,12,3.0,0.53
4uof,crystallographic structure of nucleoside diphosphate kinase from litopenaeus vannamei complexed with dadp,18,2603.9,7.94,24,12,1.5,0.61
3f7i,structure of an ml-iap/xiap chimera bound to a peptidomimetic,14,2121.3,6.33,17,8,1.0,0.57
1mai,structure of the pleckstrin homology domain from phospholipase c delta in complex with inositol trisphosphate,11,1762.0,3.68,28,5,5.0,0.82
6gxg,tryparedoxin from trypanosoma brucei in complex with cft,13,2006.2,14.24,5,5,-2.0,0.31
4qpl,crystal structure of rnf146(ring-wwe)/ubch5a/iso-adpr complex,17,2753.2,7.88,33,5,6.0,0.59
3gta,structure of an ml-iap/xiap chimera bound to a peptidomimetic,14,2121.3,6.36,17,8,1.0,0.57
4wk1,crystal structure of staphylococcus aureus psta in complex with c-di- amp,11,1496.9,7.39,11,6,1.0,0.45
2i3i,structure of an ml-iap/xiap chimera bound to a peptidomimetic,14,2121.3,6.24,17,8,1.0,0.57
3f7h,structure of an ml-iap/xiap chimera bound to a peptidomimetic,14,2121.3,6.34,17,8,1.0,0.57
4tu4,"crystal structure of atad2a bromodomain complexed with 3-(3,5- dimethyl-1,2-oxazol-4-yl)-5-[(phenylsulfonyl)amino]benzoicacid",15,2186.8,7.67,13,9,0.0,0.53
3uw5,crystal structure of the bir domain of mliap bound to gdc0152,9,1081.4,3.18,11,3,2.0,0.56
3qx9,crystal structure of mid domain from hago2 in complex with atp,14,2031.7,2.10,22,7,5.0,0.79
4qsu,structure of the bromodomain of human atpase family aaa domain- containing protein 2 (atad2) in complex with thymine,9,1366.5,9.28,4,4,0.0,0.33
4tz2,fragment-based screening of the bromodomain of atad2,15,2225.1,9.89,9,8,0.0,0.47
6s56,"crystal structure of human atad2 bromodomain in complex with n-(4- chloro-3-(n,n-dimethylsulfamoyl)phenyl)-2-(2,5-dioxo-3',4'-dihydro- 2'h-spiro[imidazolidine-4,1'-naphthalen]-1-yl)acetamide",16,2312.1,9.61,9,12,-2.0,0.50
3gt9,structure of an ml-iap/xiap chimera bound to a peptidomimetic,14,2121.3,6.27,17,8,1.0,0.57
3a6t,crystal structure of mutt-8-oxo-dgmp complex,19,2728.0,12.12,17,6,2.5,0.32
4tte,"crystal structure of atad2a bromodomain complexed with methyl 3-amino- 5-(3,5-dimethyl-1,2-oxazol-4-yl)benzoate",13,1932.3,8.26,12,6,1.0,0.46
6gnr,crystal structure of sea bream transthyretin in complex with 2-(3- chloro-2-methylanilino)pyridine-3-carboxylic acid (clonixin),7,989.5,5.08,5,2,1.0,0.43
4hp0,crystal structure of hen egg white lysozyme in complex with gn3-m,11,1781.1,12.69,7,6,-1.0,0.27
5a5q,"crystal structure of human atad2 bromodomain in complex with 3-methyl- 8-piperidin-4-ylamino-1,2-dihydro-1,7-naphthyridin-2-one hydrochloride",12,1647.2,7.52,4,10,-3.0,0.50
3sm2,the crystal structure of xmrv protease complexed with amprenavir,32,4088.4,16.02,14,18,-1.0,0.38
4qsv,structure of the bromodomain of human atpase family aaa domain- containing protein 2 (atad2) in complex with thymidine,12,1728.7,9.53,4,8,-2.0,0.42
4hpi,crystal structure of hen egg white lysozyme complex with gn2-m,9,1530.0,11.35,7,4,0.0,0.22
5lsh,human lysozyme in complex with a tetrasaccharide fragment of the o- chain of lps from klebsiella pneumoniae,8,1335.7,7.29,13,3,1.0,0.50
3hl5,crystal structure of xiap bir3 with cs3,11,1722.6,4.17,12,8,0.0,0.64
2i3h,structure of an ml-iap/xiap chimera bound to a 4-mer peptide (avpw),5,869.5,4.32,8,4,2.0,0.60
6s57,"crystal structure of human atad2 bromodomain in complex withn-(3- (azepan-1-ylsulfonyl)-4-methylphenyl)-2-(4,4-dimethyl-2,5- dioxoimidazolidin-1-yl)acetamide",18,2625.5,9.75,14,12,-1.0,0.50
6j3p,"crystal structure of the human gcn5 bromodomain in complex with compound (r,r)-36n",14,2120.5,6.84,9,9,-1.0,0.57
1m48,crystal structure of human il-2 complexed with (r)-n-[2-[1- (aminoiminomethyl)-3-piperidinyl]-1-oxoethyl]-4-(phenylethynyl)-l- phenylalanine methyl ester,13,2009.4,7.73,13,4,2.0,0.46
5mlj,"bromodomain of human gcn5 with 4-bromo-2-methyl-5-(((3r,5r)-1-methyl- 5-phenylpiperidin-3-yl)amino)pyridazin-3(2h)-one",14,2120.5,6.87,9,9,-1.0,0.57
3x00,crystal structure of the core streptavidin mutant v212 (y22s/n23d/s27d/s45n/y83s/r84k/e101d/r103k/e116n) complexed with bis iminobiotin long tail (bis-imntail) at 1.3 a resolution,16,2489.5,11.62,11,10,-2.0,0.50
5a81,"crystal structure of human atad2 bromodomain in complex with 8-(3r,4r) -3-(cyclohexylmethoxy)piperidin-4-yl-amino-3-methyl-1,2-dihydro-1,7- naphthyridin-2-one",15,2162.3,8.35,14,8,0.0,0.47
1wn6,crystal structure of blasticidin s deaminase (bsd) complexed with tetrahedral intermediate of blasticidin s,18,2311.0,7.52,13,13,-2.0,0.67
3f8c,crystal structure of multidrug binding transcriptional regulator lmrr complexed with hoechst 33342,11,1700.4,16.38,5,4,0.0,0.18
4zzd,crystal structure of multidrug resistance regulator lmrr bound to riboflavin,8,1152.7,12.63,1,2,-1.0,0.12
5chk,crystal structure of avidin - haba complex (hexagonal crystal form),18,2603.1,11.81,16,11,1.0,0.56
3slz,the crystal structure of xmrv protease complexed with tl-3,40,5523.6,23.67,28,18,1.0,0.35
5lyn,structure of the tpr domain of sgt2 in complex with yeast ssa1 peptide fragment,3,416.2,2.15,0,4,-2.0,0.67
5g2g,crystal structure of ketosteroid isomerase containing m116k mutation in the equilenin-bound form,16,2400.7,12.34,6,6,-1.0,0.31
1fao,"structure of the pleckstrin homology domain from dapp1/phish in complex with inositol 1,3,4,5-tetrakisphosphate",14,2073.1,4.16,28,4,6.0,0.64
3f7g,structure of the bir domain from ml-iap bound to a peptidomimetic,14,2121.3,6.33,17,8,1.0,0.57
4muv,"m. loti cyclic-nucleotide binding domain mutant displaying inverted ligand selectivity, cyclic-gmp bound",25,3142.9,12.65,21,10,1.0,0.44
3fwv,"crystal structure of a redesigned tpr protein, t-mod(vmy), in complex with meevf peptide",6,926.4,1.58,10,3,2.0,0.83
4zyf,discovery of nvp-cgm097 - a highly potent and selective mdm2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: hdm2 (mdm2) complexed with nvp-cgm097,21,3343.6,13.32,17,14,2.0,0.43
4mdn,structure of a novel submicromolar mdm2 inhibitor,20,3202.2,17.75,8,10,-0.5,0.30
1ogz,crystal structure of 5-3-ketosteroid isomerase mutants p39a complexed with equilenin from pseudomonas testosteroni,16,2412.4,15.11,3,7,-2.0,0.31
6n3y,human histidine triad nucleotide binding protein 1 (hint1) with bound 5'-o-[(3-indolyl)-1-ethyl]carbamoyl guanosine,25,3583.0,13.88,24,20,2.5,0.48
4rrg,editing domain of threonyl-trna synthetase from methanococcus jannaschii with l-thr3aa,23,3223.6,13.17,12,10,0.5,0.39
1hn4,"prophospholipase a2 dimer complexed with mj33, sulfate, and calcium",31,4700.2,21.39,20,10,1.5,0.39
5ipc,human histidine triad nucleotide binding protein 1 (hhint1) h112n mutant nucleoside thiophosphoramidate substrate complex,25,3543.9,13.59,24,20,2.0,0.48
4tun,crystal structure of chicken egg white lysozyme adduct with organophosphorus pesticide monochrotophos,14,2008.5,10.93,10,12,-2.0,0.43
6cq1,bcl6 btb domain in complex with 15a,24,3200.6,8.25,24,22,-1.0,0.62
4wt2,co-crystal structure of mdm2 in complex with am-7209,23,3541.2,16.43,15,12,2.0,0.39
5kma,human histidine triad nucleotide binding protein 1 (hhint1) h112n mutant nucleoside d-trp phosphoramidate substrate complex,20,2850.5,13.28,15,16,0.5,0.45
4ibb,ebola virus vp35 bound to small molecule,17,2450.2,10.58,15,8,2.5,0.47
6n3x,human histidine triad nucleotide binding protein 1 (hint1) with bound 5'-o-[1-benzyl]carbamoyl guanosine,20,2889.6,13.23,15,16,1.0,0.45
3sk2,"crystal structure of phenazine resistance protein ehpr from enterobacter agglomerans (erwinia herbicola, pantoea agglomerans) eh1087 in complex with griseoluteic acid",14,2263.8,13.22,13,4,1.0,0.43
1rnm,ribonuclease a complex with cytidylic acid (5'cmp) crystallized from 80% ammonium sulphate,13,1747.3,2.72,16,14,1.0,0.77
4ibc,ebola virus vp35 bound to small molecule,17,2450.2,10.08,15,8,2.5,0.47
6n3v,human histidine triad nucleotide binding protein 1 (hint1) with bound 5'-o-[1-ethyl]carbamoyl guanosine,20,2889.6,13.26,15,16,1.0,0.45
4rsk,structure of the k7a/r10a/k66a variant of ribonuclease a complexed with 3'-ump,13,1718.7,5.00,13,14,0.0,0.69
5i2e,"human histidine triad nucleotide binding protein 1 (hint1) with bound sulfamate inhibitor 3a:3-(5-o-{[3-(1h-indol-3-yl) propanoyl]sulfamoyl}-beta-d-ribofuranosyl)-3h-imidazo[2,1-i]purine",26,3695.7,14.31,24,20,2.5,0.46
6n3w,human histidine triad nucleotide binding protein 1 (hint1) with bound 5'-o-[3-phenyl-1-ethyl]carbamoyl guanosine,20,2889.6,13.23,15,16,1.0,0.45
1e3v,crystal structure of ketosteroid isomerase from psedomonas putida complexed with deoxycholate,18,2751.6,17.41,3,6,-2.0,0.22
5hwv,crystal structure of pas1 complexed with toluene,14,2047.8,14.90,2,2,-1.0,0.07
1rpf,the structures of rnase complexed with 3'-cmp and d(cpa): active site conformation and conserved water molecules,14,1908.6,5.96,13,14,0.0,0.64
4ibf,ebola virus vp35 bound to small molecule,16,2323.7,11.27,13,6,2.0,0.44
4ibi,ebola virus vp35 bound to small molecule,18,2592.1,11.34,14,10,1.5,0.44
1ogx,"high resolution crystal structure of ketosteroid isomerase mutant d40n(d38n, ti numbering) from pseudomonas putida complexed with equilenin at 2.0 a resolution.",17,2587.9,15.77,5,6,-1.0,0.24
4ibd,ebola virus vp35 bound to small molecule,14,2044.3,9.10,13,6,2.0,0.50
4ibe,ebola virus vp35 bound to small molecule,15,2132.2,11.39,12,8,1.0,0.47
5hva,crystal structure of dr2231 in complex with dumpnpp and magnesium.,22,3285.1,6.35,25,21,0.5,0.68
5wa8,human histidine triad nucleotide binding protein 1 (hhint1) h112n mutant nucleoside l-ala phosphoramidate substrate complex,19,2761.9,12.55,15,16,0.5,0.47
4ibg,ebola virus vp35 bound to small molecule,18,2616.9,11.62,15,8,2.5,0.44
5wa9,human histidine triad nucleotide binding protein 1 (hhint1) h112n mutant nucleoside d-ala phosphoramidate substrate complex,21,2995.4,12.30,20,16,1.5,0.48
1s89,h98n mutant of methylglyoxal synthase from e. coli complexed with phosphoglycolic acid,18,2147.0,6.45,16,12,0.5,0.56
5i2f,human histidine triad nucleotide binding protein 1 (hhint1) with bound sulfamide inhibitor bio-ams,19,2801.0,12.55,15,16,1.0,0.47
2a5c,structure of avidin in complex with the ligand 8-oxodeoxyadenosine,13,2000.4,12.44,10,8,0.0,0.46
4ibk,ebola virus vp35 bound to small molecule,18,2582.7,12.06,14,10,1.0,0.44
2a5b,avidin complexed with 8-oxodeoxyguanosine,15,2204.3,12.72,10,8,0.0,0.47
5kly,human histidine triad nucleotide binding protein 1 (hhint1) h112n mutant adenosine nucleoside phosphoramidate substrate complex,24,3455.3,13.01,24,20,2.0,0.50
2e27,crystal structure of fv fragment of anti-ciguatoxin antibody complexed with abc-ring of ciguatoxin,17,2786.9,11.24,14,10,0.0,0.53
2a8g,structure of avidin in complex with the ligand deoxyguanosine,15,2256.5,11.91,12,10,0.0,0.53
4ibj,ebola virus vp35 bound to small molecule,19,2767.4,10.49,22,10,3.5,0.53
3f8f,crystal structure of multidrug binding transcriptional regulator lmrr complexed with daunomycin,16,2294.8,20.68,4,6,-2.0,0.19
6gnm,"crystal structure of sea bream transthyretin in complex with 2,2',4, 4'-tetrahydroxybenzophenone (bp2)",14,2002.9,11.03,9,3,2.0,0.36
5vm0,the hapten triclocarban bound to the single domain camelid nanobody vhh t9,21,2867.0,8.64,25,11,2.0,0.62
6gnp,"crystal structure of sea bream transthyretin in complex with 3,5,6- trichloro-2-pyridinol (tc2p)",10,1360.0,9.46,8,2,2.0,0.40
6gnw,"crystal structure of sea bream transthyretin in complex with 2,4,5- trichlorophenoxyacetic acid (2,4,5-t)",14,2029.6,10.75,9,3,2.0,0.36
4zgk,structure of mdm2 with low molecular weight inhibitor.,15,2452.6,11.46,10,6,1.5,0.40
4cp5,ndpk in complex with (rp)-spmpapp,16,2192.2,4.43,24,10,2.5,0.62
6gon,crystal structure of sea bream transthyretin in complex with perfluorooctanoic acid (pfoa). crystallized in peg,15,2095.1,8.55,11,5,2.0,0.47
3f6g,crystal structure of the regulatory domain of licms in complexed with isoleucine - type ii,5,825.9,2.19,8,5,1.5,0.80
4d3h,structure of psta,23,3076.5,13.28,21,13,1.0,0.48
3r1v,"odorant binding protein 7 from anopheles gambiae with four disulfide bridges, in complex with an azo compound",20,3153.5,21.91,2,2,0.0,0.20
1ik4,x-ray structure of methylglyoxal synthase from e. coli complexed with phosphoglycolohydroxamic acid,19,2326.1,7.31,16,12,1.0,0.53
3zdg,crystal structure of ls-achbp complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (dmabc),9,1329.5,8.29,5,4,0.0,0.33
1egh,structure of methylglyoxal synthase complexed with the competitive inhibitor 2-phosphoglycolate,17,2126.0,6.33,16,12,1.0,0.59
3qxt,structure of an anti-methotrexate cdr1-3 graft vhh antibody in complex with methotrexate,20,2786.8,7.92,30,8,4.0,0.60
1s5z,ndp kinase in complex with adenosine phosphonoacetic acid,16,2340.9,5.67,26,10,4.0,0.62
2xog,functional and structural analyses of n-acylsulfonamide-linked dinucleoside inhibitors of ribonuclease a,20,2559.5,4.65,20,20,0.0,0.75
3d8z,rnase a- 5'-deoxy-5'-n-pyrrolidinothymidine complex,13,1772.1,2.91,17,12,2.0,0.77
2jgs,circular permutant of avidin,17,2622.5,12.83,12,9,0.0,0.47
4k55,structure of the extracellular domain of butyrophilin btn3a1 in complex with (e)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (hmbpp),9,1424.7,6.35,7,6,0.0,0.56
2uyn,crystal structure of e. coli tdcf with bound 2-ketobutyrate,10,1399.0,6.63,7,4,0.0,0.50
5ahw,crystal structure of universal stress protein msmeg_3811 in complex with camp,8,828.1,2.76,3,7,-2.0,0.50
4bcs,crystal structure of an avidin mutant,18,2540.6,11.10,12,14,-2.0,0.56
4luz,fragment-based discovery of a potent inhibitor of replication protein a protein-protein interactions,21,3112.9,10.32,33,8,5.0,0.52
3d6p,rnase a- 5'-deoxy-5'-n-morpholinouridine complex,13,1747.3,2.95,16,14,1.0,0.77
4jkw,structure of the extracellular domain of butyrophilin btn3a1 in complex with isopentenyl pyrophosphate (ipp),9,1406.7,3.96,12,6,1.0,0.67
1w4o,binding of nonnatural 3'-nucleotides to ribonuclease a,14,1887.3,5.03,16,14,1.0,0.71
1afl,ribonuclease a in complex with 5'-diphosphoadenosine 2'-phosphate at 1.7 angstrom resolution,17,2322.9,4.86,18,16,1.0,0.71
4g90,crystal structure of ribonuclease a in complex with 5e,15,2055.9,4.75,19,14,2.0,0.73
2w5g,rnase a-5'-atp complex,16,2234.3,3.99,18,16,1.0,0.75
1jn4,the crystal structure of ribonuclease a in complex with 2'- deoxyuridine 3'-pyrophosphate (p'-5') adenosine,22,2871.9,4.61,25,22,1.0,0.77
4elh,structure-activity relationship guides enantiomeric preference among potent inhibitors of b. anthracis dihydrofolate reductase,24,3265.3,14.44,18,12,1.0,0.38
4elf,structure-activity relationship guides enantiomeric preference among potent inhibitors of b. anthracis dihydrofolate reductase,24,3328.0,12.75,24,13,2.0,0.46
1jvu,crystal structure of ribonuclease a (complexed form),16,2250.6,5.41,21,14,2.0,0.69
5i7y,"brd9 in complex with cpd4 ((e)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro- 1h-pyrrolo[2,3-c]pyridin-4-yl)-n,n-dimethylbenzamide)",13,1982.5,10.90,8,5,1.0,0.38
5hrv,"crystal structure of the fifth bromodomain of human pb1 in complex with 1-ethylisochromeno[3,4-c]pyrazol-5(2h)-one) compound",16,2450.4,12.13,11,8,0.0,0.38
4erf,crystal structure of mdm2 (17-111) in complex with compound 29 (am- 8553),18,2880.9,11.66,14,8,1.5,0.39
3d6o,the rnase a- 5'-deoxy-5'-n-(ethyl isonipecotatyl)uridine complex,12,1594.1,3.48,14,12,0.5,0.75
1afk,crystal structure of ribonuclease a in complex with 5'- diphosphoadenosine-3'-phosphate,18,2437.0,4.61,20,18,1.0,0.72
4g8v,crystal structure of ribonuclease a in complex with 5a,15,2055.9,4.70,19,14,2.0,0.73
5i7x,"brd9 in complex with cpd2 (n,n-dimethyl-3-(6-methyl-7-oxo-6,7-dihydro- 1h-pyrrolo[2,3-c]pyridin-4-yl)benzamide)",11,1727.2,9.25,8,5,1.0,0.45
6pvw,rnase a in complex with cp4pa,18,2488.4,5.48,20,18,1.0,0.72
6pvv,rnase a in complex with p5a,16,2217.8,3.20,23,16,2.0,0.81
1w4q,binding of nonnatural 3'-nucleotides to ribonuclease a,15,2055.9,4.85,19,14,2.0,0.73
1u1b,structure of bovine pancreatic ribonuclease a in complex with 3'- phosphothymidine (3'-5')-pyrophosphate adenosine 3'-phosphate,23,2972.6,4.63,25,25,0.5,0.78
4g8y,crystal structure of ribonuclease a in complex with 5b,15,2055.9,4.84,19,14,2.0,0.73
1qhc,crystal structure of ribonuclease a in complex with 5'-phospho-2'- deoxyuridine-3'-pyrophosphate adenosine-3'-phosphate,23,2960.5,5.28,25,22,1.0,0.74
5tpx,"bromodomain from plasmodium faciparum gcn5, complexed with compound",14,2071.1,6.97,10,8,0.0,0.57
1w4p,binding of nonnatural 3'-nucleotides to ribonuclease a,15,2055.9,4.89,19,14,2.0,0.73
1o0f,"rnase a in complex with 3',5'-adp",16,2234.3,4.00,18,16,1.0,0.75
1o0m,ribonuclease a in complex with uridine-2'-phosphate,13,1718.7,5.05,13,14,0.0,0.69
1z6s,ribonuclease a- amp complex,15,2065.7,4.41,15,16,0.0,0.73
1o0n,ribonuclease a in complex with uridine-3'-phosphate,14,1915.9,2.97,19,14,2.0,0.79
4xy8,crystal structure of the bromodomain of brd9 in complex with a 2- amine-9h-purine ligand,12,1861.2,10.61,5,5,0.0,0.33
4elg,structure-activity relationship guides enantiomeric preference among potent inhibitors of b. anthracis dihydrofolate reductase,26,3715.4,14.21,24,13,2.0,0.42
3t2w,crystal structure of shwanavidin (f43a) - biotin complex,16,2159.9,9.66,11,10,-1.0,0.56
1uw6,x-ray structure of acetylcholine binding protein (achbp) in complex with nicotine,13,2128.2,8.17,12,5,1.0,0.62
5oh3,cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with ethosuximide,10,1711.0,11.08,7,6,-1.0,0.40
1ws4,crystal structure of jacalin- me-alpha-mannose complex: promiscuity vs specificity,10,1509.6,7.42,3,4,-1.0,0.30
1o0h,ribonuclease a in complex with 5'-adp,17,2348.4,3.93,20,18,1.0,0.76
4zbi,mcl-1 complexed with small molecules,17,2587.2,17.67,6,1,1.0,0.12
1sv3,structure of the complex formed between phospholipase a2 and 4- methoxybenzoic acid at 1.3a resolution.,13,1875.0,9.39,5,5,0.5,0.46
3bbf,crystal structure of the nm23-h2 transcription factor complex with gdp,18,2659.1,6.51,25,11,2.5,0.61
3djq,bovine seminal ribonuclease- uridine 5' diphosphate complex,14,1920.7,2.29,21,14,2.0,0.79
4qgd,crystal structure of the complex of phospholipase a2 with gramine derivative at 1.80 a resolution,16,2212.9,10.37,5,7,-0.5,0.44
3djo,bovine seminal ribonuclease uridine 2' phosphate complex,11,1512.6,2.89,17,8,2.5,0.73
3t0x,fluorogen activating protein m8vla4(s55p) in complex with dimethylindole red,19,3112.6,15.98,21,9,2.0,0.47
6r1d,"cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with compound 7d, co-crystallized",19,3140.5,18.40,14,8,0.5,0.32
6r13,cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with compound 7f,13,2152.4,13.90,7,6,-1.0,0.31
4rrf,editing domain of threonyl-trna synthetase from methanococcus jannaschii with l-ser3aa,24,3362.0,12.58,12,12,-0.5,0.42
5oh9,"cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with thiazolidine-2,4-dione",9,1521.1,8.84,7,6,-1.0,0.44
5ovv,pdz domain from rat shank3 bound to the c terminus of prosapip1,5,746.3,3.50,8,2,1.0,0.60
5oh7,"cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with imidazolidine-2,4-dione (hydantoin)",10,1711.0,10.14,7,6,-1.0,0.40
1q7a,crystal structure of the complex formed between russell's viper phospholipase a2 and an antiinflammatory agent oxyphenbutazone at 1.6a resolution,15,2148.4,10.70,9,7,0.5,0.40
3djx,bovine seminal ribonuclease- cytidine 5' phosphate complex,14,1920.7,2.17,21,14,2.0,0.79
5hrx,"crystal structure of the fifth bromodomain of human pb1 in complex with 1-butylisochromeno[3,4-c]pyrazol-5(2h)-one) compound",18,2783.8,15.79,11,8,0.0,0.33
1swg,circular permuted streptavidin e51/a46 in complex with biotin,15,2224.1,11.45,12,10,-1.0,0.53
5ii2,"crystal structure of the fifth bromodomain of human polybromo (pb1) in complex with 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4h-chromen-4-one",22,3397.9,16.27,16,10,0.0,0.36
3djp,bovine seminal ribonuclease- uridine 3' phosphate complex,14,1915.9,2.77,19,14,2.0,0.79
5var,crystal structure of kdm4a tandem tudor domain in complex with a tri- methyl lysine competitive inhibitor,12,1554.4,5.82,7,10,-2.0,0.58
5e7n,crystal structure of rpa70n in complex with vu0085636,16,2282.2,11.42,16,6,2.0,0.44
5hrw,"crystal structure of the fifth bromodomain of human pb1 in complex with 1-propylisochromeno[3,4-c]pyrazol-5(2h)-one) compound",17,2617.1,14.11,11,8,0.0,0.35
3h1x,simultaneous inhibition of anti-coagulation and inflammation: crystal structure of phospholipase a2 complexed with indomethacin at 1.4 a resolution reveals the presence of the new common ligand binding site,14,1689.5,2.81,8,9,-0.5,0.64
4qf8,crystal structure of the complex of phospholipase a2 with spermidine at 1.65 a resolution,16,2236.1,10.55,5,7,-0.5,0.44
4r4o,"crystal structure of rpa70n in complex with 5-(4-((4-(5-carboxyfuran- 2-yl)benzyl)carbamothioyl)phenyl)-1-(3,4-dichlorophenyl)-1h-pyrazole- 3-carboxylic acid",21,3112.9,10.24,33,8,5.0,0.52
5oh2,cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with pyrrolidin-2-one (butyrolactam),8,1484.2,9.70,5,4,-1.0,0.38
4r4i,"structure of rpa70n in complex with 5-(4-((6-(5-carboxyfuran-2-yl)-1- thioxo-3,4-dihydroisoquinolin-2(1h)-yl)methyl)phenyl)-1-(3,4- dichlorophenyl)-1h-pyrazole-3-carboxylic acid",21,3112.9,10.17,33,8,5.0,0.52
1td7,interactions of a specific non-steroidal anti-inflammatory drug (nsaid) with group i phospholipase a2 (pla2): crystal structure of the complex formed between pla2 and niflumic acid at 2.5 a resolution,15,2374.2,9.70,11,4,2.5,0.47
5oh4,"cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with piperidine-2,6-dione (glutarimide)",12,2013.6,13.14,7,6,-1.0,0.33
4qf7,crystal structure of the complex of phospholipase a2 with corticosterone at 1.48 a resolution,16,2212.9,10.42,5,7,-0.5,0.44
3djv,bovine seminal ribonuclease- cytidine 3' phosphate complex,15,2089.3,2.17,24,14,3.0,0.80
1ikt,liganded sterol carrier protein type 2 (scp-2) like domain of human multifunctional enzyme type 2 (mfe-2),20,3130.9,22.85,11,7,1.0,0.25
4r4c,"structure of rpa70n in complex with 5-(4-((4-(5-carboxyfuran-2-yl)-2- chlorobenzamido)methyl)phenyl)-1-(3,4-dichlorophenyl)-1h-pyrazole-3- carboxylic acid",22,3252.9,10.00,33,8,5.0,0.50
1oxr,aspirin induces its anti-inflammatory effects through its specific binding to phospholipase a2: crystal structure of the complex formed between phospholipase a2 and aspirin at 1.9a resolution,15,2316.7,11.04,8,6,0.5,0.47
4o0a,fragment-based discovery of a potent inhibitor of replication protein a protein-protein interactions,21,3112.9,9.99,33,8,5.0,0.52
4qem,crystal structure of the complex of phospholipase a2 with p-coumaric acid at 1.2 a resolution,16,2284.5,10.86,5,7,-0.5,0.50
2wq5,non-antibiotic properties of tetracyclines: structural basis for inhibition of secretory phospholipase a2.,10,1505.9,11.10,6,2,0.0,0.30
5fh7,crystal structure of the fifth bromodomain of human pb1 in complex with compound 18,17,2617.1,13.78,11,8,0.0,0.35
4qer,crystal structure of the complex of phospholipase a2 with resveratrol at 1.20 a resolution,18,2511.3,11.71,5,7,-0.5,0.44
5f2p,crystal structure of the brd9 bromodomain in complex with compound 3.,12,1861.2,10.94,5,5,0.0,0.33
4r4t,"crystal structure of rpa70n in complex with 5-(4-((4-(5-carboxyfuran- 2-yl)phenylthioamido)methyl)phenyl)-1-(3,4-dichlorophenyl)-1h- pyrazole-3-carboxylic acid",21,3112.9,10.30,33,8,5.0,0.52
5oha,cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with 2-thiohydantoin,9,1521.1,8.87,7,6,-1.0,0.44
2arm,crystal structure of the complex of phospholipase a2 with a natural compound atropine at 1.2 a resolution,12,1664.5,5.69,8,6,0.5,0.58
5f1h,crystal structure of the brd9 bromodamian in complex with bi-9564.,14,2074.5,9.83,7,7,0.5,0.36
5igm,crystal structure of the bromodomain of human brd9 in complex with bromosporine (bsp),15,2122.6,11.95,5,5,0.0,0.27
1ogd,the structure of bacillus subtilis rbsd complexed with d-ribose,14,1880.6,6.03,11,10,1.0,0.50
4zbf,mcl-1 complexed with small molecules,17,2587.2,17.78,6,1,1.0,0.12
1bai,crystal structure of rous sarcoma virus protease in complex with inhibitor,33,4227.5,17.46,16,23,-4.0,0.39
6hr2,crystal structure of protac 2 in complex with the bromodomain of human smarca4 and pvhl:elonginc:elonginb,39,6091.9,28.01,29,23,0.0,0.41
3s0d,"apis mellifera obp 14 in complex with the citrus odorant citralva (3, 7-dimethylocta-2,6-dienenitrile)",16,2449.6,17.66,5,2,1.0,0.19
3s8n,crystal structure of the grb2 sh2 domain in complex with a pyxn- derived tripeptide,7,828.8,4.35,7,6,0.5,0.71
3s0e,apis mellifera obp14 in complex with the odorant eugenol (2-methoxy- 4(2-propenyl)-phenol),16,2449.6,16.35,5,2,1.0,0.19
6r1a,cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with compound 20b,12,2013.6,12.63,7,6,-1.0,0.33
3s8l,protein-ligand interactions: thermodynamic effects associated with increasing hydrophobic surface area,7,828.8,4.36,7,6,0.5,0.71
6r11,cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with compound 5b,13,2176.5,13.80,7,6,-1.0,0.31
6e6m,crystal structure of human cellular retinol-binding protein 1 in complex with cannabidiorcin (cbdo),25,3676.0,13.98,27,11,4.0,0.44
6r0v,cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with hydrolysis product of compound 4b,14,2383.7,14.00,9,8,-0.5,0.36
5f25,crystal structure of the brd9 bromodomain in complex with compound 4.,11,1618.7,8.59,5,5,0.0,0.36
3bbb,crystal structure of the nm23-h2 transcription factor complex with dinucleotide d(ag),15,2142.0,10.16,18,6,2.0,0.53
5eq1,crystal structure of the human brpf1 bromodomain in complex with seed12,11,1687.4,8.57,4,6,-1.0,0.45
5etb,crystal structure of the human brpf1 bromodomain in complex with seed13,11,1687.4,8.49,4,6,-1.0,0.45
5eu1,crystal structure of brd9 in complex with bi-7273,15,2163.1,10.83,7,7,0.5,0.33
3s0b,apis mellifera obp14 in complex with the fluorescent probe 1-n- phenylnaphthylamine (npn),17,2694.0,18.35,4,1,1.0,0.12
3ove,crystal structure of the grb2 sh2 domain in complex with a pyxn- derived tripeptide,6,828.8,4.35,7,6,0.5,0.67
5o5a,crystal structure of the human brpf1 bromodomain in complex with bz032,15,2141.6,8.05,7,11,-2.0,0.53
3ov1,crystal structure of the grb2 sh2 domain in complex with a pyxn- derived tripeptide,6,828.8,4.36,7,6,0.5,0.67
5mgf,crystal structure of baz2b bromodomain in complex with 4-propionyl- pyrrole derivative 2,9,1355.4,9.82,3,3,0.0,0.33
6r1w,cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with compound 16b,13,2179.4,14.71,7,6,-1.0,0.31
5mge,crystal structure of baz2b bromodomain in complex with 1- methylpyridine derivative 1,10,1583.2,11.06,4,3,0.0,0.30
6r18,cereblon isoform 4 from magnetospirillum gryphiswaldense in complex with compound 11a,14,2383.7,14.11,9,8,-0.5,0.36
5e74,crystal structure of baz2b bromodomain in complex with acetylindole compound uzh50,13,1976.7,12.52,6,5,0.0,0.31
5tbm,crystal structure of pt2385 bound to hif2a-b*:arnt-b* complex,26,3715.6,15.88,18,13,2.0,0.46
1kpm,first structural evidence of a specific inhibition of phospholipase a2 by vitamin e and its implications in inflammation: crystal structure of the complex formed between phospholipase a2 and vitamin e at 1.8 a resolution.,23,3360.8,11.89,15,10,1.5,0.52
3u8k,"crystal structure of the acetylcholine binding protein (achbp) from lymnaea stagnalis in complex with ns3573 (1-(5-ethoxypyridin-3-yl)-1, 4-diazepane)",13,2128.2,8.35,12,5,1.0,0.62
4nra,crystal structure of the bromodomain of human baz2b in complex with compound-6 e11322,10,1583.2,11.14,4,3,0.0,0.30
5j7q,macrophage migration inhibitory factor bound to inhibitor k664 derivative,13,1886.0,6.02,13,7,2.5,0.54
1jq8,design of specific inhibitors of phospholipase a2: crystal structure of a complex formed between phospholipase a2 from daboia russelli pulchella and a designed pentapeptide leu-ala-ile-tyr-ser at 2.0 resolution,4,582.2,1.51,3,2,0.0,0.75
6cbf,macrophage migration inhibitory factor in complex with a pyrazole inhibitor (6a),13,1959.9,9.21,10,7,1.5,0.46
2hah,the structure of fiv 12s protease in complex with tl-3,13,1604.6,9.29,2,6,-2.0,0.23
5e73,crystal structure of baz2b bromodomain in complex with acetylindole compound uzh47,13,1976.7,12.44,6,5,0.0,0.31
5ufp,crystal structure of pt2399 bound to hif2a-b*:arnt-b* complex,27,3859.4,15.68,20,15,2.0,0.48
1fv0,first structural evidence of the inhibition of phospholipase a2 by aristolochic acid: crystal structure of a complex formed between phospholipase a2 and aristolochic acid,20,3014.5,12.65,10,8,0.5,0.50
4rvr,crystal structure of the bromodomain of human baz2b in complex with gsk2801,14,2143.4,13.69,6,5,0.0,0.29
1fiv,structure of an inhibitor complex of proteinase from feline immunodeficiency virus,11,1071.7,6.75,0,4,-2.0,0.36
5hvs,crystal structure of macrophage migration inhibitory factor (mif) with a biaryltriazole inhibitor (3i-305),14,2103.7,8.54,12,9,1.5,0.50
6cbg,macrophage migration inhibitory factor in complex with a pyrazole inhibitor (5),12,1847.2,7.63,10,7,1.5,0.50
5hvt,crystal structure of macrophage migration inhibitory factor (mif) with a potent inhibitor (nvs-2),12,1847.2,7.79,10,7,1.5,0.50
4wrb,macrophage migration inhibitory factor in complex with a biaryltriazole inhibitor (3b-190),14,2103.7,8.37,12,9,1.5,0.50
4flp,crystal structure of the first bromodomain of human brdt in complex with the inhibitor jq1,13,2054.3,12.08,5,6,-1.0,0.38
4kcx,brdt in complex with dinaciclib,13,2054.3,13.30,5,6,-1.0,0.38
3cyz,dimeric crystal structure of a pheromone binding protein from apis mellifera in complex with 9-keto-2(e)-decenoic acid at ph 7.0,15,2337.1,23.58,1,0,0.0,0.00
3u8n,"crystal structure of the acetylcholine binding protein (achbp) from lymnaea stagnalis in complex with ns3950 (1-(6-bromo-5-ethoxypyridin- 3-yl)-1,4-diazepane)",16,2554.2,7.85,15,8,1.0,0.62
3e3c,structure of grlr-lipid complex,19,2868.3,16.03,4,6,-1.0,0.32
2xbp,a novel signal transduction protein pii variant from synechococcus elongatus pcc7942 indicates a two-step process for nagk pii complex formation,10,1386.3,7.06,11,3,1.0,0.40
3d78,"dimeric crystal structure of a pheromone binding protein mutant d35n, from apis mellifera, at ph 7.0",16,2714.1,19.35,3,2,0.0,0.12
3cz1,dimeric crystal structure of a pheromone binding protein from apis mellifera in complex with the n-butyl benzene sulfonamide at ph 7.0,14,2279.3,21.42,1,0,0.0,0.00
5mwh,crystal structure of the human brpf1 bromodomain in complex with bz089,20,2902.8,10.69,15,13,-1.0,0.55
5ov8,crystal structure of the human brpf1 bromodomain in complex with bz097,17,2615.3,11.71,14,10,0.0,0.53
3qxv,structure of an anti-methotrexate cdr1-4 graft vhh antibody in complex with methotrexate,20,2862.4,9.21,27,8,3.0,0.55
4uye,"bromodomain of human brpf1 with n-1,3-dimethyl-2-oxo-6-(piperidin-1- yl)-2,3-dihydro-1h-1,3-benzodiazol-5-yl-2-methoxybenzamide",14,2052.6,8.20,6,10,-2.0,0.50
6ekq,crystal structure of the human brpf1 bromodomain complexed with bz054 in space group c2,13,1938.5,8.62,4,8,-2.0,0.46
6q3q,arabidopsis om64 tpr domain,7,949.8,4.50,4,4,0.0,0.57
1hbv,a check on rational drug design. crystal structure of a complex of hiv-1 protease with a novel gamma-turn mimetic,30,3670.2,16.80,10,12,-4.0,0.27
1dl7,the structural basis of repertoire shift in an immune response to phosphocholine,12,1792.2,8.23,9,8,-0.5,0.42
2qnq,hiv-1 protease in complex with a chloro decorated pyrrolidine-based inhibitor,30,3612.9,15.69,6,13,-5.0,0.27
1izi,inhibitor of hiv protease with unusual binding mode potently inhibiting multi-resistant protease mutants,34,4130.8,16.11,14,16,-4.0,0.35
5ji8,crystal structure of the brd9 bromodomain and hit 1,11,1721.5,10.61,5,5,0.0,0.36
3bgb,hiv-1 protease in complex with a isobutyl decorated oligoamine,35,4294.6,16.70,9,16,-5.0,0.31
1a9m,g48h mutant of hiv-1 protease in complex with a peptidic inhibitor u- 89360e,29,3778.9,15.17,18,13,0.0,0.34
2q63,hiv-1 pr mutant in complex with nelfinavir,31,3735.0,15.67,11,14,-3.0,0.29
3bgc,hiv-1 protease in complex with a benzyl decorated oligoamine,35,4294.6,16.74,9,16,-5.0,0.31
2pqz,hiv-1 protease in complex with a pyrrolidine-based inhibitor,30,3617.9,15.23,7,12,-4.0,0.27
2pwr,hiv-1 protease in complex with a carbamoyl decorated pyrrolidine-based inhibitor,35,4353.8,14.09,16,15,-3.0,0.34
1tcx,hiv triple mutant protease complexed with inhibitor sb203386,30,3723.6,16.59,10,12,-4.0,0.27
2r3w,i84v hiv-1 protease in complex with a amino decorated pyrrolidine- based inhibitor,31,3736.3,13.78,12,14,-4.0,0.32
5fh8,crystal structure of the fifth bromodomain of human pb1 in complex with compound 28,16,2450.4,11.97,11,8,0.0,0.38
2pwc,hiv-1 protease in complex with a amino decorated pyrrolidine-based inhibitor,32,3902.4,14.46,12,14,-4.0,0.31
2r3t,i50v hiv-1 protease mutant in complex with a carbamoyl decorated pyrrolidine-based inhibitor,35,4300.4,14.64,16,15,-3.0,0.34
1gnm,hiv-1 protease mutant with val 82 replaced by asp (v82d) complexed with u89360e (inhibitor),28,3280.1,13.50,7,16,-6.0,0.36
2pym,hiv-1 pr mutant in complex with nelfinavir,30,3618.9,16.05,10,13,-3.0,0.27
1gnn,hiv-1 protease mutant with val 82 replaced by asn (v82n) complexed with u89360e (inhibitor),28,3291.1,13.43,12,15,-3.0,0.36
2r43,i50v hiv-1 protease in complex with an amino decorated pyrrolidine- based inhibitor,32,3849.0,14.52,12,14,-4.0,0.31
4qgi,x-ray crystal structure of hiv-1 protease variant g48t/l89m in complex with saquinavir,31,3841.0,15.55,9,16,-5.0,0.35
2uy0,two-carbon-elongated hiv-1 protease inhibitors with a tertiary- alcohol-containing transition-state mimic,31,3786.3,16.00,11,13,-4.0,0.29
2qnn,hiv-1 protease in complex with a multiple decorated pyrrolidine-based inhibitor,33,4069.1,16.18,12,14,-4.0,0.30
2qnp,hiv-1 protease in complex with a iodo decorated pyrrolidine-based inhibitor,32,3902.4,14.66,12,14,-4.0,0.31
1sbg,an orally-bioavailable hiv-1 protease inhibitor containing an imidazole-derived peptide bond replacement. crystallographic and pharmacokinetic analysis,30,3670.2,16.55,10,12,-4.0,0.27
2bpy,hiv-1 protease-inhibitor complex,31,3860.1,18.45,10,12,-4.0,0.26
1gno,hiv-1 protease (wild type) complexed with u89360e (inhibitor),28,3384.7,18.15,6,11,-4.0,0.25
1zpa,hiv protease with scripps ab-3 inhibitor,13,1495.0,9.69,0,6,-3.0,0.23
2pyn,hiv-1 pr mutant in complex with nelfinavir,30,3618.9,16.11,10,13,-3.0,0.27
3tkw,crystal structure of hiv protease model precursor/darunavir complex,29,3550.8,17.34,5,12,-5.0,0.24
1ajv,hiv-1 protease in complex with the cyclic sulfamide inhibitor aha006,32,3953.0,16.42,11,13,-4.0,0.28
2bqv,hiv-1 protease in complex with inhibitor aha455,31,3779.6,18.17,6,13,-5.0,0.26
1iiq,crystal structure of hiv-1 protease complexed with a hydroxyethylamine peptidomimetic inhibitor,32,4016.3,21.14,5,12,-5.0,0.22
2r38,i84v hiv-1 protease mutant in complex with a carbamoyl decorated pyrrolidine-based inhibitor,34,4187.7,13.89,16,15,-3.0,0.35
2bpv,hiv-1 protease-inhibitor complex,31,3860.1,18.54,10,12,-4.0,0.26
2fle,structural analysis of asymmetric inhibitor bound to the hiv-1 protease v82a mutant,32,3799.6,15.11,12,14,-4.0,0.31
4cpw,macrocyclic transition-state mimicking hiv-1 protease inhibitors encompassing a tertiary alcohol,31,3758.9,16.54,12,14,-4.0,0.32
1ajx,hiv-1 protease in complex with the cyclic urea inhibitor aha001,29,3503.5,14.75,10,12,-4.0,0.28
4cpr,macrocyclic transition-state mimicking hiv-1 protease inhibitors encompassing a tertiary alcohol,31,3758.9,16.45,12,14,-4.0,0.32
3th9,crystal structure of hiv-1 protease mutant q7k v32i l63i with a cyclic sulfonamide inhibitor,28,3326.8,15.38,1,13,-6.0,0.25
2wl0,hiv-1 protease inhibitors containing a tertiary alcohol in the transition-state mimic with improved cell-based antiviral activity,33,4041.7,17.19,13,15,-4.0,0.33
1g2k,"hiv-1 protease with cyclic sulfamide inhibitor, aha047",32,3953.0,17.14,11,13,-4.0,0.28
1hvh,nonpeptide cyclic cyanoguanidines as hiv protease inhibitors,33,4013.1,16.83,11,13,-4.0,0.27
1izh,inhibitor of hiv protease with unusual binding mode potently inhibiting multi-resistant protease mutants,36,4590.5,18.28,15,14,-3.0,0.31
1mes,hiv-1 mutant (i84v) protease complexed with dmp323,34,4131.8,15.52,13,15,-4.0,0.32
1w5v,hiv-1 protease in complex with fluoro substituted diol-based c2- symmetric inhibitor,34,4235.8,17.80,12,14,-4.0,0.29
1hih,"comparative analysis of the x-ray structures of hiv-1 and hiv-2 proteases in complex with cgp 53820, a novel pseudosymmetric inhibitor",31,3786.3,15.93,11,13,-4.0,0.29
4a6c,"stereoselective synthesis, x-ray analysis, and biological evaluation of a new class of lactam based hiv-1 protease inhibitors",32,3868.3,17.78,8,15,-5.0,0.31
4lk7,crystal structure of pseudomonas aeruginosa lectin leca complexed with resorufin-b-d-galactopyranoside at 1.76 a resolution,6,776.1,2.58,5,5,0.5,0.50
1g35,"crystal structure of hiv-1 protease in complex with inhibitor, aha024",34,4179.8,17.96,11,13,-4.0,0.26
6haz,crystal structure of the bromodomain of human smarca2 in complex with smarca-bd ligand,21,3078.2,18.17,9,13,-1.5,0.33
4cp7,macrocyclic transition-state mimicking hiv-1 protease inhibitors encompassing a tertiary alcohol,32,3921.8,18.40,12,14,-4.0,0.31
4cpt,macrocyclic transition-state mimicking hiv-1 protease inhibitors encompassing a tertiary alcohol,31,3758.9,16.62,12,14,-4.0,0.32
4mc1,hiv protease in complex with sa526p,33,4018.5,13.83,13,15,-4.0,0.33
2cen,p1' extended hiv-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold,32,3969.5,19.61,6,13,-5.0,0.25
4mc2,hiv protease in complex with sa525p,30,3670.2,16.01,10,12,-4.0,0.27
4a6s,structure of the pail lectin from pseudomonas aeruginosa in complex with 2-naphtyl-1-thio-beta-d-galactopyranoside,12,1480.0,3.50,10,12,-0.5,0.67
1zp8,hiv protease with inhibitor ab-2,17,2130.6,13.54,1,7,-3.0,0.24
4cps,macrocyclic transition-state mimicking hiv-1 protease inhibitors encompassing a tertiary alcohol,31,3758.9,16.41,12,14,-4.0,0.32
2xye,hiv-1 inhibitors with a tertiary-alcohol-containing transition-state mimic and various p2 and p1 prime substituents,31,3758.9,16.54,12,14,-4.0,0.32
1d4j,hiv-1 protease in complex with the inhibitor msl370,33,4119.7,18.37,11,13,-4.0,0.27
1mfi,crystal structure of macrophage migration inhibitory factor complexed with (e)-2-fluoro-p-hydroxycinnamate,12,1847.2,7.76,10,7,1.5,0.50
5vl2,the hapten triclocarban bound to the single domain camelid nanobody vhh t4,21,2774.1,9.11,24,13,1.5,0.57
4ghi,crystal structure of the high affinity heterodimer of hif2 alpha and arnt c-terminal pas domains in complex with a benzoxadiazole antagonist,24,3479.9,15.20,12,12,1.0,0.42
1aaq,"hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, x-ray crystallography, and infected t-cell assays",30,3743.6,18.10,10,12,-4.0,0.27
1w5x,hiv-1 protease in complex with fluoro substituted diol-based c2- symmetric inhibitor,34,4235.8,17.72,12,14,-4.0,0.29
3zps,design and synthesis of p1-p3 macrocyclic tertiary alcohol comprising hiv-1 protease inhibitors,31,3758.9,16.71,12,14,-4.0,0.32
4ljh,crystal structure of pseudomonas aeruginosa lectin leca complexed with 1-methyl-3-indolyl-b-d-galactopyranoside at 1.45 a resolution,5,716.0,2.88,5,5,0.5,0.60
4a6b,"stereoselective synthesis, x-ray analysis, and biological evaluation of a new class of lactam based hiv-1 protease inhibitors",32,3868.3,18.16,8,15,-5.0,0.31
6gjw,structure of xiap-bir1 domain in complex with an nf023 analog,17,2087.4,5.68,20,10,3.0,0.71
1hwr,molecular recognition of cyclic urea hiv protease inhibitors,28,3363.5,14.09,10,12,-4.0,0.29
1lzq,"crystal structure of the complex of mutant hiv-1 protease (a71v, v82t, i84v) with an ethylenamine peptidomimetic inhibitor boc-phe- psi[ch2ch2nh]-phe-glu-phe-nh2",34,4204.6,18.12,13,15,-4.0,0.32
5d21,multivalency effects in glycopeptide dendrimer inhibitors of pseudomonas aeruginosa biofilms targeting lectin leca,12,1480.0,3.50,10,12,-0.5,0.67
3zyf,crystal structure of pa-il lectin complexed with npg at 1.9 a resolution,12,1480.0,3.56,10,12,-0.5,0.67
2xyf,hiv-1 inhibitors with a tertiary-alcohol-containing transition-state mimic and various p2 and p1 prime substituents,31,3758.9,16.78,12,14,-4.0,0.32
3zpu,design and synthesis of p1-p3 macrocyclic tertiary alcohol comprising hiv-1 protease inhibitors,31,3758.9,16.81,12,14,-4.0,0.32
2uxz,two-carbon-elongated hiv-1 protease inhibitors with a tertiary- alcohol-containing transition-state mimic,33,4142.9,19.16,11,13,-4.0,0.27
2q64,hiv-1 pr mutant in complex with nelfinavir,30,3618.9,16.12,10,13,-3.0,0.27
4rww,crystal structure of l. monocytogenes psta in complex with cyclic-di- amp,30,3851.9,20.99,17,14,1.5,0.37
1bwa,hiv-1 protease (v82f/i84v) double mutant complexed with xv638 of dupont pharmaceuticals,35,4495.7,18.31,17,13,-2.0,0.31
3kdd,"crystal structure of hiv-1 protease (q7k, l33i, l63i) in complex with kni-10265",34,4267.8,16.20,16,15,-3.0,0.35
1ec0,hiv-1 protease in complex with the inhibitor bea403,35,4351.9,16.89,13,15,-4.0,0.31
3rf5,"ancylostoma ceylanicum mif in complex with n-(2,3,4,5,6-pentafluoro- benzyl)-4-sulfamoyl-benzamide",15,2170.9,10.41,13,7,1.5,0.40
1hos,inhibition of human immunodeficiency virus-1 protease by a c2- symmetric phosphinate synthesis and crystallographic analysis,31,3786.3,16.41,11,13,-4.0,0.29
7upj,hiv-1 protease/u101935 complex,25,2967.9,16.53,5,8,-3.0,0.20
1w5y,hiv-1 protease in complex with fluoro substituted diol-based c2- symmetric inhibitor,34,4235.8,18.44,12,14,-4.0,0.29
2cej,p1' extended hiv-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold,32,3953.0,16.73,11,13,-4.0,0.28
3rf4,ancylostoma ceylanicum mif in complex with furosemide,16,2283.6,11.23,13,7,1.5,0.38
2p3b,crystal structure of the subtype b wild type hiv protease complexed with tl-3 inhibitor,37,4755.3,19.11,18,14,-2.0,0.32
1bwb,hiv-1 protease (v82f/i84v) double mutant complexed with sd146 of dupont pharmaceuticals,37,4801.7,18.95,18,14,-2.0,0.32
2wkz,hiv-1 protease inhibitors containing a tertiary alcohol in the transition-state mimic with improved cell-based antiviral activity,33,4142.9,19.12,11,13,-4.0,0.27
1w5w,hiv-1 protease in complex with fluoro substituted diol-based c2- symmetric inhibitor,36,4468.0,16.17,14,16,-4.0,0.33
1ec1,hiv-1 protease in complex with the inhibitor bea409,32,4050.0,20.34,10,12,-4.0,0.25
1ohr,"viracept (r) (nelfinavir mesylate, ag1343): a potent orally bioavailable inhibitor of hiv-1 protease",31,3779.6,17.47,6,13,-5.0,0.26
1d4i,hiv-1 protease in complex with the inhibitor bea425,34,4235.8,17.93,12,14,-4.0,0.29
1ebw,hiv-1 protease in complex with the inhibitor bea322,30,3670.2,16.86,10,12,-4.0,0.27
1m0b,hiv-1 protease in complex with an ethyleneamine inhibitor,32,3953.0,16.43,11,13,-4.0,0.28
1ec3,hiv-1 protease in complex with the inhibitor msa367,32,3976.2,17.84,11,13,-4.0,0.28
6b1k,macrophage migration inhibitory factor in complex with a naphthyridinone inhibitor (3a),13,1959.9,8.59,10,7,1.5,0.46
1hps,"rational design, synthesis and crystallographic analysis of a hydroxyethylene-based hiv-1 protease inhibitor containing a heterocyclic p1'-p2' amide bond isostere",31,3786.3,15.49,11,13,-4.0,0.29
1hpv,"crystal structure of hiv-1 protease in complex with vx-478, a potent and orally bioavailable inhibitor of the enzyme",30,3663.5,18.10,5,12,-5.0,0.23
1hpo,hiv-1 protease triple mutant/u103265 complex,25,3021.9,16.89,5,8,-3.0,0.20
2aqu,structure of hiv-1 protease bound to atazanavir,30,3670.2,16.55,10,12,-4.0,0.27
4j7e,"the 1.63a crystal structure of humanized xenopus mdm2 with a nutlin fragment, ro5524529",14,2287.4,11.17,7,7,0.5,0.36
4ggz,the structure of bradavidin2-biotin complex,17,2393.0,10.49,14,9,0.0,0.53
3ta0,"a. fulgidus glnk3, mgatp complex",23,3105.6,8.41,30,9,4.0,0.52
1mrw,structure of hiv protease (mutant q7k l33i l63i) complexed with kni- 577,32,3953.0,16.96,11,13,-4.0,0.28
1ebz,hiv-1 protease in complex with the inhibitor bea388,32,3953.0,17.07,11,13,-4.0,0.28
6ced,"crystal structure of fragment 3-(3-methyl-4-oxo-3,4-dihydroquinazolin- 2-yl)propanoic acid bound in the ubiquitin binding pocket of the hdac6 zinc-finger domain",10,1654.4,7.01,9,2,1.0,0.40
1c70,alternate binding site for the p1-p3 group of a class of potent hiv-1 protease inhibitors as a result of concerted structural change in 80's loop.,35,4235.2,19.15,7,14,-5.0,0.26
4j7d,"the 1.25a crystal structure of humanized xenopus mdm2 with a nutlin fragment, ro5045331",13,2053.4,12.64,7,7,1.0,0.31
1fkf,"atomic structure of fkbp-fk506, an immunophilin-immunosuppressant complex",17,2800.0,13.57,12,10,-0.5,0.41
1hxb,hiv-1 proteinase complexed with ro 31-8959,33,4085.6,18.74,7,14,-5.0,0.27
5kh3,"crystal structure of fragment (3-(5-chloro-1,3-benzothiazol-2-yl) propanoic acid) bound in the ubiquitin binding pocket of the hdac6 zinc-finger domain",11,1792.8,6.83,9,4,0.0,0.45
1eby,hiv-1 protease in complex with the inhibitor bea369,34,4235.8,18.13,12,14,-4.0,0.29
1ec2,hiv-1 protease in complex with the inhibitor bea428,32,4050.0,20.71,10,12,-4.0,0.25
3kdc,"crystal structure of hiv-1 protease (q7k, l33i, l63i) in complex with kni-10074",33,4114.9,18.03,9,13,-4.0,0.27
1dmp,structure of hiv-1 protease complex,30,3670.2,15.63,10,12,-4.0,0.27
4mc9,hiv protease in complex with aa74,30,3673.6,14.99,11,13,-4.0,0.30
6ce6,"structure of hdac6 zinc-finger ubiquitin binding domain soaked with 3, 3'-(benzo[1,2-d:5,4-d']bis(thiazole)-2,6-diyl)dipropionic acid",12,1986.4,6.95,10,5,0.0,0.50
1det,ribonuclease t1 carboxymethylated at glu 58 in complex with 2'gmp,11,1493.7,1.58,15,14,0.5,0.91
1bv9,hiv-1 protease (i84v) complexed with xv638 of dupont pharmaceuticals,34,4227.3,18.12,14,13,-3.0,0.29
1v1j,crystal structure of type ii dehydroquintae dehydratase from streptomyces coelicolor in complex with 3-fluoro,17,2320.0,8.60,19,11,2.0,0.53
1zsf,crystal structure of complex of a hydroxyethylamine inhibitor with hiv-1 protease at 2.0a resolution,31,3779.6,17.76,6,13,-5.0,0.26
6rnt,crystal structure of ribonuclease t1 complexed with adenosine 2'- monophosphate at 1.8-angstroms resolution,12,1551.4,3.92,14,11,1.0,0.58
2fmb,eiav protease complexed with an inhibitor lp-130,15,1813.4,10.66,6,5,-1.0,0.27
1bv7,"counteracting hiv-1 protease drug resistance: structural analysis of mutant proteases complexed with xv638 and sd146, cyclic urea amides with broad specificities",33,4202.3,19.85,7,13,-4.0,0.27
4a4q,"stereoselective synthesis, x-ray analysis, and biological evaluation of a new class of lactam based hiv-1 protease inhibitors",32,3868.3,17.98,8,15,-5.0,0.31
1met,hiv-1 mutant (v82f) protease complexed with dmp323,35,4451.7,17.40,13,15,-4.0,0.31
2o4l,"crystal structure of hiv-1 protease (q7k, i50v) in complex with tipranavir",30,3565.8,16.10,10,10,-3.0,0.23
5mgk,crystal structure of baz2a bromodomain in complex with 4-propionyl- pyrrole derivative 2,10,1495.4,11.08,3,3,0.0,0.30
2jdm,mutant (s22a) of pseudomonas aeruginosa lectin ii (pa-iil) complexed with methyl-a-l-fucopyranoside,14,1401.1,0.22,7,17,-5.0,0.71
1d4h,hiv-1 protease in complex with the inhibitor bea435,34,4235.8,17.86,12,14,-4.0,0.29
4mc6,hiv protease in complex with sa499,29,3557.5,15.30,10,12,-4.0,0.28
3kdb,"crystal structure of hiv-1 protease (q7k, l33i, l63i) in complex with kni-10006",35,4351.9,17.20,13,15,-4.0,0.31
1rnt,restrained least-squares refinement of the crystal structure of the ribonuclease t1(asterisk)2(prime)-guanylic acid complex at 1.9 angstroms resolution,15,2266.4,1.07,25,21,1.0,0.93
2o4k,crystal structure of hiv-1 protease (q7k) in complex with atazanavir,31,3860.1,18.37,10,12,-4.0,0.26
1hpx,hiv-1 protease complexed with the inhibitor kni-272,34,4145.7,18.81,7,14,-5.0,0.26
5mgj,crystal structure of baz2a bromodomain in complex with 1- methylpyridine derivative 1,11,1670.6,10.66,6,5,0.0,0.36
1msm,the hiv protease (mutant q7k l33i l63i) complexed with kni-764 (an inhibitor),34,4178.5,17.42,8,15,-5.0,0.29
1fkb,atomic structure of the rapamycin human immunophilin fkbp-12 complex,14,2371.3,12.15,7,10,-1.5,0.43
2jdp,mutant (s23a) of pseudomonas aeruginosa lectin ii (pa-iil) complexed with methyl-a-l-fucopyranoside,14,1401.1,1.10,7,17,-5.0,0.71
5hz9,human fabp3 in complex with 6-chloro-2-methyl-4-phenyl-quinoline-3- carboxylic acid,23,3379.9,11.74,25,9,3.0,0.52
1qbu,hiv-1 protease inhibitors wiih low nanomolar potency,32,4001.7,17.09,13,12,-3.0,0.28
1qbs,hiv-1 protease inhibitors wiih low nanomolar potency,35,4351.9,17.17,13,15,-4.0,0.31
4wn5,crystal structure of the c-terminal per-arnt-sim (pasb) of human hif- 3alpha9 bound to 18:1-1-monoacylglycerol,33,4755.0,20.61,15,15,1.0,0.39
1hvr,"rational design of potent, bioavailable, nonpeptide cyclic ureas as hiv protease inhibitors",35,4295.9,17.22,12,14,-4.0,0.29
3cm2,"crystal structure of xiap bir3 domain in complex with a smac-mimetic compound, smac010",20,3079.0,10.24,18,13,0.5,0.55
1fkh,"design, synthesis, and kinetic evaluation of high-affinity fkbp ligands, and the x-ray crystal structures of their complexes with fkbp12",16,2549.6,11.82,10,8,-0.5,0.38
1fkg,"design, synthesis, and kinetic evaluation of high-affinity fkbp ligands, and the x-ray crystal structures of their complexes with fkbp12",15,2489.5,12.40,10,8,-0.5,0.40
2i4v,"hiv-1 protease i84v, l90m with tmc126",31,3778.7,17.39,8,12,-4.0,0.26
2pk5,"crystal structure of hiv-1 protease (q7k, l33i, l63i ) in complex with kni-10075",36,4428.5,19.25,8,15,-5.0,0.28
1pro,hiv-1 protease dimer complexed with a-98881,32,3902.4,15.35,12,14,-4.0,0.31
1d4y,hiv-1 protease triple mutant/tipranavir complex,30,3619.2,16.25,10,10,-3.0,0.23
1hvl,influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease,34,4249.2,14.74,22,14,-2.0,0.35
4hbm,ordering of the n terminus of human mdm2 by small molecule inhibitors,20,3107.3,15.08,12,9,1.5,0.40
2i4w,hiv-1 protease wt with gs-8374,32,3913.5,19.34,5,12,-5.0,0.22
2wos,"structure of human s100a7 in complex with 2,6 ans",7,1004.9,8.28,6,1,1.0,0.29
2i4u,hiv-1 protease with tmc-126,31,3832.1,16.93,8,12,-4.0,0.26
2wor,"co-structure of s100a7 with 1,8 ans",8,1042.1,2.58,11,5,1.0,0.62
5a6x,structure of the lecb lectin from pseudomonas aeruginosa strain pa14 in complex with alpha-methyl-fucoside,13,1313.9,1.09,7,17,-5.0,0.77
2i4d,crystal structure of wt hiv-1 protease with gs-8373,31,3853.4,19.77,5,12,-5.0,0.23
1qbr,hiv-1 protease inhibitors wiih low nanomolar potency,35,4396.8,17.31,15,14,-3.0,0.31
1hvi,influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease,37,4642.7,16.88,22,14,-2.0,0.32
4i8z,"crystal structure of wild type hiv-1 protease in complex with non- peptidic inhibitor, grl008",30,3666.9,16.86,6,13,-5.0,0.27
4ll3,structure of wild-type hiv protease in complex with darunavir,30,3666.9,16.76,6,13,-5.0,0.27
4i8w,"crystal structure of wild type hiv-1 protease in complex with non- peptidic inhibitor, grl007",31,3755.7,17.20,7,14,-5.0,0.29
2i4x,"hiv-1 protease i84v, l90m with gs-8374",31,3693.4,18.77,5,12,-5.0,0.23
1qbt,hiv-1 protease inhibitors wiih low nanomolar potency,35,4499.9,18.53,16,12,-2.0,0.29
3zdv,"crystal structure of the lecb lectin from pseudomonas aeruginosa in complex with methyl 6-(2,4,6-trimethylphenylsulfonylamido)-6-deoxy- alpha-d-mannopyranoside",7,663.4,1.25,4,6,-1.0,0.57
4hla,crystal structure of wild type hiv-1 protease in complex with darunavir,30,3663.5,17.82,5,12,-5.0,0.23
1hvk,influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease,38,4916.0,19.67,22,14,-2.0,0.32
2pk6,"crystal structure of hiv-1 protease (q7k, l33i, l63i) in complex with kni-10033",33,4085.6,19.30,7,14,-5.0,0.27
1hvs,structural basis of drug resistance for the v82a mutant of hiv-1 protease: backbone flexibility and subsite repacking,34,3975.8,14.01,13,15,-4.0,0.32
1nh0,1.03 a structure of hiv-1 protease: inhibitor binding inside and outside the active site,23,2815.4,13.82,2,12,-5.0,0.30
3ta1,"a. fulgidus glnk3, mgadp complex",23,3105.6,7.70,30,9,4.0,0.52
1d7j,fkbp complexed with 4-hydroxy-2-butanone,10,1740.9,10.07,3,6,-2.0,0.40
1hvj,influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease,36,4476.0,15.70,22,14,-2.0,0.33
1d7i,fkbp complexed with methyl methylsulfinylmethyl sulfide (dss),9,1551.0,8.08,3,6,-2.0,0.44
1hxw,hiv-1 protease dimer complexed with a-84538,33,4069.1,15.90,12,14,-4.0,0.30
6mm2,carbon regulatory pii-like protein sbtb from cyanobium sp. 7001 bound to atp and calcium,19,2412.8,5.10,20,14,0.0,0.68
6evn,crystal structure of peptide-substrate-binding domain of human type ii collagen prolyl 4-hydroxylase complex with pro-pro-gly-pro-ala-gly- pro-pro-gly.,6,957.0,3.31,10,4,0.0,0.67
5n18,second bromodomain (bd2) from candida albicans bdf1 bound to an imidazopyridine (compound 2),14,2080.2,13.14,7,7,0.0,0.36
4m8y,"gs-8374, a novel phosphonate-containing inhibitor of hiv-1 protease, effectively inhibits hiv pr mutants with amino acid insertions",31,3620.8,17.34,5,12,-5.0,0.23
6fgg,crystal structure of baz2a bromodomain in complex with 1- methylpyridinone compound 5,11,1694.9,10.36,4,5,-1.0,0.36
2rkf,hiv-1 pr resistant mutant + lpv,28,3220.6,16.97,0,12,-6.0,0.21
4m8x,"gs-8374, a novel phosphonate-containing inhibitor of hiv-1 protease, effectively inhibits hiv pr mutants with amino acid insertions",31,3620.8,17.23,5,12,-5.0,0.23
4ejl,apo hiv protease (pr) dimer in closed form with fragment 1f1-n in the outside/top of flap,7,1154.0,6.44,12,0,3.0,0.43
1fki,"design, synthesis, and kinetic evaluation of high-affinity fkbp ligands, and the x-ray crystal structures of their complexes with fkbp12",14,2400.9,11.94,10,8,-0.5,0.43
4ej8,apo hiv protease (pr) dimer in closed form with fragment 1f1 in the outside/top of flap,7,1154.0,6.36,12,0,3.0,0.43
2rkg,hiv-1 pr resistant mutant + lpv,30,3560.7,18.34,5,12,-5.0,0.23
6dh7,crystal structure of hiv-1 protease nl4-3 i50v mutant in complex with umass1,37,4527.2,15.76,16,15,-3.0,0.32
2aoc,crystal structure analysis of hiv-1 protease mutant i84v with a substrate analog p2-nc,36,4463.3,16.24,16,15,-3.0,0.33
6dh6,crystal structure of hiv-1 protease nl4-3 i50v mutant in complex with darunavir,37,4527.2,15.59,16,15,-3.0,0.32
2avq,"kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s",35,4294.7,16.98,13,15,-4.0,0.31
6dh1,crystal structure of hiv-1 protease nl4-3 i84v mutant in complex with umass1,37,4527.2,16.01,16,15,-3.0,0.32
6dh2,crystal structure of hiv-1 protease nl4-3 i84v mutant in complex with umass6,36,4411.1,16.11,15,14,-3.0,0.31
3bvb,cystal structure of hiv-1 active site mutant d25n and inhibitor darunavir,30,3645.6,17.28,10,13,-3.0,0.27
6dh8,crystal structure of hiv-1 protease nl4-3 i50v mutant in complex with umass6,36,4411.1,16.17,15,14,-3.0,0.31
1j4r,fk506 binding protein complexed with fkb-001,17,2864.6,11.90,14,12,0.0,0.47
2aog,crystal structure analysis of hiv-1 protease mutant v82a with a substrate analog p2-nc,33,3955.8,17.97,7,14,-5.0,0.27
5jfu,hiv-1 wild type protease with grl-007-14a (a adamantane p1-ligand with bis-thf in p2 and benzylamine in p1'),31,3729.0,15.74,7,14,-5.0,0.29
6o48,wild-type hiv-1 protease in complex with a substrate analog ca-p2,36,4664.3,20.90,14,13,-3.0,0.28
6dil,hiv-1 protease with single mutation l76v in complex with tipranavir,30,3619.2,15.89,10,10,-3.0,0.23
6py0,crystal structure of mouse serum amyloid a3 (saa3) bound with retinol,20,2912.3,25.48,5,3,-1.0,0.10
6dj5,hiv-1 protease with mutation l76v in complex with grl-0519 (tris- tetrahydrofuran as p2 ligand),29,3552.7,15.40,8,12,-4.0,0.28
2avm,"kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s",34,4232.0,17.42,12,14,-4.0,0.29
2aod,crystal structure analysis of hiv-1 protease with a substrate analog p2-nc,35,4400.6,16.31,15,14,-3.0,0.31
5kqx,protease e35d-sqv,32,3924.9,17.57,11,14,-3.0,0.28
4hdp,crystal structure of hiv-1 protease mutants i50v complexed with inhibitor grl-0519,30,3666.0,16.92,8,12,-4.0,0.27
4heg,crystal structure of hiv-1 protease mutants r8q complexed with inhibitor grl-0519,29,3523.1,15.70,5,14,-5.0,0.28
4zls,"hiv-1 wild type protease with grl-096-13a (a boc-derivative p2-ligand, 3,-5-dimethylbiphenyl p1-ligand)",33,4029.6,19.96,6,13,-5.0,0.24
2qci,hiv-1 protease mutant d30n with potent antiviral inhibitor grl-98065,30,3669.5,17.48,9,12,-3.0,0.23
6dj2,hiv-1 protease with single mutation l76v in complex with lopinavir,30,3670.2,16.33,10,12,-4.0,0.27
2nmz,crystal structure analysis of hiv-1 protease mutant v82a with a inhibitor saquinavir,32,3816.1,17.08,7,14,-5.0,0.28
3nu9,crystal structure of hiv-1 protease mutant i84v with antiviral drug amprenavir,31,3729.6,16.14,7,14,-5.0,0.29
3d1x,crystal structure of hiv-1 mutant i54m and inhibitor saquinavir,31,3729.0,15.78,7,14,-5.0,0.29
2aoe,crystal structure analysis of hiv-1 protease mutant v82a with a substrate analog ca-p2,35,4392.9,21.47,11,13,-4.0,0.26
5jfp,hiv-1 wild type protease with grl-097-13a (a adamantane p1-ligand with bis-thf in p2 and isobutylamine in p1'),32,3953.0,16.94,11,13,-4.0,0.28
4hdf,crystal structure of hiv-1 protease mutants v82a complexed with inhibitor grl-0519,29,3449.9,15.21,8,12,-4.0,0.28
3cyw,effect of flap mutations on structure of hiv-1 protease and inhibition by saquinavir and darunavir,30,3826.7,19.61,6,13,-5.0,0.27
3nu5,crystal structure of hiv-1 protease mutant i50v with antiviral drug amprenavir,32,3842.3,16.75,7,14,-5.0,0.28
3cyx,crystal structure of hiv-1 mutant i50v and inhibitor saquinavira,32,3865.5,17.47,7,14,-5.0,0.28
3bva,cystal structure of hiv-1 active site mutant d25n and p2-nc analog inhibitor,34,4238.0,17.48,16,14,-2.0,0.29
3d1y,crystal structure of hiv-1 mutant i54v and inhibitor saquina,32,3918.9,17.59,7,14,-5.0,0.28
2f80,hiv-1 protease mutant d30n complexed with inhibitor tmc114,30,3672.9,16.80,10,13,-3.0,0.27
5kr0,protease e35d-apv,30,3612.2,17.99,5,13,-4.0,0.23
1sdv,crystal structures of hiv protease v82a and l90m mutants reveal changes in indinavir binding site.,33,4040.1,18.80,11,13,-4.0,0.27
3vfa,crystal structure of hiv-1 protease mutant v82a with novel p1'-ligands grl-02031,31,3676.8,16.85,6,13,-5.0,0.26
2qd6,hiv-1 protease mutant i50v with potent antiviral inhibitor grl-98065,29,3436.7,18.24,0,12,-6.0,0.21
4hdb,crystal structure of hiv-1 protease mutants d30n complexed with inhibitor grl-0519,31,3785.6,16.95,10,13,-3.0,0.26
5kqy,protease e35d-drv,31,3785.6,16.91,10,13,-3.0,0.26
2avs,"kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s",32,3922.8,17.73,11,13,-4.0,0.28
3vfb,crystal structure of hiv-1 protease mutant n88d with novel p1'-ligands grl-02031,32,3948.2,16.23,9,13,-4.0,0.28
3vf7,crystal structure of hiv-1 protease mutant l76v with novel p1'-ligands grl-02031,31,3781.5,15.08,9,13,-4.0,0.29
2f8g,hiv-1 protease mutant i50v complexed with inhibitor tmc114,30,3613.5,16.78,6,13,-5.0,0.27
6dj7,hiv-1 protease with mutation l76v in complex with grl-5010 (gem- difluoro-bis-tetrahydrofuran as p2 ligand),29,3496.8,16.19,5,12,-5.0,0.24
2avo,"kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s",32,3976.2,17.85,11,13,-4.0,0.28
2qd8,hiv-1 protease mutant i84v with potent antiviral inhibitor grl-98065,29,3497.4,17.41,5,12,-5.0,0.24
3d1z,crystal structure of hiv-1 mutant i54m and inhibitor darunavir,30,3643.0,14.91,7,14,-5.0,0.30
6e7j,"hiv-1 wild type protease with grl-042-17a, 3-phenylhexahydro-2h- cyclopenta[d]oxazol-2-one with a bicyclic oxazolidinone scaffold as the p2 ligand",31,3835.5,15.99,9,13,-4.0,0.29
3djk,wild type hiv-1 protease with potent antiviral inhibitor grl-0255a,31,3779.6,16.67,6,13,-5.0,0.26
3nu4,crystal structure of hiv-1 protease mutant v32i with antiviral drug amprenavir,32,3949.1,16.86,7,14,-5.0,0.28
5upz,"hiv-1 wild type protease with grl-0518a , an isophthalamide-derived p2-p3 ligand with the para-hydoxymethyl sulfonamide isostere as the p2' group",31,3779.6,16.90,6,13,-5.0,0.26
3pwm,hiv-1 protease mutant l76v with darunavir,29,3496.8,16.17,5,12,-5.0,0.24
3nuj,crystal structure of hiv-1 protease mutant i54v with antiviral drug amprenavir,34,4185.2,15.25,13,15,-4.0,0.32
1bdq,"hiv-1 (2:31-37, 47, 82) protease complexed with inhibitor sb203386",30,3723.6,17.47,10,12,-4.0,0.27
6dj1,wild-type hiv-1 protease in complex with lopinavir,31,3779.6,17.38,6,13,-5.0,0.26
5ult,hiv-1 wild type protease with grl-100-13a (a crown-like oxotricyclic core as the p2-ligand with the sulfonamide isostere as the p2' group),30,3666.9,16.77,6,13,-5.0,0.27
2qd7,hiv-1 protease mutant v82a with potent antiviral inhibitor grl-98065,29,3387.3,17.83,0,12,-6.0,0.21
2idw,crystal structure analysis of hiv-1 protease mutant v82a with a potent non-peptide inhibitor (uic-94017),29,3387.3,17.93,0,12,-6.0,0.21
3vf5,crystal structure of hiv-1 protease mutant i47v with novel p1'-ligands grl-02031,31,3726.2,16.81,6,13,-5.0,0.26
5jg1,hiv-1 wild type protease with grl-031-14a (a adamantane p1-ligand with tetrahydropyrano-tetrahydrofuran in p2 and isobutylamine in p1'),32,3953.0,17.04,11,13,-4.0,0.28
2wyf,crystal structure of pa-il lectin complexed with agal12bgal-o-met at 2.4 a resolution,5,719.4,1.73,6,6,0.5,0.80
3h5b,crystal structure of wild type hiv-1 protease with novel p1'-ligand grl-02031,33,4064.3,15.74,10,14,-4.0,0.30
2hs1,ultra-high resolution x-ray crystal structure of hiv-1 protease v32i mutant with tmc114 (darunavir) inhibitor,31,3893.7,16.52,11,13,-4.0,0.29
3dk1,wild type hiv-1 protease with potent antiviral inhibitor grl-0105a,31,3779.6,16.90,6,13,-5.0,0.26
3nu6,crystal structure of hiv-1 protease mutant i54m with antiviral drug amprenavir,33,4072.5,15.03,13,15,-4.0,0.33
5dgw,crystal structure of hiv-1 protease inhibitor grl-105-11a containing substituted fused-tetrahydropyranyl tetrahydrofuran as p2-ligand,29,3550.8,17.52,5,12,-5.0,0.24
1ivp,the crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors,34,4286.1,20.45,13,15,-4.0,0.29
2z4o,wild type hiv-1 protease with potent antiviral inhibitor grl-98065,31,3836.9,16.80,10,12,-4.0,0.26
3nuo,crystal structure of hiv-1 protease mutant l90m with antiviral drug amprenavir,32,3895.7,16.61,7,14,-5.0,0.28
4k3h,immunoglobulin lambda variable domain l5(l89s) fluorogen activationg protein in complex with malachite green,24,3499.6,12.68,18,18,1.0,0.58
5bry,"hiv-1 wild type protease with grl-011-11a (a methylamine bis- tetrahydrofuran p2-ligand, sulfonamide isostere derivate)",30,3666.9,16.53,6,13,-5.0,0.27
1sdt,crystal structures of hiv protease v82a and l90m mutants reveal changes in indinavir binding site.,32,3976.2,17.69,11,13,-4.0,0.28
3ok9,crystal structure of wild-type hiv-1 protease with new oxatricyclic designed inhibitor grl-0519a,30,3666.9,16.28,6,13,-5.0,0.27
5wlo,a novel 13-ring macrocyclic hiv-1 protease inhibitors involving the p1'-p2' ligands,33,4071.0,14.35,15,14,-3.0,0.33
1sdu,crystal structures of hiv protease v82a and l90m mutants reveal changes in indinavir binding site.,32,3976.2,18.00,11,13,-4.0,0.28
2hb3,wild-type hiv-1 protease in complex with potent inhibitor grl06579,31,3779.6,16.90,6,13,-5.0,0.26
3qaa,"hiv-1 wild type protease with a substituted bis-tetrahydrofuran inhibitor, grl-044-10a",29,3550.8,17.04,5,12,-5.0,0.24
6b4n,a hydroxymethyl functionality at the 4-position of the 2-phenyloxazole moiety of hiv-1 protease inhibitors involving the p2' ligands,30,3658.7,17.55,3,12,-5.0,0.23
2f81,hiv-1 protease mutant l90m complexed with inhibitor tmc114,30,3666.9,16.74,6,13,-5.0,0.27
5uov,"hiv-1 wild type protease with grl-1118a , an isophthalamide-derived p2-p3 ligand with the sulfonamide isostere as the p2' group",31,3830.2,19.45,5,12,-5.0,0.23
5bs4,"hiv-1 wild type protease with grl-047-11a (a methylamine bis- tetrahydrofuran p2-ligand, 4-amino sulfonamide derivative)",30,3666.9,17.08,6,13,-5.0,0.27
3nu3,wild type hiv-1 protease with antiviral drug amprenavir,33,4069.1,16.06,12,14,-4.0,0.30
6cdj,"hiv-1 wild type protease with grl-03314a, 6-5-5-ring fused umbrella- like tetrahydropyranofuran as the p2-ligand, a cyclopropylaminobenzothiazole as the p2'-ligand and 3,5- difluorophenylmethyl as the p1-ligand",32,4005.1,15.82,14,13,-3.0,0.31
3i6o,crystal structure of wild type hiv-1 protease with macrocyclic inhibitor grl-0216a,34,4237.7,14.94,15,14,-3.0,0.32
6dif,wild-type hiv-1 protease in complex with tipranavir,30,3619.2,16.01,10,10,-3.0,0.23
6cdl,"hiv-1 wild type protease with grl-03214a, 6-5-5-ring fused umbrella- like tetrahydropyranofuran as the p2-ligand, a cyclopropylaminobenzothiazole as the p2'-ligand and 3,5- difluorophenylmethyl as the p1-ligand",33,4171.8,16.36,14,13,-3.0,0.30
5dgu,crystal structure of hiv-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as p2-ligand grl-004-11a,30,3666.9,16.39,6,13,-5.0,0.27
1dif,hiv-1 protease in complex with a difluoroketone containing inhibitor a79285,40,5141.4,20.75,22,14,-2.0,0.30
4zip,hiv-1 wild type protease with grl-0648a (a isophthalamide-derived p2- ligand),32,3946.3,18.65,6,13,-5.0,0.25
6e9a,"hiv-1 wild type protease with grl-034-17a, (3as, 5r, 6ar)-2-oxohexahyd cyclopenta[d]-5-oxazolyl urethane with a bicyclic oxazolidinone scaff as the p2 ligand",30,3606.2,17.21,1,13,-6.0,0.23
3st5,"crystal structure of wild-type hiv-1 protease with c3-substituted hexahydrocyclopentafuranyl urethane as p2-ligand, grl-0489a",30,3663.5,17.85,5,12,-5.0,0.23
4u8w,hiv-1 wild type protease with grl-050-10a (a gem-difluoro-bis- tetrahydrofuran as p2-ligand),31,3840.3,16.27,11,13,-4.0,0.29
4dfg,"crystal structure of wild-type hiv-1 protease with cyclopentyltetrahydro- furanyl urethanes as p2-ligand, grl-0249a",31,3840.3,15.80,11,13,-4.0,0.29
1hii,"comparative analysis of the x-ray structures of hiv-1 and hiv-2 proteases in complex with cgp 53820, a novel pseudosymmetric inhibitor",32,3955.8,15.32,12,14,-4.0,0.31
5upj,hiv-2 protease/u99283 complex,20,2400.3,16.43,0,4,-2.0,0.10
6upj,hiv-2 protease/u99294 complex,18,2066.9,14.99,0,4,-2.0,0.11
4kb9,crystal structure of wild-type hiv-1 protease with novel tricyclic p2- ligands grl-0739a,29,3550.8,17.31,5,12,-5.0,0.24
3o5n,"tetrahydroquinoline carboxylates are potent inhibitors of the shank pdz domain, a putative target in autism disorders",14,1933.0,6.67,12,6,2.0,0.36
3s45,wild-type hiv-2 protease with antiviral drug amprenavir,30,3615.5,15.77,7,14,-5.0,0.30
6ixd,x-ray crystal structure of bpi-11 hiv-1 protease complex,35,4407.8,16.54,16,15,-3.0,0.34
3el4,crystal structure of inhibitor saquinavir (sqv) complexed with the multidrug hiv-1 protease variant l63p/v82t/i84v,32,3817.7,16.10,9,16,-5.0,0.34
1k6v,lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease,33,4041.7,17.78,13,15,-4.0,0.33
4xt2,crystal structure of the high affinity heterodimer of hif2 alpha and arnt c-terminal pas domains in complex with a tetrazole-containing antagonist,30,4251.5,15.06,21,18,2.0,0.50
4up5,crystal structure of the pygo2 phd finger in complex with the b9l hd1 domain and a chemical fragment,11,1401.9,6.28,3,4,-1.0,0.55
4mn3,chromodomain antagonists that target the polycomb-group methyllysine reader protein chromobox homolog 7 (cbx7),7,1112.6,3.37,5,6,-1.0,0.71
1t7j,crystal structure of inhibitor amprenavir in complex with a multi-drug resistant variant of hiv-1 protease (l63p/v82t/i84v),33,3910.6,14.84,10,17,-5.0,0.36
1k6t,lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease,33,4041.7,17.91,13,15,-4.0,0.33
2cc7,complexes of dodecin with flavin and flavin-like ligands,4,644.7,5.95,1,2,-1.0,0.25
1k6p,lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease,33,3991.1,16.29,14,16,-4.0,0.36
1k6c,lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease,33,4041.7,17.77,13,15,-4.0,0.33
6mj7,crystal structure of p62 zz domain in complex with free arginine,6,730.2,6.00,1,1,0.0,0.33
1x8d,crystal structure of e. coli yiil protein containing l-rhamnose,15,2681.9,19.07,7,4,0.5,0.20
2ccc,complexes of dodecin with flavin and flavin-like ligands,4,644.7,5.99,1,2,-1.0,0.25
1mrx,structure of hiv protease (mutant q7k l33i l63i v82f i84v ) complexed with kni-577,32,3942.1,17.51,7,14,-5.0,0.28
6nxz,crystal structure of trimethoprim-resistant type ii dihydrofolate reductase in complex with a bisbenzimidazole inhibitor,4,644.1,3.36,3,3,0.0,0.50
2ccb,complexes of dodecin with flavin and flavin-like ligands,5,784.7,6.74,1,2,-1.0,0.20
6ny0,crystal structure of trimethoprim-resistant type ii dihydrofolate reductase in complex with a bisbenzimidazole inhibitor,4,644.1,3.37,3,3,0.0,0.50
3dgo,a non-biological atp binding protein with a tyr-phe mutation in the ligand binding domain,14,2115.7,3.19,21,9,4.0,0.71
3gk1,"x-ray structure of bovine sbi132,ca(2+)-s100b",9,1416.3,11.82,2,2,0.5,0.22
3kiv,recombinant kringle iv-10/m66 variant of human apolipoprotein(a),9,1511.5,4.92,16,8,0.5,0.67
5yj8,identification of a small molecule inhibitor for the tudor domain of tdrd3,7,1134.3,1.41,5,9,-2.0,0.86
1sh9,comparing the accumulation of active site and non-active site mutations in the hiv-1 protease,33,3909.0,16.83,8,15,-5.0,0.30
3el9,crystal structure of atazanavir (atv) in complex with a multidrug hiv- 1 protease (v82t/i84v),32,3875.0,15.72,13,15,-4.0,0.34
1msn,the hiv protease (mutant q7k l33i l63i v82f i84v) complexed with kni- 764 (an inhibitor),35,4341.0,17.69,9,16,-5.0,0.31
5er4,crystal structure of calcium-loaded s100b bound to sc0025,6,918.3,3.41,2,6,-1.5,0.67
2p09,structural insights into the evolution of a non-biological protein,14,2119.4,2.26,22,10,4.0,0.79
5dkn,crystal structure of calcium-loaded s100b bound to sbi4225,5,733.9,5.64,2,4,-0.5,0.40
3zi8,structure of the r17a mutant of the ralstonia soleanacerum lectin at 1.5 angstrom in complex with l-fucose,8,1184.0,3.92,8,4,0.0,0.62
3uw4,crystal structure of ciap1 bir3 bound to gdc0152,9,1072.6,4.84,8,2,1.0,0.44
1siv,three-dimensional structure of a siv protease(slash)inhibitor complex. implications for the design of hiv-1 and hiv-2 protease inhibitors,30,3777.6,16.88,10,12,-4.0,0.27
4q1w,mutations outside the active site of hiv-1 protease alter enzyme structure and dynamic ensemble of the active site to confer drug resistance,30,3663.5,17.78,5,12,-5.0,0.23
4q1x,mutations outside the active site of hiv-1 protease alter enzyme structure and dynamic ensemble of the active site to confer drug resistance,30,3716.9,18.13,5,12,-5.0,0.23
3el5,crystal structure of nelfinavir (nfv) complexed with a multidrug variant (act) (v82t/i84v) of hiv-1 protease,32,3794.5,14.96,9,16,-5.0,0.34
1sgu,comparing the accumulation of active site and non-active site mutations in the hiv-1 protease,30,3510.1,17.18,6,13,-5.0,0.27
6fhq,crystal structure of human baz2b phd zinc finger in complex with fr 21,15,2121.3,8.28,4,10,-4.0,0.47
2o4n,crystal structure of hiv-1 protease (trm mutant) in complex with tipranavir,30,3672.6,16.37,10,10,-3.0,0.23
3ekw,crystal structure of the inhibitor atazanavir (atv) in complex with a multi-drug resistance hiv-1 protease variant (l10i/g48v/i54v/v64i/v82a) refer: flap+ in citation.,30,3727.2,18.72,10,12,-4.0,0.27
2ylc,structure of salmonella typhimurium hfq in complex with u6 rna,3,536.7,2.83,3,3,0.5,0.67
4x3k,crystal structure of chromobox homolog 7 (cbx7) chromodomain with h3k27me3 peptide,5,646.5,1.59,5,7,0.0,0.80
3lzs,crystal structure of hiv-1 crf01_ae protease in complex with darunavir,31,3783.0,15.42,7,14,-5.0,0.29
3hcm,crystal structure of human s100b in complex with s45,8,1119.5,11.05,1,1,0.0,0.12
1ceb,the structure of the non-covalent complex of recombinant kringle 1 domain of human plasminogen with amcha (trans-4- aminomethylcyclohexane-1-carboxylic acid),9,1567.5,3.17,14,7,0.0,0.78
2p3c,crystal structure of the subtype f wild type hiv protease complexed with tl-3 inhibitor,35,4408.5,19.03,8,14,-4.0,0.29
2p3a,crystal structure of the multi-drug resistant mutant subtype b hiv protease complexed with tl-3 inhibitor,35,4429.9,19.30,20,12,-2.0,0.29
3lzu,crystal structure of a nelfinavir resistant hiv-1 crf01_ae protease variant (n88s) in complex with the protease inhibitor darunavir.,30,3609.6,16.78,2,14,-6.0,0.27
3ggu,hiv pr drug resistant patient's variant in complex with darunavir,32,3797.9,13.29,10,17,-5.0,0.38
4j45,crystal structure of xiap-bir2 domain with ataa bound,9,1147.2,6.07,2,2,0.5,0.44
5epl,crystal structure of chromodomain of cbx4 in complex with inhibitor unc3866,11,1756.2,7.77,8,8,-0.5,0.45
4j48,crystal structure of xiap-bir2 domain with amrv bound,7,966.2,7.17,2,2,0.0,0.43
3t3c,structure of hiv pr resistant patient derived mutant (comprising 22 mutations) in complex with drv,31,3680.4,19.02,6,13,-5.0,0.26
1gyy,"the crystal structure of ydce, a 4-oxalocrotonate tautomerase homologue from escherichia coli, confirms the structural basis for oligomer diversity",9,1352.5,4.77,12,3,2.0,0.67
4j47,crystal structure of xiap-bir2 domain with svpi bound,9,1147.2,6.01,2,2,0.5,0.44
3s54,"hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug darunavir in space group p21212",29,3553.6,16.44,6,13,-5.0,0.28
6otg,"hiv-1 protease triple mutants v32i, i47v, v82i with grl-011-11a (a methylamine bis-tetrahydrofuran p2-ligand, sulfonamide isostere derivate)",28,3437.5,16.08,5,12,-5.0,0.25
3ttp,structure of multiresistant hiv-1 protease in complex with darunavir,31,3836.4,16.56,7,14,-5.0,0.29
5od1,structure of the engineered metalloesterase mid1sc10 complexed with a phosphonate transition state analogue,22,2999.5,10.90,26,15,3.5,0.50
4q1y,mutations outside the active site of hiv-1 protease alter enzyme structure and dynamic ensemble of the active site to confer drug resistance,30,3716.9,17.98,5,12,-5.0,0.23
2v88,crystal structure of rag2-phd finger in complex with h3r2me2sk4me2 peptide,8,1005.0,3.06,2,4,-0.5,0.75
4j46,crystal structure of xiap-bir2 domain with avpi bound,9,1147.2,6.06,2,2,0.5,0.44
5kr1,protease pr5-drv,29,3558.4,18.27,9,10,-2.0,0.21
4j44,crystal structure of xiap-bir2 domain with aiav bound,9,1147.2,6.05,2,2,0.5,0.44
1gyx,"the crystal structure of ydce, a 4-oxalocrotonate tautomerase homologue from escherichia coli, confirms the structural basis for oligomer diversity",12,1757.6,5.93,15,6,2.5,0.67
6o5a,crystal structure of multi-drug resistant hiv-1 protease pr-s17 with a substrate analog p2-nc in p61,37,4797.5,17.78,20,16,-2.0,0.38
3s43,"hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug amprenavir",32,3949.1,17.04,7,14,-5.0,0.28
1hsh,"crystal structure at 1.9 angstroms resolution of human immunodeficiency virus (hiv) ii protease complexed with l-735,524, an orally bioavailable inhibitor of the hiv proteases",35,4417.3,20.88,12,14,-4.0,0.29
1pzi,heat-labile enterotoxin b-pentamer complexed with nitrophenyl galactoside 2a,14,1977.1,2.20,24,14,2.5,0.79
2vpe,decoding of methylated histone h3 tail by the pygo-bcl9 wnt signaling complex,10,1244.6,1.50,9,11,-0.5,0.90
6eiz,a de novo designed hexameric coiled coil cc-hex2 with farnesol bound in the channel.,25,4167.5,33.96,0,0,0.0,0.00
6prf,hiv-1 protease multiple drug resistant clinical isolate mutant pr20 with grl-14213a,29,3452.8,16.46,10,13,-3.0,0.28
3a2o,crystal structure of hiv-1 protease complexed with kni-1689,36,4407.2,16.39,11,15,-4.0,0.31
4ndu,crystal structure of l. decastes alpha-galactosyl-binding lectin in complex with alpha-methylgalactoside,11,1340.2,4.73,10,10,0.5,0.64
1a94,structural basis for specificity of retroviral proteases,36,4649.7,21.77,13,14,-4.0,0.28
5vh0,rhcc in complex with pyrene,12,1928.1,7.27,12,8,-1.0,0.58
6a87,pholiota squarrosa lectin (phosl) in complex with fucose(alpha1-6) glcnac,5,786.2,3.00,3,4,-1.0,0.60
6fhu,crystal structure of baz2a phd zinc finger in complex with h3 3-mer peptide,9,1341.5,8.55,5,4,-1.0,0.33
3v2q,compcc in complex with fatty acids,29,4333.3,21.15,15,15,0.0,0.34
3v2p,compcc in complex with fatty acids,30,4500.0,21.82,15,15,0.0,0.33
3v2n,compcc in complex with fatty acids,25,3666.5,14.23,15,15,0.0,0.40
5l8a,targeting the pex14-pex5 interaction by small molecules provides novel therapeutic routes to treat trypanosomiases.,19,2715.6,6.51,24,12,2.5,0.63
4kiu,"design and structural analysis of aromatic inhibitors of type ii dehydroquinate dehydratase from mycobacterium tuberculosis - compound 49d [5-[(3-nitrobenzyl)oxy]benzene-1,3-dicarboxylic acid]",22,2973.4,7.57,30,14,3.0,0.55
2r5p,crystal structure analysis of hiv-1 subtype c protease complexed with indinavir,33,4142.9,18.86,11,13,-4.0,0.27
3ekp,crystal structure of the inhibitor amprenavir (apv) in complex with a multi-drug resistant hiv-1 protease variant (l10i/g48v/i54v/v64i/v82a)refer: flap+ in citation,31,3779.3,19.71,2,14,-6.0,0.26
3ekt,crystal structure of the inhibitor darunavir (drv) in complex with a multi-drug resistant hiv-1 protease variant (l10f/g48v/i54v/v64i/v82a) (refer: flap+ in citation.),29,3550.5,19.52,1,13,-6.0,0.24
5kr2,protease pr5-sqv,28,3367.1,16.49,11,12,-2.0,0.29
6o5x,crystal structure of multi-drug resistant hiv-1 protease pr-s17 with substrate analog ca-p2,38,4937.9,20.18,21,17,-2.0,0.37
3n7a,crystal structure of 3-dehydroquinate dehydratase from mycobacterium tuberculosis in complex with inhibitor 2,16,2150.7,6.63,19,11,2.0,0.56
3n8k,type ii dehydroquinase from mycobacterium tuberculosis complexed with citrazinic acid,17,2294.8,5.81,25,12,3.0,0.59
2cht,crystal structures of the monofunctional chorismate mutase from bacillus subtilis and its complex with a transition state analog,13,1919.2,6.31,20,4,3.0,0.62
4bj8,zebavidin,20,2796.2,11.17,14,14,-2.0,0.55
3n86,crystal structure of 3-dehydroquinate dehydratase from mycobacterium tuberculosis in complex with inhibitor 4,24,3256.4,8.61,31,17,2.0,0.58
1jqy,heat-labile enterotoxin b-pentamer with ligand bmsc-0010,16,2282.2,3.24,24,16,1.5,0.75
